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Abstract
Epigenetic processes are known to play an important role in the regulation of embry-
onic development and gene expression. Here we utilise next-generation sequencing and
bioinformatics methodologies to investigate the role of epigenetics in two different sys-
tems, heart and brain. In heart, the endocardium is a distinct understudied epithelial
population of cells that is involved in directing morphogenesis of the myocardium, valve
leaflets and trabeculae. We generate whole-genome bisulphite sequencing data for the
endocardium and endothelium and compare these data to transcriptomic profiles of these
cells. We identify a plethora of differentially expressed genes and differentially methylated
genomic regions. Through motif analysis we identify the ETS family of transcriptional
activators as likely to play a role in the development of the endocardium.
In brain, we investigate the role of the CTCF and cohesin DNA binding factors in
imprinted gene expression by performing high depth allele-specific ChIP-seq for these two
factors. We develop a novel bioinformatics approach for performing allele-specific mapping
of next-generation sequencing reads and we compare our results with existing data for
mouse liver and embryonic stem cells. We note that embryonic stem cells have fewer
unique CTCF binding sites consistent with their undifferentiated profile. We examine
CTCF and cohesin binding in the vicinity of imprinted loci and note that CTCF and/or
cohesin bind to a subset of imprinted regions, suggesting a heterogeneous mechanism for
imprinting.
Collectively, our studies examine the role of epigenetics and their interplay with tran-
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The term epigenetics was first coined by Conrad Waddington in 1942 as “the branch
of biology which studies the causal interactions between genes and their products, which
bring the phenotype into being” [Goldberg et al., 2007]. Waddington coined this term
as a counterpart to the term ‘Phenogenetics’, which referred to the descriptive study of
genetic perturbations [Waddington, 2012]. This original definition of epigenetics only
vaguely corresponds to the modern ideas about what constitutes epigenetic phenomena.
Instead, the term mostly refers to what is now termed gene regulation and the study of
protein function to give rise to the visible phenotype. The original meaning of the term
is now largely encapsulated in the field of systems biology. Further to coining the term
epigenetics, Waddington introduced the concept of ‘epigenetic landscape’ [Slack, 2002].
The term refers to an imaginary sloped surface with bifurcations on which a ball rolls. At
each bifurcation the ball is pictured to make a binary decision. The surface was originally
meant to represent states of a multi-dimentional space of cellular metabolism and the
ball a cell during development making successive fate decisions at each bifurcation of the
landscape.
The definition of the term epigenetics has since evolved to refer specifically to infor-
mation in the cell nucleus beyond the information in the primary DNA sequence, with
some sources imposing a heritability criterion [Berger et al., 2009]. As such, the term epi-
genetics now refers to phenomena that include DNA methylation, histone modifications,
the deposition of rare histone variants on chromatin and regulation by non-coding RNAs.
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The idea of the epigenetic landscape has accordingly changed and it is no longer used
to refer to states in the space of cellular metabolism, but rather states in terms of DNA
methylation and histone modifications.
1.1.2 Epigenetics in Gene Expression Regulation and Cell Fate Speci-
fication
A large body of evidence exists to suggest that epigenetic information correlates with and
may be able to influence gene expression regulation and cell fate specification, but the
mechanisms of this mode regulation are not well defined, with a few notable exceptions
such as CpG methylation in the context of CpG islands (see following Section) [Jones,
2012] .
For an epigenetic mark or process to be involved in specification of cell fate, there is a
fundamental requirement that the modification in question can propagate across cell divi-
sion. It is well established that DNA methylation is conserved across cell division (Section
1.1.3). It is also hypothesised that at least some histone modifications can be inherited
across cell divisions, although the details of histone modification preservation are not well
established despite models for transmission of some histone marks being proposed and
supported by experimental evidence [Bannister and Kouzarides, 2011]. Other epigenetic
factors such as non-coding RNAs are less likely to be preserved across cell divisions and
no general mechanism for their preservation is known.
More recent evidence suggests that epigenetic marks may also be involved in, and
provide a mechanistic explanation for, transgenerational inheritance effects, by escaping
erasure during germ line development that affects the majority of the genome [Seisenberger
et al., 2012]. Findings in this area remain controversial.
1.1.3 Methylation and Hydroxymethylation of DNA
DNA methylation refers to the addition of a methyl group to the fifth carbon position
of Cytosine (C) (see Figure 1.1). The C methylation reaction is catalysed by one of the
three DNA methyl-transferase (Dnmt) enzymes: Dnmt1, Dnmt3a and Dnmt3b1.
Dnmt1 was the first Dnmt described [Bestor et al., 1988] and is primarily regarded to
be a maintenance methyl-transferase. It exhibits auto-inhibition for de novo methylation
and is specifically targeted to replication forks by UHRF1 [Sharif et al., 2007] [Bostick
1Dnmt2 catalyses the methylation of aspartic acid tRNA [Goll et al., 2006] and will not be discussed
here.
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et al., 2007] where it methylates hemi-methylated DNA. Dnmt3a and Dnmt3b are de
novo methyl-transferases and are responsible for methylation of previously unmethylated
DNA during germ cell development [Denis et al., 2011]. The mechanism of de novo
methylation targeting is likely to involve some level of sequence specificity, guidance by
Dnmt3l (a protein highly homologous to other Dnmts but with no catalytic activity) and
RNA-directed DNA methylation [Denis et al., 2011].
The mechanism of removal of DNA methylation is not fully established but evidence
exists to support that it can be removed either passively (by non-renewal) during cell
division or actively. Evidence for passive demethylation exists in the the maternal genome
of the zygote [Rougier et al., 1998]. Active inducible demethylation has been demonstrated
in non-dividing neurons at the promoters of FGF1 and BDNF in the time scale of minutes
[Martinowich et al., 2003] and in the male pronucleus [Wossidlo et al., 2011]. Recent
evidence also suggest active demethylation in the maternal zygotic genome [Guo et al.,
2014].
The ten-eleven translocation (TET) family of enzymes has been implicated in the
removal of DNA methylation. TET enzymes are known to catalyse the oxidation of 5-
methylcytosine(mC) to 5-hydroxymethylcytosine (hmC), as well as 5-formylcytosine (fC)
and 5-carboxylcytosine [Ito et al., 2011]. hmC has been shown to be demethylated by
the action of AID and APOBEC deaminase enzymes and the action of the base excision
repair (BER) DNA glycosylation pathway [Guo et al., 2011c]. fC and caC can also be
removed by the BER DNA glycosylation [Kohli and Zhang, 2013].
hmC has been found to be particularly abundant in the brain and the embryonic stem
cells but is also present in other tissues such as lung and muscle [Bhutani et al., 2011].
Unlike other tissues DNA methylation state in embryonic stem cells has recently been
shown to be the result of a dynamic equilibrium between methylation and demethylation
[Shipony et al., 2014] and this finding is consistent with the intermediate role of hmC and
its high abundance in ESCs. The role of hmC in brain is less clear, although it has been
implicated in neuronal plasticity [Guo et al., 2011b].
The function of DNA methylation is not clear in most genomic contexts [Jones, 2012].
However, the function of CpG methylation in CpG island promoters (see below) is one
of the best understood examples of epigenetic regulation of gene expression. In this
context methylation is associated with long-term silenced genes and a chromatin state not
permissive to transcription, such as genes on the inactive X chromosome. Furthermore,
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Figure 1.1: Overview of known cytosine modifications catalysed by the DNMT and TET
enzymes families. The DNMT family of enzymes catalyses methylation of cytosine at the
5 carbon position. Enzymes in the TET family catalyse further modifications including 5-
hydroxymethylcytosine. 5-hydroxymethylcytosine can be converted to cytosine, through
the BER pathway.
DNA methylation is known to be important for silencing of transposable elements [Smith
and Meissner, 2013].
The function of DNA methylation in non-CpG island promoters and transcribed re-
gions is not understood in vertebrates [Lister et al., 2009]. More recently non-CpG methy-
lation has been shown to be mostly confined to embryonic stem cells [Arand et al., 2012].
CpG Islands
In vertebrates, the majority of cytosine methylation occurs primarily in the context of C
followed by a Guanine(G) base (CpG context) [Deaton and Bird, 2011]. This arrangement
is symmetrical, when one considers both DNA strands, and allows for preservation of the
methylation state upon DNA replication by copying information for the template strand
to the newly synthesised strand.
Mutation of cytosines occurs by deamination. Whereas non-methylated Cs can be
repaired by the cellular machinery, mCs cannot be reliably repaired and tend to be con-
verted to Ts and lost [Bird, 1980]. As a result, the frequently methylated CpG dinu-
cleotide is significantly underrepresented in mammalian genomes. CpGs in mammals are
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only encountered at the expected frequency, and thus overrepresented in comparison with
the rest of the genome, in regions termed CpG islands (CGIs), where they are usually
unmethylated [Deaton and Bird, 2011].
The majority of CGIs are found in promoter regions of genes, and the presence of
sequence elements results in an open, nucleosome depleted chromatin conformation and
favours transcriptional activation. CGIs are also frequently associated with histone H3
trimethylation at lysine 4 (H3K4me3). High methylation levels of CGIs are correlated
with long-term transcriptional repression [Deaton and Bird, 2011] [Jones, 2012].
CGIs are also found in intragenic regions but the role of intragenic CGIs is less clear,
although roles in alternative promoter usage [Jones, 2012] and alternative RNA processing
have been proposed [Maunakea et al., 2013]. Extensive variation in methylation surround-
ing CGIs has been reported and these regions have been termed CGI shores. CGI shores
have been implicated in gene regulation in cancer and may also be relevant in normal
development [Hansen et al., 2011].
1.1.4 Histone Modifications
DNA in the eukaryotic nucleus is wrapped around histone octamers composed of two
copies of each of H2A, H2B, H3 and H4 histone polypeptides. Approximately 147 base-
pairs (bp) are wrapped around each octamer with a small variable linker of approximately
80 bps between them. The solution of the histone octamer structure in 1997 showed that
the DNA is wrapped around a central core, with N-terminal chains protruding out of the
octamer [Luger et al., 1997].
Histones are known to be heavily and dynamically post-translationally modified in
the nucleus [Bannister and Kouzarides, 2011]. The majority of the modifications occur
on residues on the N-terminal chains, with only a small proportion on the central core
residues. A very large repertoire of histone modifications has been described: acety-
lation, phosphorylation, methylation, deimination, beta-N-acetylglucosamine addition,
ADP ribosylation, ubiquitination and sumoylation, proline isomerisation and even his-
tone tail clipping [Bannister and Kouzarides, 2011]. The action of the majority of these
modifications is unknown, with most of our understanding focused on a small subset of
modifications.
Some of the known histone modifications are well understood and correlate with gene
activity. In particular, some forms of lysine (K) methylation are present in well defined
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chromatin environments. Histone 3 Lysine 27 tri-methylation (H3K27me3) correlates
strongly with facultative heterochromatin and gene expression repression during devel-
opment but not with constitutive heterochromatin. Histone 3 Lysine 4 tri-methylation
(H3K4me3) is encountered in the transcription start site (TSS) of actively expressed
genes [Bannister and Kouzarides, 2011]. H3K4me3 is established co-transcriptionally by
the action of scSet1 methyl-transferase, which specifically binds to the elongating form of
the RNA polymerase II (RNApolII) via the Serine 5 phosphorylation of the C-terminal
domain (CTD). Histone 3 Lysine 36 trimethylation (H3K36me3) is also encountered in
active genes, but in the bodies rather than the TSS. Furthermore, Histone 3 Lysine 4
mono-methylation is associated with active enhancers and H3K27ac has been proposed
to distinguish active from poised enhancer elements [Creyghton et al., 2010].
In contrast to DNA methylation, there is no well established mechanism for the main-
tenance of the chromatin state across cell divisions, although chromatin state appears
to be preserved. Furthermore, it is not clear if all histone modifications are preserved
to the same extent. Some mechanisms have been proposed for particular modifications.
For example H3K27me3 may be preserved by recruitment of the Polycomb Repressive
Complex 2 (PRC2) at the replication fork by the histone mark leading to deposition of
the same histone mark at the newly synthesised DNA [Hansen et al., 2008].
1.2 Gene Regulation and Transcription Factor Binding
Gene expression requires assembly and activation of the RNA polymerase II initiation
complex at promoters of expressed genes [Zabidi et al., 2014]. Both assembly and activa-
tion are tightly regulated processes that directly control gene expression. Assembly and
initiation of the RNApolII complex is influenced by the action of transcription factors
(TFs) that bind the promoter DNA sequence and either recruit or activate other factors
or the initiation complex.
Different transcription factors have distinct DNA sequence specificities (motifs) that
are the direct result of the amino acid sequence of their DNA binding domains (DBDs) .
Over 80 DBDs are known, but the specificity of the majority of those remains unknown
[Weirauch et al., 2014]. Identification of the binding motif of TFs can be performed via
computational analysis (motif finding) of the DNA sequences to which they bind [Bailey
et al., 2009].
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The actions of TFs are regulated by control of their expression as well as post-
transcriptional modifications. Regulation of TFs by other TFs gives rise to transcrip-
tional networks, whereby a master transcriptional regulator regulates other transcription
factors that directly or indirectly control the expression of the effector proteins that give
rise to the cellular effect. Transcription factors are also regulated by post-translational
modifications, that can alter their activity either by changing their cellular localisation or
by directly activating or de-activating them. Such modifications include SUMOylation,
methylation, Ubiquitination, phosphorylation, acetylation and the binding of non-coding
RNAs [Kim and Kim, 2014] [Bogachek et al., 2014].
Regulation of expression is not the only mode of control of gene action. Similarly to
the regulation of transcription factors presented above, the action of genes is regulated by
post-translational modifications of their protein products [Doll and Burlingame, 2015].
1.3 Cardiovascular Development
Cardiovascular development is paramount to the development of the embryo as failure
of formation of vessels or the heart leads to early embryonic lethality. Formation of the
vasculature is closely linked with blood formation and occurs in two distinct processes
outlined below. Formation of the heart is also tightly linked to the development of the
great vessels and the lungs in a temporal and spatial manner. Although a number of reg-
ulators of heart patterning and vessel formation are known, it is increasingly anticipated
that epigenetic processes will be found to have a significant role in the development, and
later homeostasis of these tissues [Chang and Bruneau, 2012].
1.3.1 Formation of the Vasculature
Vascular development in the embryo can occur by two different processes: vasculogenesis
and angiogenesis. Vasculogenesis involves de novo formation of blood vessels by differen-
tiation of mesodermal cells into endothelium in the yolk sac and in the developing embryo
proper. In contrast, angiogenesis refers to the process of formation of new blood vessels
by extension of existing ones [Baldwin, 1996]. The two processes contribute in variable
degrees to the formation of vessels in different organs.
Vasculogenesis initially occurs in the yolk sac in cell aggregates termed blood islands
and later in other tissues such as the liver. After formation of blood islands, the cells
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that comprise each island differentiate with the outer area forming epithelial (marked by
the presence of PECAM-1/CD31) cells and the interior forming blood precursors [Choi
et al., 1998]. This pattern of differentiation originally suggested the existence of a com-
mon progenitor between the vascular endothelial cells and blood, and this precursor (the
hemangioblast) has now been identified [Choi et al., 1998] [Nishikawa et al., 1998].
1.3.2 Development of the Heart
Heart formation is initiated in early development, during gastrulation (E6.5-E7 in the
mouse) [Tam and Loebel, 2007]. Myocardial progenitor cells can be traced to a population
of cells in the epiblast [Abu-Issa and Kirby, 2007]. A mesodermal population of cells that
will become the adult heart after migrating through the primitive streak forms a structure
known as the cardiac crescent near the head of the embryo [Moorman et al., 2003] (Figure
1.2 A1).
At this stage the endocardium arises as a plexus in the region of the cardiac crescent
(Figure 1.2 B1). The exact origin of the endocardium remains unresolved (see Section
1.3.3 below). Traditional texts suggest that the cardiac crescent forms one endocardial
tube on each side of the embryo, and the endocardium delaminates from them following
downregulation of N-cadherin [Linask, 1992] and forms endocardial tubes in the lumen of
the myocardial tubes [Abu-Issa and Kirby, 2007] [Baldwin, 1996] [Gilbert, 2003], whereas
other literature suggests that the endocardial plexus is formed independently [Moorman
et al., 2003]. The uncertainty in spatial origin of the endocardium reflects the uncertainty
in its cellular origin.
Irrespective of the origin of the endocardium, the heart moves posteriorly as part
of general rearrangements and the left and right endocardial tubes fuse in an anterior
to posterior fashion, while being surrounded by the myocardium2 which also fuses in a
similar manner (Figure 1.2 C1 through C3). This leads to the formation of linear heart
tube continuous with the aorta and the cardinal veins. Early events in heart formation
can be visualised in vivo via the Nkx2-5 master heart regulator, which is expressed in
the early heart and continues to be expressed in the adult [Abu-Issa and Kirby, 2007].
Later events can also be visualised by myosin heavy chain (MHC) staining [Moorman
et al., 2003]. Cells that contribute to the initial stages of heart development are termed
the first heart field. At a later stage, Isl1+ cells from the second heart field migrate to
2Continuity with the mesorderm is preserved in the dorsal side in what will develop to become the
mediastinum.
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the cardiac region and contribute to the cranial end of the developing heart [Cai et al.,
2003] [Domı´nguez et al., 2012]. Later during development the neural crest also contributes
to heart development [Lepore et al., 2006].
The two heart fields have different contributions to the adult heart with the first
heart field forming the left ventricle (LV) as well as parts of the right ventricle (RV) and
atria [Chong et al., 2014]. The second heart field also contributes to the RV, the atria
and the outflow track (OFT) [Abu-Issa and Kirby, 2007] [Dyer and Kirby, 2009] [Harmon
and Nakano, 2013] .
At approximately embryonic day of development 11 (E11) the cardiac tube undergoes
rotation (Figure 1.2 D1). Cardiac rotation is initiated when the mediastinal structure
that connects the anterior section of the cardiac tube to the back of the embryo becomes
disrupted and frees the cardiac tube, which rotates under its own tension [Moorman et al.,
2003].
While the cardiac rotation is still occurring, the cardiac chambers begin to form by
septation (Figure 1.2 E1) of the lumen of the heart, expansion of the apical portion of
the heart and formation of the new myocardium [Moorman et al., 2003]. The ventricles
originate from the ventricular loop [Moorman et al., 2003].
The ventricular wall forms multiple disconnected streaks at this stage giving it a
‘spongy’ appearance, in a process termed trabeculation. Compaction later in development
will fuse these trabeculae into a more uniform and compact muscle layer.
Valve Formation
Valve formation commences at E9.5 with the excretion of extracellular matrix (ECM)
by the myocardium of the heart in the location of the future valves [DeLaughter et al.,
2011] in the OFT and atrioventricular canal (AVC) regions, leading to the formation of
the cardiac cushions [Chakraborty et al., 2010] [Hinton and Yutzey, 2011]. The cardiac
cushions will act as primitive valves in the developing heart, establishing a unidirectional
blood flow, albeit with some regurgitation [Wu et al., 2013].
Following cardiac cushion formation, a subpopulation of the endocardial cells (the
inner layer of the heart, Section 1.3.3) overlaying the cushions undergo endothelial-to-
mesenchymal transformation (EMT). EMT occurs under the control of Erg [Vijayaraj
et al., 2012] [Wu et al., 2013], a member of the ETS family of proteins. During EMT,
endocardial cells delaminate from the endothelium and invade the underlying cardiac
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Figure 1.2: Diagramatic summary of the embryonic development of the heart. The heart
is formed from anterior lateral plate mesoderm cells that migrate through the primitive
streak during gastrulation (A1), adapted from [Harris and Black, 2010]. Cardiac pro-
genitors form the cardiac crescent, here shown labelled with alpha-myocin (B1), adapted
from [Moorman et al., 2003]. The cardiac crescent forms two concentric tubes on each side
of the embryo (C1). The outer myocardial tubes fuse first followed by the inner endocar-
dial tubes (C2) into a single heart tube in the midline. (C3). The cardiac tube comprises
of an outer myocardial layer and and inner endocardial (C3). The heart tube undergoes
rotation (D1), adapted from [Moorman et al., 2003]. The heart remodels through the
formation of cardiac cushions (E1) and rearrangement of inflow and outflow tracks into
the adult four chamber structure (E2) with separate right atrium (RA), right ventricle
(RV), left atrium (LV), left ventricle (LV).
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jelly where they remodel the ECM. Initiation of EMT and valve formation requires both
myocardium and endocardium from the valvular regions [Baldwin, 1996] [Chakraborty
et al., 2010]. Transplantation experiments have shown that replacement of either the
endocardium or myocardium by respective tissue from other parts of the heart ablates
valve formation [Mjaatvedt et al., 1987], demonstrating the spatial heterogeneity of the
endocardium. A portion of the population of endocardial cells overlaying the future
valve region do not however undergo EMT. These cells remain in the epithelial layer and
proliferate to generate the valve leaflets [Wu et al., 2013].
The process of EMT is well studied due to the existence of a simple assay that allows
it to be recapitulated in vitro. Unlike EMT however, the mechanism of cardiac cushion
remodelling is poorly understood because no in vitro system exists to recapitulate these
events [de Vlaming et al., 2012].
1.3.3 Origin and Differentiation of the Endocardium
The endocardium is a layer of endothelial cells lining the internal surfaces of the ventricles
and atria of the heart. The endocardium first appears shortly after gastrulation almost
concurrently with the formation of the cardiac crescent. Future endocardial cells down-
regulate expression of the adhesion molecule N-cadherin and separate from the rest of the
cardiogenic mesoderm. The close spatial relationship of the endocardial and myocardial
populations suggests a common developmental precursor [Baldwin, 1996] as opposed to a
vascular endothelial precursor. The exact origin of the endocardium however remains the
subject of debate. Conflicting reports exist in the literature with some studies suggesting
a vascular origin [Milgrom-Hoffman et al., 2011] [Harris and Black, 2010] and others
a common origin with other cardiac cells [Misfeldt et al., 2009] [Moretti et al., 2006]
[Kattman et al., 2006]. Furthermore, it has been suggested that endocardial cells may be
able to form vasculature [Wu et al., 2012], further complicating our understanding of the
endocardium.
A multipotent progenitor originating from the second heart field (Isl1+) that can dif-
ferentiate into myocardium, smooth muscle and endothelial cells was described in ES cell
culture in 2006 by Moretti and colleagues [Moretti et al., 2006]. This cell line was termed
a multipotent, cardiovascular progenitor (MICP) and was defined by the Isl1+/Nkx2-
5+/Flk1+ expression signature and its existence in the developing embryo was confirmed.
Around the same time Kattman and colleagues, demonstrated the existence of an
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Figure 1.3: Working model of the embryonic origin of the endocardium. The endocardium
originates from a multipotent cardiovascular progenitor population that can also give rise
to other cardiac tissues. (Adapted from [DeLaughter et al., 2011]).
even more general Flk1+ cardiovascular progenitor with endothelial, cardiomyocyte and
vascular smooth muscle lineages [Kattman et al., 2006]. The relationship between the two
populations is not entirely clear but a working model [DeLaughter et al., 2011] presents
this population as a predecessor of the MICP (See Figure 1.3).
A unique endocardial identity and origin is however supported by the existence of a
distinct endocardial marker [de la Pompa et al., 1998] [Ranger et al., 1998] (see following
Section) as well as the existence of a double gene knock-out that shows specific endo-
cardial defects. The single knock-out of either of the two structurally related tyrosine
kinase receptors Tie1 or Tie2 (Tek) expressed throughout the endothelium is embryoni-
cally lethal, but does not show any defects in the initial formation of the vasculature or of
the endocardium. In contrast, the double mutant shows specific failure of the initial for-
mation of the endocardium suggesting a distinct identity for this cardiac population [Puri
et al., 1999].
1.3.4 Congenital Heart Defects
Congenital heart defects (CHD) are the most common birth defects affecting between
1% to 5% of live births [Leirgul et al., 2014] [Hoffman and Kaplan, 2002]. CHD is
subclassified into a number of individual defects with different management. These include
patent ductus arterious (failure of the ductus arteriole to close after birth), ventricular
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septal defects (defects in the septum separating the two ventricles), atrial septal defects,
pulmonic and aortic stenosis, coarctation of the aorta (narrowing of the aorta at the
ductus arteriole, tetralogy of fallot (a complex malformation characterised by pulmonary
infundibular stenosis, overriding aorta, ventricular septal defects and right ventricular
hypertrophy), complete transposition of the great arteries (where the right ventricle is
connected to the aorta and the left ventricle to the pulmonary artery), hypoplastic left and
right heart syndromes, persistent truncus arteriosus (a ventricular septal defect), single
ventricle and total anomalous pulmonary venous connection (whereby the pulmonary
veins connect to the systemic venous circulation) [Hoffman et al., 2004].
A subclass of congenital heart disease is congenital valvular disease, whereby the
cardiac valves fail to develop correctly. Congenital valve disease encompases bicuspid
aortic valve defects, mitral valve prolapse, pulmonary valve stenosis and Ebstein anomaly
of the tricuspid valve [LaHaye et al., 2014] [Lincoln and Garg, 2014].
Despite the high incidence of valve defects, treatments for this class of CHDs are not
effective due to lack of understanding of the mechanisms that lead to these malformations
[Lincoln and Garg, 2014]. Treatment is limited to surgical replacement with mechanical
or bioprosthetic valves. However such treatments have severe caveats such as the limited
durability and need for continuous coagulation [LaHaye et al., 2014].
Genetic basis for some of these malformations has been described suggesting a genetic
basis for other valvular malformations. Bicuspid aortic valve defects (one of the most
common valve malformations present in 1-2% of the population) have been linked to
NOTCH1 [McBride et al., 2008] in human and Gata5 mutations in the mouse [Bonachea
et al., 2014]. Mitral valve prolapse has been functionally associated with Marfan syndrome
which has well established genetic aetiology [LaHaye et al., 2014].
Improvements in clinical management have improved the prognosis of such defects re-
sulting in a large number of adults living with valvular CHD [Hoffman et al., 2004] posing
significant challenges in the management of resulting complications [Tutarel, 2014] and
further necessitating the understanding of the molecular aetiology of these malformations
to improve treatment. Furthermore, detailed understanding of the development of valves
may allow in vitro growing of valves from patient-derived embryonic stem cells in the
future.
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Significance of the Endocardium and its Role in Congenital Heart Defects
Beyond its primary role in the formation of an endothelial layer in the heart lumen,
the endocardium has other functions [Harris and Black, 2010]. Specifically, endocardium
is required for cardiac development and in particular trabeculation of the myocardium,
differentiation of myocytes into Purkinje conduction fibers, formation of cardiac valves
and separation of the OFT into the pulmonary artery and aorta.
The endocardium is involved in the formation of cardiac valves by partially under-
going EMT at the sites of the future valves [Wu et al., 2013] [von Gise and Pu, 2012].
Under the control of NFATc1, a portion of endocardial cells undergo EMT and invade the
cardiac cushions to form the valve mesenchyme and remodel the cardiac cushions. These
endocardial cells are responsible for valve formation, whereas endocardial cells that do
not undergo EMT will form the valve leaflet [Wu et al., 2013].
The endocardium has also been implicated in conduction fiber formation. The pres-
ence of endocardial cells is required for expression of Purkinje fiber marker genes, by these
cells. Furthermore, ablation of Neuregulin a soluble signalling protein excreted by the en-
docardium results in conduction defects, in addition to other myocardial defects [Mikawa
and Hurtado, 2007].
Ablation of Neuregulin also results in compaction and trabeculation defects exempli-
fying the role of the endocardium in these processes. Finally, the endocardial specific
knockout of Fkbp1a, a cis-trans peptidyl-prolyl isomerase results in non-compaction of
the myocardium [Chen et al., 2013].
In addition to the above, the endocardium has recently been identified as a source of
a population of cells leading to the formation of the coronary circulation during trabecu-
lation [Tian et al., 2014] directly implicating these cells in cardiac muscle vascularisation.
Given the diverse roles of the endocardium in cardiac development and the clinical
significance of CHDs, understanding the regulation, role and actions of the endocardium
during embryonic development is critical for both understanding the aetiology and im-
proving the management of these defects.
NFATc1 as a Marker and Functional Component of Endocardial Cells
Nuclear Factor of Activated T-cell (NFATc1), a calcineurin dependent transcription fac-
tor, was identified as an early marker of endocardial cell differentiation in two simultaneous
publications in 1998 [Ranger et al., 1998] [de la Pompa et al., 1998].
44
Between E8.5 and E10.5 NFATc1 expression is confined to the developing endocardium
[Misfeldt et al., 2009]. The expression is transient and later during development it is
expressed in other embryonic tissues such as limb cartilage and hair follicles [Misfeldt
et al., 2009], while in the adult NFATc1 is involved in activation of lymphocytes [de la
Pompa et al., 1998]. At E9.5 and until E11.5 NFATc1 expression is upregulated in the
OFT and AVC endocardial cells and downregulated in the rest of the endocardium [Wu
et al., 2013] [Misfeldt et al., 2009].
At the time of identification of NFATc1 as an endocardial marker it was recognised that
it was also essential for valve formation as its ablation leads to valvular defects [Ranger
et al., 1998] [de la Pompa et al., 1998]. It was later appreciated however that although
essential for valvulogenesis NFATc1 is not essential for commencement of EMT at the site
of the future valves, thus making its exact role unclear.
More recent work supports the notion that the role of NFATc1 is to block rather than
induce EMT in endocardial cells [Wu et al., 2013]. This blockage is proposed to occur in
only a portion of endocardial cells thus being the deciding factor to allocate cells between
the valve leaflet formation and valve mesenchyme. Specifically, evidence exists to support
the idea that downregulation of NFATc1 is responsible for the commencement of EMT
and in fact its presence arrests cells in a pre-EMT state at E10.5 by suppression of Snail1
and Snail2 regulators [Wu et al., 2011a]. The way in which NFATc1 levels remain high
in only a fraction of endocardial cells remains unknown.
In addition to the aforementioned role, expression of NFATc1 is proposed to promote
valve elongation [Wu et al., 2013]. It is known that NFATc1 can autoamplify itself and
thus maintain persistent expression once activated and it appears that this auto-activation
is important in the promotion of valve elongation [Zhou et al., 2005]. The mechanism by
which NFATc1 is eventually downregulated remains unclear.
Regardless of its role in the regulation of EMT and its importance in valve develop-
ment, NFATc1 serves as an excellent marker of the endocardium at E9.5 (Figure 1.4).
A NFATc1 reporter transgene that recapitulates the endogenous expression pattern has
been made by insertion of a lacZ reporter 400 bp upstream of the first exon of NFATc1
on a extra-chromosomal bacterial artificial chromosome containing the first two exons of
NFATc1 and upstream enhancer sequence [Misfeldt et al., 2009]. The BAC locus does not
entail the entirety of the NFATc1 transcript and cannot result in increased transcription
of the full-length transcript. Replacement of the lacZ reporter in this construct by a dual
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reporter [de Felipe and Ryan, 2004] including mCherry and Cerulean allows separation
of the endocardial cells via flow cytometry.
Figure 1.4: NFATc1, here transgenically labelled with lacZ, serves as an excellent marker
of the endocardium at E9.5. Reproduced from [Misfeldt et al., 2009].
1.3.5 Recapitulation of Endocardial Development by Embryoid Bodies
Differentiation of embryonic stem cells in suspension culture leads to the development of
structures called embryoid bodies [Smith, 2001]. Embryoid bodies have been found to
be able to differentiate into multiple different cell types and have been successfully used
for the identification of the embryonic precursor of the hematopoietic and endothelial cell
lines, the hemangioblast [Choi et al., 1998].
In 2007, Narumiya and colleagues demonstrated that the protocols that direct dif-
ferentiation of embryoid bodies towards cardiac cell lines also lead to the development
of endocardial-like cells [Narumiya et al., 2007]. At the time these endocardial cells in
embryoid bodies were found to have a consistent expression profile with in vivo endo-
cardium and mesodermal differentiation. Furthermore, they were found to co-localise
with myocardial cells and no endocardial differentiation was observed in the absence of
myocardium. This observation is consistent with the reciprocal interactions between the
endocardium and myocardium that are required for cardiac development.
Prior to this work, two reports outlining the existence of cardiovascular precursors
had been published [Kattman et al., 2006] [Moretti et al., 2006]. These studies showed
that the cardiovascular progenitors could give rise to endothelial cells among other cardiac
populations, but their specific endocardial identity had not been established because of
the absence of a reliable marker.
In 2009, Misfeldt and colleagues, demonstrated the presence of NFATc1+/CD31+ cells
in embryoid bodies with the use of a labelled NFATc1 construct and immunohistochemical
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analysis [Misfeldt et al., 2009]. Furthermore, in the same study a temporal expression pat-
tern of NFATc1 and other mesodermal as well as cardiac differentiation markers consistent
with mesodermal endocardial differentiation and close spatial association of endocardial
and endothelial cells in embryoid bodies were observed.
1.3.6 Epigenetics in Heart Development and Remodelling
Over the past few years it has become clear that epigenetic processes play a significant
role in the strict spatio-temporal coordination required for the development, maintenance
and remodelling of the heart. Although many genes are known to be involved in the
epigenetic regulation of heart development and remodelling, the exact mechanistic details
of their actions remain largely unknown. This in conjunction with recent developments
that have made whole-genome epigenetic interrogation possible (Section 2.2) have sparked
great interest in the epigenetic processes that regulate the heart and cardiovascular disease
[Baccarelli et al., 2010].
An extensive body of evidence supporting the role of epigenetic processes in cardiac
development, physiological remodelling and disease exists and examples are presented
here.
The basic question of epigenetic heterogeneity of heart tissue has been demonstrated
by identifying epigenetic differences between the RV and LV via small scale qPCR [Mathiyala-
gan et al., 2010]. Larger studies have examined the evolution of chromatin marks during
cardiac cell specification and have identified novel regulators of cardiac cell specifica-
tion (such as Meis2 ) [Paige et al., 2012] [Wamstad et al., 2012] . These studies have
demonstrated whole genome epigenetic analysis is a viable methodology for identification
of cardiac regulators and have shown that temporal epigenetic changes can be used to
discriminate regulatory from constitutively expressed cardiac genes [Paige et al., 2012].
The utility of whole-genome approaches in elucidating heart specific epigenetic ap-
proaches that have been refractory to more classical analysis was shown by Blow and col-
leagues by performing p300 histone acetyl-transferase (HAT) specific ChIP-seq in hearts
from E11.5 mouse embryos [Blow et al., 2010]. In this study the investigators were able
to identify over 3,000 candidate heart enhancers that are otherwise poorly conserved and
demonstrate that most are functional by generating and characterising transgenic mice
for a subset of them.
Furthermore, specific epigenetic regulators have been linked with cardiac develop-
47
ment. Brg1, a subunit of the BAF complex, controls temporal and spatial expression
of Adamts1 metaloprotease in the endocardium and myocardium to control extracellular
matrix deposition. It also directly controls gene expression in the myocardium, with its
deletion leading to temporally specific cardiac defects [Chang and Bruneau, 2012]. Brg1
can control the switch of MHC isoform expression in adult hypertrophic cardiomyopathy
from the adult isoform to the fetal isoform [Chang and Bruneau, 2012]. It is well estab-
lished that during cardiac hypertrophy the adult αMHC is down-regulated and the fetal
isoform βMHC is upregulated. Multiple Histone Deacetylase (HDAC) mutations have
also been associated with different forms of cardiac hypertrophy [Tingare et al., 2013].
Cardiac failure and hypertrophy have also been more directly associated with H3K4me3
changes [Kaneda et al., 2009].
A number of associations between epigenetic factors and human heart defects have
been found. For example, Wolf-Hirschhorn syndrome is characterised by growth retar-
dation, craniofacial malformations, learning disabilities and heart defects and occurs as
a result of a deletion of chromosome 4q16.3, which includes a gene coding for a H3K36
methyltransferase. H3K36 methyltransferase ablation results in atrial and ventricular sep-
tal defect [Vallaster et al., 2012]. The CHARGE syndrome, characterised by heart defects
among other abnormalities is closely associated with genetic mutations of the Chd7 gene,
a member of the chromodomain ATP-dependent chromatin modifiers [Vallaster et al.,
2012].
Collectively, the above indicate that epigenetic processes may have a significant and
clinically relevant role in heart development and provide justification for further studies
into the epigenetic processes that act during heart development.
1.3.7 Epigenetics of the Vascular Endothelium
Epigenetic processes are also known to regulate gene expression in the vascular endothe-
lium in a number of loci [Yan et al., 2010].
Nos3 is the endothelial subtype of Nitric Oxide (NO) synthetase. NO is a molecule
critical for endothelial regulation and signalling. Nos3 expression has been found to be
epigenetically regulated. Initial evidence for epigenetic regulation of Nos3 originated from
a transgene expressed in all cell types irrespectively constitutive expression of Nos3 in
that cell type. It was however observed that the expression of the transgene could be
controlled by methylation [Krause et al., 2013], suggesting an epigenetic mechanism for
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constitutive regulation of the gene. The importance DNA methylation [Chan et al., 2004]
and histone modifications [Fish et al., 2005] in Nos3 regulation has been confirmed in in
vivo. In agreement with the above Nos3 has been found to be epigenetically regulated in
human umbilical endothelium [Krause et al., 2013].
Epigenetic gene regulation in the endothelium has also been demonstrated in the
Notch4 locus. The Notch signalling pathway is a critical pathway in angiogenic vascular
remodelling and Notch4 is preferentially expressed in endothelial cell. Cell-type specific
histone modifications have been found to play a role in regulation of Notch4 [Wu et al.,
2005].
The promoter of VWF has also been found to be regulated by recruitment of HDACs
by NFY [Peng and Jahroudi, 2003] and E-selectin expression in response to TNF induction
has been associated with histone hyperacetylation, phosphorylation, and methylation
[Edelstein et al., 2005]. Finally, Robo4, an endothelial specific protein, is known to be
regulated by differential methylation of its promoter by specific demethylation during
development [Okada et al., 2014].
Overall the above locus-specific evidence point towards a greater genome-wide role for
epigenetic regulation of gene expression in the endothelium.
1.3.8 Epigenetics of the Endocardium
The contribution of epigenetic processes in the developing endocardium has not been
investigated. However, given that the endocardial tissue is an endothelial tissue with
possible cardiac origin and that epigenetic processes are known to regulate gene expression
in both endothelium and heart, it is highly likely that the same processes also have a role
in endocardial development and differentiation.
To date transcriptional regulators that are unique to the endocardium have not been
identified and many of the transcriptional regulators identified in this tissue are shared
with the endothelium. Furthermore, the endocardium is largely morphologically identical
to the endothelium (Prof. Scott Baldwin, personal communication) during development
and exhibit morphological differentiation later in development, suggesting the presence
of latent information that manifests later in development, compatible with a distinct
epigenetic identity for this population.




Imprinting refers to the parent-of-origin specific expression of some genes in mammals and
flowering plants [Reik and Walter, 2001] (Figure 1.5). Imprinting was first described in the
early 1980s after pronuclear transplantation technology allowed the generation of embryos
with uniparental disomies (UPDs). The examination of these embryos revealed that the
effect of some UPDs depended on their origin strongly suggesting the non-equivalence of
the parental genomes [Surani et al., 1984] [McGrath and Solter, 1984]. Since these initial
discoveries parent-of-origin specific expression of approximately 150 in the mouse and 72
genes in human has been described [Williamson et al., 2014] [Morison et al., 2005].
Figure 1.5: Example of a hypothetical maternally imprinted locus, only the maternally
inherited copy is expressed; the paternally inherited copy is silenced.
1.4.1 Functional Significance of Imprinting
The functional significance of imprinting remains unresolved [Patten et al., 2014]. Several
theories have been proposed to explain this phenomenon but no theory has been con-
clusively shown to account for all the known imprinted loci. It is possible that different
explanations can account for imprinting at different loci.
Theory of Coadaptation
The theory of coadaptation suggests that imprinting has evolved as a result of genetic
compatibility or incompatibility of loci between the mother and the offspring leading
to selective abortion and/or implantation of embryos [Wolf and Hager, 2006] [Wolf and
Hager, 2009] [Wolf and Brandvain, 2014].
The theory proposes that when matching alleles between the mother and the offspring
are beneficial, the paternal allele (which may be incompatible with the maternal allele) is
silenced. This situation may for example arise in loci the protein product of which may
result in an immune response from the mother against the foetus. Conversely, according
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to the theory of coadaptation, when it is beneficial for the maternal and paternal alleles
to mismatch the maternal allele (that will match at least one of the maternal allele) is
silenced. In either of this type of locus, imprinting can potentially increase fitness of the
offspring by effectively ‘hiding’ from the mother the allele that has the potential to reduce
fitness.
The coadaptation theory can account for the excess of maternally imprinted genes in
comparison to the paternally imprinted genes. Furthermore, the theory can potentially
account for an excess of maternally expressed genes in the placenta in mammals and in
early seed development in endosperms.
Theory of Parental Conflict
The theory of parental conflict suggests that imprinting has evolved as a result of conflict
between the paternal and maternal genomes [Moore and Haig, 1991]. According to this
theory, the paternal genes have an evolutionary advantage when they promote the transfer
of nutrients from the mother to the offspring and the maternal genes have an advantage
when they limit this transfer. The theory of parental conflict is based on the observations
that androgenetic mouse embryos show limited embryo development but excess extra-
embryonic tissues, whereas the reverse pattern is observed in parthenogenetic embryos.
Furthermore, a similar pattern is observed in humans with some UPDs, the most well
described being the deletion of 15q11-13, the maternal loss of which gives rise to Angelman
syndrome and the paternal loss giving rise to Prader-Willi syndrome (see Section 1.4.2
below)
The theory of parental conflict is further supported by the imprinting pattern of Igf2
and its receptor Igf2r in the mouse. Igf2 encodes for an insulin-like growth factor that
is embryonically expressed and is involved in nutrient transfer between the mother and
the foetus. The Igf2 gene and its receptor exhibit opposing imprinting patterns with
Igf2 maternally expressed and Igf2r paternally expressed. Igf2, that is widely paternally
expressed including in extraembryonic tissues, promotes embryo growth (and transfer of
nutrients from the mother to the embryo); accordingly paternal Igf2 mutants display
smaller size at gestation. In contrast, the Igf2r receptor, one of the receptors for Igf2,
which may sequester and ameliorate the action of Igf2 in other receptors, is maternally
expressed [Halg and Graham, 1991].
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1.4.2 Imprinting in the Brain
Many imprinted genes are highly expressed in the brain or spinal cord [Davies et al., 2005]
and the importance of imprinting mechanisms in the brain and its development has been
highlighted by a number of separate lines of evidence.
Imprinting has been implicated in a number of syndromes that affect brain devel-
opment including Angelman and Prader-Willi syndromes [Keverne, 1997]. Prader-Willi
syndrome is characterised by mild mental retardation, obesity, hypotonia, hypothalamic
disfunction and psychoses [Davies et al., 2005]. Paternal selection of the 15q11-13 locus
results in Prader-Willi syndrome, but in contrast, maternal deletion of the locus results
in Angelman syndrome [Lewis et al., 2014]. Angelman syndrome is also characterised by
mental retardation, but also movement disorders, easily provoked laughter and speech
difficulties [Larson et al., 2014].
Furthermore, specific imprinted genes are implicated in brain development and func-
tion. The imprinted Peg3 gene, has been implicated in maternal care behaviour [Murphy
et al., 2001] [Keverne et al., 1996] and polymorphisms in this gene have been associ-
ated with different maternal care in mice strains [Chiavegatto et al., 2012]. Furthermore,
duplication of the maternal but not paternal Nnat gene results in aberrant cerebral de-
velopment.
Further evidence for the importance of imprinting in the developing brain originates
from the distinct contributions of androgenetic and parthenogenetic cells in brain chimeric
embryos. Androgenetic cells, containing only a chromosomal compliment from the father,
contribute primarily to the hypothalamus, whereas parthenogenetic cells contribute to
the cortex and hippocampus but not the hypothalamus. In addition, parthenogenetic
cells enhance brain growth whereas androgenetic cells diminish it [Keverne et al., 1996].
In the mouse, at post-natal day 21 (P21), the post-natal growth spurt has been largely
completed and the reduction in neuronal numbers that is observed in the adult at (P50)
has not yet occurred. At this time point, the neurons make up approximately 50% of the
total brain cells and glia account for approximately 48%, with other cell types such as
oligodendrocytes accounting for part of the remainder [Lyck et al., 2007].
Collectively, the above support an extensive role for imprinting in the brain and make
this tissue suitable for investigation of this phenomenon.
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1.4.3 Imprinting and Epigenetic Gene Regulation
At the molecular level imprinting has been shown to be mechanistically underpinned by
the differential methylation of the two parental alleles that is established during game-
togenesis. Furthermore, methylation marks responsible for imprinting escape large scale
resetting of the methylome during implantation and later development [Hajkova et al.,
2008] [Hajkova, 2010] [Cowley and Oakey, 2012], leading to differentially methylated re-
gions in the adult organism.
An important distinction between imprinting control regions (ICRs) and differentially
methylated regions (DMRs) must be made at this point. DMRs comprise all the genomic
locations that are differentially methylated between the two parental alleles and include
regions that have no effect on gene expression and regions of which the methylation
pattern is not established in gametes. In contrast, ICRs are regions which are defined
by knockout technology in mice and which when ablated have been shown to control the
imprinting of defined genes.
Unlike methylation at most loci, where methylation is positively correlated with the
repression of gene expression, DNA methylation at imprinted loci may positively correlate
with activation or repression of genes as the mechanisms of translation of the methylation
patterns into parent-of-origin specific expression are diverse. These mechanisms include
promoter methylation, antisense transcript expression and the boundary element estab-
lishment, as is the case for the H19 /Igf2 locus (Section 1.5.3).
1.5 CTCF
The CCCTC-binding factor (CTCF), a 727 amino acid protein, was first identified as one
of two regulators that bound a poorly conserved 50-60 bp sequence upstream of the chicken
c-myc gene, that contained the CCCTC central motif sequence [Lobanenkov et al., 1990].
It was cloned and further characterised as a highly conserved multivalent transcriptional
repressor six years later [Filippova et al., 1996]. At the time it was appreciated that it can
bind heterologous DNA sequences via the combinatorial action of its Zinc-finger domains.
Concurrently, it was independently discovered as a silencer of the chicken lysozyme gene
and named NeP1 [Baniahmad et al., 1990]. It was not until the gene was cloned and
sequenced that it was realised that NeP1 and CTCF were the same protein [Burcin et al.,
1997].
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CTCF is ubiquitously expressed and highly conserved protein with near 100% amino
acid sequence identify between human, mouse and chicken and furthermore, its deple-
tion is embryonically lethal prior to implantation, suggesting an important role in cell
maintenance [Phillips and Corces, 2009] .
CTCF has been shown to have insulator function by binding to boundary elements
between enhancers and promoters and abrogating expression in enhancer blocking as-
says [Bell et al., 1999]. As a result of this work, CTCF is now widely considered to
be primarily an insulator [Phillips and Corces, 2009]. Other evidence however suggests
CTCF involvement in a diverse repertoire of functions in addition to insulation. Specif-
ically, CTCF has been implicated in transcriptional regulation [Vostrov and Quitschke,
1997] [Kuzmin et al., 2005], X chromosome inactivation, large scale organisation of the
genome via looping, V(D)J recombination in lymphocytes [Guo et al., 2011a], association
with lamina-associated domains and imprinting [Phillips and Corces, 2009].
More recently CTCF has been implicated in the evolution of genomic organisation via
propagation of its novel binding sites via retrotransposition [Schmidt et al., 2012]. The
same study revealed a previously unappreciated second 9 bp binding motif at a consistent
spacing from the canonical CCCTC binding motif that correlates with stronger binding
and better conservation across species.
1.5.1 Insulator Role of CTCF
As aforementioned, CTCF is best known as an insulator protein that prevents the ac-
tion of activating sequence elements extending past its binding site. The role of CTCF
in enhancer insulation was first proposed in 1999 based on work on the β-globin locus
demonstrating the existence of a 42 bp sequence element that is necessary for enhancer
blocking and that concurrently binds CTCF [Bell et al., 1999].
The insulator role of CTCF was later described in more detail at the H19 /Igf2 locus,
where it is responsible for imprinting via insulation of enhancer action in a parent-of-
origin allele-specific manner. CTCF has been shown to demarcate regulator domains and
abrogate correlation of expression of nearby genes in a genome-wide manner [Xie et al.,
2007], consistent with a genome-wide insulator role.
The mechanism of action of CTCF as an insulator is unknown, although it is hypoth-
esised that insulation involves formation of loops via dimerisation [Phillips and Corces,
2009]. This raises the possibility that CTCF may only be necessary for the genomic or-
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ganisation required or associated with enhancer blocking activity and does not directly
act as an insulator.
1.5.2 Transcriptional Activation Role of CTCF
CTCF binding has been shown to be activating in at least two loci, Irak2 [Kuzmin et al.,
2005] and amyloid β-protein precursor promoter [Vostrov and Quitschke, 1997].
In the amyloid β-protein precursor promoter the activating function has been mapped
further through the use of deletions to the C-terminus. The C-terminus is independent
of the Zinc-finger DNA binding domain, suggesting a specific role in transcriptional acti-
vation. In the Irak2 locus, CTCF has been, by deletion of its binding site, shown to play
a major role in the promoter activity of the Irak2 gene.
Despite these known instances of activation, the genomic distribution of CTCF is
dissimilar to that of canonical transcription factors and only a small portion of CTCF
binding sites are in the proximal (2.5 kb) promoter region of genes [Kim et al., 2007].
The mode of action of CTCF in loci where it has an activating role has not been
elucidated in great detail, although limited evidence exists to suggest that it can recruit
RNApolII to gene promoters [Chernukhin et al., 2007].
1.5.3 Role of CTCF in Imprinting
CTCF is part of a mechanism that connects epigenetic marks and expression in the context
of imprinting. CTCF binding is known to be inhibited by prior DNA methylation and
also inhibit methylation of DNA to which it is bound [Phillips and Corces, 2009], allowing
it to provide a functional link between DNA methylation and control of expression. The
role of CTCF in imprinting is best studied in the H19 /Igf2 locus. This locus contains
a single ICR, which is differentially methylated between the two paternal alleles during
gametogenesis and survives nuclear reprogramming.
On the maternal chromosome the ICR is unmethylated, whereas in the paternal it
is methylated. Downstream of the ICR lies the H19 gene locus and further downstream
tissue-specific enhancers. Approximately 90 kb upstream of the ICR lies the coding region
for Igf2 (Figure 1.6) [Kanduri et al., 2000].
CTCF binds to the H19 /Igf2 ICR in a methylation sensitive way, directing the ac-
tion of the downstream enhancer elements. On the paternal unmethylated copy of the
locus, CTCF does not bind and the enhancers are able to activate the more distant Igf2
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promoter. In the maternal copy, however, CTCF does bind and it limits the action of
the enhancer elements to the more proximal H19 locus. This results in maternal expres-
sion of H19 and paternal expression of Igf2 [Phillips and Corces, 2009]. The action of
CTCF in this locus is mediated by the formation of loops on the maternal Igf2 making
it inaccessible to enhancer elements [Yoon et al., 2007].
CTCF has also been implicated in the imprinting of other loci, such as that of
Meg1/Grb10. In this locus, CTCF binding sites have been found in the mouse pro-
moter of the Meg1/Grb10 transcript but not at the human homologue correlating with
the different imprinted status of this gene in the two species [Hikichi et al., 2003].
Given the above roles of CTCF in the control of gene expression in response to DNA
methylation and its potential role in nuclear organisation CTCF has been proposed to be
part of a more general heritable epigenetic system [Phillips and Corces, 2009].
1.5.4 Role of CTCF in Genomic Organisation
A role for CTCF in genome organisation has been proposed on the basis of both its
ubiquity and association with lamina-associated domains (LADs). LADs are large (0.1-
1 Mb) genomic locations of low gene density and repressed expression that physically
localise to the nuclear periphery. CTCF has been found in a low (10-15%) but significant
proportion of the borders of LADs suggesting a role in definition of their boundaries
[Guelen et al., 2008]. In addition, CTCF binding sites have been found to correlate with
domains of distinct histone modifications [Handoko et al., 2011], further supporting a role
in genomic organisation. Finally, CTCF mediated inter-chromosomal interactions have
been found to have a role in X-chromosome inactivation [Phillips and Corces, 2009].
1.6 Cohesin
Cohesin is a multimeric protein complex with a well-described role in sister chromatin
cohesion from the S-phase until chromatin segregation [Onn et al., 2008]. It comprises
two SMC (structural maintenance of chromosomes) subunits, Smc1 and Smc3, as well as
Scc3 and Rad21 (also known as Med1). Smc1 and Smc3 can dimerise and form a 45-nm
ring structure, to which Scc3 and Rad21 bind [Onn et al., 2008].
Cohesin connects chromosomes throughout their length during replication, but its
action is antagonised by the Wapl protein, resulting in separation of the two sister chro-
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Figure 1.6: Simplified structure of the H19 /Igf2 imprinted locus. Allele-specific binding
of CTCF on the differentially methylated ICR blocks the action of the enhancer element
resulting in coupled imprinting of the H19 or Igf2 transcripts.
matids, with the exception of the centromeric region which is protected from the action
of Wapl. Removal of the cohesin at the centromere, by cleavage of the Rad21 subunit, by
Separase results in disassociation of the two sister chromatids during anaphase [Ocampo-
Hafalla and Uhlmann, 2011].
In addition to the above well-established role, cohesin has been implicated in tran-
scriptional regulation, DNA repair [Onn et al., 2008] and chromatin organisation [Sofueva
et al., 2013]. These additional roles of cohesin are supported by the continued expression
of cohesin after mitosis, including in non-proliferating cells (such as neurons) [Schmidt
et al., 2010] and the existence of mutants that show minimal replication defects but give
rise to a class of severe developmental conditions termed cohesinopathies, that include
Roberts and Cornelia de Lange Syndromes [Skibbens et al., 2013].
Cohesin has been implicated in transcriptional regulation in a number of loci, including
regulation of the homeobox genes in Drosophila melanogaster and the expression of Runx1
and Runx3 genes in Danio rerio during development. Furthermore, cohesin has been
found to associate with pluripotency transcription factors in ES cells and be essential for
maintenance of pluripotency, suggesting a regulatory role. In addition, cohesin functions
as a boundary element in the regulation of the silent mating cassette in yeast [Onn et al.,
2008]. A genome-wide role for cohesin in gene expression has also been established, by
its association with active enhancers and promoters genome-wide [Seitan et al., 2013].
Finally, in the context of transcriptional regulation, cohesin has been associated with
transcriptional termination [Gullerova and Proudfoot, 2008].
Cohesin has been found to co-localise with CTCF during interphase [Parelho et al.,
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2008] [Wendt et al., 2008]. In addition to extensive co-localisation throughout the genome,
cohesin has been found to specifically interact with CTCF via its Scc3 subunit at the c-
myc locus. CTCF has been found to be required for recruitment of cohesin to chromatin
genome-wide, although a CTCF independent role has also been described. Finally, cohesin
has been implicated in imprinted expression through allele-specific co-localisation with
CTCF at the H19/Igf2 and the Kcnq1ot1 loci [Stedman et al., 2008] [Lin et al., 2011]
and a role in allele-specific chromatin structure has been proposed [Nativio et al., 2009].
In combination with CTCF, cohesin has also been implicated genome-wide in chro-
mosomal domain organisation, by the demarcation of loops that define independently
regulated domains [Sofueva et al., 2013], functional interactions within pre-exisiting chro-
mosomal compartments [Seitan et al., 2013] and formation of long-range chromosomal
interactions at developmentally regulated loci [Hadjur et al., 2009].
1.7 Specific Aims of the Investigation
The work presented here sought to investigate two questions relating to the role of epige-
netic processes in two distinct systems, heart and brain.
The genome-wide role of DNA methylation was examined in a model of the mouse
developing endocardium. The endocardium examined was isolated from embroid body dif-
ferentiation culture at the equivalent of embryonic day 9.5 of mouse embryo development.
The methylome profile of the endocardium was compared to that of other endothelial
tissue from the same model with the aim of identifying distinct epigenetic regulators that
drive the phenotypic and morphological differences between the endocardium and the
endothelium.
The transcriptomes of the endocardium and endothelium were also examined in or-
der to evaluate the extent to which transcriptional regulation accounts for phenotypic
differences between the endocardium and endothelium later in development and to iden-
tify differentially regulated genes between the two tissues. Furthermore, motif analysis
was used to identify transcription factors that potentially bind and regulate differentially
expressed genes.
In addition the transcriptomic and epigenetic datasets generated were combined in
order to identify the extent to which epigenetic differences coincide with transcriptomic
differences and potentially regulate the latter.
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In mouse brain, the extent of genome-wide allele-specific binding of CTCF and co-
hesin at postnatal day 21 was assessed. The aims of this investigation were to identify the
prevalence of allele-specific binding of these two nuclear organisation factors and further-
more identify the extent to which allele-specific binding of these two factors colocalise.
The extent to which allele-specific binding of these factors contributes to known imprinted
sites was assessed, with the aim of understanding the uniformity of the mechanisms that
establish and propagate imprinted gene expression in a genome-wide scale.
1.8 Summary
Epigenetic processes include DNA methylation and histone modifications and contribute
to gene regulation, including imprinted gene expression, and development.
The heart is the first functional organ during development and is of critical importance
for the subsequent development of the embryo. Multiple lines of evidence suggest that the
development of the heart involves epigenetic processes. The endocardium, an endothelial
layer lining the internal surface of the heart is a cardiac population of high significance
in valvular development and heart remodelling, but remains relatively understudied. The
advent of next-generation sequencing methodologies, creates the opportunity to epigenet-
ically and transcriptomically characterise populations of cells such as the endocardium to
an unprecedented level. The thesis presented examines the methylome and transcriptome
of the endocardial cell population.
CTCF is a Zinc-finger protein primarily known as an insulator, but with a known role
in transcriptional regulation. CTCF is known to be involved in parent-of-origin regulation
of gene expression in certain loci, but the role of this protein has not been assessed genome-
wide in an allele-specific manner. Furthermore cohesin, a protein complex with a known
role in sister chromatin cohesion during cell division, is known to co-localise with CTCF
during interphase and may have a previously unappreciated role in imprinting. This thesis
examines the genome-wide distribution of these two proteins in an allele-specific manner




2.1 Drop Culture, Differentiation and FAC Sorting of
Transgenic ES Cells
The culture and differentiation of transgenic mouse embryonic stem (ES) cells, presented
in this section, was carried out in Vanderbuilt University, TN, USA by Mr Kevin Tomp-
kins in the Baldwin Laboratory.
Mouse ES cells previously transfected with the NFATc1-mCherry construct [Misfeldt
et al., 2009] were washed twice with phosphate buffered saline (PBS) . Mouse embryonic
fibroblasts (MEFs) were depleted by lifting cells with trypsin and re-plating on 0.1%
w/v gelatin for 30 minutes. Supernatant from the attached MEFs was transferred to a
15 mL tube and centrifuged at 500 g for 5 minutes. Supernatant was removed and the
cells washed twice in differentiation media (DM) [IMDM (Invitrogen, Cat No. 21056),
15% FBS Atlas (Lot No. 80312), 2 mM L-glutamine, Penicilin/streptomycin 1000 U/mL,
Transferrin 200 µg/mL, 500 mM L-ascorbic acid, 0.45 mM M-Monothioglycerol]. After the
second wash, cells were spun down as above and resuspended in DM at 25,000 cells/mL.
Using a 8 channel pipette ten rows of 20 µL were transferred onto the lid of a square Petri
dish.
After 2 days of growth, cells were washed from the Petri dish using 3 mL of DM media
and transfered to a 15 mL conical vial. Volume was adjusted to 15 mL and EBs were
allowed to settle at the bottom on the tube. The supernatant was removed and EBs were
resuspended in 10 mL of DM media. The suspension was then transferred to a a 100 mm
suspension dish (Fisher Cat. No 430591). The cells were placed on an orbital shaker at
35 revolutions per minute for 48 hours. After 48 hours the cells were plated on 0.1% w/v
60
gelatin coated 100 mm dishes and media changed after 48 hours.
Plated cells were washed with 10 mL PBS and 5 mL of fresh Accutase were added
for 15 to 30 minutes at room temperature on platform shaker. Cells were gently pipetted
repeatedly and 5 mL of FACS bufferer were added. The suspension was filtered with a
100 µL sterile cell strainer (Fisher, Cat No: 22363549) for cell clumps and centrifuged at
500 g for 5 minutes. The supernatant was removed and the cells were re-suspended in
10 mL of FACS buffer. Cell count was estimated and cells were centrifuged as above and
resuspended at a density of 106 per 100 µL in FACS buffer. Anti-CD31 antibody (BD
Pharmingen, Cat No: 551262) was added at 1:200 dilution and cells were incubated at
4 ◦C for one hour with agitation every 5 minutes. Cells were washed 3 times in FACS
buffer and re-suspended at a density of 5 106 cells/mL in FACS Buffer. Cells were sorted
in the Vanderbuild University FACS Core Facility. The sorted cells were centrifuged and
the supernatant removed. The cells were snap frozen in liquid Nitrogen and shipped on
dry ice to London, UK.
2.2 Next-generation Sequencing
Next-generation sequencing (ng-seq) refers to a set of technologies that allow the sequenc-
ing of DNA samples with very high-throughput and low per-base cost. These technologies
allow interrogation of the entire genome in a single experiment. Competing technologies
are available and the focus here will be on the Illumina R©platform as this was utilised in
the context of this work. The Illumina R©technology is based on millions of reversible dye-
terminators reactions performed in parallel on DNA immobilised and locally amplified on
a glass surface via bridge PCR (Figure 2.1 B). The Illumina R©HiSeq 2000 instruments
can generate up to ten billion base-pairs of sequence data per experiment in the course of
approximately two weeks. First applications of next-generation sequencing have focused
on the sequencing of genomic sequence. However, the technology is now routinely applied
to sequencing of the transcriptome, identification of (non-histone) protein binding sites,
identification of DNA methylation with base-pair resolution as well as identification of
histone modifications.
Utilisation of the technology requires the preparation of a ‘DNA library’, a solution
of DNA in which all the DNA fragments are of relatively uniform size and have identical
sequence (adaptors) at their ends, though which they can be manipulated (Figure 2.1 A).
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Figure 2.1: A. Outline of library preparation for ng-seq. Overhangs of fragmented DNA
are removed and an ‘A’ overhang added. Adaptors are ligated and all fragments are
amplified. B. Outline of sequencing reactions: the library is bound to the flowcell and
amplified via bridge PCR. Sequencing is performed using reversible terminator technology.
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The technology allows sequencing of fragments present in the library and yields data files
containing read sequences (raw reads) along with quality information. The information
in the raw reads is then processed bioinformatically to produce useful information.
After quality control, the first step in processing is almost invariably alignment. In
the alignment step, the origin of the reads in the reference sequence is identified. The
reference sequence is usually the reference genome of the organism in question, although
for some applications – notably RNA-seq this may be different. Alignment is performed
using an aligner program. The processing of the ng-seq data following alignment differs
depending on the type of the experiment and the downstream application. Downstream
processing is examined in more detail in the following sections.
It must be noted that sequence generation can be performed in two distinct modes,
single-end sequencing and paired-end sequencing. In single-end sequencing, every DNA
fragment is sequenced from one end generating a sequence that can be individually
mapped to the genomic reference. In paired-end sequencing, each DNA fragment is se-
quenced from both ends generating two linked read sequences that are expected to map
in close proximity on the genomic sequence. In addition to increasing available sequence,
paired-end sequencing allows for better mapping of raw reads by constraining the mapping
of read pairs to location where both read align condordantly.
2.2.1 Histone and DNA Binding Factor ChIP-seq
Chromatin Immunoprecipitation followed by next generation sequencing (ChIP-seq) al-
lows the identification of binding sites of both histone and non-histone proteins across
the genome [Valouev et al., 2008]. Furthermore, it can be used to interrogate histone
modifications across the genome. The methodology is based on chromatin immunopre-
cipitation followed by ng-seq. In ChIP protocols, DNA quantification can be performed
via quantitative PCR (qPCR) in a locus-specific fashion. In ChIP-seq, the precipitation
is instead coupled to ng-seq by using the output of the precipitation as the input for the
preparation of a ng-seq library.
ChIP is based on the concept of specifically selecting DNA binding factors from the
chromatin solution via a specific antibody (Ab) and simultaneously isolating the DNA
to which they are specifically bound (Figure 2.2). For this reason, ChIP protocols are
frequently preceded by a cross-linking step to reinforce DNA-protein interactions via
covalent links, although its importance is diminished – and the step is sometimes omitted
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– when expected protein-DNA interactions are strong, as is the case for histone ChIP.
Furthermore, to allow for the specific isolation of the DNA binding to factors of interest,
the chromatin suspension is sonicated to fragment the DNA and prevent pull-down of
distant DNA fragments via the DNA sugar-phosphate backbone. After the precipitation
is performed, the cross-links are reversed and the proteins are digested away allowing for
the identification of the DNA fragments to which the proteins of interest were bound via
ng-seq.
ChIP-seq Data Processing
The aim of ChIP-seq data processing is to identify distinct genomic locations, ‘peaks’,
where enrichment has occurred during immuno-precipitation. The first step in ChIP-seq
data processing is the mapping of reads to the genome, in a similar way to that for other
ng-seq experiments. Following alignment, identification of peaks and assignment of a
significance score is performed [Pepke et al., 2009].
Identification of peaks is a complex process owing to the fact that the distribution
of reads that arise from the non-enrichment based processes is not random, but displays
highly complex biases. For this reason an input sample is usually sequenced, allowing
identification of locations of high read density where enrichment has not occurred [Pepke
et al., 2009].
Due to the fact that fragmentation of DNA occurs while the protein of interest remains
bound, the distribution of reads surrounding any peak display a characteristic bimodal
distribution (Figure 2.3) [Anders and Huber, 2010]. The distance difference between the
reads that align to the two sides of the peaks (the ‘peak shift’) is related to the insert size
in the case of paired-end sequencing, but as it cannot be accurately predicted from it, it
is empirically estimated. After identification of the peak shift, reads are shifted so as to
produce distinct peaks that can be computationally identified (Figure 2.3).
Identification of peaks is performed after peak shifting with specialised computer pro-
grams, referred to as ‘peak callers’. Over 30 different peak callers, such as Useq [Nix
et al., 2008] and MACS [Zhang et al., 2008], have been developed making selection of
the appropriate algorithm difficult [Wilbanks and Facciotti, 2010]. The approaches of
these programs vary dramatically, from simple count based sliding window approaches
to specific search for strand-specific read patterns indicative of binding [Wilbanks and
Facciotti, 2010].
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Figure 2.2: Overview of ChIP protocol for histone modifications. Chromatin is fragmented
via mechanical or enzymatic means. Nucleosomes with modifications of interest are con-
jugated to an immobilised specific antibody. Non-specific interactions are abolished via
washing the sample. The DNA bound to the nucleosomes of interest is eluted via revers-
ing crosslinks and quantified against the general chromatin background. Quantification
can be performed via qPCR or in the case of ChIP-seq via ng-seq.
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Figure 2.3: Overview of computational correction of the peakshift in ChIP-seq read data.
ChIP-seq reads align on either side of the binding sites of the protein of interest. Iden-
tification of this offset allows for the correction of the read position via computational
shifting of the peaks and yields better defined binding events.
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Allele-specific ChIP-seq
ChIP-seq is generally performed in such a manner that differential binding of a protein,
or the presence of a histone modification between the two parental alleles can not be
distinguished. If however, the tissue on which ChIP-seq is performed on originates from
the offspring of a cross between two divergent strains of animals, polymorphisms – such as
single nucleotide polymorphisms (SNPs) – between the two parental alleles can be used to
identify the allelic origin of some of the the next-generation sequencing reads. The strains
of animals used for the cross need to be sufficiently divergent so that a large proportion of
reads overlap a polymorphism. In this manner, the origin of each of the peaks identified by
a ChIP-seq experiment can be traced to specific parental alleles. In order to discriminate
parent-of-origin effects from sequence-specific effects, reciprocal crosses are employed,
whereby the dam and the sire strains are exchanged and the experiment is performed on
animals obtained from both crosses.
2.2.2 Whole-genome Bisulphite Sequencing
Whole genome bisulphite sequencing (WGBS) or BS-seq refers to next-generation se-
quencing coupled with bisulphite conversion of DNA [Bock, 2012] [Wu et al., 2011b]. As
detailed in Section 1.1.3, DNA can be methylated at the 5 carbon position of C. Interro-
gation of mC can be performed by means of bisulphite conversion followed by sequencing
(Figure 2.4). Bisulphite conversion can be used to identify mC because incubating DNA
with sodium bisulphite exclusively converts unmethylated C to uracil (U), whereas mC
is unaffected. U is then converted to thymine (T) via the action of a non-uracil sensitive
DNA polymerase. After bisulphite treatment, the DNA can be sequenced via Sanger
sequencing or in the case of WGBS via next-generation sequencing. By comparison to
the original sequence mCs can be identified. In this way, BS-seq allows genome-wide
identification of methylation status at a single base-pair resolution.
Processing of Whole-genome Bisulphite Sequencing Data
Bioinformatic processing of bisulphite next-generation sequencing data is more challenging
than that of data obtained from other next-generation sequencing experiments because
the sequence data can no longer be directly aligned to the genomic sequence [Krueger
and Andrews, 2011]. Furthermore, difficulties in aligning are compounded by the fact
that the majority of the sequence generated is composed of only three bases (A, T and
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Figure 2.4: Outline of determination of methylation status of cytosine via sodium bisul-
phite conversion on a sample sequence. The DNA is sequenced twice, once via con-
ventional sequencing and once after treatment with sodium bisuphite and amplification.
Unmethylated Cs are read as Ts after conversion, whereas mC are not changed, allowing
bioinformatic determination of the original modifications.
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G), as opposed to four, making unique alignment of reads much more challenging. For
this reason, long paired-end (in excess of 100 bp) reads are employed in WGBS. This
aids alignment by providing longer sequence, improving confidence of the alignment and
discriminating between competing alignment possibilities.
Alignment of BS-seq data is accomplished by aligning in silico fully converted reads
(i.e. reads for which even methylated Cs are converted to Ts) to a fully in silico con-
verted genome [Krueger and Andrews, 2011]. This ensures that the methylation status of
different loci does not affect the probability of alignment, ameliorating any potential bias.
The alignment is further complicated by the fact that in silico conversion of DNA gives
rise to four possible genomic sequences to align to because the final sequence depends on
which strand the bisulphite conversion is applied to. All possible sequences are prepared
and alignment is carried out against all four in the case of non-directional libraries, or
only two when libraries are prepared in a way that preserves directionality.
2.2.3 RNA-seq and mRNA-seq
Sequencing of RNA species derived from a biological sample through the use of next-
generation sequencing is referred to as RNA-seq [Wang et al., 2009]. RNA-seq has some
significant differences, in the experimental protocol and data processing steps that are the
result of the sequencing of RNA as opposed to DNA species. Unlike traditional sequencing
libraries, RNA-seq utilises an initial reverse transcriptase reaction to convert RNA to copy
DNA (cDNA) before preparation of the sequencing library in a manner similar to that
previously outlined.
In comparison to other methodologies that can sequence and quantify RNA, such as
microarrays, RNA-seq has the advantage that it can interrogate the transcriptome without
being limited to known transcribed loci, allowing the discovery of novel tissue-specific
transcripts and not introducing a bias towards previously examined loci [Mortazavi et al.,
2008]. Furthermore RNA-seq can accurately quantify transcript levels with a greater
dynamic range and better accuracy [Fu et al., 2009].
A major drawback of RNA-seq is that due to the high levels of ribosomal RNA (rRNA)
transcripts being present in cells, a large percentage of the sequenced species originate
from rRNA loci. This results in the majority of the generated sequence consisting of
multiple copies of the rRNA species that are not otherwise informative of differences in
cellular function.
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The mRNA-seq protocol attempts to circumvent this problem by allowing only RNA
species with a poly(A) signal to be incorporated in the library. This is accomplished by
specific selection of RNA species containing the poly(A) signal by means of immobilised
poly(T) sequences. Other methodologies for the removal of rRNA are available, such
as specific removal of ribosomal RNA. Specific removal of the ribosomal RNA has the
distinct advantage in comparison to mRNA-seq that it can sequence non-poly-adenylated
transcripts that are not rRNA and are functional, such as microRNA species.
RNA-seq allows the accurate quantification of RNA species. It is however known that
the reverse transcriptase reaction and the subsequent PCR amplification can introduce
artefacts. More recent methodologies that allow detection and elimination of such biases
through the use of unique molecular barcodes have been developed [Islam et al., 2014].
RNA-seq Data Processing
As outlined above, RNA-seq data processing differs significantly compared to the process-
ing of other ng-seq data. Unlike other protocols, RNA-seq data is usually not aligned to
the genomic reference, but rather to a in silico generated transcriptome, that takes into
account splicing events and allows mapping across exon junctions. Optionally mRNA-
seq data can be aligned to the genome in an attempt to identify novel splice sites and
expression of non-annotated genomic loci [Trapnell et al., 2010].
Following mapping, the reads aligning to each transcript are quantified and compared
between conditions to identify differentially regulated genes or transcripts. Quantification
can be performed by obtaining a simple count [Anders and Huber, 2010] of the number of
reads that align to each transcript or by calculation of a metric such as FPKM (Fragments
per Kilobase per Million reads) that normalises the reads counts for the length of each
transcript and for the library size [Trapnell et al., 2013].
The advantages of either approach are not clear. The main argument for the FPKM
approach is that it takes into account the size of the transcript in question and the
library size. However, consideration of the overall transcript length is not important
for identifying the differential expression of the same transcript between two conditions.
Comparison of expression level of transcripts within the same sample, where an absolute
measure of expression would be of value, is not however recommended as sequencing
efficiency of different transcripts can vary widely. In contrast count based methods, such
as DESseq, rely on a statistical framework that is more robust and can still take into
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account the overall library size.
2.3 Endocardial and Endothelial Cell Methylome Analysis
2.3.1 WGBS Library Preparation and Optimisation
The protocol development, optimisation and initial replicate was performed by the author.
The second replicate was performed by Mr Samuele Maria Amante.
The protocol for whole genome bisulphite sequencing (WGBS) library generation was
developed from the Reduced Representation Bisulphite Sequencing (RRBS) protocol pub-
lished by Meissner and colleagues [Meissner et al., 2005]. In particular, the protocol was
modified and enzyme based fragmentation was replaced by sonication as described below.
DNA for WGBS was isolated by Mr Kevin Tompkins in the Baldwin Laboratory and
shipped on dry ice. Approximately 100 ng of DNA were diluted with Tris-EDTA Buffer
in a 1.5 mL LoBind tube (Axygen, Cat No. MCT-150-L-C) to a total volume of 120 µL.
The DNA was carefully loaded in a Covaris sonication tube (Covaris, microTUBE AFA
Fiber pre-split 6x16mm, Part No.: 520045, Lot No.: 001958) and sonicated (duty cycle
10%, intensity 4%, cycles per burst 200, time 6 cycles of 70 s each, frequency sweep mode,
temperature 4◦C to 7◦C). The fragmented DNA was then transferred to a clean 1.5 mL
LoBind tube. The DNA was then concentrated using the QIAGEN MinElute R©PCR
Purification Kit (Cat. No: 28004, Lot: 148027401) and eluted in 44 µL of Elution Buffer.
Next-generation sequencing libraries were prepared using the NEBNext R©ChIP-Seq Li-
brary Prep Master Mix Set for Illumina R©(Cat. No. E6240S, Lot No: 0131201) according
to manufacturers’ instructions until up to and including the dA-tailing step. Cleanup after
End Repair, dA-tailing and Adaptor Ligation was performed using the QIAGEN MinElute
R©PCR Purification Kit (Cat. No: 28004, Lot: 148027401). For replicate 1, custom pre-
hybridised methylated paired-end (PE) adaptors from Sigma were used during adaptor
ligation, whereas for replicate 2 NEBNext R©Multiplex Oligos for Illumina R©(Methylated
Adaptor, Index Primers Set 1) (Cat. No E7535S) adaptors were used.
After adaptor ligation, bisulphite conversion was performed using the Zymo Research,
EZ DNA Methylation Kit (Cat No: D5001, Lot No.: ZRC176186) in a LoBind tube. The
incubation protocol for methylation arrays was used (15 cycles of 1 hour 50 ◦C incubation
with 95 ◦C temperature spike for 30 seconds and hold at 4 ◦C for at least 10 minutes).
Desulphunation was performed on the column as per manufacturers’ instructions and the
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converted DNA was eluted in 10 µL of molecular biology grade water.
DNA was first amplified with Pfu Turbo Cx Hotstart DNA polymerase Agilent, (Cat.
No. 600410). The reaction was prepared as shown in Table 2.1. Custom HPLC purified
PE primers from Sigma were used. The solution was mixed thoroughly by pipetting and
split into five 10 µL aliquots and placed in a thermocycler (MJ Research PTC-200). The
program shown in Table 2.2 was executed.
Table 2.1: Reaction composition of WGBS library initial amplification with Pfu DNA
polymerase.
Bisulphite converted DNA 5 µL
10X turbo buffer 5 µL
PE primer 1 (5 µM) 2 µL
PE primer 2 ( 5 µM) 2 µL
dNTPs 10mM each 1 µL
Pfu Cx polymerase Hotstart (Agilent, Cat. No.: 600410) 1 µL
Sterile Nuclease Free H2O 34 µL
Total 50 µL
Table 2.2: Reaction temperature cycle of WGBS library initial PCR amplification with
Pfu DNA polymerase.
1 Initial denaturation 95 ◦C 2 minute
2 Denaturation 95 ◦C 30 seconds
3 Anneling 65 ◦C 30 seconds
4 Extension 72 ◦C 45 seconds
5 Repeat from 2 7 times
6 Final Extension 72 ◦C 10 minutes
7 Temperature Hold 4 ◦C indefinitely
The DNA from the five reactions was pooled and purified using the Qiagen Minelute
PCR Purification Kit (Cat. No.: 28004) and was amplified again using Platinum Pfx
Turbo DNA polymerase. The Pfu PCR reaction composition is shown in Table 2.3.
The solution was mixed thoroughly by pipetting and split into five 10 µL aliquots and
placed in a thermocycler. The program shown in Table 2.4 was executed.
The PCR mix was electrophorised on a 3% w/v low melting point NUSIEVE R©GTG
R©agarose (Cat. No: 50080, Lot: AG2475) gel for 1 hour at 85 V and a band from 300 bp
to 700 bp was excised. DNA was extracted using the Qiagen Minelute Gel Extraction Kit
(Cat No: 28606) and following manufacturers’ instructions. The DNA was not heated
after QC buffer addition but vigorously vortexed for at least 5 minutes and until no gel
was visible. This modification of the protocol was introduced because heating of the
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Table 2.3: Reaction composition of WGBS library second amplification with Platinum
Pfx DNA polymerase.
DNA from Pfu Reaction 10 µL
10x Pfx Buffer 5 µL
MgSO4 (50 mM) 2 µL
dNTPs 10 mM each 2 µL
PE Primer 1 (5 µM) 2.5 µL
PE Primer 2 (5 µM) 2.5 µL
Platinum Pfx polymerase (Invitrogen, Cat No: 11708-013) 0.8 µL
Sterile Nuclease Free H2O 25.2 µL
Total 50 µL
Table 2.4: Reaction temperature cycle of WGBS library second PCR amplification with
Platinum Pfx DNA polymerase.
1 Initial denaturation 94 ◦C 2 minutes
2 Denaturation 94 ◦C 20 seconds
3 Anneling 65 ◦C 30 seconds
4 Extension 68 ◦C 30 seconds
5 Repeat from 2 11 times
6 Final Extension 68 ◦C 5 minutes
7 Temperature Hold 10 ◦C indefinitely
sample at this stage has been found to introduce a GC bias [Quail et al., 2008]. The DNA
was eluted in 10 µL and quantified with the quBit instrument (Section 2.4) and its size
distribution examined with the Agilent Bioanalyser or Agilent Tapestation (Section 2.5).
2.3.2 WGBS Library Sequencing
Cluster generation and sequencing of the WGBS libraries was performed in the BRC
Sequencing Facility on a HighSeq 2000 Illumina R© Sequencer. A low amount phiX control
DNA was added by the sequencing facility for quality control purposes.
2.3.3 Bioinformatic Processing of WGBS Data
Basecalling of the raw read data was performed with Casava (version 1.8.0) on the BRC
HPC computing cluster, the following parameters were specified in addition to the stan-
dard parameters specifying data location paths.
−−use−bases−mask Y100 , N7 , Y100
−−no−eamss
−−p o s i t i o n s−format pos . txt
−−f o r c e
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−−f a s tq−c l u s t e r−count 500000000
−−ignore−miss ing−s t a t s
−−ignore−miss ing−bc l
−−ignore−miss ing−c o n t r o l
The quality of the read data was assessed using the FastQC program (version 0.10.0).
Sequences identified as of low quality by the sequencer software were removed using the
fastq illumina filter utility. Adapter sequences were removed using TrimGalore (ver-
sion 0.2.5).
The phiX genome was obtained in FASTA format from RefSeq (Sequence ID: NC 001422.1).
The Bowtie index of the phiX genome was built with bowtie-build. Reads were aligned
to the phiX reference genome using the Bowtie 1 aligner (version 0.12.8) [Langmead et al.,
2009] with the --un flag to keep unaligned reads and save them for later processing. Reads
that successfully aligned to the phiX genome were discarded.
The remaining (unaligned) reads were aligned to the bisulphite converted mm9 ver-
sion of the mouse genome using Bismark (version 0.14.2) [Krueger and Andrews, 2011]
and Bowtie 1 (version 1.1.1) [Langmead et al., 2009] as the underlying aligner. Methyla-
tion extraction was performed using the bismark methylation extractor tool from the
Bismark package [Krueger and Andrews, 2011].
Methylation data from the bismark methylation extractor tool were summarised
on a per genomic position basis using a custom Perl script. The script counted instances
of methylated and unmethylated occurrences of Cs in the data for each genomic position
independently (Appendix Section C.2).
Summarisation to CGIs and testing for differential methylation was performed using
custom scripts developed in the context of this project. Whole-genome analysis was per-
formed using the bsseq R package (version 3.1) [Hansen et al., 2012] . Mapping identified
differentially methylated region and CGIs to genomic element classes was performed with
the CEAS tool [Shin et al., 2009].
Examination of the overlap of the identified DMRs with cardiac histone marks and
DNAse hypersensitivity sites was performed using custom R and UNIX shell scripts (Sec-
tion C.3). Permutation testing was performed by generating permuted datasets with the
bedtools suite shuffle command and counting the number of overlaps between each mark
and the identified peaks. 1,000 permutations were performed for each mark.
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2.4 DNA Sample and Library Quantification
The Qubit fluorometer instrument with the Qubit dsDNA HS Assay Kit (Cat No: Q32854,
Lot: 1429806) was used for the quantification of all libraries prior to final dilution and
sequencing. Samples and reagents were allowed to reach room temperature for at least
30 minutes prior to quantification. Samples were prepared according to manufacturers’
instructions. Specifically, 200 µL of working solution were prepared per sample analysed
by mixing DNA HS Reagent with Qubit buffer in 1:200 ratio. 1 µL of sample, in some
cases pre-diluted 1:10 as described, was diluted to a total volume of 200 µL with working
solution, mixed and incubated for 3 minutes. Similar preparation was performed for
standards, but 10 µL or each standard were diluted in a total volume of 200 µL of working
solution. Instrument calibration was performed prior to every set of measurements.
2.5 Next-generation Sequencing Library Size Estimation
Library size estimation was performed with either the Agilent Bioanalyser or the Agilent
TapeStation instruments in the BRC Genome Sequencing Facility.
The Agilent Bioanalyser with the DNA 1000 Kit was used for identification of the
fragment size distribution of some DNA samples. Manufacturers’ instructions were fol-
lowed for chip sample preparation. Specifically, gel-dye mix was prepared by allowing the
reagents to reach room temperature for 30 minutes, the dye concentrate was vortexed and
spun down and 25 µL of dye were added to the DNA matrix vial. The tube was vortexed
and transfered into a spin filter and spun in a microcentrifuge for 15 minutes at 2240
g. In some cases previously prepared gel-dye mix, provided by the Genomic Sequencing
facility, was used. 9 µL of the prepared gel-dye were added to the G well of a new DNA
chip and the chip was primed using the priming station for 60 seconds and released. After
5 seconds the plunger was returned to the 1 mL position and the chip was removed from
the priming station. 9 µL of the gel-dye mix were pipetted into the appropriate wells. 5
µL of DNA marker was pipetted into each of the sample wells and 1 µL of marker ladder
was pipetted into the ladder well. 1 µL of sample or deionised water was pipetted into
each sample well.
The Agilent TapeStation instrument was alternatively used with the D1K HS Kit to
identify fragment size distribution of DNA samples, as noted in the text. Manufacturers’
instructions were followed for sample preparation. 2 µL of DNA sample were mixed with
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1 µL of marker and loaded into the Tapestation instrument.
2.6 qPCR Quantification of Library Concentration
qPCR quantification of pooled libraries was performed to ensure correct balancing of the
individual component libraries. Quantification was performed using the KAPA Biosys-
tems Illumina Quantification Kit ABI Prism R©qPCR Mix (Cat No. KK4835, Lot No:
Z48350000271) according to manufacturers’ instructions.
A 1:1000 dilution of each library was prepared and a qPCR plate with technical
triplicates of the reaction shown in Table 2.5 was prepared along with one reaction for each
of the standard concentrations. The qPCR protocol shown in Table 2.6 was executed on
the qPCR instrument. Library concentration was calculated against the 452 bp standard
as outlined in the results section.
Table 2.5: KAPA SYBR qPCR reaction composition.
KAPA SYBR R©FAST qPCR Master Mix containing Primer Premix 12 µL
PCR-grade water 4 µL
Diluted library DNA or DNA standard (1 - 6) 4 µL
Total 20 µL
Table 2.6: KAPA SYBR qPCR reaction temperature cycle.
1 Initial activation denaturation 95 ◦C 5 minutes
2 Denaturation 95 ◦C 30 seconds
3 Annealing extension data acquisition 45 ◦C 45 seconds
4 Repeat from step 2, 34 times
2.7 Endocardial and Endothelial Cell
Transcriptome Analysis
2.7.1 RNA Extraction Protocol
RNA was extracted from FAC sorted endocardial and endothelial cells using the QIAGEN
RNeasy R©Mini Kit (Cat No: 74104, Lot No: 145038477). All kit reagents and columns
were allowed to cool for at least one hour on ice prior to the RNA isolation.
Frozen shipped cells were thawed by addition of ice cold PBS and incubation on ice
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for 5 minutes. Cells were isolated by centrifugation at 1600 g for 5 minutes and aspiration
of the supernatant. Cells were lysed by addition of 350 µL of RLT buffer and incubation
on a Thermoshaker at 1400 rpm for 3 minutes at 4 ◦C. The lysate was centrifuged for 3
minutes at maximum speed and supernatant was moved to a clean tube. 350 µL of 70%
v/v ethanol was added to the lysate and mixed by pipetting 10 times. The sample was
transferred to a pre-chilled RNease Mini spin column placed in a collection tube and spun
for 15 seconds at maximum speed. The flow-through was discarded and the column was
washed successively with 700 µL of Buffer RW1 and 500 µL of Buffer RPE and separated
by centrifugation for 15 seconds at maximum speed. Finally 500 µL of Buffer RPE was
added and the column was centrifuged for 2 minutes at maximum speed. The column
was transferred to a new collection tube and centrifuged at full speed for 1 minute. The
column was placed in a new 1.5 mL collection tube and 30 µL of RNA-free water were
added to the membrane. The column was incubated at room temperature for 1 minute
and spun for 1 minute at maximum speed to elute the RNA.
2.7.2 RNA Quantification and Quality Assessment
RNA quantity was assessed using the QuBit R©RNA HS Assay (Molecular Probes, Cat.
No. Q32852, Lot: 1416120). All reagents were allowed to reach room temperature for
at least 30 minutes prior to quantification and 200 µL of working solution were prepared
for each sample and standard by mixing RNA reagent and RNA Buffer in 1:200 ratio.
For each standard 10 µL of standard were mixed with 190 µL of working solution and
for each sample 1 µL of sample was mixed with 199 µL of working solution. All samples
and standards were mixed and incubated at room temperature for 2 minutes prior to
quantification.
RNA quality was assessed using the TapeStation R6K Tape and Reagents (Agilent,
Cat No. 5067-5367 and 5067-5368). 4 µL of Sample Buffer were mixed with 1 µL of
sample and the samples were incubated at 72 ◦C for 3 minutes before being placed on ice
for 2 minutes. The samples were centrifuged before being analysed with the Tapestation
2200 instrument (Agilent, Cat No: G2964AA).
2.7.3 RNA Extraction Optimisation
Prior to extracting the RNA from endocardial and endothelial cells, the protocol was
optimised to ensure that an adequate quantity and quality of RNA could be extracted.
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Figure 2.5: Gel representation of Tapestation data for RNA used in RNA optimisation
trial. Initial isolation (left) was performed in triplicate and displayed quality of DNA
lower than the minimum required (8.0) for library preparation. Repetition with cooled
reagents showed improvement, that also correlated with the amount of time the reagents
had remained on ice, samples with DNAse were prepared after samples without DNAse.
Optimisation was performed on NIH/3T3 aliquots of 100,000 cells each, provided by
Dr Mike Cowley and Mr Samuel Amante. Separate RNA preparations were uniquely
identified with letter codes followed by “ trial” as shown in Tables 2.7 and 2.8.
Initial triplicate isolations at room temperature (RT) yielded RNA of low quality as
assessed on the Tapestation platform (Figure 2.5). The isolation was repeated in duplicate
with and without a DNAse treatment step. Surprisingly, the DNAse treatment improved
the RNA quality (Welch Two Sample T-test, p-value <0.032) (Figure 2.5). This was
attributed to the fact that the preparation including the DNAse was performed after
the incubation without DNAse and reagents and all solutions had remained on ice for a
longer period of time. In subsequent preparations all solutions were pre-chilled on ice for
a minimum of one hour and the RIN quality score was consistently above 8.0 without
DNAse treatment (see Figure 3.20).
The quantity of extracted RNA was assessed on a new RNA preparation using the
quBit instrument to confirm that sufficient material could be isolated to meet the mini-
mum requirements (0.1 µg) for the library preparation protocol (Table 2.7).
The stability of purified RNA at 4 ◦C and at room temperature was also assessed to
gain an understanding to the care required when handling RNA prior to cDNA synthesis.
Results are presented in Table 2.8. RNA was incubated at 4 ◦C or at RT and the RIN
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Table 2.7: RNA quantification of trial RNA preparation.
Sample ID Concentration (µg/mL) Volume (mL) Total RNA (µg)
1st 2nd Mean
E trial 24.3 24.2 24.3 50 2.15
Table 2.8: RNA stability assessment of trial RNA preparation. RNA is incubated at the
defined temperature for the time indicated and the RIN is measured. RNA was stable for
several hours both at 4◦C and Room Temperature (RT).
Time(hours) 0 5 24
Temperature (◦C) 4 RT
Sample Id
B trial 5.8 5.7 N/A
D trial 8.6 8.5 8.4
number was measured at the end of the incubation period. RNA is essentially stable at
RT for over 24 hours following purification, suggesting that degradation occurs during
extraction and further supporting the importance of pre-chilled reagents.
2.7.4 RNA-seq Library Preparation and Sequencing
Snap frozen cells, provided by the Baldwin lab, were thawed by addition of 0.5 mL ice-
cold PBS and RNA was extracted using the QIAGEN RNeasy Mini Kit as described in
Section 2.7.1 by the author. All reagents of the QIAGEN RNeasy Mini Kit and all tubes
used were pre-chilled on ice for a minimum of one hour. RNA samples were kept on ice at
all times. RNA quality was assessed as described in Section 2.7.2 and the quality of the
RNA was found to be equal or above 8.0 for all samples that were used for sequencing.
RNA-seq libraries were prepared immediately following RNA purification, using the
Illumina R©Stranded mRNA LT kit (Part Number: RS-122-2101, LOT: 401884) following
the published low throughput protocol from the TruSeq Stranded mRNA Sample Prepa-
ration Guide (Part Number 15031047, Rev. D, September 2012). Fragmentation time
was modified to 1 minute as per Table 21 of Appendix A of the Illumina sample prepa-
ration guide to one minute, to allow for longer insert sizes compatible with the 100 bp
paired-end sequencing protocol.
Cluster generation and sequencing was performed by the BRC Sequencing Facility.
Sequencing was performed in paired-end mode with 100 to 101 cycles per read with
indexing.
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2.7.5 RNA-seq Data Basecalling, Quality Control and Alignment
Basecalling was performed on the BRC HPC Cluster with Casava (version 1.8.0). Con-
figuration of the casava parameters was performed using the configureBclToFastq.pl
script. The following non-standard parameters were passed to the configuration script




−−f a s tq−c l u s t e r−count 500000000
furthermore the input directory and sample sheet were specified with the options
respectively.
Quality control was performed with FastQC (version 0.10.1) [Andrews, 2014]. Reads
were trimmed using the fastx trimmer program from the fastx toolkit [Pearson et al.,
1997] with the parameters -Q33 -f 21, to handle quality scores correctly and trim the
first 21 bp of all reads, respectively.
The reference transcriptome was built once prior to alignment of individual samples
with the -p 8 -G [reference-gtf] --transcriptome-index options on the mm9 ver-
sion of the mouse genome. Alignment was performed with Tophat 2 [Kim et al., 2013]
(version 2.0.10) and Bowtie 2 [Langmead and Salzberg, 2012] (version 2.1.0) with the
following command line arguments
−p 8 −−transcr iptome−index [ path−to−index ]
−−l i b r a r y−type f r−secondstrand
against the reference transcriptome. Reads that did not align to the transcriptome
were aligned to the genome.
Duplicate identification and removal was performed with the Picard Toolkit version
1.105 [Li et al., 2009] using the REMOVE DUPLICATES=TRUE flag.
Annotation assembly was performed using cuﬄinks (version 2.1.1) [Trapnell et al.,
2013] for each sample individually starting from the aligned de-duplicated reads. The
reference UCSC annotation was provided as a reference with the --GTF-guide option.
Individual annotations were merged using cuffmerge from version of 2.1.1 of cuﬄinks.
The reference annotation and genomic sequence were provided using the --ref-gtf and
--ref-sequence options.
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2.7.6 Identification of Differential Expression
Differential expression was identified with Cuffdiff (version 2.1.1) [Trapnell et al., 2013].
The program was run with the following command line parameters
−v −o output −− l a b e l s EC,ET
−−num−threads 8
−−l i b r a r y−type f r−secondstrand input /merged . g t f
[ Endocardial−bam− f i l e s ] [ Endothe l ia l−bam− f i l e s ]
The R package CummeRbund [Goff et al., 2012] was used for producing some of the plots
of the data.
2.7.7 GO Term Analysis of Differentially Expressed Genes
Gene Ontology overrepresentation analysis of the differentially expressed genes was per-
formed using GO-Elite (version 1.2 beta) [Zambon et al., 2012]. The pruned output
results were used for subsequent analysis. Results were filtered in accordance with the
recommended settings in Microsoft Excel. Specifically the number of genes changed was
required to be greater than two, Z-score was required to be greater than 1.96 and adjusted
p-value was required to be less than 0.05.
2.7.8 Identification of Differentially Regulated Transcription Factors
Genes identified as differentially regulated in the transcriptome analysis and annotated
with GO term “sequence-specific DNA binding transcription factor activity” (GO:0003700)
were identified using a custom SQL script. A copy of the assocdb version of the GO term
database was retrieved and installed locally from http://www.geneontology.org/ (date of
retrieval: 15/02/2014). The database was queried using the mysql script in Section C.4
of the Appendix.
The list of differentially regulated transcription factors was further expanded by merg-
ing the results of the above analysis with alternative methods of transcription factor iden-
tification. In particular, the intersection of the list of differentially regulated genes with
two lists of known transcription factors were independently produced [Kanamori et al.,
2004] [Zhang et al., 2012] and merged. Intersection of the lists was performed with custom
UNIX shell commands.
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2.7.9 Identification of TF Binding Distribution near TSSs
In order to define a search interval for the motif analysis presented in the following section,
the distribution of known transcription factor binding peaks was examined. An R script
(Section C.5) was developed to retrieve ENCODE TF ChIP-seq data from the UCSC
browser database and map them to the nearest TSS site, within a search interval of 20
kb, utilising the ChIPseeker R package [Yu, 2014]. A 20 kb cutoff was selected after trial
and error suggested that all the examined TFs bind near baseline levels well prior to this
cutoff.
Initially all TF tracks from the ENCODE project [The ENCODE Project Consortium,
2012] were processed, however some non-canonical TFs were identified in this dataset, such
as CTCF and cohesin. All proteins for which ChIP data was available were subsequently
checked in the NCBI gene database for definite evidence of transcription factor function
and only those for which such evidence could be found were subsequently used. The
examined transcription factors comprised E2f4, Max, Nrsf, Tcf3, Usf1, Gata1a, Tal1,
Gata2, Ets1, Mxi1, Nrf2, Gcn5 and Usf2.
2.7.10 Transcription Start Site Motif Analysis
Sequences for TSS motif analysis were obtained using a custom R script (Section C.6).
Overlapping genomic windows of 1 kb each with a 0.5 kb overlap were obtained for the
region extending 5 kb downstream to 5 kb upstream of each TSS of interest preserving
directionality of the TSS. The positive dataset consisted of the TSS regions of significantly
upregulated genes, whereas the negative dataset of genes that were not identified as
differentially regulated, exhibited a log2(fold change) smaller than 0.02, were marked as
having sufficient data by cuffdiff and had a mean FPKM greater than 10, these genes
were selected using a custom awk script from the cuffdiff output.
Motif analysis was performed with the online DREME tool (version 4.10.0 patch
4) [Bailey et al., 2009]. Identification of motifs was performed with the online version of
the TOMTOM tool [Bailey et al., 2009] against the ‘JASPAR Vertebrates and UniPROBE
Mouse’ database.
The distribution of the identified motifs was examined with the FIMO tool of the
MEME Suite. The output of the tool was processed with a custom R script to generate
the distribution of the individual motifs.
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2.8 Identification of Allele-specific CTCF
Binding Sites in the Mouse Brain
2.8.1 CTCF and Cohesin ChIP-seq
This work was performed by Dr Adam Prickett prior to the commencement of the work
presented here.
CTCF and Cohesin ChIP-seq was performed on postnatal day 21 (P21) mouse brain
on F1 offspring of crosses between C57Bl6 (Bl6) females and Mus musculus castaneus
(castaneus) males (BxC) and vice versa (CxB).
Chromatin Isolation
This work was performed by Dr Adam Prickett prior to the commencement of the work
presented here.
Banked P21 mouse brains were homogenised in 1 mL of PBS pH 8.0 in the presence
of Protease Cocktail Inhibitors (Roche, Catalogue Number: 04693132001). Nuclei were
separated by centrifugation at 5000 rpm for 5 minutes. All subsequent centrifugations
were at 5000 rpm for 3 minutes and resuspension was in 1 mL of PBS. Nuclei were washed
3 times and cross-linked in 1 mL of 5 mM DTBP (Pierce, Catalogue Number: 20665) on
ice for 30 minutes. The nuclei were washed twice in PBS, followed by a wash in 0.1 M
Tris-HCl pH 8.0, 1.5 M NaCl and two washes with PBS. Nuclei were cross-linked in 1%
formaldehyde in PBS for 10 minutes at 37 ◦C and washed three times in PBS. Lysis was
performed in 50 mM Tris-Hcl pH 8.0, 1% w/v SDS, 10 mM EDTA supplemented with
0.1 mM PMSF.
DNA quantification was performed with the Nanodrop instrument (Thermo Scientific).
Chromatin Sonication
This work was performed by Dr Adam Prickett prior to the commencement of the work
presented here.
Chromatin sonication was performed using a probe sonicator in nine 30 s intervals,
with 30 s periods on ice at an amplitude setting of 40. 15 µL of sample was subjected to
reverse cross-linking and electrophoresed on a 1% w/v agarose gel. Reverse cross-linking
was achieved by adding 6 µL 5 M NaCl and 9 µL of water and incubating at 100 ◦C for 1
hour. The sample was subsequently incubated with 10 µg RNAse A and 18 µg Proteinase
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K at RT for 15 minutes.
Pre-clearing of the prepared chromatin was performed by incubating 80 µL of Protein
A agarose fast flow beads (Millipore, Cat No: 16156) , 1x complete protease inhibitor
(Roche, Cat No: 04693132001), and Buffer (15 mM Tris-HCl pH 8.0, 165 mM NaCl, 20%
Triton X-100, 1.2 mM EDTA) to a total volume of 600 µL at 20 rpm for 4 hours. Beads
were subsequently separated by centrifugation and discarded.
8.5 µL of anti-CTCF (Millipore, Cat No 07-729) or anti-IgG (Abcam, Cat No: ab17890)
or 3 µL of anti-Rad21 (Abcam, Cat No: ab992) was added to the chromatin and diluted
to 600 µL with the aforementioned buffer. The solution was rotated overnight at 4 ◦C,
transfered to Spin X columns (Costar, Cat No 8160), 60 µL of ProteinA beads were added
and the columns were rotated for 2 hours at 4 ◦C.
Beads were washed in 800 µL of Buffer (20 mM Tris HCl pH 8.0, 150 mM NaCl, 0.1%
SDS, 1% Triton X-100, 2 mM EDTA) by rotation at 4 ◦C for 15 minutes. The beads were
washed again with the same buffer as above but with a total of 5 mM NaCl under the
same conditions. A final wash was performed with buffer (10 mM Tris-HCl pH 8.0, 250
mM NaCl, 1% Igepal, 5% sodium deoxycholate, 1 mM EDTA). Beads were resuspended in
400 µL of water, 16 µL of 5 M NaCl were added and the solution was incubated overnight
at 65 ◦C. DNA was purified by Phenol:Chloroform extraction.
2.8.2 Read Alignment and Identification of CTCF Enrichment Sites
This work was performed by Dr Reiner Schulz prior to this project and was also replicated
by the author.
ChIP-seq read data were aligned to the mm9 built of the Mouse genome using Novoalign
(version 2.07.11). Duplicates were removed using PicardTools MarkDuplicates.jar com-
mand. Peaks were identified at a permissive cutoff of FDR 0.5 using the USeq [Nix et al.,
2008] package utilising the DEseq algorithm [Anders and Huber, 2010].
2.8.3 Filtering of CTCF and Cohesin Binding Sites
CTCF and Cohesin binding regions, with a Phred scaled 1 FDR exceeding 13 (95% calling
accuracy), were selected independently using a custom UNIX shell script. The resulting
peaks were expanded by 500 bp upstream and downstream and overlapping peaks were
merged. All subsequent work was performed on this expanded and merged peak dataset.
1The Phred scale, mainly used for next-generation sequencing read scores is a log scale transformation
in common use in Bioinformatics. The Phred score is defined as Q = −10log10P [Illumina, 2011]
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2.8.4 Identification of Reads and SNPs within Regions of Interest
For performance reasons in subsequent processing the lists of SNPs and of reads were
adjusted to include only the corresponding entries that overlapped or where fully within
the CTCF or Cohesin sites, using the interesectBed command of Bedtools [Quinlan and
Hall, 2010].
2.8.5 Mapping of Individual Reads to Alleles
Individual reads were assigned to alleles by means of a custom Perl script utilising the
samtools Perl library [Li et al., 2009]. SNPs between the two parental strains were initially
loaded to memory in one array per chromosome and sorted by genomic position. Aligned
reads were read using the samtools Perl library and individually inspected for overlap
with the polymorphisms by performing a binary search for the start position of the read
in the SNP array and subsequently a linear search for its end. For all SNPs encountered
in the interval, the matching parental allele was noted along with the sequencing score
of the base pair, provision was made for single letter codes representing more than one
base. The read was then assigned to a parental allele on the basis of the best base pair
that overlapped a SNP. If no parental allele could be matched the read was recorded as
unassigned. The above methodology was implemented in the script shown in Section C.1
of the Appendix.
2.8.6 Summarisation of Allele-specificity
Allele information from reads was first summarised per read pair. Every read pair was
assigned according to the mapping of the read with the best SNP between the two strains
present. If the read with the best SNP was unassigned, the read pair was assigned
according to the mapping of the other read. Read pair mapping information was then
adjusted for data obtained from CxB crosses so that the assignments were reflecting
parental origin (maternal/paternal) as opposed to strain of origin. Counts of maternal
and paternal reads were obtained, separately for each previously called CTCF and cohesin
region. A probability value for the rejection of the null hypothesis (H0), that the ratio of
the reads observed a 1:1 ratio, was obtained by means of a two-sided binomial test. This
was implemented in R [R Development Core Team, 2008].
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2.8.7 Identification of Allele-specific Sites
Allele-specific sites were identified using a MySQL script. Data were loaded and sorted
according to p-value. Allele-specificity was assessed by means of a Bonferroni corrected
p-value cutoff, adjusted for the total number of regions examined for CTCF and Cohesin
separately.
2.8.8 Identification of the CTCF Binding Motif
The MEME suite [Bailey et al., 2009] was used to confirm that the known CTCF bind-
ing motif was overrepresented in the identified CTCF binding sites. In particular the
meme-chip tool was used to subsample the CTCF peaks and run the MEME motif iden-
tification tool on that sample. The analysis was also repeated using the best sub-window
peaks identified by USeq – instead of the expanded and merged version of the peaks used
throughout and described above. The repeated analysis reproduced the results with a
higher lever of significance.
2.8.9 Assessment of Tissue-specificity of CTCF Binding Peaks
The tissue specificity of the CTCF peaks was assessed by comparison with CTCF peaks
obtained in liver and ES cells. Data in the public domain were utilised [Schmidt et al.,
2012] [Chen et al., 2008]. As the peak calling from liver and ES cell data was performed by
different groups using dissimilar methodologies, it was considered necessary to standardise
the peak size. To this end, peak size was optimised to identify the inflection point at which
the majority of interactions are due to chance. In particular the peak size for all peaks was
reduced to 1 bp and progressively increased. The number of peak overlaps for each step
were counted and plotted. The optimal size of 1 kb was identified and used throughout.
Peak overlaps were calculated using the intersectBed program from the BedTools suite
with the ‘-u’ switch. [Quinlan and Hall, 2010].
2.8.10 Identification of CTCF Peaks that do not Contain the Canonical
Motif
Genomic sequence for the CTCF peaks was obtained using the Galaxy tool [Goecks et al.,
2010] [Giardine et al., 2005]. The sequences were analysed with the FIMO tools (part of
the MEME suite [Bailey et al., 2009]) to identify sequences that contained the canonical
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CTCF motif as previously identified. These sequences were removed and their genomic
coordinates obtained via custom UNIX shell scripts.
2.8.11 Identification of Putative Tissue-specific Binding Sites
The tissue-specific regions not containing the canonical motif, were prepared by applying
the methodology described in Section 2.8.9 to the peaks not containing the CTCF canon-
ical motif described in Section 2.8.10. These peaks were then processed with MEME to
identify underlying motifs present exclusively in some tissues [Bailey et al., 2009].
2.8.12 Bisulphite Conversion and Cloning of Magel2 promoter
The work described in this section was performed by Ms Siobhan Hughes.
Genomic DNA extracted from P21 BxC and CxB mouse brain tissue using the DNeasy
Blood and Tissue Kit (QIAGEN, Cat No: 69504) was bisulphite converted using the
EZ DNA Methylation-Direct Kit (Zymo Research, Cat No: D5020) according to the
manufacturers’ protocol. 2 µL of converted DNA was PCR amplified using the BSMagel
F1 and R1 primers (Table A.1 of the Appendix) using Hot Star Taq DNA Polymerase
(QIAGEN, Cat. No.: 203205) in a 25 µL reaction and incubated in a thermocycler using
the protocol in Table 2.9.
Table 2.9: Colony PCR amplification
1 Initial activation and cell lysis 95 ◦C 15 minutes
2 Denaturation 95 ◦C 30 s
3 Annealing 53 ◦C 50 s
4 Extension 72 ◦C 30 s
5 Repeat from step 2, 44 times
6 Final Extension 72 ◦C 5 minutes
7 Hold 4 ◦C indefinitely
Following amplification, the PCR mix was electrophoresed on a 1.5% w/v LMP agarose
gel on ice at 80 V for 90 minutes. DNA was recovered from the bands using the MinElute
gel extraction Kit (QIAGEN, Cat No: 28604) according to the manufacturers’ instruc-
tions. 20 ng of DNA were ligated to the pGEM-T Easy vector (Promega, Cat. No.:
A1360) with overnight incubation. The DNA-vector construct was transformed into the
completed E. coli cells (provided by Dr Sabrina Bo¨hm) by incubation on ice for 30 min-
utes and heat shock at 42 ◦C for 45 seconds. The cells were returned to ice for a further
of 2 minutes. 100 µL of S.O.C. medium (Invitrogen, Cat No: 46-0821) were added to
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the cells and the cells were incubated at 37 ◦C for 1 hour with shaking. The cells were
subsequently plated on Ampicillin (200 µL of 50 µg/mL in 100 mL), IPTG (8.4 µL of 1
M in 100 mL), X-Gal (100 µL of 40 mg/mL in 100 mL) plates and incubated overnight
at 37 ◦C. Colonies were picked and incubated in 50 µL LB and ampicillin (0.05 µg/mL)
at 37 ◦C for 2 hours with shaking, before grown overnight at room temperature.
2 µL of the growing culture was used directly in a PCR reaction with SP6 and T7
primers (Table A.1)(10 mM each) in 1.1X Reddy Mix (Thermo Scientific, Cat No: AB-
06608/LD). The PCR program shown in Table 2.10 was executed
Table 2.10: Insert amplification PCR
1 Initial activation and cell lysis 96 ◦C 6 minutes
2 Denaturation 96 ◦C 60 s
3 Annealing 55 ◦C 90 s
4 Extension 72 ◦C 60 s
5 Repeat from step 2, 34 times
6 Final Extension 72 ◦C 5 minutes
7 Hold 4 ◦C indefinitely
The PCR products were electrophoresed on a 1% w/v agarose gel and the correct
product size was confirmed. 2.5 µL of the PCR reaction mix was added to 10.5 µL of
H2O and 2 µL Illustra ExoStar (1 µL Illustra Alkaline Phosphatase and 1 µL Illustra
Exonuclease) (GE Healthcare, US78220) and incubated at 37 ◦C for 15 minutes followed
by 94 ◦C for 15 minutes.
Sanger Sequencing
Sequencing reactions were prepared on a 96 well plate by adding 2.5 µL of the previously
treated DNA to 2 µL of 5X sequening Buffer, 0.4 µL of 10 µM Primer, 4.6 µL water and 0.5
µL Big Dye Terminator v3.1 (Invitrogen, Cat. No: 4337454) to each well. The sequencing
reaction was performed by placing the plate in a PCR thermocycler and executing the
program shown on Table 2.11.
DNA was precipitated by addition of 30 µL of 100% v/v ethanol and 1 µL of 3 M
Sodium Acetate and incubation at 4 ◦C for 20 minutes. The plate was centrifuged at
3060 g at 4 ◦C for 20 minutes. The supernatant was removed and 30 µL of 70% v/v
Ethanol were added before the plate was centrifuged again at 4 ◦C for 10 minutes. The
supernatant was removed and the plate was allowed to dry at room temperature for 20
minutes. The DNA was resuspended in 10 µL of Hi-Di formamide (Applied Biosystems,
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Table 2.11: Sanger sequencing reaction temperature cycle.
1 Initial activation 96 ◦C 1 minute
2 Denaturation 96 ◦C 30 s
3 Annealing 58 ◦C 15 s
4 Extension 62 ◦C 60 s
5 Repeat from step 2, 29 times
6 Hold 4 ◦C indefinitely
Cat No: 4311320) and 10 µL 1 mM EDTA was added to empty wells. The plate was
incubated at 94 ◦C for 2 minutes, followed by a 5 minute incubation on ice before being




Regulators of Endocardial Cells
The heart is made of three distinct tissue layers, the endocardium, the myocardium and
the epicardium. The inner endocardial layer is an endothelial population of cells lining
the ventricles and atria of the heart that is known to have an important role in the devel-
opment of the heart. Despite its importance, the endocardium is relatively understudied
compared to the myocardial population.
Interest in the endocardium stems from the fact that it has an essential role in heart
formation and in particular valve formation, trabeculation of the ventricles and transd-
ifferentiation of cardiac muscle to Purkinje conduction fibres via reciprocal interactions
with the myocardium. Given that the aetiology of congenital malformations of the heart,
especially that of valvular defects, is poorly understood and that the pathways that lead
to these defects are likely to involve endocardial cells, this is a cell population of great
interest.
Although the origin of the endocardial population is known to be in the lateral plate
mesoderm, its exact relation to other heart cell populations is not clear (Section 1.3.3).
Studies have shown that it separates from the myocardial population before formation
of the heart tube but its exact origin remains elusive. The existence of a cardiogenic
progenitor cell that is able to give rise to all heart populations, including endocardium,
is well described [Moretti et al., 2006] [Kattman et al., 2006], but the extent to which
endocardial cells in the embryo originate from this precursor has not been defined. Fur-
thermore, conflicting data exist suggesting that the endocardial cells originate from a
vascular endothelial precursor [Milgrom-Hoffman et al., 2011]. Other evidence suggest
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that the endocardium can give rise to coronary arteries, further complicating our under-
standing of these cells [Wu et al., 2012].
Between E8.5 and E9.5 of development, endothelial cells can be identified by the
expression of the NFATc1 transcription factor [Misfeldt et al., 2009]. The presence of a
distinct marker at a specific developmental stage suggests that the endocardial cells are to
a considerable extent a functionally uniform population at that time point. Furthermore,
the double knockout of two related tyrosine kinase receptors (Tie1-/- Tie2-/-) expressed in
all vasculature during late development and in the adult displays cardiac specific defects
but no early vascular defects, suggesting a specific identity for the endocardium [Harris
and Black, 2010].
Despite its ubiquitous presence in the endocardium and its function as a transcription
factor, NFATc1 is unlikely to be a master regulator of endocardial identity. The NFATc1
double knockout mice do not show absence of the endocardium, although they show
aberrant valve formation [Ranger et al., 1998]. NFATc1 expression does not precede the
specification of the endocardium and is furthermore expressed in other tissues during
development, such as cartilage during limb development [Misfeldt et al., 2009] and in the
adult it has a role in the the activation of T-cells.
Epigenetic and transcriptomic characterisation of the endocardium was undertaken in
the course of this project. The embryoid body cardiac differentiation model was used to
isolate endocardial and endothelial cells for analysis in sufficient quantities. The embryoid
body differentiation model of endocardial cells has been shown to recapitulate endogenous
temporal and spatial expression patterns [Misfeldt et al., 2009] (Section 1.3.5).
Cells bearing the NFATc1+/CD31+ endocardial signature were isolated from embryoid
bodies with flow cytometry and compared to endothelial cells (NFATc1-/CD31+) from
the same source. Endothelial cells were used as a background population for comparison
as they represent a cell type of identical morphology and similar function, that does not
however possess the unique properties of the endocardium, such as the ability to undergo
EMT or induce trabeculation. Furthermore, endothelial cells can be obtained in quantities
equal to or greater than endocardial cells from mouse embryoid bodies.
Our initial hypothesis was that epigenetic processes have a major role in endocardial
cell identity. This hypothesis was based on unpublished differential expression microar-
ray analyses performed prior to and outside the scope of this project that suggested no
transcriptional differences between endocardium and endothelium (Prof. Scott Baldwin,
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Personal Communication). Furthermore, at the time point examined (E9.5 equivalent),
the endocardial and endothelial cells are morphologically identical, but manifest differ-
ential responses to exogenous stimuli later in development, suggesting the existence of
hidden variables that may be of epigenetic identity.
3.1 Cell Isolation
3.1.1 Isolation of Cells from Embryoid Body Cultures
Isolation of endocardial and endothelial cells from embryoid bodies was performed by
members of the Baldwin Lab, TN, USA and it is presented here for reference pur-
poses. Briefly, embryonic stem cells that were transfected with the NFATc1-mCherry
BAC, derived from the NFATc1-nuc-LacZ BAC transgene reported by Misfeldt and col-
leagues [Misfeldt et al., 2009], were propagated on primary embryonic fibroblasts and
differentiated in embryoid body cultures for two days. After culture on a rotary orbital
shaker for 48 hours, the cells were plated on gelatine. Plated cells were allowed to differ-
entiate for at least 7 days before being harvested. Detailed experimental procedures can
be found in Section 2.1.
Endocardial and endothelial cells were disassociated and isolated by flow cytometry
on the basis of the presence of the mCherry (expressed under the control of NFATc1
promoter and enhancer) and CD31 markers. Endocardial cells were isolated as the
NFATc1+/CD31+ population and endothelial cells as the NFATc1-/CD31+ population.
Representative FACS isolation plots for individual markers and doubly labelled cells can
be seen in Figure 3.1.
3.2 Genome-Wide Methylation Analysis
3.2.1 Establishment of the WGBS protocol
A protocol for performing whole genome bisulphite sequencing was established using the
published whole genome reduced representation bisulphite sequencing (RRBS) as a start-
ing point [Meissner et al., 2005]. The RRBS protocol generates bisulphite converted se-
quencing libraries enriched for CGIs by digestion using a methylation insensitive enzyme,
followed by size selection for a fraction with high representation of CGIs.
The enzymatic digestion step was substituted with acoustic shearing, to ensure un-
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Figure 3.1: Representative FAC sorting plots provided by the Baldwin Laboratory. A.
Sorting of unlabelled cells B. Sorting of CD31 labelled cells C. Sorting of mCherry labelled
cells D. Sorting of double labelled cells. Colour is used to signify the sorting designation
of each cell.
93
Figure 3.2: Bioanalyser trace of WGBS next-generation sequencing library prepared with
NIH/3T3 MEF DNA for protocol validation. The trace shows a distinct peak at 400 bps.
The peaks at 122 bp and 10,380 bp are lower and upper marker peaks respectively used
for size estimation.
biased and uniform fragmentation, and next-generation sequencing library preparation
was performed using a commercially available library preparation kit. A flowchart of the
protocol can be found in Figure 3.3. After sonication the DNA was end-repaired, A-tailed
and methylated adaptors were ligated. The library was subsequently bisulphite converted
using a commercially available kit and amplified in two steps. Note that only half the
bisulphite converted DNA is used for amplification, with the other half stored for later
usage.
The WGBS protocol was first attempted on NIH/3T3 mouse embryonic fibroblasts
(MEFs) to a favourable outcome (Figure 3.2) before proceeding to use it on DNA from
endocardial and endothelial cells.
3.2.2 Experimental Design and Library Preparation
At the commencement of this project, two batches of DNA from flow sorted embryoid
bodies for each of endocardial and endothelial cells were available. The samples were
quantified after a 1:10 dilution of 1 µL of each sample using the quBit instrument (Table
3.1) and the total amount of DNA in each sample was calculated (Table 3.2). The total
amount of DNA was judged not to be sufficient for WGBS on the basis of previous
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Figure 3.3: Flowchart of WGBS library preparation protocol. The DNA is sheared by
sonication and a next generation sequencing library is prepared by end-repairing, dA-
tailing and adaptor ligating. Custom made methylated adaptors are used during adaptor
ligation. The library is bisulphite converted and half the sample is used for subsequent
processing, the remaining sample is stored. Amplification of the library fragments is
performed by two consecutive rounds of PCR amplification. The first round is performed
using Pfu DNA polymerase, an enzyme that can read through U. The second round
is performed with Pfx DNA polymerase. DNA of the appropriate size is selected by gel
electrophoresis and quality is assessed. DNA purification is performed between the shown
steps.
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attempts with NIH/3T3 fibroblasts. The samples were therefore pooled and quantified
again. Table 3.3 shows the mass, volume and expected and actual concentrations of
samples after pooling. The close correspondence of the actual and expected concentrations
confirms that pooling has been performed correctly.
Four libraries were prepared from the first replicate samples, three of which were
sequenced on seven Illumina R©Hiseq 2000 lanes (Table 3.4). Libraries EC0 and ET1 were
prepared in a single batch. Pooled DNA was sonicated and its size distribution assessed
using the Agilent Bioanalyser (Figure 3.4). The Bioanalyser trace for ET1 displayed a
sharp peak at a molecular weight of 374 bp, but the broad peak of the DNA was otherwise
unaffected. The sharp peak was attributed to an air bubble in the capillaries and was
consistent with similar observations by other users of the instrument.
Library EC0, in comparison to library ET1, was judged to be unsuccessful given
that it was nearly undetectable on the Tapestation analysis (Figure 3.5). Subsequent
re-analysis of the quantification data revealed that this library could have been sequenced
(Table 3.5 compare EC0 with ET2), although it was indeed suboptimal. Library EC1
was prepared to replace library EC0 from bisulphite converted DNA remaining from the
preparation of library EC0 (only the post-bisulphite amplification steps were repeated).
During preparation of libraries EC0 and ET1 it was noticed that the size selection resulted
in fragments suboptimal for 200 bp paired-end sequencing and the size-selection step was
adjusted appropriately for library EC1 (Figure 3.5). Library ET2 was prepared from
bisulphite converted DNA from the ET1 library preparation to optimise the insert size.
These libraries (ET1, EC1 and ET2) were all prepared using DNA from the sample pool
of embyoid cells and were therefore treated as technical replicates in subsequent analysis.
Two further libraries (one from endocardial and one from endothelial DNA) were
prepared from independent pools of cells that became available later in the course of
the project constituting a biological replicate. These libraries are identified as EC2 and
ET3. Preparation of these libraries was performed by Mr Samuele Maria Amante, using
the protocol developed by the author. The molar concentration of these libraries was
calculated using a qPCR assay and the fragment size information shown in Figure 3.5.
The molar concentration of all libraries was calculated (Table 3.6). Libraries were
diluted to 10 nM before being sequenced.
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Figure 3.4: Bioanalyser gel (A) and trace representation (B,C) of fragment size analysis for
endocardial and endothelial DNA after sonication and prior to library preparation. Both
libraries show peaks of comparable size at around 200 bp, suitable for library preparation
(note different scale). The endothelial library shows a sharp spurious peak slightly smaller
than 400 bp, see text for more details.
Table 3.1: Quantification of diluted DNA samples used for replicate 1 of the WGBS and
calculation of original concentration. Endocardial sample 2 was more concentrated than
other samples. This discrepancy was consistent with the sample quantification by our
collaborators after the DNA isolation and prior to shipping (data not shown).
Concentration (µg/mL)
Read 1 Read 2 Mean
Endocardial 1 Diluted 0.256 0.245
Original 2.56 2.45 2.51
Endocardial 2 Diluted 1.67 1.64
Original 16.7 16.4 16.6
Endothelial 1 Diluted 0.342 0.367
Original 3.42 3.67 3.55
Endothelial 2 Diluted 0.201 0.202
Original 2.01 2.02 2.02
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Table 3.2: Calculation of total amount of DNA present in samples of replicate 1 prior
to pooling. Some samples contained less than 50 ng of DNA that was considered the
minimum required for library preparation.
Concentration (ng/µL) Volume (µL) Total DNA (ng)
Endocardial 1 2.51 19 47.7
Endocardial 2 16.6 19 315.4
Endothelial 1 3.55 19 67.5
Endothelial 2 2.02 19 38.4
Table 3.3: Total DNA calculation of DNA samples used for WGBS after pooling.
mT (ng) VT (µL) cexpected (ng/mL) cactual (ng/mL)
Endocardial 363.1 38 9.56 7.75
Endothelial 105.9 38 2.79 3.11
Table 3.4: Summary, number of lanes sequenced and status of prepared libraries for
WGBS of endocardial and endothelial cells.
Library Cell type Status Lanes Count Biological Rep. Notes
EC0 Endocardial FAIL 0 1 dilute; small insert
ET1 Endothelial OK 1 1 small insert size
EC1 Endocardial OK 3 1
ET2 Endothelial OK 3 1
EC2 Endocardial OK 0.5 2
ET3 Endothelial OK 0.5 2
Figure 3.5: Estimation of the size of WGBS libraries using the Agilent Tapestation. The
size distribution is displayed as a gel. All libraries are of the appropriate size. Library
EC0 is clearly more dilute than ET1. Library ET1 was smaller than the ideal size and
was later repeated as ET2, see text for details.
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Table 3.5: DNA quantification of 1:200 or 1:2000 dilution of prepared WGBS libraries
using the quBit. All libraries contained enough DNA for sequencing.
Dilutions Read 1 Read 2 Mean
EC0 1:200 8.48 ng/mL 9.87 ng/mL
original 1.70 µg/mL 1.97 µg/mL 1.84 µg/mL
ET1 1:200 32.9 ng/mL 33.9 ng/mL
original 6.58 µg/mL 6.78 µg/mL 6.68 µg/mL
EC1 1:2000 3.95 ng/mL 4.01 ng/mL
original 7.89 µg/mL 8.02 µg/mL 7.96 µg/mL
ET2 1:2000 1.04 ng/mL 0.98 ng/mL
original 2.08 µg/mL 2.00 µg/mL 2.04 µg/mL
Table 3.6: Calculation of molar concentration of WGBS libraries. The molar concentra-
tion for EC0 was not calculated, as a reliable insert size estimate was not available. The
concentrations of libraries EC2 and ET3 was determined directly via qPCR.
Library Concentration (µg/mL) Insert Size (bp) Concentration (nM)
EC0 1.84 N/A N/A
ET1 6.68 183 55.31
EC1 7.96 250 48.24
ET2 2.04 326 9.48
EC2 N/A 275 158.38
ET3 N/A 283 102.57
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3.2.3 Sequencing Results
Cluster generation and sequencing was performed by the BRC genomic facility as outlined
in Section 2.3.2.
One lane of the ET1 library was initially sequenced before proceeding to sequence three
lanes of each EC1 and ET2 as shown in Table 3.4. In addition, one multiplex lane of a 1:1
mix of the EC2 and ET3 libraries was sequenced. Sequenced lanes are identified by the
library ID and a serial number indicating the number of times the originating library has
been sequenced. For example, ET2-3, indicates the third lane sequenced from the second
library from endothelial cells. Total cluster and read counts obtained are shown in Table
3.7. The depth of sequencing was based on that employed by other WGBS experiments
and personal communication with experts in these methodologies (Dr. Miguel Branco,
personal communication).
An instrument failure occurred during the sequencing of lanes EC1-2 and ET2-2 lead-
ing to termination of sequencing before completion of all cycles for the reverse read, this
led to 100 bp forward reads but only 60 bp reverse reads for those lanes. Libraries of the
second biological replicate were multiplexed and sequenced on a single lane.
Table 3.7: Read pair count for whole genome bisulphite sequencing of endocardial and
endothelial cells prior to quality control.












Figure 3.6: Simplified outline of the per-lane WGBS pipeline developed in the context of
this project. Some quality evaluation steps have been omitted for clarity. See main text
page 101 for details.
3.2.4 Bioinformatic Processing
The bioinformatic processing pipeline developed and utilised is shown diagrammatically
in Figure 3.6. The numbers in the following text refer to step numbers in that Figure.
Individual lanes were treated as technical replicates and analysis was initially performed
on a per-lane basis and subsequently data were summarised on a per-feature basis. Details
of the processing can be found in Section 2.3.3.
Basecalling was performed with Casava (1) and read quality was initially assessed
with FastQC (2) (Figure 3.7). The initial quality assessment revealed a large range of per
base quality values with several lanes including reads of low quality. This was attributed
to overloading of the sequencer lane.
The basepair composition was found to be consistent with bisulphite conversion, with
Cs underrepresented and Ts overrepresented. This trend however was not consistent
throughout the read length, with the basepair composition approximating 25% towards
the end of the reads. This suggested read-through into the unmethylated adaptor, which
was consistent with adaptor sequence overrepresentation identified by FastQC.
Reads marked as filtered by the sequencer instrument were removed (3). The sequencer
instrument marks reads from removal on the basis of proximity and overlap of clusters as
well as lack of sequence complexity. Given the overloading of some of the flowcells, this
was therefore judged to be necessary, despite the considerable loss of clusters at this step
(see Figure 3.10). Quality was assessed again (not shown in Figure 3.6).
Adaptor trimming was performed with trim galore (4). Adaptor trimming was
deemed to be essential given the increase in Cs towards the ends of the reads as de-
scribed above. A total of 14.4% of the total number of bases were trimmed from 62.7%
101
Figure 3.7: Quality plots of raw forward reads, prior to quality control, for lane EC1-1.
These plots are broadly representative of other lanes, although some lanes did show con-
siderably lower quality, see text. (A) Phred scaled quality score box plot as a function of
read position suggests good overall read quality and displays the expected quality drop
towards the 3’ end. (B) Base incorporation percentage as a function of read position,
suggests bisulphite conversion was successful (overall percent of Cs lower than expected
and overall % of Ts higher than expected). The cycle-to-cycle incorporation variability
suggests either an instrument malfunction or overrepresentation of specific sequences in
the library. Increasing C and decreasing T percentage suggests reading into the methy-
lated (and unconverted) adaptor. (C) Average read quality per read is high, but displays
a long tail of low quality reads. (D) GC% distribution does not match the expected
distribution as expected from WGBS. (E) Duplication level of reads, shows a moderate
to high duplication level, which may be attributable to overrepresented sequences. (F)
K-mer content as a function of read position, shows overrepresentation of several k-mers
in a position specific manner.
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Figure 3.8: Percent of total trimmed reads and total trimmed bases. A considerable
portion of all the reads was trimmed to some extent, while the overall percent of bases
trimmed was lower than 30% for all libraries.
of the total reads (see Figure 3.8).
Trimmed reads were aligned to the phiX reference genome to remove phiX DNA added
for quality control purposes after library construction and prior to sequencing by the
sequencing facility (5), reads that successfully aligned to the phiX genome were removed.
The contribution of the phiX reads to the total read count was small (see Figure 3.10).
This step was not performed on the multiplexed samples as phiX reads were not barcoded
and were discarded during the demultiplexing step.
Quality was evaluated again with FastQC, see Figure 3.9 (6). By comparing Figures
3.8 and 3.9 it is evident that the quality control steps have resulted in improvement of
the data quality. Phred scaled per-base quality scores are consistently above 29 (>99.9%
accuracy) (panels A), sequence composition is stable throughout the read (panels B),
reads with low mean quality scores are absent (panels C), GC distribution resembles the
expected distribution with a second mode at 61% methylation (panels D), that is inter-
preted as the methylated (unconverted) component of the genome, duplication estimates
are below 20% and the majority of duplication is of low copy number (panels E) and
k-mer content is considerably more stable throughout the reads (panels F).
The reads were bisulphite converted in silico and aligned to the in silico bisulphite
converted genome, using Bismark [Krueger and Andrews, 2011] (Section 2.3.3).
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Figure 3.9: Quality plots of raw forward reads, following quality control, for lane EC1-
1, compare with Figure 3.7 on page 102. These plots are representative of other lanes.
(A) Phred scaled quality score box plot as a function of read position shows consistently
high and improved quality scores. (B) Base incorporation percentage as a function of read
position does not show significant cycle-to-cycle variation and no overall trend towards the
3’ end of the read is evident supporting successful removal of the majority of the adaptor
sequences. (C) Average quality per read distribution plot shows improvement compared to
pre-quality control. (D) GC% distribution shows a clear bimodal distribution, potentially
corresponding to methylated and unmethylated genomic regions. (E) Duplication rate is
considerably lower and furthermore shows reduction of reads with more than 10 multiple
copies. (F) K-mer content as function of read position is now consistent throughout reads
with no abrupt changes suggesting that overrepresented sequences are of low abundance
and no significant positional fragmentation bias remains.
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Figure 3.10: Barchart of read counts for WGBS for several steps of the analysis. The
majority of lost reads were attributable to removal of reads filtered by the sequencer, this
was due to the overloading of the flowcell that resulted in overlapping clusters.
De-duplication was attempted with two different approaches but was not performed in
the final version of the processing pipeline. This was because de-duplication with Picard
tools resulted in files that did not contain the appropriate flags from Bismark required for
methylation extraction. Furthermore, de-duplication using a custom experimental script
packaged with Bismark was not successful due to the very high memory requirements of
the script that rendered it impractical to complete its execution. Given that duplication
rates following quality control were estimated not to be excessively high (Figure 3.9) and
the aforementioned technical difficulties, this step was omitted and no significant adverse
effects are expected because duplication rates were low.
The methylation information from all reads was obtained (8) and summarised on a
per base-pair position (9) using a custom script. Summarisation per-base position prior
to summarisation per feature was necessary to ensure that unequal coverage of Cs within
each feature does not result in preferential weighting of highly covered C positions.
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Figure 3.11: Overview of methylation at the known imprinted Gnas locus displaying
hemimethylated CGIs. Hemimethylation of imprinted loci suggests that the methylation
profile of the cells examined is not perturbed and is relevant to the in vivo context.
3.2.5 Visual Inspection
The data were visually inspected on the UCSC Genome Browser at the read and methyla-
tion level. The read data were not found to exhibit read patterns indicative of significant
duplication, displayed the anticipated mismatches to the genomic sequence at the ma-
jority of C residues and coverage appeared to be uniform. The methylation pattern was
consistent with a hypermethylated genome and hypomethylated CpG islands.
3.2.6 Methylation at Imprinted Loci
Methylation at imprinted loci, where methylation levels are expected to approximate
50% was examined at each locus. The majority of the loci exhibited methylation patterns
consistent with the methylation of only one of the two alleles. An example of this can be
seen in the Gnas locus (Figure 3.11).
The methylation of all the imprinted loci was quantified and is presented in Figure
3.12. The majority of the loci are in a hemimethylated state. Only three loci exhibited a
methylation state incompatible with hemimethylation (Slc38a4, Rasgfr1 and Peg13 ).
The reason for loss of the expected methylation pattern at these loci could either be
due to a previously unknown tissue specific loss of allele-specific methylation in endothelial
cells at these sites or alternatively due to the loss of the normal methylation pattern at
these loci in the particular ES cell line used in this analysis.
The presence of the expected methylation patterns in the majority of the examined
imprinted loci and expected pattern of CpG methylation throughout the genome serves
as an internal control and demonstrates that the epigenetic profile of these cells is not
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Figure 3.12: Summary of methylation of imprinted loci. The majority (16/21) of the
loci are in an hemimethylated state. Only three of the remaining loci exhibit methyla-
tion suggestive of a completely methylated or unmethylated state (Slc38a4, Rasgfr1 and
Peg13 ). These data support the notion that the epigenetic state of the cell cultures is
largely unperturbed.
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significantly altered as a result of the growth conditions. This supports the notion that
the cells are appropriate for the analysis.
In the course of the above analysis, a novel region exhibiting hemimethylation was
identified at the vicinity of Inpp5f locus in both tissues. Although this study did not
generate allele-specific data, the proximity of this hemi-methylated region to a known
DMR suggests that it may be methylated in an allele-specific manner. The biological
significance of this finding was not evaluated further as it was outside the scope of the
present investigation.
3.2.7 Differential Methylation of CGIs
Data from the WGBS experiment were processed as described in Section 2.3.3. Briefly,
reads were subjected to quality control, aligned to the in silico bisulphite converted
genome and methylation information was extracted and summarised to the CpG level.
The coverage distribution of CpGs in each sample was examined (Figure 3.13 A and
B) and a minimum coverage cutoff of 3 reads was set. Furthermore CpGs with coverage
in excess of 100 were excluded in order to exclude regions with high levels of duplication.
This was considered necessary given than per read level duplicate removal had not been
performed, due to technical constraints.
The data were summarised to the CGI level. A script was developed (initially with
MySQL and later with bedmap [Neph et al., 2012]) to perform the summarisation.
The dataset of known CGIs was prepared by producing the union of the datasets of
CGIs obtained from UCSC genome browser CGI track [Gardiner-Garden and Frommer,
1987] and CGIs identified by Bird and colleagues via CAP-seq [Illingworth et al., 2010].
Overlapping regions between the two datasets were merged. These two datasets were
used as Illingworth and colleagues demonstrated that a portion of the functional CpG
islands in the mouse have not been computationally detected and can be detected by
means of CAP-seq. This dataset was not however used in isolation to avoid exclusion of
well described CGIs that were not identified in this particular assay.
The distribution of the number of informative CpGs per CGI were examined (Figure
3.13, C). Only CGIs with at least 10 informative CpGs were considered for further analy-
sis. Filtering of CGIs was performed so as to remove CGIs where differential methylation
cannot be reliably detected and reduce the extent to which multiple testing correction
required.
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The methylation of individual CGIs between the two conditions was examined by
means of a scatter plot (Figure 3.14). Of particular interest was the overall deviation
from the 45 degree line that was observed. This trend suggests overall hypermethylation
in the endocardium across many CGIs. This hypermethylation is consistent with a model
of differentiation whereby endocardial cells are a more differentiated subtype of the en-
dothelium, gaining methylation as they differentiate. Alternatively, this may signify a con-
siderable contribution of undifferentiated hypomethylated cells to the CD31+/NFATc1-
population. The later possibility is partly supported by the upregulation of some pluripo-
tency factors in the endothelial population such as Nanog observed in the transcriptomic
analysis of this population (see page 142).
The possibility existed however, that this overall difference in methylation between
the two conditions was the result of the differential conversion efficiency between the
two samples, that manifests as differential methylation. The conversion efficiency was
estimated by examining the fraction of Non-CpGs that are methylated in Table 3.8. The
overall difference in non-CpG (in both the CHG and CHH contexts) methylation between
the two conditions is small (less than 1%), displays a trend opposite to that observed in
methylation in the CpG context and is not statistically significant (p-value 0.36 and 0.71
for the CHG and CHH contexts respectively). The above in combination suggest that
differential conversion efficiency is not the cause of the observed methylation trend.
Differential methylation was examined following an approach similar to that employed
by the limma R package [Smyth, 2005]. The relationship of the standard deviation to
the mean methylation was modelled using a spline function (Figure 3.15). The model
predictions of standard deviation were used as input to multiple independent T-tests
to identify differential methylation events. 1,641 differentially methylated CGIs were
detected at the 0.05 p-value level of significance. However, none of these were significant
after FDR multiple testing correction, even after stringent reduction of the number of
CGIs examined on the basis of number of informative CpG per CGI. The top hits of
these analysis are presented in Table A.2 of the Appendix. Given that the results of this
analysis have not been corrected for multiple testing, a high number of false positives is
expected and per locus validation of these results particularly important.
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Figure 3.13: (A) Logarithmic scale histogram of CpG coverage in each sample. (B)
Logarithmic scale histogram of CpG coverage in each sample for the coverage range 0 -
50. (C) Stacked histogram of informative CpGs per CGI for each sample.
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Figure 3.14: Scatter plot of mean methylation in endocardial and endothelial cells. The
scatter plot suggests hypermethylation of endocardial DNA.
Figure 3.15: Relationship between standard deviation and mean methylation of CGIs.
The relationship was modelled with a spline function (red line) and the predicted values
were used for multiple independent T-tests to assess methylation differences.
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Table 3.8: Percent methylated C’s in each genomic context. Endocardial CpG methylation
is higher than endothelial methylation, in contrast to that of other genomic contexts that
do not recapitulate this trend, suggesting that this difference is not the result of differential
conversion rates between the samples.
Sample %me CpG %me CHG %me CHH
EC replicate 1 73.87% 0.53% 0.43%
EC replicate 2 76.20% 1.40% 1.40%
ET replicate 1 70.85% 0.53% 0.43%
ET replicate 2 74.50% 2.20% 2.30%
EC mean 75.03% 0.97% 0.92%
ET mean 72.68% 1.36% 1.36%
3.2.8 Genomic Context of Differentially Methylated CGIs
The genomic distribution of differentially methylated CGIs (at the p-value <0.05 signif-
icance level) was examined and compared with that of all CGIs examined (Figure 3.16).
The distribution of the differentially methylated CGIs did not differ appreciably from that
of all the genomic CGIs examined. Most noticeable was a depletion in distal intergenic
regions and enrichment in Promoters and 5’UTRs, potentially signifying a regulatory role
in gene expression of a subset of these CGIs.
112
Figure 3.16: Genomic distribution of all examined and differentially methylated CGIs in
comparison to genomic composition. Differentially methylated CGIs are underrepresented
in distal intergenic regions and are enriched in promoters, 5’ UTRs and coding exons.
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3.2.9 Detection of Genome-wide Differential Methylation
Further to the per-CGI analysis described above differential methylation was detected on a
genome-wide level using the BSmooth algorithm [Hansen et al., 2012]. BSmooth generates
a smoothed methylation profile for each replicate independently by sharing methylation
information between nearby CpGs. Identification of differentially methylated regions is
subsequently performed by calculation of T-statistic and identification of genomic regions
consistently displaying extreme T-statistic values.
In the context of this analysis, DMRs were called as significantly differentially methy-
lated if the T-statistic was beyond the lower or upper 1% of its empirical distribution and
furthermore the mean difference in methylation between the two samples exceeded 20%
and the locus was supported by at least 20 informative CpGs. These cutoffs were more
stringent that the values recommended by the BSmooth algorithm authors.
This analysis identified a total of 1,128 differentially methylated regions between the
endocardium and the endothelium. Most (1,083/1,128) of these sites were hypermethy-
lated in the endocardium (Table 3.9), consistent with the observations of the per-CGI
analysis presented above. The size of the detected DMRs was in the range of 116 to 1,661
bps with a median size of 539 bps. Full results of this analysis can be found in Table
A.3 of the Appendix. The five significant loci that displayed the maximal methylation
differences between the two tissues are shown in Figure 3.19 as examples.
The following sections examine the genomic context of the DMRs identified here, their
overlap with other epigenetic marks and the functional roles of genes in close proximity.
Table 3.9: Number of identified hyper- and hypo- methylated genome-wide differentially
methylated genomic regions. The majority of the regions are hypermethylated consistent
with previous observations in the course of this analysis.




3.2.10 Genomic Context of Differentially Methylated Genomic Regions
The genomic distribution of the genomic DMRs identified above was examined and is
presented in Figure 3.17 where it is compared to the proportion of the genome constituting
each class of genomic sequence.
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The majority (62%) of the detected DMRs are in the vicinity of coding regions, while
38% are in distal intergenic regions. Despite that, DMRs are underrepresented in intronic
regions and distal intergenic locations in comparison to the overall genomic composition.
Furthermore, DMRs are overrepresented in the vicinity of annotated genes and particu-
larly in coding exons. This distribution suggests that the differential methylation may be
linked to the differential regulation of expression of transcripts. The relationship between
differential methylation and differential expression is examined later in this thesis.
In addition to examining the distribution of DMRs with respect to functional status
of the genome, the distribution of DMRs was compared to the DNAse I, H3K36me3,
H3K27me3, H3K27ac and H3K4me3 profiles from cardiac tissue obtained from the EN-
CODE project [The ENCODE Project Consortium, 2012]. Cardiac tissue constitutes a
useful proxy for the epigenetic profiles of endocardium as both are tissues of mesodermal
origin and developmentally related. However, its utility is limited by the considerable de-
velopmental distance between the two tissues. The results of this analysis are presented
in Figure 3.18.
The overlap of all the marks examined was higher than expected by chance (p <0.001
for all marks) as evaluated by means of permutation testing. Despite the considerable
developmental distance between the endocardium and the adult heart, 508 of the 1,128
DMRs identified, overlapped a histone mark or a DNAse I hypersensitive site in heart,
suggesting functional significance of the differentially methylated sequences. Overall,
the examination of the genomic location of the identified DMRs suggests that at least
some of these sites are functionally important and the methylation changes observed are
biologically relevant.
Given that considerable overlap between the identified DMRs and transcribed ge-
nomic regions was observed in the above analysis, the specific overlap of the identified
DMRs with known genes was examined. Of the 1,128 identified DMRs, 696 were found
to directly overlap the genomic location of 381 unique genes. GO term overrepresenta-
tion analysis of the list of these genes revealed significant associations with terms related
development processes such as “developmental process” and “anatomical structure mor-
phogenesis” (Table 3.10). This finding, strongly suggests a functional role for these DMRs
in development of the endocardium.
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Figure 3.17: Genomic distribution of differentially methylated regions in comparison to
genomic composition. DMRs are overrepresented in the vicinity of annotated genes, but
not introns or distal intergenic regions.
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Figure 3.18: Heatmap of overlap of peaks as identified by the ENCODE project with the
DMRs identified in this study. The numbers on the left signify the number of DMRs
that were found to overlap each mark. The significance of the overlaps was assessed by
means of permutation testing (p <0.001 in all cases, denoted by ***). Overall, 508 of
the 1,128 (45%) DMRs were found to overlap at least one mark suggesting that they are
functionally significant.
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Figure 3.19: Visualisation of the methylation profile of the top five most significant differ-
entially methylated genomic locations (pink boxes) and 5 kb flanking regions. Individual
CpGs are denoted as notches at the bottom of the plots. Endocardial replicates are
displayed red and endothelial in blue.
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Table 3.10: Significantly overrepresented Molecular Function
GO Terms in the set of genes directly overlapping identified
DMRs between the endocardium and the endothelium. The
terms reveal a connection of the identified DMRs with devel-
opmental processes, strongly suggesting a functional role for
these sites in the development of the endocardium.
GO Term ID Description P-value FDR q-value
GO:0044767 single-organism developmental process 1.46E-12 1.67E-08
GO:0032502 developmental process 3.76E-12 2.15E-08
GO:0009653 anatomical structure morphogenesis 1.81E-09 5.19E-06
GO:0048856 anatomical structure development 1.38E-09 5.26E-06
GO:0048869 cellular developmental process 5.42E-09 1.24E-05
GO:0048858 cell projection morphogenesis 1.25E-07 2.39E-04
GO:0048812 neuron projection morphogenesis 2.78E-07 4.55E-04
GO:0007275 multicellular organismal development 3.64E-07 4.64E-04
GO:0032990 cell part morphogenesis 3.39E-07 4.85E-04
GO:0044763 single-organism cellular process 5.04E-07 5.78E-04
GO:0032989 cellular component morphogenesis 1.09E-06 1.14E-03
GO:0030030 cell projection organization 2.63E-06 2.52E-03
GO:0016043 cellular component organization 4.52E-06 3.46E-03
GO:0009987 cellular process 4.03E-06 3.55E-03
GO:0048513 organ development 4.47E-06 3.66E-03
GO:0048646 anatomical structure formation involved in morphogenesis 6.04E-06 4.08E-03
GO:0030154 cell differentiation 6.02E-06 4.31E-03
GO:0071840 cellular component organization or biogenesis 9.89E-06 6.30E-03
GO:0035108 limb morphogenesis 2.73E-05 1.56E-02
GO:0035107 appendage morphogenesis 2.73E-05 1.65E-02
GO:0008347 glial cell migration 3.34E-05 1.74E-02
GO:0002040 sprouting angiogenesis 3.34E-05 1.83E-02
GO:0044260 cellular macromolecule metabolic process 3.90E-05 1.94E-02
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GO:0051093 negative regulation of developmental process 4.06E-05 1.94E-02
GO:0048519 negative regulation of biological process 4.68E-05 2.07E-02
GO:0010604 positive regulation of macromolecule metabolic process 4.53E-05 2.08E-02
GO:0043170 macromolecule metabolic process 5.18E-05 2.20E-02
GO:2000026 regulation of multicellular organismal development 8.13E-05 3.33E-02
GO:0002175 protein localization to paranode region of axon 9.70E-05 3.84E-02
GO:0008283 cell proliferation 1.06E-04 4.06E-02
GO:0044237 cellular metabolic process 1.12E-04 4.16E-02
GO:0045944 positive regulation of transcription from RNA polymerase II promoter 1.44E-04 5.17E-02
GO:0050793 regulation of developmental process 1.69E-04 5.55E-02
GO:0009893 positive regulation of metabolic process 1.69E-04 5.70E-02
GO:0010648 negative regulation of cell communication 1.94E-04 5.71E-02
GO:0035113 embryonic appendage morphogenesis 1.92E-04 5.79E-02
GO:0010721 negative regulation of cell development 1.67E-04 5.81E-02
GO:0006807 nitrogen compound metabolic process 2.05E-04 5.88E-02
GO:1901343 negative regulation of vasculature development 1.92E-04 5.95E-02
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Table 3.11: RNA Samples, cell types and description of DNA samples used for RNA-
seq library preparation. The letters A-H are used throughout to refer to the particular
libraries.
Sample ID Sample Name Cell Type Description
A s1 ec EC Endocardial Replicate 1
B s1 et ET Endothelial Replicate 1
C s2 ec EC Endocardial Replicate 2
D s2 et ET Endothelial Replicate 2
E s4 ec EC Endocardial Replicate 3
F s4 et ET Endothelial Replicate 3
G old ec EC Endocardial Replicate 4
H old et ET Endothelial Replicate 4
3.3 Transcriptome Analysis of Endocardial and Endothelial
Cells from Embryoid Bodies
3.3.1 Initial Reanalysis of Preexisting mRNA-seq Data
At the commencement of this project externally generated RNA-seq data were available
for endocardial and endothelial cells. Initial data quality assessment with FastQC demon-
strated a very high duplication rate, estimated in excess of 70% and generally low quality
of the reverse reads. First reads were de-duplicated without reference to the genomic
alignment and the remaining data were processed with the Tuxedo suite (as outlined in
the next sections), but did not yield any significant hits and further work on these data
was abandoned.
3.3.2 Experimental Design
RNA-seq was repeated on endocardial and endothelial cells in its entirety in the context of
this project. Four pseudo-biological replicates from independent embryoid body culture
pools were sequenced for each cell type. Four replicates were employed as past experience
with these cell types suggested that any effect sizes would be small and therefore a higher
number of replicates was desired to detect these changes to a high significance level (Prof.
Baldwin, personal communication).
3.3.3 Library Preparation and Sequencing Results
Frozen FACS sorted cell samples were shipped from the Baldwin laboratory. RNA was
extracted, quantified and its quality determined as outlined in Section 2.7.1 and before
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Figure 3.20: Gel representation of TapeStation data for RNA-seq input RNA. The quality
of all samples is equal to or exceeds the minimum of 8.0 RIN.
libraries were prepared (Section 2.7.4). Identifiers, sample names, and sample description
can be found in Table 3.11.
The samples were quantified using the Qubit instrument, results of the quantification
are shown in Table 3.12, the total amount of RNA was in all cases above the minimum
0.1 µg required. The quality of the extracted RNA was assessed using the Tapestation
RNA High Sensitivity assay (Figure 3.20). All samples had a RIN of 8.0 or higher and
were suitable for library preparation.
Table 3.12: RNA sample quantification and estimated volume and calculation of total
RNA. RNA was above minimum (0.1 µg) required for library preparation.
Sample Readings (µg/mL) Volume (µL) Total RNA (µg)
1st 2nd Mean
A 9.74 9.56 9.65 46 0.44
B 9.24 9.27 9.26 46 0.42
C 10.10 10.20 10.15 46 0.43
D 8.47 8.58 8.53 46 0.39
E 24.10 23.60 23.85 46 1.10
F 4.10 4.90 4.50 46 0.21
G 13.00 12.80 12.90 46 0.59
H 15.70 14.60 15.2 46 0.70
Directional poly(A) selected libraries were prepared as discussed in Section 2.7.4. The
fragment size of the libraries was estimated using the Agilent Tapestation instrument (see
Figure 3.21). Due to a fault of the reagent batch provided, accurate size estimation was
not possible and insert sizes were, by comparison to past runs and the expected insert
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Figure 3.21: Gel representation of Tapestation fragment size distribution data used for
RNA-seq library size estimation. Individual libraries are shown as separate lanes (A-H).
The size distribution of DNA fragments in all libraries was similar and consistent with an
insert size of 300 bp. Marker information was not complete and accurate size estimation
was not possible.
size was estimated to 300 bps. This value was selected to be higher than the expected
median fragment size, as use of a lower fragment size than that of the sample would lead
to more concentrated libraries that would overload the flowcell lane and yield no useful
data.
Libraries were diluted 1:1000 and quantified via qPCR (see Table 3.13), normalised
to 10 nM and subsequently pooled. The pooled libraries was sequenced on a single lane
of a Illumina R©HiSeq 2000 instrument. Addition of phiX control DNA library, cluster
generation and sequencing was performed by the BRC Sequencing Facility. The total
cluster count of 83 million (see Table 3.14) was low compared to the optimal instrument
run, which produces in excess of 100 million cluster counts. The lower number of clusters
was however offset by the very high quality of reads and no read removal was required
during quality control, as outlined in the next sections.
3.3.4 Bioinformatic Processing
The data produced during sequencing were bioinformatically processed to identify differ-
entially regulated genes between the two cell types. Processing consisted of basecalling,
assessment of the quality of the obtained data, filtering of the data based on the quality
control, alignment to the transcriptome and genome, building of a reference annotation
and differential expression analysis. In contrast to the BS-seq analysis outlined above
phiX DNA removal was not explicitly performed as the individual libraries were barcoded
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Table 3.13: RNA-seq library qPCR quantification and dilution calculations. The cor-
rection factor corrects for the insert size difference from the insert size fragment of the
standard reference library and is used to calculate the diluted corrected library concen-
tration. The final dilution volume is the final volume in which 1 µL of the original library


















A 618 300 1.51 931 931 466
B 1028 300 1.51 1549 1549 774
C 1048 300 1.51 1579 1579 789
D 879 300 1.51 1324 1324 662
E 691 300 1.51 1041 1041 521
F 672 300 1.51 1012 1012 506
G 556 300 1.51 838 838 419
H 641 300 1.51 966 966 483
Table 3.14: Adaptor identifiers, adaptor sequences and Raw Cluster Counts for the
mRNA-seq libraries. The total cluster count was lower than expected from a HiSeq
lane, but sufficient for differential gene expression analysis.
Sample ID Adaptor ID Adaptor Sequence Raw Cluster Count
A AR005 ACAGTG(A) 9,293,011
B AR006 GCCAAT(A) 12,422,156
C AR012 CTTGTA(A) 11,140,829
D AR019 GTGAAA(C) 7,837,534
E AR002 CGATGT(A) 10,553,367
F AR004 TGACCA(A) 11,097,369
G AR007 CAGATC(A) 10,035,665
H AR013 AGTCAA(C) 10,088,855
Total 83,468,813
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and phiX reads did not carry barcodes. These steps are outlined in more detail in the
following sections.
Quality Control
Basecalling was performed with Casava as outlined in section 2.7.5. Quality control was
performed with the FastQC toolkit. A representative output example is shown in Figure
3.22; output from FastQC runs on the entire dataset were visually examined. The read
quality was judged to be adequate on the basis of the base quality per position plot (Fig
3.22 A) and reads were not removed or trimmed on the basis of this score.
Unexpectedly, the base pair composition at the 5’ end of all reads (both forward and
reverse) was not uniform as expected (Fig 3.22 B). The source of this characteristic was
not identified but it is hypothesised to be the result of sequence-dependent fragmentation,
due to fragmentation by chemical means being employed (as opposed to sonication). In
addition, the presence of self-ligated adaptors could be the source of this contamination.
The presence of a k-mer poly(A) peak further suggest that the fragmentation is not
random (Fig 3.22 F).
On this basis the first 20 base-pairs of each read were removed and not examined in the
subsequent steps. This was done to minimise mapping bias from these sequences. Given
the long paired-end sequencing employed and the fact that the actual read sequence is of
no importance in RNA-seq – other than to ensure correct mapping of the reads – this is
expected to have no adverse effect in subsequent data analysis.
DNA duplication rates as identified by FastQC were very high (in excess of 50%) and
were initially a cause for concern. It must be noted that FastQC utilises a hash table to
estimate duplication rates and only tracks the first 50 bps of the first two hundred thou-
sand sequences; furthermore it does not take into account the paired nature of the reads.
The reported high duplication at this stage was ignored and duplication estimation and
removal was performed after alignment taking into account both ends of each fragment.
This revealed a much lower duplication rate.
Alignment
Alignment was performed using Tophat 2 and Bowtie 2 as the underlying aligner against
the mm9 version of the mouse genome as outlined in Section 2.7.5. Alignment was per-
formed against the annotated transcriptome and any unaligned reads were subsequently
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Figure 3.22: Initial quality control plots of RNA-seq sample A first reads; these plots are
representative of other samples. (A) Phred scaled quality score box plot as a function of
read position reveals very high quality of all reads (B) Base incorporation percentage as a
function of read position shows variable composition at the 5’ end but stable throughout
the read, this could be attributed to non-random fragmentation. (C) Average quality per
read distribution plot, shows very high quality of all reads with a short left-hand tail. (D)
GC% distribution closely matches the expected distribution. (E) Duplicate distribution
reveals very high duplication rate, this plot is not representative of the true duplication
rate (see main text). (F) k-mer content as a function of read position is highly uniform
after the first 10 bp, with the exception of poly(A) overrepresentation, which is consistent
with mRNA-seq.
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Table 3.15: Counts of aligned and concordantly aligned unique read pairs, show a very
low percentage of discordant read pairs and a high overall unique alignment rate.
Sample Input Aligned Discordant Condordant Unique
A 9,293,011 8,578,317 1.6% 7,956,505 (86%)
B 13,422,156 12,463,769 1.4% 11,636,058 (87%)
C 11,140,829 10,443,478 1.3% 9,835,121 (88%)
D 7,837,534 7,232,682 1.4% 6,805,494 (87%)
E 10,553,367 9,870,866 1.2% 9,378,143 (89%)
F 11,097,396 10,307,804 2.0% 9,465,814 (85%)
G 10,035,665 9,376,667 1.2% 8,832,287 (88%)
H 10,088,855 9,339,070 1.4% 8,807,181 (87%)
Mean 87%
aligned to the genomic sequence to identify novel transcripts. As shown in Table 3.15,
approximately 87% of all read pairs were uniquely and concordantly aligned to the tran-
scriptome, which is sufficient for the purposes of this investigation and above the expected
value. As the number of non-condordant reads was very low and did not exceed 2.0% in
any sample these reads were not removed.
Duplicate Read Identification and Removal
As aforementioned, initial duplication estimation suggested a very high duplication rate.
Duplicate identification and removal was performed with the Picard toolset as outlined in
Section 2.7.5. This revealed a much lower duplication rate of approximately 10% (Figure
3.23).
Estimation of the duplicate rate with the Picard software package is much more robust
than estimation with FastQC, as it takes into account the end position of each sequenced
fragment and can therefore distinguish between fragments that start at the same position
due to chance. Overestimation of the duplication rate by FastQC highlights the difficulties
of accurately removing duplicates when aligning against a small reference (in this case
the transcriptome), as identical reads become more frequent due to chance and are not
PCR amplification artefacts.
Annotation Building
A transcriptome annotation was built independently for every sample using the cufflinks
program. Individual annotations were merged using cuffmerge as described in Section
2.7.5. The merged annotation contains 25,263 genes of which 23,221 (91.1%) are present
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Figure 3.23: Duplication rate per library for mRNA-seq libraries as identified post-
alignment by the Picard toolkit, were low and did not exceed 12% for any of the samples.
Duplication rates calculated with Picard were in disagreement with duplication rates
calculated with FastQC (see main text for details).
in the reference annotation of 23,366 transcripts.
This suggests that 2,042 novel transcripts have been identified, whereas 145 known
transcripts have not been included in the annotation (Figure 3.24). The 145 genes not
included in the annotation were identified and a manual inspection of the mapped reads
and merged annotation was performed in approximately 20 of these loci at random. In all
cases the merged annotation included a transcript of the correct structure at the location,
but the transcript was not correctly mapped to the common gene identifier. This suggests
that a programmatic error in cuffmerge prevents correct annotation of a small portion of
the genes in the final annotation, but does not result in their exclusion from the analysis.
This is therefore not expected to adversely affect subsequent analysis.
Confirmation of Expression Pattern of NFATc1
The read mapping pattern of NFATc1, the marker used for separation of the two examined
cell populations via FACS, was examined using the UCSC genome browser prior to further
analysis (Figure 3.25). A considerably higher number of reads mapped to NFATc1 in
endocardial samples. Given the approximately equal number of reads in every library,
(see Table 3.15) the excess of reads in the endocardial samples suggested upregulation of
NFATc1 in the endocardium and confirmed that no sample mislabelling had occurred.
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Figure 3.24: Comparison of Reference UCSC annotation from refFlat with annotation
built from mRNA-seq on endocardial and endothelial cells, reveals that the overwhelm-
ing majority of annotated genes were detected in at least one cell type and 7,384 novel
transcripts were discovered.
3.3.5 Differential Expression of Genes and Transcripts
Differential expression analysis was performed with cuffdiff as outlined in Section 2.7.6.
This algorithm was selected for the differential expression analysis of this dataset after
comparison of the results between cuffdiff, limma [Smyth, 2005] and DESeq [Anders and
Huber, 2010]. The comparison revealed that cuffdiff was the only algorithm that suc-
cessfully identified the NFATc1 gene, the known marker on which the two cell populations
were selected as differentially regulated between the two cell types.
The FPKM distribution of individual libraries was assessed (Figure 3.26 A). Libraries
EC1 and EC4 displayed considerable deviation from the FPKM distribution of other
samples. This was however not recapitulated in the FPKM histogram plot (Figure 3.26
B). It is of interest to note that libraries EC1 and EC4, displayed the highest number of
missing values for genes in the annotation and this resulted in the boxplot being skewed,
whereas the histograms, which do not report missing values, are not. When genes with
missing values were manually excluded, the distribution of all samples was highly similar
to each other (Figure 3.27) and consistent with a stable FPKM range of values.
The CV as function of FPKM is reported in Figure 3.26 C. The CV is as expected
higher for both samples at low expression values and smaller at higher expression values.
The CV is also consistently higher for endothelial samples. This is expected because the
endothelial samples represent a more diverse and heterogenous population compared to
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Figure 3.25: Raw mapped reads at the NFATc1 locus from the mRNA-seq experiment.
(A,B) Reads from two replicates of the endocardial samples. (C,D) Reads from two
replicates of the endothelial samples. Visual inspection confirms that samples are correctly
labelled as NFATc1 is over-expressed in endocardial samples. All four replicates of each
sample were examined during the analysis.
130
the more restrictive endocardial cell population.
The analysis identified 711 differentially expressed genes between endocardial and en-
dothelial cells, of which 299 were upregulated in the endocardium and 411 downregulated
in the endocardium. A plot of the negative log-transformed p-values against the log
transformed fold change (Volcano plot) is shown in Figure 3.28. Note that the cuffdiff
program utilises an empirically generated distribution to calculate p-values and in the
interest of processing speed p-values are capped to minimum of 5 10−5. This exceeds the
significance threshold.
The top hits, by fold-change are presented in Tables 3.16 and 3.17 for genes upregu-
lated in the endocardium and endothelium respectively. The complete list of differentially
regulated genes can be found in the Appendix Table A.4.
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Figure 3.26: (A) Boxplot of log transformed FPKM values for individual libraries. Li-
braries EC1 and EC4, the libraries with the lowest read counts, show an unusual dis-
tribution due to missing values, see text page 129 for details. (B) Per-replicate FPKM
distribution, samples EC1 and EC4 do not show an unusual distribution, suggesting that
the unusual pattern in panel A is due to inclusion of these values as noughts. (C) Co-
efficient of variation as a function of log transformed FPKM values. Consistent with a
more heterogenous population, endothelial cells show a consistently higher coefficient of
variance. (D) Plot of mean expression in both cell types (A, x-axis) vs difference of means
of each sample (M) shows no systematic trends in expression differences as a function of
absolute expression.
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Figure 3.27: Boxplot of log10 transformed FPKM values for endocardial and endothe-
lial samples after discarding missing values, on a per sample basis. The distributions
are highly similar demonstrating that the sample specific differences observed can be
attributed to missing data.
Figure 3.28: Volcano plot of differential expression between endocardial and endothelial
cells. Significant hits appear in red. The p-value axis are capped, due to the way that
cuffdiff generates p-values.
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Table 3.16: Top 50 significantly upregulated genes in endo-
cardial cells by fold change.
Gene Locus EC expression ET expression p-value q-value Fold Change
Oit3 chr10:58885707-58904527 5.20 0.30 5.00E-05 2.50E-03 17.15
Slc32a1 chr2:158436493-158441483 5.13 0.31 5.00E-05 2.50E-03 16.56
Gad2 chr2:22477846-22549397 4.57 0.43 5.00E-05 2.50E-03 10.68
Ptprb chr10:115738429-115826594 2.53 0.25 5.00E-05 2.50E-03 9.93
- chr15:72333348-72335718 2.09 0.22 5.50E-04 1.78E-02 9.60
Sost chr11:101823771-101828329 4.49 0.51 5.00E-05 2.50E-03 8.77
Ccm2l chr2:152891690-152907471 2.85 0.34 1.15E-03 3.19E-02 8.30
Cdh5 chr8:106625524-106668402 37.48 4.59 5.00E-05 2.50E-03 8.17
Sox7 chr14:64562542-64569569 10.68 1.39 5.00E-05 2.50E-03 7.67
Erg chr16:95581810-95751972 11.47 1.51 5.00E-05 2.50E-03 7.58
Nos3 chr5:23870636-23897961 6.88 0.94 5.00E-05 2.50E-03 7.35
Grap chr11:61466822-61486279 6.70 0.91 5.00E-05 2.50E-03 7.33
Lyve1 chr7:117994120-118006467 1.68 0.23 1.25E-03 3.41E-02 7.31
Dusp2 chr2:127161894-127164113 7.11 0.98 5.00E-05 2.50E-03 7.24
Rasip1 chr7:52882906-52894462 12.56 1.84 5.00E-05 2.50E-03 6.82
Eltd1 chr3:151100845-151208045 3.66 0.54 5.00E-05 2.50E-03 6.80
Skap1 chr11:96325904-96620936 5.66 0.84 5.00E-05 2.50E-03 6.78
Gimap4 chr6:48634576-48642061 2.02 0.30 2.00E-04 7.94E-03 6.69
Samsn1 chr16:75859038-75909511 4.03 0.62 5.00E-05 2.50E-03 6.48
Ushbp1 chr8:73908172-73919704 2.22 0.35 5.00E-05 2.50E-03 6.33
Tie1 chr4:118143795-118162454 40.45 6.62 5.00E-05 2.50E-03 6.11
Cd93 chr2:148262386-148269271 13.66 2.26 5.00E-05 2.50E-03 6.05
Kcne3 chr7:107325179-107333379 8.80 1.46 5.00E-05 2.50E-03 6.01
- chr15:72337445-72342362 1.73 0.29 1.00E-04 4.56E-03 5.97
- chr16:95580786-95581555 10.43 1.76 5.00E-05 2.50E-03 5.94
Adra2a chr19:54119671-54123472 3.92 0.67 5.00E-05 2.50E-03 5.88
Icam2 chr11:106238969-106243955 13.43 2.29 5.00E-05 2.50E-03 5.87
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Gimap6 chr6:48651581-48658243 6.43 1.11 5.00E-05 2.50E-03 5.80
Emcn chr3:137004041-137094033 7.16 1.24 5.00E-05 2.50E-03 5.77
Ikzf1 chr11:11586215-11672929 4.18 0.74 5.00E-05 2.50E-03 5.65
Esam chr9:37335673-37345904 3.97 0.72 1.70E-03 4.33E-02 5.54
Egfl7 chr2:26436575-26448202 12.09 2.19 5.00E-05 2.50E-03 5.52
Myct1 chr10:4739751-4752813 2.78 0.51 1.50E-04 6.36E-03 5.49
Myzap chr9:71352153-71440167 9.76 1.79 5.00E-05 2.50E-03 5.46
Esam chr9:37335673-37345904 27.65 5.10 5.00E-05 2.50E-03 5.42
Tspan8 chr10:115254339-115286949 2.12 0.39 7.00E-04 2.15E-02 5.41
Gfi1b chr2:28464969-28477502 8.33 1.54 5.00E-05 2.50E-03 5.40
Abi3 chr11:95685813-95707045 4.32 0.83 1.00E-04 4.56E-03 5.19
Pcdh12 chr18:38426745-38444055 3.60 0.70 5.00E-05 2.50E-03 5.13
Sox18 chr2:181404541-181406345 4.31 0.85 1.50E-04 6.36E-03 5.08
Csgalnact1 chr8:70880679-71259045 4.68 0.93 5.00E-05 2.50E-03 5.06
Adora2a chr10:74779687-74797533 4.71 0.93 5.00E-05 2.50E-03 5.05
Mmrn2 chr14:35188689-35217472 12.11 2.41 5.00E-05 2.50E-03 5.01
Acer2 chr4:86520317-86566785 13.32 2.66 5.00E-05 2.50E-03 5.00
Thsd1 chr8:23337774-23371804 4.92 0.99 5.00E-05 2.50E-03 4.98
Tal1 chr4:114729365-114744360 31.18 6.31 5.00E-05 2.50E-03 4.94
Mpo chr11:87607285-87617914 2.37 0.48 5.50E-04 1.78E-02 4.92
Afap1l1 chr18:61889053-61946316 17.92 3.69 5.00E-05 2.50E-03 4.85
Gngt2 chr11:95685813-95707045 21.37 4.46 1.75E-03 4.41E-02 4.79
Igf1 chr10:87321800-87399792 8.47 1.78 5.00E-05 2.50E-03 4.77
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Table 3.17: Top 50 significantly upregulated genes in en-
dothelial cells by fold change.
Gene Locus EC expression ET expression p-value q-value Fold Change
- chr15:96991387-96991826 0.00 2.55 5.00E-05 2.50E-03 High
- chr7:36255279-36256279 0.00 38.35 2.00E-03 4.91E-02 High
Gm10324 chr13:66214388-66223772 0.22 6.41 9.50E-04 2.74E-02 29.32
- chr13:98252715-98274765 0.12 2.13 5.00E-05 2.50E-03 17.29
4930500J02Rik chr2:104399333-104411586 0.10 1.60 9.50E-04 2.74E-02 16.68
- chr13:98278330-98283216 0.11 1.78 6.50E-04 2.05E-02 16.53
Tdh chr14:64111183-64127929 0.75 10.95 5.00E-05 2.50E-03 14.52
Gdf3 chr6:122555420-122560089 0.28 4.04 5.00E-04 1.67E-02 14.43
Gm2381 chr7:50067562-50122604 0.19 2.64 5.00E-04 1.67E-02 13.68
AU018091 chr7:3154659-3169204 0.88 11.07 5.00E-05 2.50E-03 12.56
Tdrd12 chr7:36278628-36322763 0.40 5.02 1.60E-03 4.12E-02 12.52
BC024139, Eppk1 chr15:75931917-75956986 0.12 1.47 2.50E-04 9.49E-03 12.30
Fgf4 chr7:152047290-152051148 0.36 4.35 5.00E-05 2.50E-03 12.21
- chr9:118308486-118313594 0.15 1.77 2.50E-04 9.49E-03 11.78
Alox15 chr11:70157648-70165533 0.29 3.16 1.00E-04 4.56E-03 10.94
Utf1 chr7:147129754-147131011 0.85 9.21 2.00E-04 7.94E-03 10.78
Sptbn2 chr19:4711222-4752352 0.39 4.13 5.00E-05 2.50E-03 10.65
Gpa33 chr1:168060590-168096641 0.30 3.20 4.00E-04 1.40E-02 10.65
Folr1 chr7:109006844-109019302 0.43 4.59 5.00E-05 2.50E-03 10.62
Pou5f1 chr17:35642976-35647722 3.87 39.95 5.00E-05 2.50E-03 10.32
Esrp1 chr4:11259184-11313930 0.23 2.27 1.40E-03 3.74E-02 9.94
Slc28a1 chr7:88259684-88315302 0.23 2.23 2.00E-04 7.94E-03 9.80
Aire chr10:77492766-77526360 0.31 3.04 5.00E-05 2.50E-03 9.79
Trap1a chrX:135774764-135892277 1.38 13.49 5.00E-05 2.50E-03 9.79
Mcf2 chrX:57309132-57400820 0.16 1.51 1.55E-03 4.03E-02 9.72
Esrrb chr12:87702066-87862578 0.65 6.28 5.00E-05 2.50E-03 9.71
Zfp42 chr8:44380420-44392363 1.04 10.10 5.00E-05 2.50E-03 9.70
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Gm13242 chr4:145126547-145419626 0.55 5.21 1.60E-03 4.12E-02 9.56
Tfap2c chr2:172375092-172384121 0.41 3.92 5.00E-05 2.50E-03 9.55
Sox1 chr8:12385770-12436732 0.34 3.21 5.00E-05 2.50E-03 9.43
Ano9 chr7:148287117-148303705 0.31 2.86 1.00E-04 4.56E-03 9.35
Wnt8b chr19:44567961-44590041 0.30 2.83 1.00E-04 4.56E-03 9.33
Smc1b chr15:84895118-84962387 0.23 2.12 1.00E-04 4.56E-03 9.28
Ap3b2 chr7:88605284-88638811 0.29 2.64 5.00E-05 2.50E-03 9.22
Rfx4 chr10:84218792-84369283 0.33 2.99 5.00E-05 2.50E-03 9.15
Nkx2-1 chr12:57632923-57637895 0.36 3.25 2.00E-04 7.94E-03 8.91
Gm13247 chr4:145651165-145696039 0.53 4.69 5.00E-05 2.50E-03 8.84
Fezf2 chr14:13174405-13179290 0.43 3.69 2.00E-04 7.94E-03 8.68
Wnt1 chr15:98620287-98624261 0.64 5.51 5.00E-05 2.50E-03 8.57
2410141K09Rik chr13:66519049-66542054 2.10 18.01 1.15E-03 3.19E-02 8.57
Wnt7b chr15:85365866-85424138 0.26 2.20 5.00E-05 2.50E-03 8.53
Dppa5a chr9:78214860-78216006 35.20 298.69 5.00E-05 2.50E-03 8.49
Foxb1 chr9:69605516-69608747 0.19 1.63 1.70E-03 4.33E-02 8.38
Mlxipl chr5:135582760-135614252 0.18 1.50 3.50E-04 1.26E-02 8.27
Nanog chr6:122657585-122664639 2.20 18.08 5.00E-05 2.50E-03 8.23
Miat chr5:112642247-112657968 1.81 14.87 5.00E-05 2.50E-03 8.20
Sim2 chr16:94085504-94348638 0.47 3.80 5.00E-05 2.50E-03 8.12
Pcdh8 chr14:80166578-80171119 0.64 5.20 5.00E-05 2.50E-03 8.11
Mpped1 chr15:83610452-83688904 0.21 1.72 5.00E-05 2.50E-03 8.07
D7Ertd143e chr7:3217861-3221016 0.61 4.87 5.00E-05 2.50E-03 8.05
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Associations of Differentially Regulated Genes with Endocardial Development
A number of the genes found to be over-expressed in the endocardium have known links to
endocardial or cardiac development. The identification of these genes in our investigation
supports the relevance of the embryoid body differentiation model of the endocardium to
the in vivo differentiation process. This section discusses genes with known connections
to endocardial or cardiac development, as well as Oit3, a gene not previously associated
with heart development but exhibiting the maximal fold-change in the mRNA-seq data.
In addition, the pluripotency factors that were unexpectedly found to be upregulated
in the endothelium are discussed. The presence of pluripotency factors is unexpected
because the FACS sorting protocol employed was originally expected to exclusively isolate
differentiated endothelial cells.
Oit3, also known as Lzp, is the top hit from the mRNA-seq data by fold change and
shows 17-fold upregulation in the endocardium compared to the endothelium. A literature
search revealed no known function for Oit3 in the heart or the endocardium. An Oit3 null
mouse has been generated [Yan et al., 2012] and has been found to survive to adulthood
without any gross developmental abnormalities, suggesting the absence of major cardiac
anomalies. Characterisation of the null mouse has revealed defects primarily in the kidney,
although a full characterisation of the mouse is not reported in literature. Interestingly,
earlier publications have demonstrated Oit3 expression in heart muscle via qPCR but not
via immunohistochemistry [Shen et al., 2009]. It is therefore possible that its endocardial
specific expression detected in the RNA-seq data has previously been misattributed to
the myocardium.
Ptprb, the fourth hit by fold-change, is a cell surface protein showing 10-fold up-
regulation in the endocardium. Ptprb is also known as Ve-ptp [Wansleeben et al., 2011]
and has been found to be essential for maintenance and remodelling, but not for formation,
of blood vessels [Ba¨umer et al., 2006]. Furthermore, it has been shown to associate with
Tie2 [Ba¨umer et al., 2006], one of the two genes the knock-out of which completely ablates
the endocardium, and negatively regulate its action [Winderlich et al., 2009] (Figure 3.29
B). Ptprb truncation has been shown to have widespread endothelial cell defects, but also
specific endocardial defects, with absent trabeculation and failure of attachment of the
endocardium to the myocardium, suggesting a more specific role in the heart [Ba¨umer
et al., 2006] that has not been investigated. A specific role for Ptprb in the heart is further
supported by its high expression in the OFT and developing heart valves [Dominguez
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et al., 2007].
Cdh5, also known as VE-Cadherin and CD144, is a major component of endothelial
adherens junctions [Dejana and Orsenigo, 2013]. Cdh5 displays 8-fold up-regulation in
the endocardium compared to the endothelium. Expression of Cdh5 in the endocardium
is known to occur [Narumiya et al., 2007], however, its over-expression in comparison to
other endothelial cells has not been documented previously.
Sox7 is a transcription factor and member of the SoxF family of transcription factors
that comprises Sox7, Sox17 and Sox18. The SoxF family is known to have important
roles in the development of the cardiovascular system [Francois et al., 2010] and Sox7 in
concert with Sox18 have been found to be essential in cardiogenesis in Xenopus laevis.
Sox7 is upregulated 8-fold in the endocardium in the RNA-seq data, along with the
other two members of the SoxF family (Sox17 2-fold, Sox18 2-fold). Sox7 has previously
been shown to be expressed in the developing endocardium at E8.75 [Sakamoto et al.,
2007] among other mesodermaly derived endothelial tissues [Wat and Wat, 2014] and its
deletion displays specific endocardial defects [Sakamoto et al., 2007].
Interestingly, Sox7 has previously been shown to directly regulate expression of Cdh5,
discussed above, by direct binding to its promoter region [Costa et al., 2012] and further-
more is directly regulated by Etv2 [Behrens et al., 2014], which is also upregulated in the
endocardium (3-fold). Etv2, also known as Etsrp71, is a member of the ETS family of
transcription factors, a TF family independently identified in the context of this work as
relevant to endocardial development (Section 3.3.9). This finding suggests that a pathway
of Etv2, Sox7, Cdh5 activation is active in the endocardium (Figure 3.29 A). Etv2 has
independently been shown to be indispensable in endocardial development and has been
shown to be directly regulated by Nkx2-5, and in turn regulate Tie2 [Ferdous et al., 2009]
(Figure 3.29 A and B), one of the two tyrosine receptors that when knocked-out in mice
results in complete and specific ablation of the endocardium.
Erg is a transcription factor and a member of the ETS family upregulated 8-fold
in the endocardium. Erg has previously been shown to be a regulator of EMT in the
valvular endocardium [Vijayaraj et al., 2012] and has been implicated in cardiac cushion
formation [Schachterle et al., 2012]. Furthermore, Erg regulates expression of the Gata4
transcription factor that is known to be expressed in several cardiovascular lineages (Fig-
ure 3.29 C). Erg physically interacts with Klf2 and results in the up-regulation of Flk1,
also known as Kdr and Vegrf2, (one of the markers of the MICP, see Section 1.3.3), which
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Figure 3.29: Summary of selected published gene relationships discussed in the main
text. Genes upregulated in the mRNA-seq data are annotated by fold type and cell type
of upregulation (EC endocardial, ET endothelial)
140
is also significantly upregulated in the endocardium 2-fold.
Nitric oxide synthetase 3 (Nos3 ), also known as endothelial Nos (eNos), is 7-fold up-
regulated in the endocardium (Figure 3.29 D). Nitric oxide (NO) is a signalling molecule
implicated in a diverse repertoire of processes [Liu and Feng, 2012]. In contrast to nitric-
oxide produced by Nos1 and Nos2, nitric-oxide produced by Nos3 has a role confined to
intracellular signalling [Liu and Feng, 2012]. Nos3 is known to have a role in heart devel-
opment and a specific role in the endocardium. Mutations in Nos3 result in congenital
heart disease in the mouse and humans and Nos3 null mice have been found to display
atrial septal defects with high incidence [Nadeau et al., 2010] and defective bicuspid aor-
tic valves [Liu and Feng, 2012]. In the context of the atrial septum formation, Nos3 has
been shown to have a specific role in endocardial cell survival and to be regulated by the
genetically interacting Tbx5 and Gata4 transcription factors [Nadeau et al., 2010]. Inter-
estingly, Nos3 is known to be regulated by an ETS family member protein Elf1 [Huang
et al., 2005].
Tie1, an orphan tyrosine kinase receptor, shows 6-fold upregulation in the endo-
cardium. Tie1 has been strongly associated with endocardial development as it is one
of the two genes (with Tie2 ) that when disrupted result in specific ablation of the endo-
cardium [Puri et al., 1999]. Furthermore, Tie1 -null mice display a reduction in endocar-
dial cell numbers and heart developmental abnormalities [Dumont et al., 1994] (Figure
3.29 B).
Egfl7, also known as VE-statin, is upregulated 5-fold in the endocardium and is a
known regulator of angiogenesis. Egfl7 promotes angiogenesis via the Stat3 signalling
cascade [Chim et al., 2014]. Stat3 is also significantly upregulated in the endocardium
(1.5-fold), suggesting that the same pathway may be active in the endocardium. The gene
body of Eglf7 contains the gene for microRNA-127. MicroRNA-127, is directly regulated
by ETS family members Ets1 and Ets2 [Harris et al., 2010] that are both upregulated
in the endocardial mRNA-seq data and has been implicated in vascular development
[A´sgeirsdo´ttir et al., 2012].
Tal1, a DNA binding transcription factor [Deleuze et al., 2007] that is upregulated
5-fold in the endocardium, has also been previously linked to endocardial development.
A Tal1 Danio rerio mutant with abnormal segregation of the endocardium has been
described [Bussmann et al., 2007] and furthermore Tal1 has been found to influence the
distribution of endocardial cell junctions in vivo and also be required for the maintenance
141
of the cell identity for the endocardium in the mouse [Schumacher et al., 2013]. In the
context of the hemangioblast, the progenitor of haematopoietic and epithelial cells that
precedes formation of the endocardium (Section 1.3.1), Tal1 has been shown to directly
target the promoter region of Runx1 [Landry et al., 2008] (Figure 3.29 E), a TF that
shows 3-fold upregulation in the endocardium. Ablation of Tal1 has been found to result
in Runx1 downregulation [Van Handel et al., 2012].
In addition to the aforementioned factors, all four factors known to direct angiogenesis
are upregulated in the endocardium. These factors comprise Notch4 (upregulated 3-fold),
Dll4 (upregulated 4-fold), Vegfr1 (also known as Flt1, upregulated 2.5-fold) and Vegfr
(also known as Kdr and Flk, upregulated 3-fold) (Figure 3.29 F). These four factors are
involved in angiogenesis by directing the growth of developing vessels [Jakobsson et al.,
2010] and computational models suggest that they are sufficient for the patterning of
vessels, in response to exogenous gradients. Establishment of signalling via this angiogenic
pathway is by ETS transcription factors [Wythe et al., 2013]. Specifically the activity of
the Dll4 enhancer is regulated by ETS factors Etv2 and Erg, both of which are upregulated
in the endocardium in the mRNA-seq data.
Finally, it must be noted that NFATc1 – the marker of the endocardium used for FAC
sorting – is upregulated 4-fold in the endocardium.
Several genes are upregulated in the endothelium, and conversely downregulated in the
endocardium. Given that the endothelium examined represents the average background
population of endothelial cells in the embryoid bodies and no particular subpopulation of
the endothelium, genes that appear to be upregulated in this tissue could be upregulated
in any subcomponent of it, or be specifically downregulated in the endocardium. It is
therefore difficult to draw specific conclusions from the group of candidate genes upreg-
ulated in the endothelium. It is however interesting to note that two of the four known
pluripotency factors appear highly differentially expressed in the endothelium compared
to the endocardium.
Specifically, Pou5f1 (also known as Oct3/4 ) is 8-fold upregulated in the endothelium
and Sox2 is 5-fold upregulated. Furthermore, Nanog, [Chambers and Tomlinson, 2009] is
8-fold upregulated. The upregulated pluripotency factors are all part of the LIF pathway
[Niwa et al., 2009] that is responsible for maintenance of pluripotency of ES cells during
culture on MEFs (Section 2.1). Expression of these genes, suggests that MEFs may survive
into the hanging drop EB culture, despite their irradiation and depletion. Selection for
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CD31+ that might be expected to result in the depletion of pluripotent cells is probably
not completely effective as a result of CD31 expression by pluripotent cells [Robson et al.,
2001].
3.3.6 Differential Promoter Usage and Alternative Splicing
Although the aim of this investigation did not explicitly include the identification of differ-
entially spliced transcripts and the experimental design was not such as to allow complete
identification of these events, this analysis was possible and was therefore performed.
A limited number of transcripts in the dataset were found to display differential pro-
moter usage or alternative splicing. These are displayed in Table 3.18 along with locus
position, uncorrected and corrected p-values.
Four genes have been found to show alternative splicing. Afap1l1 (Actin filament as-
sociated protein 1-like 1), a gene encoding for a protein of unknown function, has recently
been described as a regulator of cellular morphology in colorectal cancer [Takahashi et al.,
2014]. Different Afap1l1 isoforms may potentially be responsible for subtle cytoskeletal
differences between the endocardium and the endothelium. Myocd (Myocardin) is de-
scribed as essential for myocardial survival and is known to be a transcriptional regulator
in smooth muscle cells [Huang et al., 2009]. However, a role in the pathogenesis of vascular
disease has been proposed [Zheng, 2014] and its role in the endothelium is corroborated
by our data. Lphn2 is a putative uncharacterised protein and no information of Ccser2
exists in literature.
Three genes exhibit alternative promoter usage. Sall2 (sal-like 2) is described as a
transcription factor in literature and has been implicated in cancer [Farkas et al., 2013],
but is not otherwise known to have a role in heart or vascular development. Egfl7 (epider-
mal growth factor-like protein 7) is a secreted angiogenic factor with well characterised
role in vascular development and a known role in endothelial proliferation [Nichol and
Stuhlmann, 2011]. Although Egfl7 is known to make use of alternative promoter sites,
an endocardial-specific isoform of the protein product has not been previously described
and its identification in this assay warrants further investigation. Gpm6b (neuronal mem-
brane glycoprotein M6-b) has been previously been shown to display sexually dimorphic
expression in the heart and may therefore represent a false positive [Isensee et al., 2008].
Of the above hits, Afap1l1, Sall2, Eglf6 and Gpm6b also appear to have a difference
in expression levels between the two cell types in the differential expression analysis.
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Table 3.18: All transcripts showing alternative promoter usage or alternative splicing
between endocardial and endothelial cells.
Gene Locus p-value q-value
Splicing
Afap1l1 chr18:61889053-61946316 5.00E-05 0.0234125
Lphn2 chr3:148478549-148617605 5.00E-05 0.0234125
Myocd chr11:64990071-65083491 5.00E-05 0.0234125
Ccser2 chr14:37688121-37781950 5.00E-05 0.0234125
Promoter
Sall2 chr14:52930851-52948345 5.00E-05 0.02115
Egfl7 chr2:26436575-26448202 5.00E-05 0.02115
Gpm6b chrX:162676874-162826965 0.00015 0.0423
3.3.7 Gene Ontology Term Overrepresentation Analysis
The set of differentially expressed genes was assessed for overrepresentation of Gene On-
tology (GO) terms using a pruned tree approach with GO-Elite [Zambon et al., 2012] as
outlined in Section 2.7.7. The ten most significant terms of each analysis split by Biolog-
ical Process, Cellular Component and Molecular Function can be found in Tables 3.19,
3.20 and 3.21. Full results can be found in Tables A.5, A.6 and A.7 of the Appendix.
The results are consistent with the expectations from these cell lines with terms such
as “developmental process”, “cell adhesion”, “regulation of developmental process”, “reg-
ulation of cell migration”, “regulation of response to stimulus” comprising the most signif-
icantly overrepresented terms. In particular, the prominence of the term “developmental
process” is notable as it is the most significant term in the biological process GO term
analysis with a p-value of 0.01 and reaffirms with the active developmental process endo-
cardial cells are undergoing.
It is of interest to note that the term “response to fluid shear stress” appears in the list
of significantly overrepresented GO terms suggesting that the haemodynamic environment
may have an influence on the transcriptome of the endocardium. Genes associated with
this term comprise Cited2, Ets1, Mef2c, Nos3, Smad6 and Tgfb1. This would not be
unprecedented [Banjo et al., 2013] and would support a model where the endocardium
arises from the the endothelium and the differences from other endothelium are primarily
the result of the local haemodynamic environment.
The differentially expressed genes were stratified by upregulation in either endocardial
or endothelial cells and GO term analysis was repeated in both sets separately. The
most significant results of the analysis for genes upregulated in the endocardium and
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endothelium are shown in Tables 3.22 through 3.27. Complete tables of the results of the
analysis can be found in Tables A.8 through to A.10 and A.11 through to A.13 of the
Appendix.
It is of interest to note that whereas the genes upregulated in the endothelium are asso-
ciated with general developmental terms (such as “anatomical structure development” and
“embryonic pattern specification”), endocardially upregulated genes appear to have more
specific enrichment for haematopoietic development (“regulation of erythrocyte develop-
ment”, “regulation of mast cell differentiation”) while still showing overrepresentation of
endothelial genes (“endothelial cell differentiation”, “angiogenesis”). The stratified anal-
ysis, confirms that the term “response to fluid shear stress” is specifically associated with
endocardially upregulated genes.
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Table 3.19: Ten most significantly overrepresented, pruned,
biological process GO terms from the differential expression
analysis. Terms are sorted by ascending adjusted p-value and
then by descending Z-score.
Ontology Name (Ontology-ID) Percent Changed Z-Score Adjusted P-value
developmental process(GO:0032502) 8.06 16.86 1.01E-02
cell adhesion(GO:0007155) 13.56 14.43 1.01E-02
regulation of developmental process(GO:0050793) 9.63 12.97 1.01E-02
regulation of cell migration(GO:0030334) 15.00 12.17 1.01E-02
regulation of response to stimulus(GO:0048583) 7.94 11.07 1.01E-02
positive regulation of biological process(GO:0048518) 6.71 11.05 1.01E-02
regulation of cell proliferation(GO:0042127) 9.29 10.83 1.01E-02
response to external stimulus(GO:0009605) 9.87 10.55 1.01E-02
negative regulation of cellular process(GO:0048523) 6.88 10.17 1.01E-02
negative regulation of locomotion(GO:0040013) 20.35 10.17 1.01E-02
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Table 3.20: Ten most significantly overrepresented, pruned,
cellular component GO terms from the differential expression
analysis. Terms are sorted by ascending adjusted p-value and
then by descending Z-score.
Ontology Name(Ontology-ID) Percent Changed Z-Score Adjusted P-value
extracellular region part(GO:0044421) 9.31 11.34 1.01E-02
plasma membrane part(GO:0044459) 7.58 11.03 1.01E-02
cell surface(GO:0009986) 13.41 10.80 1.01E-02
plasma membrane(GO:0005886) 6.61 10.59 1.01E-02
neuron projection(GO:0043005) 9.38 8.04 1.01E-02
dendrite terminus(GO:0044292) 75.00 8.02 1.01E-02
extracellular region(GO:0005576) 6.71 7.74 1.01E-02
membrane raft(GO:0045121) 10.14 5.54 1.01E-02
cell periphery(GO:0071944) 21.74 4.95 1.01E-02
extrinsic to membrane(GO:0019898) 10.92 4.67 1.01E-02
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Table 3.21: Ten most significantly overrepresented, pruned,
molecular function GO terms from the differential expression
analysis. Terms are sorted by ascending adjusted p-value and
then by descending Z-score.
Ontology Name(Ontology-ID) Percent Changed Z-Score Adjusted P-value
protein binding(GO:0005515) 4.93 11.59 1.01E-02
pattern binding(GO:0001871) 18.07 10.69 1.01E-02
calcium ion binding(GO:0005509) 10.87 10.52 1.01E-02
extracellular matrix binding(GO:0050840) 28.95 8.85 1.01E-02
RNA polymerase II regulatory region sequence-specific DNA binding(GO:0000977) 22.22 8.41 1.01E-02
Wnt receptor activity(GO:0042813) 35.00 7.93 1.01E-02
chemorepellent activity(GO:0045499) 60.00 7.09 1.01E-02
retinoic acid binding(GO:0001972) 44.44 6.91 1.01E-02
transmembrane receptor protein kinase activity(GO:0019199) 16.67 6.87 1.01E-02
icosanoid binding(GO:0050542) 50.00 6.40 1.01E-02
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Table 3.22: Ten most significantly overrepresented, pruned,
biological process GO terms from the genes upregulated in
the endocardium. Terms are sorted by ascending adjusted
p-value and then by descending Z-score.
Ontology Name (Ontology-ID) Percent Changed Z-Score Adjusted P-value
regulation of erythrocyte differentiation(GO:0045646) 32.26 14.55 1.20E-02
regulation of mast cell differentiation(GO:0060375) 100.00 14.46 1.20E-02
endothelial cell differentiation(GO:0045446) 55.56 13.75 1.20E-02
regulation of gamma-delta T cell activation(GO:0046643) 66.67 13.53 1.20E-02
angiogenesis(GO:0001525) 12.90 13.33 1.20E-02
JAK-STAT cascade involved in growth hormone signaling pathway(GO:0060397) 75.00 12.46 1.20E-02
regulation of cell motility(GO:2000145) 9.07 12.28 1.20E-02
response to fluid shear stress(GO:0034405) 37.50 12.22 1.20E-02
regulation of angiogenesis(GO:0045765) 13.64 11.93 1.20E-02
hemopoiesis(GO:0030097) 15.79 11.89 1.20E-02
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Table 3.23: Ten most significantly overrepresented, pruned,
cellular component GO terms from the genes upregulated in
the endocardium. Terms are sorted by ascending adjusted
p-value and then by descending Z-score.
Ontology Name (Ontology-ID) Percent Changed Z-Score Adjusted P-value
plasma membrane(GO:0005886) 3.25 8.90 1.20E-02
cell periphery(GO:0071944) 21.74 8.26 1.20E-02
cell surface(GO:0009986) 6.15 7.65 1.20E-02
plasma membrane part(GO:0044459) 3.24 7.12 1.20E-02
acrosomal membrane(GO:0002080) 25.00 6.92 1.20E-02
transport vesicle(GO:0030133) 10.71 5.90 1.20E-02
extracellular region part(GO:0044421) 3.26 5.26 1.20E-02
cell projection(GO:0042995) 3.21 5.01 1.20E-02
cell fraction(GO:0000267) 2.66 3.70 1.20E-02
intrinsic to Golgi membrane(GO:0031228) 11.11 4.93 2.18E-02
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Table 3.24: Ten most significantly overrepresented, pruned,
molecular function GO terms from the genes upregulated in
the endocardium. Terms are sorted by ascending adjusted
p-value and then by descending Z-score.
Ontology Name (Ontology-ID) Percent Changed Z-Score Adjusted P-value
RNA polymerase II regulatory region sequence-specific DNA binding(GO:0000977) 15.87 9.73 1.20E-02
protein binding(GO:0005515) 2.32 9.73 1.20E-02
pattern binding(GO:0001871) 7.23 6.37 1.20E-02
calcium ion binding(GO:0005509) 4.35 6.17 1.20E-02
core promoter sequence-specific DNA binding(GO:0001046) 15.38 6.03 1.20E-02
sequence-specific DNA binding transcription factor activity(GO:0003700) 3.54 5.26 1.20E-02
guanyl-nucleotide exchange factor activity(GO:0005085) 6.33 5.25 1.20E-02
enzyme activator activity(GO:0008047) 4.49 4.80 1.20E-02
chromatin binding(GO:0003682) 4.38 4.01 1.20E-02
receptor signaling protein activity(GO:0005057) 6.41 3.74 1.20E-02
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Table 3.25: Ten most significantly overrepresented, pruned,
biological process GO terms from the genes upregulated in
the endothelium. Terms are sorted by ascending adjusted
p-value and then by descending Z-score.
Ontology Name(Ontology-ID) Percent Changed Z-Score Adjusted P-value
cell-cell adhesion(GO:0016337) 14.44 15.26 2.07E-02
anatomical structure development(GO:0048856) 5.84 13.59 2.07E-02
embryonic pattern specification(GO:0009880) 25.49 12.40 2.07E-02
forebrain anterior/posterior pattern formation(GO:0021797) 66.67 11.66 2.07E-02
anatomical structure morphogenesis(GO:0009653) 6.52 11.65 2.07E-02
axon guidance(GO:0007411) 15.75 11.51 2.07E-02
axis specification(GO:0009798) 20.00 11.15 2.07E-02
multicellular organismal development(GO:0007275) 6.83 11.02 2.07E-02
tube formation(GO:0035148) 16.16 10.46 2.07E-02
cellular developmental process(GO:0048869) 4.87 9.78 2.07E-02
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Table 3.26: Ten most significantly overrepresented, pruned,
cellular component GO terms from the genes upregulated in
the endothelium. Terms are sorted by ascending adjusted
p-value and then by descending Z-score.
Ontology Name(Ontology-ID) Percent Changed Z-Score Adjusted P-value
extracellular matrix(GO:0031012) 9.94 10.87 2.07E-02
cell-cell junction(GO:0005911) 9.06 8.63 2.07E-02
extracellular region(GO:0005576) 4.67 8.30 2.07E-02
fibrillar collagen(GO:0005583) 33.33 8.00 2.07E-02
extracellular space(GO:0005615) 5.60 7.80 2.07E-02
cell surface(GO:0009986) 7.26 7.54 2.07E-02
lateral plasma membrane(GO:0016328) 20.69 7.44 2.07E-02
axon(GO:0030424) 8.37 6.82 2.07E-02
apical plasma membrane(GO:0016324) 7.73 6.40 2.07E-02
plasma membrane(GO:0005886) 3.36 6.18 2.07E-02
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Table 3.27: Ten most significantly overrepresented, pruned,
molecular function GO terms from the genes upregulated in
the endothelium. Terms are sorted by ascending adjusted
p-value and then by descending Z-score.
Ontology Name(Ontology-ID) Percent Changed Z-Score Adjusted P-value
chemorepellent activity(GO:0045499) 60.00 9.55 2.07E-02
extracellular matrix binding(GO:0050840) 21.05 8.69 2.07E-02
transmembrane-ephrin receptor activity(GO:0005005) 50.00 8.66 2.07E-02
pattern binding(GO:0001871) 10.84 8.51 2.07E-02
calcium ion binding(GO:0005509) 6.52 8.46 2.07E-02
inorganic anion exchanger activity(GO:0005452) 33.33 8.00 2.07E-02
Wnt receptor activity(GO:0042813) 25.00 7.60 2.07E-02
axon guidance receptor activity(GO:0008046) 37.50 7.40 2.07E-02
heparan sulfate proteoglycan binding(GO:0043395) 28.57 7.34 2.07E-02
Wnt-protein binding(GO:0017147) 20.00 6.66 2.07E-02
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Table 3.28: Transcription Factors upregulated in endocardial cells.
Asb4 Foxh1 Myb Shank3
Bcl6b Gata1 Myc Smad6
Cbfa2t3 Gata2 Nfatc1 Sox17
Cited2 Gfi1b Nfe2 Sox18
Elk3 Hhex Notch4 Sox7
Erg Hoxb3 Ppp1r13b Stat3
Ets1 Ikzf1 Ppp1r16b Stat5a
Ets2 Lmo2 Rab11a Stat5b
Etv2 Lyl1 Rreb1 Tal1
Fli1 Mef2c Runx1 Zfp711
Zfpm1
3.3.8 Identification of Differentially Regulated Transcription Factors
In order to derive a list of differentially expressed transcription factors, the set of differ-
entially expressed genes was searched for genes that are known to act as transcription
factors. The intersection of the differentially expressed genes with the union of three
independent annotated lists of transcription factors was obtained.
Differentially regulated genes between the endocardium and the endothelium that
were annotated with the GO Term “sequence-specific DNA binding transcription factor
activity” (GO:0003700) were obtained. This term was selected as the most relevant term
to TFs after manual inspection of the GO ontology. A custom MySQL (see Appendix
Section C.4) query was performed against a local copy of the GO database.
The list of transcription factors identified above was further expanded by obtaining the
intersection of the differentially regulated genes with the list non-redundant transcription
factors identified by Kanamori and colleagues [Kanamori et al., 2004] and independently
with the list of mouse only transcription factors generated by Zhang and colleagues [Zhang
et al., 2012], as described in Section 2.7.8.
Upregulated and downregulated transcription factors are presented in Tables 3.28 and
3.29 respectively. These lists can be used for prioritisation of genes more likely to have a
regulatory as opposed to effector role.
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Table 3.29: Transcription Factors downregulated in endocardial cells.
Aire Gm13242 Pax6 Sox3
Arnt2 Grhl2 Plagl1 Tcea3
Bnc1 Lhx2 Pou3f1 Tfap2a
Dbx1 Lmx1a Pou5f1 Tfap2c
Dmrt1 Mlxipl Rfx2 Tox3
Elavl2 Mycl1 Rfx4 Utf1
Elf3 Nanog Sall1 Ybx2
Esrrb Nkx2-1 Sall2 Zbtb16
Fezf2 Nr2f2 Sim2 Zfhx4
Foxa2 Nr5a2 Six3 Zfp296
Foxb1 Otx1 Sox1 Zfp42
Gli1 Otx2 Sox2 Zfp534
Gm13051 Pax3 Sox21 Zic2
Zic3
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3.3.9 Transcription Start Site Motif Analysis
The identification of a single or small subset of transcription factors (TF) or sequence ele-
ments that are involved in the restricted phenotypic differences of endocardial cells would
be of particular interest because it could constitute a starting point for the identification
of upstream regulators and would provide insight into the processes that functionally
differentiate the endocardium from other endothelium. To this end, genomic regions sur-
rounding the TSS of the genes upregulated in the endocardium were examined further.
Some of the regulators of endocardial identity are likely to regulate transcription by direct
binding to specific sequences of the TSS in downstream genes. On this basis, the sequence
of the TSSs of differentially regulated genes are likely to be enriched in specific sequences
bound by these factors.
In order to identify these potentially overrepresented sequences, motif analysis was
performed on the genomic regions adjacent to the TSS of genes upregulated in the endo-
cardium. A search interval for the motif analysis was defined on the basis of the binding
pattern of TFs as determined by re-analysis of the ENCODE ChIP-seq data, described in
Section 2.7.9. Briefly, ENCODE peak data [The ENCODE Project Consortium, 2012] for
twelve TFs were downloaded from the UCSC browser and the distribution of the peaks in
relation to the nearest TSS, within 20 kb, was plotted (See Figure 3.30 and A.1 through
to A.5). Visual examination of the plots revealed that although TFs display varying pat-
terns of binding, binding frequency around TSSs is close to background levels no more
than 5 kb from either side of the TSS for the TFs examined.
A 10 kb window surrounding the TSS of upregulated genes was therefore used for
motif analysis using DREME [Bailey et al., 2009]. This window was further subdivided
into 1 kb intervals overlapping by 500 bps. Overlapping intervals were employed so as
to ensure that motifs present at the boundary of two intervals can be identified by the
analysis. Motif analysis was performed on these intervals against a background of matched
sequences obtained from TSSs of stably expressed genes, as described in Section 2.7.10
with a stringency cut-off of E-value less than 0.05. The analysis identified 22 unique
motifs in the TSSs of upregulated genes.
The TOMTOM tool was subsequently used to match overrepresented motifs identified
above to known motifs of TFs. The TOMTOM tool reports all known motifs matching
each supplied motif with different degrees of similarity and confidence in the match. A
high level of stringency was required to report a match as significant in the context of
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Figure 3.30: Binding distribution of six representative transcription factors (E2F4,
Gata1a, Ets1, Gata2, Fli1, Gcn5) prepared using publicly ENCODE data. The vertical
axis denotes peak density - the fraction of all the peaks at each position. The horizontal
axis denotes distance from the nearest TSS.
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this analysis; specifically, a motif was reported only if its E-value and q-value were both
smaller than 0.05. The TOMTOM analysis identified 45 known motifs that match the
22 unique motifs identified by the DREME analysis, with some newly identified motifs
matching multiple known ones. The full results of this analysis are presented in Table
3.30.
Some of the identified motifs correspond to factors previously associated with car-
diovascular development, supporting the relevance of this analysis in the discovery of
factors that regulate endocardial development. Specifically, the motifs of five members
(Ehf, Erg, Ets1, Fli1 and Elf1 ) of the ETS family of transcription factors were identified
as matching overrepresented motifs (CTTCCKS, CTTCCTS, ASAGGAAR, RCAGGAA,
GGAAGGW). The ETS family of TFs has been previously associated with cardiac and
coronary development [Vijayaraj et al., 2012], regulation of the master cardiac enhancer
Gata4 [Schachterle et al., 2012] and recently heart mesoderm specification [Nie and Bron-
ner, 2015].
Further to the ETS family motifs, the motifs of Zic3, Mzf1 and Brachyury were
identified. Zic3 mutations are known to result in congenital heart disease [Cowan et al.,
2014], whereas Brachyury (T ) is a known regulator of mesoderm specification and Mzf1
has been found to modulate mouse cardiogenesis along with Nkx2.5 [Doppler et al., 2014].
In addition to the above factors, several other factors were identified and are shown in
Table 3.30 that may also be involved in endocardial development. The most prominent
of which was Ehf that was identified with the minimum q-value of 3.3e-5. Ehf has not
previously been associated with endocardial development.
In order to further confirm the biological relevance of the motifs identified and to val-
idate the discovery analysis, the distribution of the identified motifs in the promoters of
both upregulated and stably expressed genes was examined. All the motifs identified were
more frequently present in the sequences of the upregulated promoters compared to stably
expressed promoters (Table 3.31). Furthermore, the distribution of 12 of the 22 motifs
(CCCCAYCC, AGGGGVC, GGAAGGW, CCCMYTCC, CACGBGC, CCCTGRR, CT-
GRGGC, CTCTSMCC, BTCCCCA, CTTCCKC, CAGGGAS, AGGAGGD) displayed a
distribution significantly different (Kolmogorov-Smirnov Test) from a uniform distribu-
tion suggesting that the positioning of the motifs is significant and that the motifs are
likely to be of functional importance. The results of this analysis are shown in Figures
3.31, 3.32 and Tables 3.31 and 3.34.
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Table 3.30: Overrepresented motifs identified by DREME
in the promoter regions of genes overexpressed in the endo-
cardium that have been identified by TOMTOM as matching
to a known motif sequence.
Window Motif Motif Name Motif Alt Name DREME E-value TOMTOM p-value TOMTOM E-value TOMTOM q-value
-5000 CACGBGC MA0281.1 CBF1 9.60E-04 9.18E-06 8.99E-03 3.71E-03
-5000 CACGBGC MA0569.1 MYC4 9.60E-04 9.18E-06 8.99E-03 3.71E-03
-5000 CACGBGC MA0449.1 h 9.60E-04 1.07E-05 1.05E-02 3.71E-03
-5000 CACGBGC MA0566.1 MYC2 9.60E-04 1.17E-05 1.15E-02 3.71E-03
-5000 CACGBGC MA0357.1 PHO4 9.60E-04 3.63E-05 3.55E-02 7.72E-03
-5000 CACGBGC MA0464.1 Bhlhe40 9.60E-04 3.65E-05 3.58E-02 7.72E-03
-5000 CACGBGC MA0568.1 MYC3 9.60E-04 4.81E-05 4.71E-02 7.86E-03
-5000 GGTGTSA MA0009.1 T 1.50E-02 8.54E-06 8.36E-03 1.67E-02
-5000 CTGTGS MA0332.1 MET28 4.70E-02 1.15E-05 1.13E-02 2.25E-02
-5000 CTGTGS MA0335.1 MET4 4.70E-02 4.66E-05 4.56E-02 4.56E-02
-4500 CCCMYTCC MA0516.1 SP2 1.50E-06 2.82E-05 2.76E-02 4.50E-02
-4500 GTGACCM MA0016.1 usp 3.00E-03 1.90E-05 1.86E-02 3.70E-02
-4500 GTGACCM MA0016.1 usp 3.00E-03 2.02E-05 1.98E-02 3.94E-02
-3500 CCCCAYCC MA0599.1 KLF5 1.70E-03 1.23E-05 1.20E-02 1.57E-02
-3500 CCCCAYCC MA0039.2 Klf4 1.70E-03 1.77E-05 1.73E-02 1.57E-02
-3500 CCCCAYCC UP00099 2 Ascl2 secondary 1.70E-03 2.44E-05 2.39E-02 1.57E-02
-3500 CCCCAYCC MA0599.1 KLF5 1.70E-03 1.97E-05 1.93E-02 2.47E-02
-3500 CCCCAYCC MA0039.2 Klf4 1.70E-03 3.22E-05 3.15E-02 2.47E-02
-3500 CCCCAYCC UP00099 2 Ascl2 secondary 1.70E-03 3.81E-05 3.73E-02 2.47E-02
-3000 GGAAGGW MA0149.1 EWSR1-FLI1 3.50E-02 1.02E-05 9.95E-03 1.99E-02
-2500 AGGGGVC MA0366.1 RGM1 2.80E-05 2.12E-05 2.07E-02 4.13E-02
-2500 AGGGGVC MA0342.1 MSN4 2.80E-05 4.91E-05 4.80E-02 4.79E-02
-2500 CTTCCKC MA0080.3 Spi1 2.50E-04 4.32E-05 4.23E-02 4.77E-02
-2500 CTTCCKC MA0598.1 EHF 2.50E-04 4.89E-05 4.78E-02 4.77E-02
-2000 CTTCCTS MA0598.1 EHF 1.10E-02 1.70E-08 1.66E-05 3.30E-05
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-2000 CTTCCTS MA0474.1 Erg 1.10E-02 3.34E-06 3.27E-03 3.25E-03
-2000 CTTCCTS MA0098.2 Ets1 1.10E-02 2.26E-05 2.21E-02 1.18E-02
-2000 CTTCCTS MA0475.1 FLI1 1.10E-02 2.42E-05 2.37E-02 1.18E-02
-2000 CTTCCTS MA0473.1 ELF1 1.10E-02 3.39E-05 3.32E-02 1.32E-02
-1500 CCCTGRR MA0524.1 TFAP2C 2.20E-10 2.31E-05 2.26E-02 4.49E-02
-1500 CCCTGRR MA0154.2 EBF1 2.20E-10 4.68E-05 4.58E-02 4.55E-02
-1000 ASAGGAAR MA0081.1 SPIB 6.80E-11 1.51E-05 1.48E-02 1.59E-02
-1000 ASAGGAAR MA0474.1 Erg 6.80E-11 1.63E-05 1.59E-02 1.59E-02
-1000 ASAGGAAR MA0080.3 Spi1 6.80E-11 4.29E-05 4.20E-02 2.79E-02
-1000 BACCCCA MA0595.1 SREBF1 3.80E-08 1.79E-05 1.75E-02 1.74E-02
-1000 BACCCCA MA0596.1 SREBF2 3.80E-08 1.79E-05 1.75E-02 1.74E-02
-1000 BTCCCCA MA0056.1 MZF1 1-4 3.80E-08 1.74E-05 1.70E-02 3.40E-02
-500 RCAGGAA MA0475.1 FLI1 2.20E-09 4.08E-06 3.99E-03 7.37E-03
-500 RCAGGAA MA0474.1 Erg 2.20E-09 7.56E-06 7.40E-03 7.37E-03
-500 RCAGGAA MA0098.2 Ets1 2.20E-09 1.36E-05 1.33E-02 8.85E-03
-500 HTGGGGA MA0056.1 MZF1 1-4 8.20E-06 2.54E-05 2.48E-02 4.97E-02
-500 CACCCTK MA0112.2 ESR1 2.00E-05 2.49E-05 2.44E-02 4.88E-02
-500 RCAGGAA MA0475.1 FLI1 2.20E-09 4.08E-06 3.99E-03 7.37E-03
-500 RCAGGAA MA0474.1 Erg 2.20E-09 7.56E-06 7.40E-03 7.37E-03
-500 RCAGGAA MA0098.2 Ets1 2.20E-09 1.36E-05 1.33E-02 8.85E-03
-500 HTGGGGA MA0056.1 MZF1 1-4 8.20E-06 2.54E-05 2.48E-02 4.97E-02
-500 CACCCTK MA0112.2 ESR1 2.00E-05 2.49E-05 2.44E-02 4.88E-02
0 GGGTGTS MA0270.1 AFT2 1.50E-02 1.33E-06 1.30E-03 2.60E-03
0 GGGTGTS MA0493.1 Klf1 1.50E-02 2.20E-05 2.15E-02 2.15E-02
500 CAGGGAS MA0540.1 DPY-27 2.10E-07 1.64E-05 1.60E-02 3.21E-02
500 CTGRGGC MA0524.1 TFAP2C 5.10E-05 8.86E-06 8.68E-03 1.72E-02
500 CTGRGGC MA0003.2 TFAP2A 5.10E-05 2.05E-05 2.00E-02 1.99E-02
500 CACAGMAG UP00102 2 Zic1 secondary 2.10E-02 2.16E-05 2.11E-02 4.22E-02
500 CACAGMAG UP00006 2 Zic3 secondary 2.10E-02 4.49E-05 4.40E-02 4.40E-02
2000 AGGGGS MA0342.1 MSN4 7.60E-08 4.89E-05 4.79E-02 4.72E-02
2000 AGGGGS MA0366.1 RGM1 7.60E-08 4.89E-05 4.79E-02 4.72E-02
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2000 BCGGRG MA0348.1 OAF1 4.50E-05 2.04E-05 2.00E-02 3.93E-02
2000 CCMCAC MA0493.1 Klf1 2.30E-03 3.38E-05 3.31E-02 4.94E-02
2500 AGGAGGD MA0528.1 ZNF263 2.20E-02 1.40E-05 1.37E-02 2.74E-02
3000 CTCTSMCC MA0504.1 NR2C2 4.10E-05 1.52E-05 1.49E-02 2.99E-02
3000 CCAYAG MA0332.1 MET28 5.40E-03 3.94E-06 3.86E-03 7.71E-03
3000 CCAYAG MA0335.1 MET4 5.40E-03 2.29E-05 2.24E-02 2.24E-02
3000 CGGRGA MA0348.1 OAF1 2.20E-02 7.97E-06 7.81E-03 1.55E-02
3000 CGGRGA MA0437.1 YPR196W 2.20E-02 4.12E-05 4.03E-02 2.87E-02
3500 CCCCTK MA0364.1 REI1 6.50E-07 1.43E-05 1.40E-02 2.40E-02
3500 CCCCTK MA0342.1 MSN4 6.50E-07 3.69E-05 3.61E-02 2.40E-02
3500 CCCCTK MA0366.1 RGM1 6.50E-07 3.69E-05 3.61E-02 2.40E-02
3500 CCCCTK MA0155.1 INSM1 6.50E-07 5.02E-05 4.91E-02 2.44E-02
3500 GCCRCA MA0334.1 MET32 1.20E-05 4.57E-06 4.47E-03 8.95E-03
3500 GCCRCA MA0333.1 MET31 1.20E-05 9.14E-06 8.95E-03 8.95E-03
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One possible mechanism of upregulation of genes with a specific motif in their promoter
region is the upregulation of an activating TF that binds to the promoter region of the
gene and leads to an increase in gene expression.
The above analysis identified motifs in the promoters of upregulated genes, and iden-
tified TFs that bind to those motifs but did not examine the transcription status of
these factors and their possible differential regulation in the endocardium. Given this,
all the TFs identified above as matching a motif were cross-referenced with the list of
differentially regulated genes.
Five transcription factors with binding sites in upregulated genes that also displayed
differential expression were identified (Table 3.32). Only three of these transcription fac-
tors (Erg, Ets1 and Fli1) are upregulated. These three TFs also belong to the ETS family
of transcription factors, further exemplifying the role of this family in the endocardial de-
velopment. Furthermore, the match of the identified CTTCCTS motif to the ETS motifs
was highly significant (Figure 3.33).
It must be noted that all the ETS family members display a highly similar motif to each
other [Wei et al., 2010] and the analysis presented here may not be able to distinguish
the binding of these factors on the basis of sequence similarity alone. The identified
motifs may therefore bind other upregulated members of the ETS family and not one
of the factors identified by the TOMTOM analysis. For this reason all the members of
the ETS family that are differentially expressed in the endocardium (Table 3.33) may be
considered as potential regulators of the endocardial identity.
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Table 3.31: Mean number of motif occurances of each motif in the stable and upregulated
set of promoters. Consistent with their identification by DREME all the motifs are more
frequently identified in the upregulated set of promoter sequences.























Table 3.32: Transcription factors that are differentially regulated in the endocardium and
their binding motif is overrepresented in the TSS of upregulated genes. All three TFs
that are upregulated are also members of the ETS family of transcription factors.






Table 3.33: ETS family members differentially regulated between endocardial and en-
dothelial cells.









Figure 3.31: Independent identification of the distribution of motifs identified by the
DREME analysis the promoters of upregulated (green) and stably (red) expressed genes
reveals distinct distribution of some but not all of the motif sequences. The distributions
are normalised and the height of the peak does not represent absolute abundance of the
motif in each dataset. (1/2)
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Figure 3.32: Independent identification of the distribution of motifs identified by the
DREME analysis the promoters of upregulated (green) and stably (red) expressed genes
reveals distinct distribution of some but not all of the motif sequences. The distributions
are normalised and the height of the peak does not represent absolute abundance of the
motif in each dataset. (2/2)
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Figure 3.33: Motif sequence alignment of Erg binding motif (top) with the identified
CTTCCTS motif (e-value = 3.27e-3, q-value = 3.25e-3).
Table 3.34: Significance of deviation of motif distribution from the uniform as assessed
by means of the Kolmogorov-Smirnov Test for each individual motif. Multiple testing

























3.4 Comparison of Methylation and Transcriptomic Data
3.4.1 Genome-wide Relationship between Promoter CGI Methylation
and Expression
The well described relationship between promoter CGI methylation status and expression
was investigated in the datasets generated. For each annotated gene, the mean expression
FPKM value of the gene was compared with the methylation of CGIs directly overlapping
the transcription start site. The methylation status was categorised as low (<50%), or
high(>50%) and the distribution of methylation for each class of CGI was plotted (Figure
3.35). The expected pattern of low methylation correlating with higher expression and
vice versa was observed.
The robustness of the above result as a function of the distance between each CGI
and gene pair was examined for both samples in combination and separately. The results
of this analysis are shown in Figure 3.36. The top part of panel A shows the p-value of
the association between the methylation status of CGIs and nearby genes as a function of
distance. The association is significant for genomic distances in excess of 200 kb, however
the ratio of the mean expression of genes with high and low methylation in their promoters
(the overall magnitude of the effect) is reduced when the distance between the CGI and
gene exceeds 10 kb and is severely diminished within 50 kb. This suggests that majority
of direct interactions between methylation status and transcription state are limited by
genomic distance, although interactions may persist up to 200 kb.
3.4.2 Differentially Regulated Genes Overlapping Differentially
Methylated CGIs
The list of identified CGIs was cross-referenced with the list of differentially regulated
genes, in order to identify genomic loci where changes in methylation coincide and may
be functionally linked to control of gene expression in the context of endocardial differ-
entiation. The robustness of this result as a function of the distance between CGIs and
transcribed loci is examined in Figure 3.37. The number of overlapping loci increases
approximately linearly with distance. On the basis of the analysis presented in the pre-
vious section, a distance cutoff of 50 kb was selected, as interactions beyond this point
are unlikely to be direct. This analysis identifed 150 genomic locations where differential
methylation and transcription colocalise and may be functionally linked. Full results of
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Figure 3.34: Boxplot of the mean expression of genes directly overlapping CGIs stratified
by mean methylation level of CGIs, in both tissues. Genes overlapping highly methy-
lated CGIs display significantly lower expression than genes overlapping CGIs with low
methylation levels (p-value = 8.44e-29, heteroskedastic two sample T-test).
Figure 3.35: Boxplot of the mean expression of genes directly overlapping CGIs stratified
by mean methylation level of CGIs, for the endocardium and the endothelium individually.
Genes overlapping highly methylated CGIs display significantly lower expression than
genes overlapping CGIs with low methylation levels (EC p-value = 2.305e-03, ET p-value
= 4.202e-23; heteroskedastic two sample T-test).
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Figure 3.36: Relationship between CGI methylation and gene expression levels as a func-
tion of distance. Green denotes p-values below 0.05 and red equal to or in excess of
0.05. (A, top) p-value of association between methylation and expression as a function
of distance for all data combined. The association is significant for over 200 kb. (A, bot-
tom) ratio of the mean expression of genes overlapping low and high methylated CGIs,
the magnitude of the association diminishes within 10 kb (see panel B). The relationship
between CGI methylation and expression is recapitulated for Endocardial (panels C and
D) and Endothelial cells (panels E and F) individually.
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Figure 3.37: Number of times methylation and expression changes colocalise as a function
of distance between respective DMRs and genes.
this analysis can be found in Table A.14 of the Appendix.
It is of interest to note that several genes of known importance appear in the results
of this analysis. These include Tal1, which among others is critical for regulation of
intercellular junction in the endocardium, Tie1 a tyrosine kinase receptor which is critical
for the development of the endocardium as well as Elf3 a member of the ETS family of
transcription factors that are identified in Section 3.3.9 as potential regulators of the
endocardial identity.
3.4.3 Differentially Regulated Genes Overlapping DMRs
Further to the above, the list of differentially methylated regions identified genome-wide
was cross-referenced to the list of differentially regulated genes with the aim of identifying
genomic loci where methylation and gene expression are potentially functionally linked.
Similarly to the above analysis the cut-off distance for the two changes to be considered
to be colocalised was set to 50 kb.
The analysis revealed that 107 DMRs colocalise with 97 differentially expressed genes
between the endocardium and the endothelium. Hypermethylation is weakly anticorre-
lated with expression (Spearman ρ = -0.22). The results of this analysis can be found in
Table 3.35. Similar to the analysis reported above, DMRs in the vicinity of known endo-
cardial regulators such as Tal1 and Tie1 were identified, further supporting the biological
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Table 3.35: Overlaps of identified DMRs with differentially
regulated genes, within a distance cutoff of 50 kb. This anal-
ysis identified some well established regulators of endocardial
identity such as Tal1 and Tie1 as potentially epigenetically
regulated. Some genes appear multiple times as they can
have multiple isoforms or overlap more than one DMR.
Gene DMR Locus EC methylation ET methylation EC expression ET expression
Novel Transcript chr7:20055181-20055460 73.0% 43.9% 5.02 1.75
Novel Transcript chr8:124793057-124793175 72.1% 44.4% 1.80 3.24
Novel Transcript chr8:124820289-124820793 30.6% 51.1% 1.80 3.24
Abca4 chr3:121787724-121788914 68.6% 40.8% 1.80 3.28
Ablim1 chr19:57064818-57065598 78.4% 47.2% 15.33 10.01
Adam11 chr11:102639062-102639563 65.8% 42.8% 0.78 1.98
Adcy4 chr14:56380507-56380930 40.6% 16.1% 3.60 1.19
Adcy4 chr14:56434090-56434667 73.2% 49.2% 3.60 1.19
Adora2a chr10:74816185-74817404 58.1% 80.1% 4.71 0.93
Alox5ap chr5:150057323-150058420 35.9% 59.0% 13.46 3.78
Ano9 chr7:148274750-148274879 78.4% 52.4% 0.31 2.86
Aqp3 chr4:41044457-41044778 73.1% 46.3% 0.86 4.42
B4galnt4 chr7:148211594-148212613 72.1% 39.5% 8.56 15.26
B4galnt4 chr7:148274750-148274879 78.4% 52.4% 8.56 15.26
BC068157 chr8:4206269-4206850 55.2% 23.4% 0.61 2.88
Bcl6b chr11:70028833-70029223 53.3% 27.6% 4.24 0.90
Capn5 chr7:105313648-105314322 77.3% 49.8% 15.25 7.23
Ccm2l chr2:152896544-152896824 43.1% 23.0% 2.85 0.34
Celsr2 chr3:108187823-108188389 83.4% 52.8% 1.98 5.90
Cep170b chr12:113958407-113959505 65.0% 34.8% 6.79 10.60
Cldn3 chr5:135442964-135443614 78.9% 50.9% 0.59 3.61
Cldn4 chr5:135442964-135443614 78.9% 50.9% 3.95 19.31
Clic6 chr16:92475463-92476098 55.5% 32.4% 9.27 3.22
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Clic6 chr16:92468411-92468768 80.5% 58.2% 9.27 3.22
Col8a2 chr4:126002087-126002467 74.6% 45.8% 8.90 15.02
Col8a2 chr4:125923594-125924274 82.2% 59.7% 8.90 15.02
Csf1r chr18:61228464-61228781 76.0% 52.7% 10.79 4.20
Csf1r chr18:61225022-61225835 49.3% 26.6% 10.79 4.20
Cyp26a1 chr19:37765321-37765560 34.0% 11.5% 19.22 10.68
Cyp26a1 chr19:37762177-37762475 52.9% 32.7% 19.22 10.68
Cyp26a1 chr19:37814091-37814949 56.4% 77.6% 19.22 10.68
Dbx1 chr7:56887804-56888417 65.3% 32.0% 0.51 3.88
Ddah2 chr17:35154731-35154891 80.8% 58.8% 158.03 108.21
Dll1 chr17:15519420-15519960 80.6% 59.4% 1.08 3.65
Dnaaf3 chr7:4434397-4434994 86.5% 62.6% 3.67 8.86
Dsg2 chr18:20759818-20760284 84.9% 53.9% 7.66 11.89
Dst chr1:34093309-34093859 84.1% 61.2% 9.80 16.06
Ehbp1l1 chr19:5751116-5751276 40.8% 19.9% 10.02 6.10
Elf3 chr1:137114015-137114765 71.5% 42.4% 0.66 4.83
Epb4.1 chr4:131478296-131478516 62.6% 42.4% 37.69 25.74
Esrrb chr12:87720288-87721157 77.9% 43.7% 0.65 6.28
Exoc3l chr8:107860607-107860809 73.6% 44.9% 4.72 1.48
Ezr chr17:6940931-6941564 74.8% 50.2% 55.86 79.12
Ezr chr17:6988252-6988957 80.4% 59.1% 55.86 79.12
Fam198b chr3:79683120-79683489 84.2% 58.3% 2.95 0.97
Fam65a chr8:108090552-108090881 50.2% 20.4% 37.58 20.41
Flt4 chr11:49403109-49403751 85.9% 64.2% 14.91 3.56
Foxa2 chr2:147849058-147849438 73.3% 48.4% 0.96 3.54
Fzd10 chr5:129099014-129099686 78.1% 53.3% 13.82 8.78
Gata2 chr6:88154810-88156434 62.6% 41.6% 8.45 2.07
Gdf3 chr6:122513110-122513678 79.8% 57.5% 0.28 4.04
Grap2 chr15:80416857-80417546 78.6% 55.3% 10.22 5.09
Grik3 chr4:125212061-125213486 50.7% 15.6% 0.68 2.47
Hhex chr19:37507291-37507847 76.1% 53.9% 15.41 4.11
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Ifi30 chr8:73269722-73269943 86.8% 54.0% 38.63 60.68
Ifi30 chr8:73309871-73310263 80.4% 53.4% 38.63 60.68
Ifi30 chr8:73334834-73335143 76.8% 49.9% 38.63 60.68
Ifitm1 chr7:148192086-148193168 88.7% 62.9% 49.99 92.19
Igf1 chr10:87323389-87323840 57.1% 32.1% 8.47 1.78
Igfbpl1 chr4:45801580-45802815 58.7% 79.1% 0.68 2.82
Lefty1 chr1:182824490-182825286 54.9% 27.8% 1.09 4.65
Lfng chr5:141088065-141088599 55.9% 34.7% 2.40 5.90
Lmo2 chr2:103843358-103843795 70.0% 38.1% 26.72 6.16
Lmo2 chr2:103843358-103843795 70.0% 38.1% 3.42 1.04
Ltbp4 chr7:28066903-28067263 76.2% 50.4% 5.45 11.82
Lyve1 chr7:117952877-117953693 86.9% 66.2% 1.68 0.23
Map7 chr10:19861332-19862037 80.3% 50.3% 1.59 4.47
Msi1 chr5:115894491-115895052 88.4% 61.2% 23.36 42.97
Myh14 chr7:51857056-51858580 52.7% 25.7% 0.49 1.32
Nr5a2 chr1:138696965-138697319 91.0% 69.4% 0.40 1.46
Pecam1 chr11:106468008-106468818 81.0% 50.9% 52.41 28.46
Plxnd1 chr6:115912422-115912546 84.0% 62.7% 42.55 13.29
Polg chr7:86503189-86504238 35.9% 63.3% 83.43 52.70
Pou3f1 chr4:124344632-124345709 61.9% 37.0% 0.40 1.43
Ppp1r13b chr12:113027316-113027845 84.6% 55.8% 14.51 8.75
Ptrf chr11:100819860-100820506 45.7% 25.5% 26.92 18.03
Rasip1 chr7:52887987-52888323 68.3% 42.7% 12.56 1.84
Rcsd1 chr1:167565599-167566481 72.5% 48.5% 20.12 10.46
Sesn3 chr9:14050690-14051104 61.9% 38.8% 6.57 10.60
Sh2b3 chr5:122278315-122278607 62.6% 35.1% 17.13 8.22
Sh3tc1 chr5:36083518-36083985 47.7% 21.4% 3.92 1.83
Skap1 chr11:96338361-96338945 90.2% 66.9% 5.66 0.84
Slc30a10 chr1:187308178-187308821 88.1% 65.2% 4.53 1.83
Slc4a1 chr11:102217890-102218476 79.4% 57.5% 1.60 4.06
Slc7a8 chr14:55330531-55330769 87.5% 62.5% 4.96 2.23
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Smad6 chr9:63801417-63801870 80.0% 41.3% 22.69 15.14
Smad6 chr9:63775068-63775725 50.0% 24.7% 22.69 15.14
Smad6 chr9:63766729-63767498 53.8% 74.2% 22.69 15.14
Snhg11 chr2:158222992-158223588 87.9% 67.0% 13.70 21.40
Spint2 chr7:29997949-29998493 63.5% 39.3% 7.60 20.60
Spock2 chr10:59570816-59571512 58.2% 36.8% 1.23 4.31
Tal1 chr4:114751244-114752324 65.2% 42.3% 31.18 6.31
Tal1 chr4:114751244-114752324 65.2% 42.3% 6.20 1.32
Tal1 chr4:114751244-114752324 65.2% 42.3% 5.76 1.21
Tcea3 chr4:135846684-135847192 49.2% 17.6% 0.73 4.96
Tdgf1 chr9:110817103-110817617 80.1% 48.3% 3.34 14.76
Tgfb1 chr7:26430147-26430915 75.7% 50.7% 41.90 27.61
Tgfb1 chr7:26489381-26490333 38.0% 13.9% 41.90 27.61
Tie1 chr4:118108001-118108883 81.0% 52.6% 40.45 6.62
Tie1 chr4:118190073-118190950 61.8% 33.6% 40.45 6.62
Tinagl1 chr4:129807866-129808438 73.3% 51.9% 27.21 41.91
Tinagl1 chr4:129825701-129826354 87.5% 66.4% 27.21 41.91
Tnfaip2 chr12:112661520-112662384 40.5% 20.5% 24.62 7.49
Tnfrsf19 chr14:61623709-61624298 38.0% 13.2% 9.47 17.47
Ushbp1 chr8:73928811-73929522 63.0% 37.7% 2.22 0.35
Wnt1 chr15:98626660-98627388 60.9% 39.3% 0.64 5.51
Wnt7b chr15:85337985-85338351 81.0% 58.9% 0.26 2.20
Wwc1 chr11:35610726-35611148 73.5% 51.7% 3.52 8.43
Zfpm1 chr8:124793057-124793175 72.1% 44.4% 28.72 14.06
Zfpm1 chr8:124820289-124820793 30.6% 51.1% 28.72 14.06
Zfpm1 chr8:124849801-124850807 24.3% 45.6% 28.72 14.06
Zfpm1 chr8:124845529-124845986 35.3% 57.8% 28.72 14.06
Zic2 chr14:122852090-122852827 69.2% 43.8% 1.97 5.17
Zswim5 chr4:116502237-116503120 62.7% 38.4% 0.80 2.00
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relevance of methylation in these loci.
3.5 Discussion
The endocardium is an epithelial layer of cells lining the lumen of the ventricles and atria in
the developing and adult heart. This cell population has significant roles in trabeculation
of the myocardium, differentiation of cardiomyocytes into conduction fibers, EMT at sites
of valve formation and septation of the OFT into the pulmonary artery and aorta [Harris
and Black, 2010]. More recently the endocardium has been found to be the source of part
of the coronary vasculature [Tian et al., 2014].
The endocardium first appears after gastrulation at the same time as the formation of
the cardiac crescent, the primitive structure that will give rise to the adult heart [Baldwin,
1996] [Gilbert, 2003] [Abu-Issa and Kirby, 2007]. The origin of the endocardium remains
unclear however, with conflicting reports in the literature of a vascular or cardiac origin.
NFATc1 has been identified as a transient marker of the endocardium that is ex-
clusively expressed in all of the endocardium between E8.5 and E9.5 [Ranger et al.,
1998] [de la Pompa et al., 1998]. Shortly after E9.5 NFATc1 expression pattern is al-
tered and it ceases to be expressed in the entirety of the endocardium. At this point
NFATc1 is downregulated in the ventricular endocardium and upregulated at the sites of
valve formation, where it has a role in the control of EMT [Wu et al., 2013] [Zhu et al.,
2013]. A transgenic construct, utilising the unique expression pattern of NFATc1, allows
identification of endocardial cells in vivo and in culture [Misfeldt et al., 2009].
Endocardial development has been previously shown to be recapitulated during em-
bryoid body differentiation [Narumiya et al., 2007] [Misfeldt et al., 2009]. Isolation of
endocardial cells from embryoid bodies has the significant advantage that hundreds of
thousands of cells can be effectively isolated. Isolation of similar numbers of cells from
embryos is technically challenging.
In the context of this work, embryoid body derived endocardial cells were compared
with embryoid body derived endothelial cells in order to identify unique epigenetic and
transcriptional regulators of this cardiac cell line. Cells were isolated from embryoid
bodies using the NFATc1 marker outlined above and the CD31 surface molecule unique
to the endothelium. Endocardial cells were identified by the double positive signature
NFATc1+/CD31+, whereas endothelial cells were identified as NFATc1-/CD31+.
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It was hypothesised that epigenetic processes, and genomic methylation in particular,
contribute strongly to the identity of the endocardium and are a determining factor in
its differentiation from other endothelium. This hypothesis was based on the identical
morphology of the endocardium and endothelium, as well as prior microarray and RNA-
seq differential expression analysis that suggested that no differentially regulated genes
existed between the two cell types. A plethora of prior evidence for the role of epigenetic
processes in heart development further supported this hypothesis (Section 1.3.6).
Whole genome-methylation analysis was performed on endocardial and endothelial
cells. A library preparation protocol for WGBS was developed using the RRBS proto-
col as a template. The protocol was used to prepare WGBS libraries from endocardial
and endothelial cells. A pipeline for the processing of the resulting data and for the
identification of differentially methylated CGIs and genomic DMRs was developed.
A similar but not identical methylome profile was identified in the two cell types
examined. This is consistent with a common developmental origin for endocardial and
endothelial cells, suggesting a vascular precursor for the endocardium. However, the
present study did not examine the methylation profiles of cardiac progenitors, so the
proximity of the identified profile to those progenitors could not be determined. It is
therefore impossible to evaluate if the endocardial methylation profile is more similar to
the endothelial methylation profile or that of the early heart precursors.
Differential methylation analysis was performed at the CGI level and at the whole
genome level using a smoothing algorithm. CGI methylation analysis revealed 1,641
differentially methylated islands between the two cell types at the p <0.05 level of signif-
icance. However, none of these islands were significantly differentially methylated after
multiple testing correction and their distribution did not appreciably depart from the
distribution of all examined CGIs. Subsequent, whole genome analysis identified a 1,128
windows of differential methylation that were preferentially enriched at functional ge-
nomic sites and enriched in the vicinity of transcribed genes related to developmental
processes.
The analysis of the above cell populations was extended to an analysis of their tran-
scriptome. As aforementioned, past microarray and transcriptomics analyses by others
had proved to be unfruitful. With an expectation for low effect sizes mRNA-seq was per-
formed on independent quadruplicate pools of endocardial and endothelial cells. In sharp
contrast to past results, this analysis identified a large number of differentially regulated
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genes, including genes already implicated in the endocardial identity.
Gene Ontology (GO) overrepresentation analysis was performed on the list of differ-
entially regulated genes in aggregate and stratified by cell type of upregulation. Results
of the aggregate analysis were consistent with the endocardial and endothelial identity
of the population compared. Interestingly, the GO term analysis suggested differential
regulation of genes that respond to the local hemodynamic environment. The strati-
fied analysis suggested an enrichment of both vascular and haematopoietic specifically in
the endocardium and confirmed that genes related to response to fluid shear stress are
specifically overrepresented in the endocardium.
In an effort to identify factors that may have an upstream role in specification and
maintenance of the endocardial identity, the transcription start sites of the upregulated
genes were search for the overrepresentation of sequence motifs. After stringent testing
criteria 22 motifs were identified that closely resembled 45 known motif sequences.
In order to prioritise by likely biological significance, the identified motifs were mapped
to cellular factors that are known to bind them and the list of the obtained cellular
factors was cross-referenced to the list of differentially regulated genes. This analysis was
expected to identify differentially regulated factors that directly bind to the promoters
of and influence the expression of other genes. Five differentially regulated transcription
factors were found to match overrepresented motifs, of which the only upregulated ones
were members of the ETS family of transcription factors. Members of the ETS family of
transcription factors are known to play a role in vascular differentiation and the present
analysis suggests that they may have a more specific role in endocardial differentiation.
Comparison of the methylome and transcriptome data generated, revealed the ex-
pected pattern of promoter hyper-methylation being associated with lower expression of
genes, suggesting that the methylome profiles of the cells are consistent with the tran-
scriptome profiles generated. This pattern was observed independently for endocardial
and endothelial cells and persisted when up to 200 kb separated the two elements. Specific
comparison of the list of differentially regulated transcripts and differentially regulated
CGIs identified 150 genomic locations that show alteration in both methylation and ex-
pression status. Further comparison of the list of the identified DMRs with differentially
expressed genes identified 97 genes that overlap DMRs, some of which are known to
have a role in endocardial development. This establishes a potential direct link between
endocardial development and differential methylation in this tissue.
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3.5.1 Limitations of the Present Study
A significant limitation of the design of this study is the analysis of endocardial cells
past the time point of specification. Although the exact time point of specification of
the endocardial cell line is not known, it can be reasonably hypothesised to occur prior
to the time of the first appearance of the endocardium by downregulation of N-cadherin.
This event precedes E8.5, the earliest time point of NFATc1 expression. This limitation is
significant because there is no certainty that traces of the early molecular events that result
in specification will persist at E9.5. This limitation is however not currently surmountable
as no markers for the endocardium prior to NFATc1 are known. Only single cell analysis
(see following Section) combined with micro-dissection could potentially overcome this
limitation without the discovery of an earlier marker. Such an investigation however is
extremely technically demanding.
In addition, another limitation of the work presented here is that the whole-genome
bisulphite sequencing assay employed can not distinguish between hydroxymethylation
and methylation of DNA. Consequently the level of both DNA modifications is measured.
This limitation of the bisulphite conversion reaction is not relevant in most tissues as the
levels of hydroxylmethylation are low. Given however that the endocardial cells examined
are obtained by differentiation of the embryonic stem cells, in which hydroxylmethylation
is known to play a significant role, the inability to distinguish between the two cytosine
modification states may hamper the analysis. It is however expected that such influence
will be small given that differentiation of embryonic stem cells for approximately seven
days has occurred in vitro and the cells examined are morphologically distinct from the
embryonic cells used for differentiation. This limitation can be overcome, at a signifcant
financial cost, by oxidative bisulphite sequencing which can distinguish between the two
DNA modifications [Booth et al., 2013].
Despite the above, the analysis presented here is important because it establishes
that transcriptomic and epigenetic differences exist between the two cell lines, justifying
a more challenging investigation. Furthermore, the present study provides us with an
array of candidates that upon further investigation may include currently unknown earlier
endocardial markers and guide further analyses.
In summary, the work presented here has for the first time provided us with compre-
hensive epigenomic and transcriptomic profiles for endocardial and endothelial cells. The
differential expression analysis has identified a plethora of differentially regulated genes
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between the two cell types, providing us with an expansive list of candidates for further
characterisation. Differential methylation analysis has provided us with a list of 1,128
candidate regions of between the two cell types. The functional significance of these sites
is supported by their overlap with epigenetic marks with known regulatory functions, as
well as being in the vicinity of genes associated with developmental processes. Bioinfor-
matic analysis was used to identify specific members of the ETS family of transcription
factors as likely regulators of a large number of the genes differentially expressed.
3.5.2 Further Work
The results of the genome-wide analyses presented here should be validated using locus
specific qPCR assays prior to further investigation. Differentially regulated genes should
be prioritised for validation using functional criteria, such as transcription factor activity
and lists of these genes are presented in the context of this work. Differentially methy-
lated regions should also be validated using locus specific assays. Prioritisation of these
regions is more challenging but DMRs that colocalise with genes known to be relevant
to endocardial development, such as Tal1 constitute important targets in addition to the
regions that display maximal methylation changes.
The model of differentiation used here has previously been shown to recapitulate
embryonic development to a significant extent, however differences to the in vivo differ-
entiation process can be expected. It would thus be of value to examine the spatial and
temporal expression of the differentially expressed genes identified here via immunohis-
tochemistry and in situ hybridisation in E9.5 and earlier mouse embryos. This analysis
is expected to provide more clear evidence on the biological relevance of these hits. Fur-
thermore, examination of earlier time points has the potential to identify some of the
differentially expressed genes as novel early markers of the endocardium.
The applicability of the embryoid body differentiation model in the context of endo-
cardiogenesis has been previously assessed by examination of selected marker genes and
the spatial and temporal pattern of endocardial growth [Misfeldt et al., 2009]. It would
be of particular interest to compare the transcriptomic profiles of in vivo endocardial cells
and endothelial cells. This comparison has the potential to reaffirm the relevance of the
model and can point to differences between the two cell types. Efforts to complete this
type of analysis in the context of the project were hampered by technical challenges in
isolating the required number of cells from E9.5 embryo hearts and making the mRNA-seq
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libraries, within the time constraints of this project.
The above difficulties could be overcome by the application of single cell mRNA-seq
techniques. Furthermore, the application of single cell technologies has the potential to
overcome the challenges associated with heterogeneous populations of cells. As afore-
mentioned, the endocardium is a heterogeneous population as the ventricular portion
has clearly distinct properties from that of valvular endocardium at later developmental
stages. The endothelial population examined is also highly diverse. Application of single
cell mRNA-seq to cells isolated from embryos would allow unprecedented spatial and tem-
poral resolution, allowing the identification of regulators of specific events (such as EMT
and trabeculation) in the development of the endocardium and assessment of the homo-
geneity of the endocardium at different time points. A recent study has demonstrated the
feasibility of this approach in the elucidation of alveolar progenitor cells [Treutlein et al.,
2014].
Analysis of other epigenetic events beyond methylation continues to be of particular
interest. In particular, assessment of the - less stable and more closely related to tran-
scriptional regulation - histone modifications via ChIP-seq would be of interest. These
analyses are however very technically challenging with low number of cells and will not
be applicable to cells from mouse embryos. Some progress in the isolation of chromatin
from low numbers of cells was reported by the author, but it was not feasible to obtain
sufficient DNA after immuno-precipitation within the time limits of this project.
In addition to the examination of histone modifications via ChIP-seq, the identification
of binding sites of the transcription factors identified as upregulated in the context of this
project would be of interest, this is especially true for transcription factors in the ETS
family. Finally, efforts to identify the binding sites of NFATc1 in endocardial cells are
under way.
3.6 Conclusion
In conclusion, in an effort to identify factors that are responsible for the endocardial
identity, the work presented here compared the methylome and transcriptome of endo-
cardial and endothelial cells. The study identified 1,128 differentially methylated genomic
locations between the two cell types. Transcriptome analysis revealed extensive expres-
sion changes between the two cell types and identified 711 differentially regulated genes.
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GO term analysis confirmed that the expected biological processes were overrepresented
in the list of differentially regulated genes. Interestingly, the overrepresented GO terms
suggest that the local haemodynamic environment may have a contribution to the endo-
cardial phenotype. Motif analysis of the promoter regions of differentially regulated genes,
suggested a previously unappreciated role for ETS family members in endocardial devel-
opment, seven members of which show differential regulation between the endocardium
and the endothelium.
Examination of the methylome and transcriptome data in concert, confirmed the
known relationship between promoter CGI and gene body expression in our dataset and
identified 150 loci where the methylation pattern is altered in concert with gene expression.
The present study has provided valuable evidence suggesting that both methylome
and transcriptome differences between endocardial and endothelial cells have a role in the
specification of the endocardium and has provided us with a plethora of candidates for




Allele-specific CTCF and cohesin
Binding in the Mouse Brain
Part of the work presented in this chapter has been published previously in [Prickett et al.,
2013] and selected Figures and Tables are reproduced in the context of this work. Unless
noted, the author has had a major contribution to or prepared in their entirety all the
Figures and Tables reproduced here.
CTCF is an 11 Zn-finger DNA binding factor first characterised by Filippova and
colleagues [Filippova et al., 1996]. CTCF is usually described as an insulator protein,
although roles in transcriptional regulation and nuclear organisation have emerged (Sec-
tion 1.5). CTCF is known to bind unmethylated DNA preferentially and this preference
is responsible for its well characterised regulation of the H19 imprinted locus, where it is
implicated to the allele-specific expression of the H19 and Igf2 transcripts (1.5.3). CTCF
is therefore known to be part of a mechanism that mediates the conversion of underlying
epigenetic signals (in this case methylation) to expression differences. CTCF has also been
directly proposed to be part of a wider system of heritable epigenetic regulation [Phillips
and Corces, 2009], although this has not been demonstrated experimentally.
Cohesin is a protein complex with a well described role in sister chromatin cohesion
and their segregation during anaphase (Section 1.6). In addition, cohesin is known to
co-localise with CTCF during interphase and has furthermore been implicated in tran-
scriptional regulation in the Interferon-γ locus [Hadjur et al., 2009].
Given the close association of CTCF and cohesin, the well characterised role of CTCF
in the regulation of imprinting at the H19 locus, the known role of regulation of expression
by cohesin and the proposed action of CTCF as part of an heritable epigenetic mechanism,
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we performed allele-specific ChIP-seq on post-natal day 21 (P21) mouse brain. Brain is
a tissue in which imprinting is known to occur extensively and of the 104 imprinted
transcripts known in the mouse [Schulz et al., 2008], more than 50 are known to be
expressed in the brain [Wilkins, 2008].
4.1 ChIP-seq for Detection of Parent-of-origin Specific
Binding of CTCF and cohesin
4.1.1 Interspecies Crosses, ChIP-seq and Sequencing
Reciprocal crosses between C57BL6J (Bl6) and castaneous mouse strains were performed
and F1 progeny P21 brain tissue was banked before this project. The experimental design
is shown diagrammatically in Figure 4.1. BxC animals derive from a cross where the dam
is Bl6 and the sire castaneous and CxB animals from crosses where the sire is Bl6 and
the dam castaneous.
Reciprocal crosses were used to differentiate between allele-specific DNA binding in a
sequence dependent manner from true parent-of-origin specific binding and furthermore
ensured that mapping bias to the reference sequence (Bl6) was not influencing the results
(Section 4.6.4).
ChIP-seq for CTCF and cohesin was performed separately by Dr Adam Prickett on
the above tissues as described in Section 2.8.1. In total, four sequencing libraries were
prepared and sequenced, two corresponding to the CTCF ChIP-seq and two to the cohesin
ChIP-seq.
Paired-end sequencing of the libraries was performed on four lanes of an Illumina
GAIIx instrument by the BRC Genomics Facility. One instrument lane per library was
used for sequencing. Details of the libraries sequenced and raw read counts for the ChIP
experiments and the input can be found in Table 4.1.
4.1.2 Primary ChIP-seq Data Analysis
Quality control of the reads and alignment to the mm9 reference genome was performed
by Dr Reiner Schulz as detailed in Section 2.8.2. Duplicate reads were identified and
removed using the Picard toolkit. Percent duplication rates are shown in Figure 4.2. The
level of duplication was low and conducive to further analysis.
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Table 4.1: CTCF and cohesin ChIP-seq library read counts.
Library Read Count Duplicate Reads
CTCF BxC 118,102,950 3,659,373
CTCF CxB 126,716,090 6,589,034
Rad21 BxC 130,812,978 7,572,405
Rad21 CxB 115,163,984 7,207,008
input CTCF BxC 33,786,908 8,881,349
input CTCF CxB 32,960,735 1,907,527
input Rad21 BxC 33,843,811 2,961,489
input Rad21 CxB 34,237,535 2,287,633
Figure 4.1: Summary of experimental design. ChIP-seq was performed for CTCF and
the rad21 cohesin subunit on P21 brain in BxC and CxB F1 hybrid animals. Adapted
from [Prickett et al., 2013]. Figure prepared by Dr Adam Prickett.
Figure 4.2: Duplication rate across all examined libraries. Duplication rate low and was
less than 10% for all libraries. Adapted from [Prickett et al., 2013].
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Figure 4.3: Bar plot of the number of CTCF and cohesin peaks after initial identification
at FDR 0.5, refinement to FDR 13 and expansion and merging. Expansion and merging
of peaks has a minor effect on the total count of peaks.
4.1.3 Identification of CTCF and cohesin Binding Sites
Identification of CTCF and cohesin binding sites with USeq was performed prior to this
work. Peaks were initially detected as detailed in Section 2.8.2 to a very permissive cutoff
of Phred scaled False Discovery Ratio 0.5 (3% accuracy). This was performed by Dr
Reiner Schulz, all subsequent work was performed by the author.
The set of peaks was refined to include only peaks of FDR 13 or higher (95% accu-
racy) by filtering using a custom UNIX script to discard peaks unlikely to be biologically
relevant. Peaks in the resulting set were expanded by +/-500bp and overlapping peaks
were merged.
Expansion and merging of overlapping peaks was not essential at this processing stage,
however it was important for subsequent analysis (Section 4.6.2) and was performed here
for consistency. The number of peaks throughout the processing pipeline is shown in
Figure 4.3. Out of the approximately 70,000 peaks in each dataset, 20,000 peaks were
removed by merging.
4.1.4 Overlap of CTCF and cohesin Binding Sites
CTCF and cohesin have been previously reported to co-localise, although independent
roles have also been reported. In order to confirm this observation, we assessed the
overlap of the detected peaks.
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Figure 4.4: Venn diagram of overlap of CTCF and cohesin binding sites in the mouse
brain. Approximately half of their binding sites are shared (55% of CTCF and 51%
of cohesin), supporting concerted and independent action for both proteins. Adapted
from [Prickett et al., 2013].
Although an intuitively simple concept, peak overlap between two datasets is not
trivial to calculate because the number of overlaps between two sets of genomic intervals
A and B can either refer to the number of elements in A overlapping one of more elements
in B or vice versa. These two numbers are not by definition equal and may in fact differ
considerably. For the context of all subsequent work, peak overlaps were calculated as the
mean of the two reciprocal overlap calculations. For this reason, the sum of the number
of peaks may not always accurately recapitulate the total sum of peaks reported. Peaks
were reported as overlapping when an overlap of at least 1 bp between the two peaks
existed.
CTCF and cohesin peaks show considerable overlap and share between 51.4% and
55.1% of their binding sites. This observation supports a model where CTCF and cohesin
act in concert but can also act independently. Importantly, these data support a much
greater CTCF-independent role for cohesin than previously reported.
4.2 Identification of the Canonical CTCF Motif
In order to confirm the specificity of our ChIP-seq, we sought to identify the known
canonical CTCF binding motif [Schmidt et al., 2012], [Chen et al., 2008] in the sequence
underlying the detected peaks. Identification of the motif was performed via the MEME-
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Figure 4.5: Results of CTCF motif discovery with MEME on ES Cells, liver and brain
datasets. The canonical CTCF motif is identified in all three datasets with a high degree
of confidence and shows high similarity between the three tissues. Adapted from [Prickett
et al., 2013].
ChIP motif discovery tool [Bailey et al., 2009] on the brain dataset produced in the context
of this study and datasets from liver and ES cells (Figure 4.5), as described in Section
2.8.11. The analysis revealed the canonical motif as the top hit (p-value=2.9e-199) in
brain, and also confirmed its presence in other tissues. Our analysis did not identify the
12 bp second binding motif identified by Schmidt and colleagues [Schmidt et al., 2012].
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Table 4.2: Cytosine methylation from [Xie et al., 2012] within CTCF binding sites iden-
tified in the present study, stratified by sequence context. CTCF binding sites are hypo-
methylated compared to the genome consistent with the known preference of CTCF for
unmethylated DNA. Adapted from [Prickett et al., 2013].
% Cytosine Methylation
Cytosine context Genome-wide Within CTCF binding site p-value
CpG 60.80% 51.90% <1e-6
non-CpG 2.50% 2.10% <1e-6
4.3 Examination of Methylation Status across CTCF
Binding Sites
CTCF is known to preferentially bind unmethylated DNA and this specificity is respon-
sible for its allele-specific activity at the H19/Igf2 locus. We sought to confirm this
relationship genome-wide.
Whole-genome methylation data for brain [Xie et al., 2012] were obtained and the
overall level of methylation in the CpG and non-CpG context was compared to the level
of methylation in CTCF binding regions (Table 4.2). As expected, cytosine methylation
was significantly lower within CTCF binding peaks.
Unexpectedly, the difference in methylation in the non-CpG context was smaller than
in the CpG context, suggesting that CpG methylation has greater influence on CTCF
binding. This finding is somewhat surprising given that the canonical CTCF binding site
does not contain CpGs. This difference can potentially be reconciled by the observation
that the relative change in percent methylation is in both cases 0.15 of the genome-wide
methylation, but the difference is exacerbated by the baseline difference in methylation
in the two sequence contexts.
4.4 Tissue-specificity of CTCF Peaks without the Canoni-
cal Motif
CTCF has been reported as a multivalent DNA binding factor that can bind a diverse set
of sequences using a different combinations of Zn-fingers [Filippova et al., 1996]. CTCF
is however known to primarily bind a fixed motif, a finding replicated in the context of
this study, and furthermore shown to be tissue invariant (Section 4.2), yet some CTCF
binding locations do not contain the canonical motif sequence.
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We investigated the relationship between tissue specificity and inclusion of the canon-
ical motif in three tissues, using three datasets from liver [Schmidt et al., 2012], ES
cells [Chen et al., 2008] and brain.
Initially, the number of overlapping peaks between the peak datasets was obtained.
Given that the datasets were derived using different computational approaches and by
different research groups we sought to find a peak size that will maximise specific overlaps
without introducing excessive spurious hits. Optimisation of the peak size was performed
by reducing the peak size in all samples to 1 bp and iteratively increasing it while calculat-
ing the number of overlaps observed. This optimisation was performed on an alternative
ESC dataset from [Kagey et al., 2010], which was initially used in this project. The op-
timisation was not repeated in the dataset from Chen and colleagues [Chen et al., 2008]
and is expected to be relevant as the inflection point was invariant for all the original
datasets compared, suggesting that it would be similar for the dataset from Chen and
colleagues.
The relationship between the number of overlapping peaks and the peak size is shown
in Figure 4.6. The figure shows a rapid increase in the number of peak overlaps as the
peak sizes increase from 0 to +/- 1kb and a plateau of non-specific overlaps after that
point. For comparison, the same analysis was performed with our dataset (brain) against
a randomly generated dataset to demonstrate that no inflexion point is present when
interactions are random. On the basis of these results, a peak size of +/- 500bp was
selected as this was the minimum size that coincided with the inflection point in all tissue
combinations.
Using the size-adjusted peaks from all three datasets, we identified the number of
overlaps between the three datasets (Figure 4.7 A) using the intersectBed tool. The
three tissues share 25,269 peaks, which represents between 41.1% and 68.6% of the in-
dividual datasets. This level of overlap is consistent with an invariant role for CTCF in
all cell types. Tissue-specific peaks for ES cells were considerably lower than for other
tissues (5.1% against 29.1% in brain and 31.2% in liver), consistent with a basic state of
differentiation and addition of new CTCF binding sites during specification.
In accordance with past observations, we hypothesised that the consensus CTCF motif
is involved in tissue-invariant CTCF binding. Peaks containing the canonical motif were
removed from each dataset to a cutoff of 10−4 using a custom pipeline utilising the FIMO
motif matching tool (part of the MEME suite [Bailey et al., 2009]) as described in Section
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2.8.11.
The results of the overlap analysis are shown in Figure 4.7 B. In sharp contrast to
the previous analysis the number of overlapping peaks between the datasets is between
1.7% and 2.1%, whereas tissue specific peaks constitute the overwhelming majority of
peaks. These results suggest that tissue-specific binding of CTCF may be dependent on
tissue-specific motifs or recruitment of CTCF by other factors.
4.5 Identification of Tissue-specific CTCF Motifs
The observation that a very low number of peaks without the canonical motif are present
in all three tissues examined raises the possibility that CTCF binds to tissue specific mo-
tifs, possibly synergistically with other factors. Such a suggestion would not be without
precedent. In the original characterisation of CTCF, Fillipova and colleagues [Filippova
et al., 1996] mutated specific Zn-fingers and demonstrated that CTCF can bind to het-
erologous sequences using different combinations of these DNA binding domains.
In order to investigate this possibility we performed de novo motif discovery analysis
using the MEME-ChIP tool on tissue specific peaks [Bailey et al., 2009]. In addition to
the canonical CTCF motif, this analysis identified a secondary motif in liver and ES cells
with the sequence ACTCCAGTTCCAGGG with a high degree of confidence (Figure 4.8).
A motif resembling this motif was also found in brain (Figure 4.8). The identification
of a motif highly significant in three different independent datasets suggests that this
motif may be biologically relevant. This motif does not resemble the secondary CTCF
binding motif identified by Schmidt and colleagues, downstream of the canonical CTCF
motif [Schmidt et al., 2012]. Furthermore, an additional sequence motif was found in ES
cells (Figure 4.9) also at a high degree of confidence.
These findings indicate that secondary CTCF binding motifs may be present in tissue
specific CTCF peaks that otherwise remain masked in analyses by the high abundance of
the canonical motif. Further investigation in a more expansive set of tissue specific peaks
is required to confirm these findings.
4.6 Analysis of Genome-wide Allele-specific Binding of CTCF
As aforementioned, the data generated in the context of this project was from animals
derived from reciprocal crosses between Bl6 and castaneous mice strains. This allows for
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Figure 4.6: Plot of number of overlapping peaks against peak size for different dataset
combinations suggests peak overlaps with a peak size smaller than 1 kb are specific and
are not found in the comparison to a random dataset. In contrast, increase in overlaps
beyond 1 kb appear to be largely random. On the basis of these plots a conservative peak
size of 1 kb (+/- 500 bp) was used for the analysis.
192
Figure 4.7: (A) Venn diagram of overlap of all CTCF peaks between ESC, liver and brain
tissues. More than half of binding sites are shared between tissues suggesting a conserved
function across tissues, after size adjustment. ESCs show the smallest number of unique
CTCF peaks, consistent with an undifferentiated state. (B) Venn diagram of overlap
of CTCF peaks not containing the canonical CTCF motif, shows poor overlap between
tissues, suggesting binding to non-canonical motif is highly tissue specific. Adapted from
[Prickett et al., 2013].
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Figure 4.8: Motifs identified in tissue-specific CTCF peak sets. The motifs in ES cells
and liver closely resemble each other.
Figure 4.9: Motif identified in ES cell specific subset of CTCF peaks.
identification of mono-allelic binding events of CTCF and cohesin.
Individual reads overlapping CTCF or cohesin binding sites were examined for overlaps
with known SNPs between the two parental mouse strains obtained from the Wellcome
Trust Sanger Sequencing Centre Website [Yalcin et al., 2012]. Individual reads were
assigned to one of the parental alleles on the basis of the best quality SNP (see following
Section for details). Assignments from forward and reverse reads in read pairs were
subsequently merged and the assignments to parental strains (Bl6 or Cast) were converted
to assignments to parental origin (maternal or paternal) and data from reciprocal crosses
were merged.
The counts of maternal and paternal assignments were generated for each CTCF or
cohesin binding site. Allele-specific binding was assessed by means of a binomial test
corrected for multiple testing via Bonferroni correction.
4.6.1 Read Assignment to Alleles
Assignment of reads to alleles was performed using a custom script (Appendix C.1). The
approach is diagrammatically outlined in Figure 4.10. The known SNPs between the two
parental strains were initially loaded into memory in a hash of arrays structure and sorted
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for quick access (Figure 4.10, Step 1).
All reads were then processed individually and a binary search was performed for the
start of each in the array corresponding to the aligned chromosome. The end of the read
is then detected by linear search from the start position. Binary search for the end of the
read was empirically found to be slower than linear search. This is because the number
of SNPs in every read is small and also smaller than the number of steps required for the
tracking of the end position in binary search.
After all the SNPs overlapping the read in question were identified, the SNP with
the best read quality was sought and the assignment was performed on the basis of that
polymorphism. In some cases assignment was not possible and the read was marked as
unassigned.
4.6.2 Peak Size Adjustment and Filtering
In order to improve detection power CTCF and cohesin peaks were expanded by +/-500
bp and any overlaps arising were merged. This operation increased power to detect weak
mono-allelic sites in close proximity by combining the peaks, but is expected to have
negative impact in the detection of CTCF peaks of opposite parental allele binding in
close proximity. Such a locus is not known to exist and this was not considered to be a
significant caveat to the analysis. Expansion of peaks by 500 bp also has the advantage
of ensuring that subsequent processing will take into account the assignment of reads
partially overlapping the initially identified peak boundaries. The number of peaks before
and after the expansion and merging of overlaps is shown in Figure 4.11.
4.6.3 Pipeline Optimisation
The assignment of individual reads to alleles is computationally intensive as it requires
binary search of a large array of SNPs for every individual read. For this reason, the
reads processed were filtered before assignment so as to exclude reads that do not overlap
regions of CTCF or cohesin binding and to exclude reads that cannot be assigned due
to a lack of known SNP between the parental strains. For similar reasons the number
of peaks that did not contain a SNP between the parental strains were removed (Figure
4.11).
Only 47 million of the total 465 million reads sequenced overlaid peaks that could be
assigned. Furthermore, only 38% of the reads in these regions overlaid a SNP and an
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Figure 4.10: Schematic of algorithm for assignment of reads to alleles. The assignment is
performed in two discrete steps. In step 1, the SNP information between the two parental
strains is loaded onto memory and in step 2 individual reads are examined and assigned
to parental alleles. In step 1 the SNP information is loaded into memory and saved in
a hash (A) of per chromosome arrays (B) each containing SNP information sorted by
chromosome position. In step 2, the start and end genomic position of every read (D) is
retrieved and a binary search for it is performed against the SNP array for the relevant
chromosome (F 1 and 2). The end position is found by linear search from the start
position (F3). All the SNPs found between the start and end position are loaded into a
temporary array (G) along with quality information from the read examined. The best
quality position is selected and used to assign the read to a parental strain (H).
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Figure 4.11: Count of processed CTCF and cohesin peaks across the analysis. A significant
drop of the count of peaks occurs upon expansion and merging of peaks, but relatively
few peaks do not overlap a SNP or an informative read. Adapted from [Prickett et al.,
2013].
even smaller number (approximately 12 million) could be conclusively assigned (Figure
4.12). This observation exemplifies the importance of deep sequencing performed here for
mono-allelic identification of peaks.
4.6.4 Reference Mapping Bias is Ameliorated by the Reciprocal Cross
Experimental Design
A read mapping bias toward the reference (Bl6) allele was detected in the analysis (Figure
4.13 A) as expected. This bias is present because reads from the castaneous allele are
less likely than reads from the Bl6 allele to align to the reference (Bl6) genome and an
imbalance of aligned reads is generated. By employing a reciprocal cross design this bias
was removed when read mapping was assigned to parental alleles and no overall bias
remained (Figure 4.13 B).
4.6.5 Genome-wide Allele Specific CTCF and cohesin Binding Sites
The allele-specific analysis of binding sites of CTCF and cohesin described above, identi-
fied 21 genome-wide significant sites of parent of origin specific binding, shown in Table
4.3. Analysis of the cohesin binding sites did not identify any significant allele-specific
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Figure 4.12: Read counts analysed across pipeline. Only a small portion of the total reads
(not shown) overlays CTCF or cohesin peaks. The next single largest loss of reads occurs
because more than half the reads cannot be assigned to a parental strain due to lack of a
good quality informative SNP. Adapted from [Prickett et al., 2013].
Figure 4.13: (A) Read assignments of CTCF and cohesin reads to parental strains. As
expected, read assignment shows reference bias towards Bl6 allele. (B) Read assignments
of CTCF and cohesin reads to parental origin. No residual parental origin bias remains
after reciprocal cross data are merged. Adapted from [Prickett et al., 2013].
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Table 4.3: Genome-wide significant regions of allele-specific
CTCF binding. Adapted from [Prickett et al., 2013].
Genomic Locus Binding Allele Binding:Nonbinding P-value Nearest genes Notes
chr7:149,764,416-149,768,874 maternal 10.26 1.11E-74 H19, Igf2 Known imprinted gene region
chr15:72,638,890-72,641,957 paternal 12.64 1.35E-57 Peg13, Trappc9 Known imprinted gene region
chr7:6,678,325-6,681,689 paternal 5.51 1.17E-30 Zim2 (Peg3) Known imprinted gene region
chr6:30,686,300-30,688,046 paternal 9.38 9.10E-15 Mest Known imprinted gene region
chr7:69,543,049-69,547,037 paternal 3.37 1.35E-12 Magel2 Known imprinted gene region
chr7:69,580,613-69,582,990 paternal 5.58 2.05E-10 Magel2 Known imprinted gene region
chr7:69,323,407-69,325,218 paternal 6.56 3.91E-10 Magel2 Known imprinted gene region
chr10:74,395,653-74,404,537 maternal 1.48 1.28E-09 Rtdr1, Gnaz No known imprinted genes within 20Mb
chr7:69,526,343-69,528,366 paternal 4.11 3.10E-09 Magel2 Known imprinted gene region
chr7:69,372,124-69,373,922 paternal 8.00 3.26E-09 Ndn,Magel2 Known imprinted gene region
chr2:180,079,574-180,091,367 maternal 1.46 5.84E-09 Gata5, Gm14318 6Mb from Gnas locus
chr7:69,608,918-69,610,897 paternal 5.60 6.90E-09 Peg12, Mkrn3 Known imprinted gene region
chr14:69,941,084-69,946,555 paternal 1.52 1.68E-08 Gm16677, Entpd4, Loxl2 5Mb from Htr2a imprinted locus
chr7:69,353,580-69,355,185 paternal 5.09 2.15E-08 Ndn, Magel2 Known imprinted gene region
chr7:69,519,941-69,521,489 paternal 5.30 3.38E-08 Magel2 Known imprinted gene region
chr14:69,994,239-70,003,685 paternal 1.50 3.98E-08 Entpd4, AK086749, Loxl2 5Mb from Htr2a imprinted locus
chr10:120,737,183-120,739,873 paternal 2.73 4.75E-08 Tbc1d30 No known imprinted genes within 20Mb
chr3:121,236,161-121,244,419 maternal 1.67 6.85E-08 A530020G20Rik, Slc44a3 No known imprinted geneson chromosome 3
chr15:27,817,069-27,819,622 maternal 2.30 6.95E-08 Trio No known imprinted genes within 20Mb
chr13:25,098,042-25,100,314 maternal 2.13 9.98E-08 Mrs2, Gpld1 No known imprinted genes within 20Mb
chr6:60,631,333-60,634,328 paternal 2.16 2.47E-07 Snca 1.6Mb from Herc3
Table 4.4: Top 20 monoallelic hits of cohesin binding. None
of the hits shown here are significant after multiple testing
correction. Only one of the hits coincides with a known im-
printed locus (H19 ).
Genomic locus Binding Allele binding:nonbinding p-value Nearest Genes
chr7:134005379-134008113 paternal 3.9 3.85E-05 Hirip3
chr4:137237242-137240531 maternal 2.0 4.83E-05 Rap1gap
chr4:102979455-102980951 paternal 8.0 4.92E-05 Oma1
chr14:124619379-124623521 paternal 1.9 7.67E-05 Fgf14
chr5:112854608-112863824 paternal 1.4 7.99E-05 Sez6l
chr9:57939590-57940910 paternal 3.5 9.02E-05 Ccdc33
chr1:92481547-92493579 maternal 1.3 1.03E-04 Cops8
chr7:149763790-149770322 maternal 1.3 1.08E-04 H19
chr19:44445191-44450206 paternal 1.5 1.45E-04 Scd4
chr4:135878479-135881216 maternal 2.5 2.17E-04 Hnrnpr
chr5:148229197-148231785 maternal 1.8 2.21E-04 D5Ertd605e
chr6:42297399-42299927 maternal 3.5 2.47E-04 Zyx
chr9:103896310-103901797 paternal 1.4 2.62E-04 Nphp3
chr15:73789131-73790376 maternal 3.7 2.72E-04 Mroh5
chr1:170149664-170152248 paternal 2.4 3.17E-04 Pbx1
chr7:141756647-141760385 maternal 1.6 4.07E-04 Dock1
chr12:60064197-60066451 maternal 2.0 4.99E-04 Sec23a
chr1:62842761-62844278 paternal 5.5 5.34E-04 Nrp2
chr14:56146298-56147522 paternal 4.3 5.35E-04 Nrl
chr13:43186238-43191856 paternal 1.5 5.41E-04 Phactr1
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binding sites, although several regions fell just short of the 1e-6 cutoff (Table 4.4).
Four of the known ICRs (H19/Igf2, Peg13, Zim2 and Mest) were identified in the
CTCF allele-specific analysis, demonstrating that our approach can detect known sites.
Four other regions were within 6 Mb of loci known to contain imprinted genes (Gnas,
Htr2a and Herc3 ). Eight of the other regions clustered near the imprinted Peg12/Magel2
locus and the remaining five regions were not in the vicinity of known imprinted loci.
4.6.6 CTCF and cohesin Binding at Known DMRs
We interrogated CTCF and cohesin binding in the vicinity of 22 known DMRs. The
results are shown in Table 4.5. We observed CTCF and/or cohesin binding in 19 of
the 22 DMRs examined. Twelve sites were found to be bound by both proteins, three
exclusively by CTCF and four exclusively by cohesin. No binding of either factor was
found at three loci.
Mest and Zim2 gDMRs were not previously known to bind CTCF in a parent-of-origin
specific manner.
Given the very small portion of reads that were used for allele-specific assignment of
peaks (Section 4.6.3), we considered the possibility that allele-specific binding occurs in
some sites that did not exceed the multiple testing correction cutoff. The 95% confidence
intervals of the read ratios were examined (Figure 4.14), this work was performed in
collaboration with Dr Adam Prickett and Dr Jeniffer Mollon. A trend towards the binding
to the unmethylated allele was observed for Grb10, Mcts2, Cdh15, Nespas, Zrsr1, Peg10
and Meg3/Dlk1 DMRs. Biallellic binding was observed at the Inpp5f v2 and Plagl1 loci.
As aforementioned, no cohesin genome-wide significant binding sites were observed.
Confidence interval analysis suggested that cohesin also tends to bind to the unmethylated
allele in concert with CTCF, but exhibits an attenuated bias. This is consistent with a
model whereby CTCF binds DNA in an allele-specific manner and subsequently recruits
cohesin in a stochastic or temporally regulated manner.
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Figure 4.14: Plot of 95% confidence interval of ratio of maternal to paternal reads for
CTCF and cohesin in the known imprinted loci shown in Table 4.5.
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Table 4.5: CTFC and cohesin allele-specific binding in the vicinity of known
DMRs. Adapted from [Prickett et al., 2013].
CTCF and cohesin binding
gDMR information (Wamidex) CTCF Cohesin
gDMR name gDMR position Methylated Allele CTCF binding? Binding allele Allele specific p-value Cohesin binding? Binding allle Allele binding p-value
CTCF and cohesin precisely colocalised at gDMR
Grb10 chr11:11,925,485-11,925,790 Maternal Yes N/A N/A Yes N/A N/A
H19/Igf2 chr7:149,766,168-149,768,424 Paternal Yes Maternal* 1.11E-74* Yes Maternal 1.08E-04
Inpp5f v2 chr7:135,831,788-135,832,156 Maternal Yes Bi-allelic N/A Yes Bi-allelic N/A
Mcts2 chr2:152,512,491-152,513,011 Maternal Yes N/A N/A Yes N/A N/A
Mest chr6:30,686,709-30,687,273 Maternal Yes Paternal* 9.00E-15* Yes Paternal 0.0414
Nnat chr2:157,385,786-157,387,398 Maternal Yes N/A N/A Yes N/A N/A
Peg13 chr15:72,636,765-72,642,079 Maternal Yes Paternal* 1.35E-57* Yes Paternal 5.50E-03
Plagl1 chr10:12,810,276-12,810,604 Maternal Yes Bi-allelic N/A Yes Bi-allelic N/A
CTCF and cohesin not precisely colocalised at gDMR
Cdh15 chr8:125,387,861-125,390,344 Maternal Yes Paternal 0.0463 Yes N/A N/A
Nespas chr2:174,121,208-174,126,482 Maternal Yes N/A N/A Yes N/A N/A
Zrsr1 chr11:22,871,842-22,872,319 Maternal Yes N/A N/A Yes Bi-allelic N/A
Zim2 (Peg3) chr7:22,871,842-22,872,319 Maternal Yes Paternal* 1.16E-30* Yes Paternal 0.049
CTCF binding only
Peg10 chr6:4,697,209-4,697,507 Maternal Yes N/A N/A No N/A N/A
Meg3/Dlk1 chr12:110,761,563-110,768,989 Paternal Yes N/A N/A No N/A N/A
Impact chr18:13,130,706-13,132,250 Maternal Yes N/A N/A No N/A N/A
Cohesin binding only
Igf2r-air chr17:12,934,163-12,935,573 Maternal No N/A N/A Yes N/A N/A
Gnas-exon1A chr2:174,153,279-174,153,502 Maternal No N/A N/A Yes N/A N/A
Kcnq1ot1 chr7:150,481,060-150,481,397 Maternal No N/A N/A Yes N/A N/A
Snurf/Snrpn chr7:67,149,878-67,150,301 Maternal No N/A N/A Yes N/A N/A
No binding
Nap1l5 chr6:58,856,690-58,857,056 Maternal No N/A N/A No N/A N/A
Rasgrf1 chr9:89,774,406-89,774,691 Paternal No N/A N/A No N/A N/A
Slc38a4 chr15:96,885,270-96,886,284 Maternal No N/A N/A No N/A N/A
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Figure 4.15: Paternal binding sites of CTCF binding near the Magel2 locus (triangles).
CpG islands are shown in the bottom track. This locus was the only locus identified by
our analysis with eight monoallelic CTCF binding sites in close proximity. Reproduced
from [Prickett et al., 2013].
4.6.7 The Magel2 Locus
A particularly interesting result of this investigation was the observation that 8 CTCF
paternal allele-specific binding sites cluster in the vicinity of the Magel2 locus (Figure
4.15). Such organisation is not seen anywhere else in the genome in our analysis and has
not been previously reported in the literature.
Given the above and that no known DMR existed in that locus at the time, the
methylation of the CpG island at the promoter of Magel2 was assayed via bisulphite
conversion and colony PCR. This assay was performed by Ms Siohban Hughes as described
in Section 2.8.12. The assay confirmed the presence of a maternally methylated DMR as
shown in Figure 4.16. This DMR was independently reported in literature shortly after
our analysis was complete [Xie et al., 2012].
4.7 Discussion
We performed high-depth allele-specific ChIP-seq of CTCF and the rad21 subunit of
cohesin, two nuclear proteins that are known to bind in close proximity and have a
known role in gene regulation, in the mouse brain at post-natal day 21. We searched for
and identified the canonical CTCF motif in our peak set and we compared it with the
canonical motif identified in liver and ES cells, confirming the specificity of our immuno-
precipitation.
Comparison of the overlap of the binding sites of CTCF and rad21 showed considerable
overlap of the binding sites of the two proteins, with over 50% of the sites between the
two shared. This suggests that the two factors act in concert as has been established in
the literature, but also have significant roles in isolation.
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Figure 4.16: Methylation at the Magel2 promoter CpG island shows parent-of-origin
specific methylation of the maternal allele. Filled and empty cycles represent methylated
and unmethylated CpGs respectively. Adapted from [Prickett et al., 2013].
CTCF is known to have a higher affinity for unmethylated DNA. Using brain methyla-
tion data from others [Xie et al., 2012] we compared the methylation over CTCF binding
regions with methylation on non CTCF binding regions. Consistent with the affinity of
CTCF for unmethylated DNA, regions found by our assay to bind CTCF, displayed lower
methylation levels than the genomic mean. Unexpectedly the difference in methylation
was more profound in the CpG context. This was despite that no CpG dinucleotides ap-
pear in the canonical CTCF motif. The discrepancy between the difference in methylation
in CpG and non-CpG content may be attributable to the lower genome-wide methylation
of non-CpG Cs.
We investigated the tissue specificity of CTCF peaks, by comparing our dataset with
datasets from liver and ES cells. We found a significant overlap between different cell
types, but also a significant proportion of tissue specific peaks. Tissue-specific peaks in
ES cells were many fewer that in other tissues. This is consistent with a basal set of
CTCF binding peaks in ES cells that is expanded and refined during differentiation.
Furthermore, we investigated the tissue specificity of CTCF peaks after subtraction
of peaks containing the canonical CTCF motif. We observed a very different pattern
than reported above. The overlap of peaks not containing the canonical motif between
tissues was found to be very poor. This suggests that the canonical motif is implicated
in binding in peaks that are tissue invariant, whereas tissue specific peaks are the result
of a separate binding mechanism, such as binding to a different motif or recruitment by
other factors. CTCF is known to be able to use different combination of Zn-fingers to
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bind divergent sequences [Filippova et al., 1996].
This prompted us to perform de novo motif discovery on the tissue-specific CTCF
peaks. We independently identified a novel motif in all three tissues with high degree of
confidence. Furthermore, we identified a tissue specific motif in ES cells. The biologi-
cal relevance of these motifs is unclear but their discovery warrants further biochemical
investigation.
Making use of the allele-specific nature of our data, we developed a pipeline for the
identification of mono-allelic binding events and we applied it to the CTCF and cohesin
datasets. We identified 21 regions of parent-of-origin allele-specific binding for CTCF. The
majority (16/21) of the identified allele-specific peaks overlaid or where in the vicinity
of a known imprinted locus. Eight of the identified loci were in close proximity near
the Peg12 /Magel2 locus in an unprecedented configuration. No allele-specific peaks were
identified for cohesin.
We cross-referenced our allele-specific data with the list of known DMRs. We observed
CTCF and/or cohesin binding in 19 of the 22 DMRs. Only about half the sites were found
to be bound by both proteins and a smaller portion exclusively by one of the proteins.
This finding supports the notion that binding is mechanistically diverse. The timepoint
of establishment of DMRs was not a determinant of which factors were bound to it,
suggesting that the mechanistic diversity independent of the establishment mechanism.
Allele-specific binding of CTCF was observed in five DMRs in a pattern consistent with
the known methylation at these sites, with CTCF appearing bound to the unmethylated
allele in all cases. Cohesin allele-specific binding was not observed. Confidence interval
analysis demonstrated a more polarised binding pattern for CTCF than cohesin in the
majority of the DMRs examined. This is consistent with a model where allele-specific
binding of CTCF influences, but does not directly dictate cohesin binding.
4.7.1 Further Work
The work presented in this chapter presents further questions in both the context of
specific loci and genome-wide.
The tissue-specific motif analysis has resulted in the identification of two previously
unappreciated motifs. The biological relevance of these motifs is unknown and further
investigation is in order. It would be of particular interest to assess the affinity of CTCF
for the motif found by biochemical assays. Our analysis has given rise to the distinct
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possibility that other tissue specific motifs are present in tissues other than the ones
examined. A comprehensive identification of CTCF ChIP-seq data sets in other tissues
in the literature and application of our analysis on these would thus be of interest.
CTCF monoallelic binding in sites with no known imprinted genes may point to novel
imprinted genes. Validation of these loci was performed by others subsequent to the
work presented here and did not result in the identification of any novel imprinted genes.
Excluding the possibility that these loci represent false positives in our analysis this
suggests that the loci in question may be evolutionary remnants of imprinted regions, that
still maintain an allele-specific chromosomal organisation but do not display imprinted
expression. Alternatively, these could be tissue-specific imprinted loci outside of the brain.
Finally, the Magel2 locus identified in this study presents the identification of an un-
precedented genomic organisation with eight paternal binding sites with 200 kb. This
unusual genomic organisation warrants further investigation. The presence of this organi-
sation patterns should be assessed in other tissues, followed by a comprehensive investiga-
tion into the transcripts resulting from this locus, accompanied by their allelic-specificity.






The modern definition of epigenetics encompasses a diverse range of biological phenomena
that share the common feature of providing a mechanism of stable, and according to some
definitions heritable across cell divisions, storage of information in cells other than that
encoded in the primary DNA sequence.
The work presented in this thesis utilises next-generation sequencing and bioinfor-
matics methodologies to investigate the interplay between epigenetic and transcriptional
processes in two different biological systems. The systems examined are sufficiently di-
verse so as to inform on the expansive and diverse role of epigenetics, while addressing
outstanding specific questions of interest in their particular areas.
Specifically, the methylome and transcriptome of the specialised heart cell line com-
prising the endocardium, are examined and are juxtaposed with those of other endothelial
cells. Furthermore, the genomic distributions of CTCF and cohesin, proteins implicated
in a diverse set of biological process including transcription and imprinting are inves-
tigated in an allele-specific manner and integrated with genome-wide methylation data
from other independent studies in whole brain.
The work presented here is timely given the advent of next-generation sequencing
technologies and the emergence of bioinformatics methodologies that for the first time al-
low the investigation of epigenetic marks and transcription in the whole genome scale at
a relatively low cost. Other studies based on genome-wide interrogation of the transcrip-
tome and epigenome have revealed methylation changes in the specification of embryonic
stem cells to germ layers [Gifford et al., 2013] and methylome changes later in blood
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differentiation [Zilbauer et al., 2013].
The work presented here expands on our understanding of the epigenetic landscape
during development that has been established by a multitude of independent studies.
Large concerted efforts such as the ENCODE and BluePrint projects are addressing sim-
ilar questions in large scale.
5.2 Epigenetics and Transcriptomics in Endocardial and
Endothelial Differentiation
We examined the transcriptional and epigenetic landscape of endocardial and endothelial
cells. The endocardium is a specialised type of epithelium that lines the atria and ven-
tricles of the developing and adult heart. It is a tissue of particular interest because it is
involved in a number of processes of cardiac development including trabeculation of the
ventricles, septation of the heart, valve leaflet and coronary circulation formation [Harris
and Black, 2010] [Tian et al., 2014]. Given the contribution of this cell lineage to heart de-
velopment and given that congenital abnormalities are amongst the most common causes
of early morbidity and mortality, understanding the role of the endocardium is critical.
Our initial hypothesis was that epigenetic differences and in particular differential
DNA methylation were primarily responsible for cell-fate decisions and specification of
the endocardial lineage. We expected to observe only subtle differences in gene expression,
consistent with epigenetics playing a role in tissue specific gene expression and differen-
tiation. This hypothesis was based on the identical functionality and highly similar mor-
phology of the endocardium and the endothelium in early but not late development that
suggested the presence of latent information in these cells, prior data that did not identify
any transcriptional differences between the two cell lines and several studies suggesting ex-
tensive contribution of epigenetic processes in cardiac development in general [Baccarelli
et al., 2010] [Mathiyalagan et al., 2010] [Paige et al., 2012] [Wamstad et al., 2012] [Chang
and Bruneau, 2012] [Vallaster et al., 2012].
We addressed this question using an in vitro differentiation model of the endocardium,
that has been shown to recapitulate endocardial development [Narumiya et al., 2007]
[Misfeldt et al., 2009], and contrasted this cell line to cultured endothelial cells from the
same system, using a specific marker of the endocardium (NFATc1) to isolate these cells
via flow cytometry.
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In contrast to past data and our expectations, we observed a considerable number of
both transcriptomic changes and methylome changes, suggesting that both gene regula-
tion and epigenetic processes have a role in endocardial differentiation.
Using the generated transcriptomic dataset and bioinformatics methodologies, we
identify specific members of the ETS family of transcription factors, a family that has been
independently implicated in hematopoietic and vascular development, as likely to play an
important role in the development of the endocardium. Furthermore, we prioritised the
identified differentially regulated genes using different criteria for further experimental
assessment of their functional significance.
We assessed methylome changes on a per CGI basis as well as genome-wide after
using a smoothing algorithm to improve our power to detect differential methylation
events. The genomic distribution of the observed methylome changes was assessed and
an over-representation of differentially methylated CGIs in the vicinity of protein coding
regions was observed. This was in agreement with past results by others, suggesting that
terminal differentiation methylome changes occur primarily intragenically [Deaton et al.,
2011]. On the genome-wide level we observed enrichment of DMRs in coding regions but
also overlap with functional genomic elements. Furthermore, the genes that were in the
vicinity of DMRs were significantly associated with GO Terms strongly suggesting devel-
opmental role and therefore providing evidence for the role of the DMRs in endocardial
differentiation.
Furthermore, interplay between the methylome and transcriptional regulation was
observed. We were able to confirm that the well-described pattern of inverse correlation
between CGI methylation and transcription is observed in each tissue individually and
examined the nature of this relationship as a function of genomic distance. This, in
conjunction with the expected methylation at the vast majority of the known imprinted
loci, reaffirms the known connections between the epigenome and gene regulation and
supports the robustness and relevance of both the datasets generated here. We also
examine overlaps between the set of genomic DMRs identified and the set of differentially
expressed genes detected. These overlaps included genes that are well known regulators of
the endocardium, such as Tie1 and Tal1, potentially providing a link between epigenetic
regulation and endocardial development.
The observations presented in the context of this work suffer from the caveats discussed
extensively in Section 3.5.1. Importantly, the design of this study was such that it did not
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allow the analysis at the time of specification. The endocardial cells were examined after
differentiation occurred, at a time point at which initiating event in the endocardial spec-
ification may not persist. The methylation assay furthermore suffers from the limitation
that hydroxylmethylation can not be distinguished from DNA methylation. Although hy-
droxylmethylation is not present in most differentiated tissues, it may be relevant in this
context because the endocardial cells examined here are directly derived from differenti-
ation of ES cells and hydroxylmethylation may persist. Finally, the data generated were
not validated using locus specific assays or by functional downstream analysis. Ideally,
validation of the results presented here would be performed in vivo endocardium to es-
tablish their validity in this context before functional validation in the form of knockdown
of identified expressed factors and genetic manipulation of differentially methylated loci
is pursued.
Despite the above, the work supports a role for both the methylome and the transcrip-
tome in the differentiation of the endocardium and suggests that in the future the two
should be examined in concert to obtain a complete understanding of the differentiation
of this tissue. The results furthermore support the idea that other epigenetic marks are
involved in this differentiation process and provide justification for further studies of the
epigenetics of the endocardium.
5.3 Allele-specific CTCF and cohesin Binding in the Mouse
Brain and the Role of DNA Methylation
We assessed the genome-wide distribution of CTCF and cohesin in an allele-specific man-
ner by performing high-depth ChIP-seq for these two factors in post-natal day 21 whole
brain from the offspring of Bl6 and casteneous mice strains. We related the generated
data to gene expression in the genomic context of imprinted genes, the correct expression
of which is critical for development [Surani et al., 1984] [McGrath and Solter, 1984]. Brain
was utilised because a large portion of all known imprinted genes are expressed in this
tissue [Schulz et al., 2008] [Wilkins, 2008].
CTCF is a Zn-finger protein traditionally categorised as an insulator, but with known
roles in the regulation of gene expression, chromosomal organisation and regulation of
imprinting [Phillips and Corces, 2009], most prominently at the H19 locus [Kanduri
et al., 2000]. CTCF is known to preferentially bind unmethylated DNA and can, through
211
selective DNA binding, link DNA methylation and gene regulation. The ubiquity of
CTCF, its genome-wide organisational function and methylation sensitivity has led to
the proposal that CTCF is part of a heritable epigenetic system [Phillips and Corces,
2009], a claim that has not so far been substantiated.
Cohesin is a protein complex with an established role in sister chromatid cohesion
during nuclear division [Onn et al., 2008] [Ocampo-Hafalla and Uhlmann, 2011] that is
known to associate closely with CTCF [Parelho et al., 2008] [Wendt et al., 2008] and is
also believed to regulate gene expression.
In addition to the examination of the interplay between epigenetics in the form of DNA
methylation and the binding of these transcription associated factors, we addressed ques-
tions that this system presents in its own right. Specifically, we assessed the homogeneity
of imprinting mechanisms as judged by the presence of CTCF and cohesin and under the
assumption that CTCF binds a significant portion of imprinted loci in an allele-specific
manner, we searched for the existence of novel and previously uncharacterised imprinted
loci.
In line with observations made in other studies [Wendt et al., 2008] [Lin et al., 2011],
we observed that CTCF and cohesin share approximately half their binding sites, sug-
gesting that the two factors can work synergistically but also in isolation. We identified
the canonical CTCF motif in sites of CTCF binding, reaffirming the robustness of our
data. Using publicly available data from other studies we confirmed the genome-wide
preference for CTCF for unmethylated DNA [Xie et al., 2012]. Furthermore, we assessed
the tissue specificity of CTCF peaks by comparison with ChIP-seq data from liver and
brain [Schmidt et al., 2012] [Chen et al., 2008]. We observed significant overlap, but also
noted a paucity of ES cell specific peaks suggesting that the binding repertoire of CTCF
expands upon differentiation in a tissue specific manner. The peak overlap of CTCF in
different tissues was found to be very poor when only CTCF peaks not containing the
canonical motif were examined, pointing towards non-sequence specificity mechanisms
from binding at these sites.
We utilised the allele-specific nature of our data to investigate the parent-of-origin
specific binding of CTCF and cohesin in a genome-wide scale. After multiple testing
correction, we observed 21 sites of allele-specific binding many of which were in the vicinity
of known imprinted loci. Further examination of the Magel2 locus revealed the presence of
eight CTCF binding peaks, a configuration not encountered anywhere else in the genome.
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We confirmed the presence of a novel DMR in the Magel2 locus, which was shortly after
independently reported in literature.
We examined the binding of CTCF and cohesin near known imprinted loci. We
observed high heterogeneity in the binding of CTCF and cohesin. CTCF was found to
bind to the unmethylated allele in all cases where parent-of-origin specific binding was
observed, suggesting a strong link between epigenetics and imprinted expression in this
system. Cohesin was not found to be bound allele-specifically to any genomic locations
inclusive of imprinted loci, although its binding was biased toward the binding allele of
CTCF in all cases, suggesting recruitment by CTCF.
Overall, our results point towards a heterogenous role of regulation of expression by
CTCF and cohesin, which however displays well-defined mechanistic properties in allele-
specific DNA binding.
5.4 Concluding Remarks
Two dissimilar tissues were examined in the context of this work. The methylome and
transcriptome of the highly specialised endocardium in culture at the embryonic day
equivalent of E9.5 and genome-wide CTCF and cohesin parent-of-origin specific binding
in whole brain at post-natal day 21. The two systems contrast sharply in a number of
features, namely developmental time-point, germ-layer, tissue specificity level and in vitro
against in vivo setting. In both cases we observe interplay between the methylome and
transcriptional processes, supporting the notion that examination of both processes is
important for complete understanding of gene regulation and cellular behviour.
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Table A.2: List of first 100 differentially methylated CGIs between the Endo-
cardium and the Endothelium ordered by increasing p-value.
Locus Endocardial Methylation Endothelial Methylation Methylation Difference p-value FDR
chr11:96849230-96849675 61.7 19.3 42.4 8.42E-03 0.35
chr15:25293805-25294929 62.8 21.3 41.5 9.03E-03 0.35
chr10:79858041-79858366 85.1 42.1 43.1 1.02E-02 0.35
chr7:53604045-53604704 54.9 16.3 38.6 1.03E-02 0.35
chr18:25636808-25637256 79.4 36.6 42.8 1.04E-02 0.35
chr7:126883244-126883727 53.3 15.2 38.1 1.05E-02 0.35
chr2:17821267-17821621 86.5 44.5 42.0 1.06E-02 0.35
chr11:104432676-104433180 66.1 27.1 39.0 1.09E-02 0.35
chr10:62884306-62884659 90.0 51.0 39.0 1.10E-02 0.35
chr12:118397878-118398412 59.3 21.7 37.6 1.14E-02 0.35
chr7:50898665-50899035 87.0 48.0 39.0 1.22E-02 0.35
chr13:59940407-59940888 85.8 46.3 39.5 1.22E-02 0.35
chr16:21332922-21333753 37.2 6.8 30.4 1.24E-02 0.35
chr8:87519536-87520140 80.0 40.0 40.0 1.24E-02 0.35
chr10:14479796-14480502 24.7 2.0 22.7 1.24E-02 0.35
chr7:108209677-108210318 49.8 15.0 34.8 1.26E-02 0.35
chr17:27856866-27857115 78.3 38.9 39.4 1.27E-02 0.35
chr7:20011351-20011713 79.3 40.0 39.2 1.29E-02 0.35
chr14:22505660-22506378 68.6 31.7 36.8 1.30E-02 0.35
chrX:71166644-71167703 20.1 0.7 19.5 1.32E-02 0.35
chr7:50930311-50931282 79.3 40.5 38.9 1.32E-02 0.35
chr4:114321126-114321723 58.8 23.6 35.3 1.33E-02 0.35
chr12:81066267-81066916 56.0 21.3 34.8 1.35E-02 0.35
chr10:79599013-79599571 72.7 35.8 37.0 1.37E-02 0.35
chrX:138740031-138740707 60.4 25.4 35.0 1.37E-02 0.35
chr9:109954396-109954859 76.4 38.7 37.7 1.38E-02 0.35
chr14:99712200-99712722 72.6 36.2 36.3 1.42E-02 0.35
chr2:29700771-29702248 46.1 14.0 32.1 1.45E-02 0.35
chr11:5162974-5163465 78.8 41.6 37.2 1.46E-02 0.35
chr10:93774282-93775331 27.3 4.5 22.8 1.48E-02 0.35
chr16:13867911-13868628 56.4 22.9 33.5 1.48E-02 0.35
chr12:75050520-75051192 49.5 17.0 32.5 1.49E-02 0.35
chr7:135010165-135010795 90.4 58.3 32.1 1.51E-02 0.35
chr4:124583319-124583859 24.2 3.4 20.8 1.51E-02 0.35
chr16:14292328-14292801 62.4 28.5 33.8 1.51E-02 0.35
chr16:33517179-33517756 43.7 12.9 30.8 1.52E-02 0.35
chr12:84961715-84962239 77.7 41.3 36.4 1.52E-02 0.35
chr3:65197122-65197496 87.0 52.6 34.4 1.53E-02 0.35
chr9:63801197-63802016 79.5 43.1 36.4 1.54E-02 0.35
chr1:75356650-75358015 45.7 14.5 31.2 1.54E-02 0.35
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chr2:173935288-173936859 41.4 11.9 29.5 1.57E-02 0.35
chr3:95044597-95045098 70.5 36.0 34.4 1.58E-02 0.35
chr14:106292368-106292828 47.3 16.0 31.3 1.58E-02 0.35
chr17:34048518-34048958 82.6 46.9 35.7 1.58E-02 0.35
chr6:84055242-84056106 32.3 7.3 25.0 1.59E-02 0.35
chr15:102780056-102780582 52.3 20.2 32.1 1.59E-02 0.35
chr1:180298620-180299510 23.8 3.7 20.1 1.61E-02 0.35
chr8:109632921-109633464 79.8 44.2 35.6 1.62E-02 0.35
chr1:182824345-182825199 54.9 23.1 31.9 1.65E-02 0.35
chr8:124217435-124217840 77.9 42.9 35.0 1.66E-02 0.35
chr11:99793315-99793744 78.0 43.0 35.0 1.66E-02 0.35
chr4:150462668-150463188 86.4 53.2 33.1 1.67E-02 0.35
chr5:61459925-61460401 96.7 70.9 25.8 1.68E-02 0.35
chr13:113441941-113442916 82.2 47.5 34.7 1.68E-02 0.35
chr5:116003836-116004208 87.9 55.9 31.9 1.68E-02 0.35
chr10:5977292-5977533 84.2 50.2 34.0 1.69E-02 0.35
chr15:25710655-25711741 82.3 47.9 34.4 1.71E-02 0.35
chr5:97516050-97516941 88.9 58.3 30.7 1.72E-02 0.35
chr4:139560413-139560892 66.2 33.8 32.4 1.74E-02 0.35
chr7:134358010-134358521 72.7 39.2 33.4 1.74E-02 0.35
chr9:54539061-54539756 48.2 17.9 30.2 1.74E-02 0.35
chr9:27598695-27599548 32.5 8.4 24.2 1.76E-02 0.35
chr2:59681213-59681733 88.8 58.4 30.4 1.76E-02 0.35
chr8:123407141-123407674 65.8 33.7 32.1 1.77E-02 0.35
chr10:20119711-20120527 83.0 49.4 33.6 1.77E-02 0.35
chr19:46781729-46782218 48.2 18.2 30.0 1.78E-02 0.35
chr3:89103529-89104014 51.9 21.3 30.6 1.78E-02 0.35
chr5:143690518-143691443 20.8 3.2 17.6 1.78E-02 0.35
chr3:159158100-159158671 13.8 0.4 13.4 1.79E-02 0.35
chr18:61808674-61809085 86.0 54.2 31.9 1.80E-02 0.35
chr17:45941983-45943077 40.9 13.2 27.7 1.80E-02 0.35
chr8:86296406-86297097 48.6 18.7 29.9 1.80E-02 0.35
chr7:31640030-31640428 89.4 60.0 29.4 1.81E-02 0.35
chr4:115796125-115796544 12.5 0.0 12.5 1.84E-02 0.35
chr5:149842687-149843490 50.0 20.2 29.8 1.84E-02 0.35
chr1:44255391-44256133 75.4 42.5 33.0 1.85E-02 0.35
chr8:86184960-86185394 74.4 41.6 32.8 1.85E-02 0.35
chr13:93564256-93565180 49.7 20.0 29.7 1.86E-02 0.35
chr4:43419193-43419680 20.6 3.4 17.2 1.86E-02 0.35
chr5:120141042-120141437 14.2 0.8 13.4 1.86E-02 0.35
chr6:112896704-112897438 35.8 10.7 25.1 1.87E-02 0.35
chr2:151401457-151402277 27.4 6.5 20.9 1.87E-02 0.35
chr10:81816853-81817518 16.1 1.6 14.5 1.87E-02 0.35
chr17:71011650-71012339 89.2 60.3 28.8 1.88E-02 0.35
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chr8:109241777-109242386 63.1 32.3 30.9 1.90E-02 0.35
chr17:13102514-13103073 77.9 45.1 32.8 1.90E-02 0.35
chr6:47974378-47975698 75.6 43.1 32.5 1.91E-02 0.35
chr11:97361128-97362869 61.6 31.0 30.6 1.92E-02 0.35
chr14:76654766-76655262 61.2 30.7 30.5 1.92E-02 0.35
chr1:72908839-72909278 89.5 61.4 28.1 1.93E-02 0.35
chr3:88011040-88011606 31.2 8.6 22.6 1.93E-02 0.35
chr15:12763065-12764056 82.7 50.6 32.1 1.93E-02 0.35
chr6:89185575-89186168 84.5 53.3 31.2 1.95E-02 0.35
chr11:94253874-94254371 56.3 26.4 29.9 1.95E-02 0.35
chr4:53488083-53488470 82.6 50.7 31.9 1.96E-02 0.35
chr15:89377737-89379428 70.7 39.3 31.4 1.96E-02 0.35
chr4:138894006-138894469 78.6 46.4 32.2 1.98E-02 0.35
chr7:29329020-29329804 54.9 25.3 29.5 1.98E-02 0.35
chr1:89371543-89372426 36.2 11.5 24.7 1.98E-02 0.35
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A.3 Differentially Methylated Genomic Regions between
the Endocardium and the Endothelium
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Table A.3: Full list of differentially methylated genomic loci between the endo-
cardium and the endothelium as identified by the analysis utilising BSmooth,
ordered by methylation difference between the two tissues.
Genomic Locus Area T-statistic Endocardial Methylation Endothelial Methylation Mean Methylation Difference Methylation in Endocardium
chr11:20550017-20550548 121.61 81.1% 30.2% 50.9% hyper
chrX:154006656-154007063 123.92 86.8% 36.9% 50.0% hyper
chr11:96817033-96817576 164.59 84.3% 35.5% 48.8% hyper
chr4:153880639-153881227 113.16 73.4% 25.3% 48.1% hyper
chr8:91769076-91769532 132.12 68.8% 23.9% 44.8% hyper
chr18:25636890-25637087 108.62 79.8% 36.1% 43.7% hyper
chr8:64028283-64028744 200.36 77.9% 36.5% 41.4% hyper
chr15:25293946-25294414 309.43 67.5% 26.3% 41.2% hyper
chr3:148585565-148586109 116.54 88.1% 47.8% 40.3% hyper
chr7:50930490-50930781 81.40 80.2% 40.0% 40.2% hyper
chr4:138894197-138894354 99.77 74.4% 34.3% 40.1% hyper
chr4:117040019-117040677 147.29 84.2% 44.8% 39.4% hyper
chr11:116967987-116968706 112.43 76.0% 36.6% 39.3% hyper
chr5:7622306-7622586 76.25 81.2% 42.1% 39.1% hyper
chr11:104432697-104433410 203.62 65.6% 26.6% 39.0% hyper
chr9:63801417-63801870 196.96 80.0% 41.3% 38.6% hyper
chr12:84961946-84962112 58.45 76.6% 38.7% 37.9% hyper
chr10:26047327-26047995 116.69 79.1% 41.3% 37.8% hyper
chr15:59482983-59483306 82.34 82.8% 45.0% 37.8% hyper
chr11:114403263-114403975 116.45 77.9% 40.2% 37.8% hyper
chr13:113442131-113442504 81.43 78.9% 41.4% 37.5% hyper
chr14:55250863-55251098 82.27 82.6% 46.0% 36.7% hyper
chr8:72817084-72817565 73.83 84.1% 47.6% 36.6% hyper
chr4:123000050-123000422 177.37 66.1% 29.6% 36.4% hyper
chr14:8972127-8973204 111.57 70.9% 34.5% 36.4% hyper
chr7:53604302-53604654 101.23 53.7% 17.4% 36.3% hyper
chr6:142845417-142846067 88.96 83.2% 47.0% 36.2% hyper
chr11:97811095-97811915 177.03 78.3% 42.1% 36.1% hyper
chr9:83557758-83558664 162.18 76.0% 40.0% 36.0% hyper
chr12:119898955-119900124 75.74 62.0% 26.1% 35.9% hyper
chr2:24534514-24534988 209.60 81.3% 45.5% 35.8% hyper
chr9:110533954-110534504 95.38 65.1% 29.6% 35.5% hyper
chr17:27856820-27857320 166.46 80.5% 45.1% 35.4% hyper
chr18:46876036-46876695 107.88 82.0% 46.6% 35.4% hyper
chr6:72680493-72680944 86.68 82.8% 47.7% 35.1% hyper
chr4:125212061-125213486 130.58 50.7% 15.6% 35.0% hyper
chr14:56519271-56519756 84.84 74.3% 39.3% 35.0% hyper
chr11:28930542-28930822 98.69 80.7% 45.8% 34.9% hyper
chr8:44876887-44877618 85.29 76.9% 42.1% 34.8% hyper
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chr2:31160427-31160688 65.00 81.4% 46.7% 34.7% hyper
chr10:120752173-120752764 162.85 73.2% 38.5% 34.7% hyper
chr6:52273000-52273700 100.62 63.5% 29.0% 34.6% hyper
chr2:147702816-147703764 129.93 76.8% 42.3% 34.5% hyper
chr10:20119828-20120526 263.17 83.3% 48.9% 34.4% hyper
chr1:89178205-89179039 137.65 81.9% 47.5% 34.3% hyper
chr7:13556679-13556924 87.58 82.2% 48.0% 34.2% hyper
chr12:87720288-87721157 134.17 77.9% 43.7% 34.2% hyper
chr7:133768119-133768628 89.56 83.7% 49.5% 34.2% hyper
chr14:55098383-55098699 92.35 57.4% 23.2% 34.2% hyper
chrX:138740315-138740713 107.79 58.0% 24.0% 34.1% hyper
chr3:95044758-95045100 110.63 69.9% 35.9% 34.1% hyper
chr1:179492014-179492920 167.67 89.1% 55.2% 33.9% hyper
chr12:111736298-111736957 96.44 82.0% 48.1% 33.9% hyper
chr15:27980776-27981645 226.39 69.1% 35.3% 33.8% hyper
chr9:113897783-113898366 92.15 78.7% 44.9% 33.8% hyper
chr2:168519698-168520288 102.38 64.9% 31.2% 33.7% hyper
chr2:150237786-150238319 117.77 78.1% 44.4% 33.7% hyper
chr5:144143301-144143635 97.99 79.6% 45.8% 33.7% hyper
chr3:68385653-68386262 105.27 79.3% 45.7% 33.6% hyper
chr5:151249330-151249927 81.29 84.4% 50.9% 33.6% hyper
chr15:55708482-55708897 74.19 75.4% 42.0% 33.4% hyper
chr10:120131616-120132067 86.54 71.8% 38.5% 33.4% hyper
chr7:56887804-56888417 76.82 65.3% 32.0% 33.3% hyper
chr7:149766621-149768046 287.28 87.8% 54.5% 33.3% hyper
chr8:10805689-10806092 97.68 54.5% 21.3% 33.1% hyper
chr14:29330909-29331627 135.31 72.3% 39.2% 33.1% hyper
chr4:125222430-125222877 59.95 68.3% 35.2% 33.1% hyper
chr3:21222765-21223114 88.76 84.7% 51.8% 33.0% hyper
chr14:105826684-105827339 139.54 70.5% 37.5% 33.0% hyper
chr15:27924612-27925488 113.33 69.3% 36.4% 32.9% hyper
chr11:5163165-5163515 94.81 78.5% 45.6% 32.9% hyper
chr9:114547118-114547781 76.87 81.9% 49.0% 32.9% hyper
chr3:66900683-66900925 102.75 91.0% 58.1% 32.8% hyper
chr8:109632819-109633508 121.87 78.5% 45.8% 32.8% hyper
chr8:73269722-73269943 79.16 86.8% 54.0% 32.8% hyper
chr10:79509265-79510337 72.25 69.9% 37.1% 32.7% hyper
chr2:87366209-87366535 70.58 71.6% 38.8% 32.7% hyper
chr4:136019237-136019486 69.33 46.7% 14.0% 32.7% hyper
chr7:148211594-148212613 75.05 72.1% 39.5% 32.6% hyper
chr10:93693157-93693587 111.40 77.0% 44.5% 32.5% hyper
chr3:52760307-52760810 97.77 83.3% 50.8% 32.4% hyper
chr5:65799006-65799736 126.34 74.9% 42.5% 32.4% hyper
chr11:44645791-44646249 105.95 49.0% 16.6% 32.4% hyper
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chr11:120044927-120045408 96.34 66.8% 34.5% 32.4% hyper
chr11:3387833-3388588 118.15 77.7% 45.3% 32.4% hyper
chr12:12700495-12701526 244.17 57.8% 25.4% 32.3% hyper
chr13:52975064-52976007 91.10 70.1% 37.9% 32.3% hyper
chr7:78528053-78528603 118.63 70.4% 38.3% 32.2% hyper
chr2:173191080-173191315 99.19 69.4% 37.3% 32.1% hyper
chr3:153568685-153569035 155.32 73.1% 41.0% 32.1% hyper
chr14:22336557-22336788 94.48 82.1% 50.0% 32.1% hyper
chr9:96444280-96444757 77.76 71.2% 39.1% 32.0% hyper
chr2:83532327-83533271 108.54 69.2% 37.2% 32.0% hyper
chr15:25562473-25563160 84.10 87.2% 55.2% 31.9% hyper
chr7:29957746-29958208 135.20 76.6% 44.7% 31.9% hyper
chr4:114321291-114321618 106.51 57.3% 25.4% 31.9% hyper
chr2:103843358-103843795 96.17 70.0% 38.1% 31.9% hyper
chr4:126901908-126902545 115.12 60.1% 28.2% 31.9% hyper
chr8:4206269-4206850 160.25 55.2% 23.4% 31.9% hyper
chr6:23222610-23223675 130.42 51.8% 20.0% 31.8% hyper
chr9:110817103-110817617 142.35 80.1% 48.3% 31.8% hyper
chr11:76171083-76171334 65.22 73.8% 42.0% 31.8% hyper
chr3:36962467-36962746 164.50 79.7% 47.9% 31.8% hyper
chr1:129897370-129898094 71.72 85.8% 54.0% 31.8% hyper
chr17:5418663-5419303 119.05 84.8% 53.0% 31.8% hyper
chr5:33854489-33855593 131.17 79.7% 48.0% 31.7% hyper
chr1:162962729-162963711 70.35 82.6% 51.0% 31.7% hyper
chr8:73026052-73026374 62.30 61.9% 30.3% 31.6% hyper
chr13:12199582-12200010 88.78 72.3% 40.7% 31.6% hyper
chr17:18046692-18047335 245.33 69.4% 37.7% 31.6% hyper
chr4:149033577-149034159 118.16 81.1% 49.5% 31.6% hyper
chr18:69837437-69838038 125.39 86.4% 54.8% 31.6% hyper
chr4:135846684-135847192 213.57 49.2% 17.6% 31.6% hyper
chr8:86192552-86192929 99.51 69.2% 37.7% 31.5% hyper
chr1:163373007-163373968 137.61 65.2% 33.7% 31.5% hyper
chr10:58003391-58003733 121.81 80.8% 49.3% 31.4% hyper
chr16:43142871-43143259 183.14 83.0% 51.6% 31.4% hyper
chr4:14606912-14607206 72.75 78.5% 47.1% 31.4% hyper
chr13:14057735-14058074 81.99 78.5% 47.2% 31.3% hyper
chr9:39203548-39203848 77.02 81.9% 50.6% 31.3% hyper
chr10:94638146-94638844 117.67 69.4% 38.2% 31.3% hyper
chr12:85913238-85913949 82.72 58.7% 27.5% 31.2% hyper
chr19:57064818-57065598 101.77 78.4% 47.2% 31.2% hyper
chr8:46136332-46136765 131.64 87.5% 56.2% 31.2% hyper
chr2:165658869-165659522 82.22 84.5% 53.3% 31.2% hyper
chr2:106696495-106697317 86.39 74.6% 43.5% 31.1% hyper
chr8:11279391-11279803 87.06 72.8% 41.8% 31.1% hyper
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chr11:115119008-115119217 70.91 66.2% 35.2% 31.0% hyper
chr8:124859685-124859999 128.73 45.5% 14.5% 31.0% hyper
chr12:118397824-118398305 108.47 58.0% 27.1% 31.0% hyper
chr18:20759818-20760284 115.35 84.9% 53.9% 31.0% hyper
chr15:93333574-93334094 145.65 83.1% 52.3% 30.8% hyper
chr11:34964809-34965604 180.55 84.1% 53.3% 30.8% hyper
chr12:106959841-106960413 76.92 79.6% 48.8% 30.8% hyper
chr11:43466414-43466817 70.31 74.9% 44.1% 30.8% hyper
chr17:45942669-45942994 128.33 38.0% 7.3% 30.7% hyper
chrX:166419731-166420074 82.09 82.9% 52.3% 30.7% hyper
chr1:154762425-154763580 65.91 80.1% 49.5% 30.7% hyper
chr5:134714011-134714456 82.26 84.3% 53.6% 30.6% hyper
chr11:96440246-96440681 113.92 66.7% 36.1% 30.6% hyper
chr2:120965087-120965692 209.04 70.2% 39.6% 30.6% hyper
chr15:8544799-8545602 96.68 82.5% 51.9% 30.6% hyper
chr8:124217553-124217926 71.47 78.0% 47.4% 30.6% hyper
chr15:55040178-55040661 106.41 78.1% 47.5% 30.6% hyper
chr3:108187823-108188389 163.54 83.4% 52.8% 30.5% hyper
chr2:29110478-29111264 114.35 76.2% 45.7% 30.5% hyper
chr3:65460533-65461071 117.73 65.2% 34.7% 30.5% hyper
chr9:109954369-109954889 124.45 75.4% 44.9% 30.5% hyper
chr1:186634432-186634830 98.49 59.8% 29.4% 30.4% hyper
chr5:114570042-114570523 66.19 84.0% 53.6% 30.4% hyper
chr7:135010044-135010639 175.80 88.6% 58.2% 30.4% hyper
chr3:50513551-50514177 86.49 78.7% 48.4% 30.4% hyper
chr19:43647741-43648429 119.00 88.6% 58.3% 30.4% hyper
chr17:69557035-69557497 89.65 80.7% 50.3% 30.3% hyper
chr9:22707765-22708325 71.57 85.0% 54.7% 30.3% hyper
chr7:127741433-127741781 116.41 61.3% 31.0% 30.3% hyper
chr12:113958407-113959505 113.23 65.0% 34.8% 30.2% hyper
chr11:116951603-116952944 95.73 78.4% 48.2% 30.2% hyper
chr19:46798935-46799509 113.20 81.2% 51.0% 30.2% hyper
chr8:98125047-98125535 80.22 80.0% 50.0% 30.1% hyper
chr5:116003709-116004100 123.89 88.4% 58.3% 30.1% hyper
chr10:19861332-19862037 77.87 80.3% 50.3% 30.1% hyper
chr1:52546812-52547220 95.74 79.9% 49.8% 30.0% hyper
chr2:26026217-26027130 89.19 67.7% 37.7% 30.0% hyper
chr11:20556345-20557360 128.87 61.5% 31.5% 30.0% hyper
chr11:106468008-106468818 77.68 81.0% 50.9% 30.0% hyper
chr4:117003245-117004132 87.26 78.3% 48.3% 30.0% hyper
chr8:23779930-23780438 83.60 87.8% 57.8% 30.0% hyper
chr11:113570080-113570880 134.07 59.9% 30.0% 29.9% hyper
chr12:88254354-88254948 96.80 86.3% 56.3% 29.9% hyper
chr8:109241931-109242163 85.55 59.7% 29.7% 29.9% hyper
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chr13:99343432-99344453 266.12 80.0% 50.1% 29.9% hyper
chr2:152253151-152253878 115.04 54.0% 24.1% 29.9% hyper
chr4:26645556-26645945 78.76 78.3% 48.4% 29.9% hyper
chr2:126186491-126187372 165.61 78.2% 48.4% 29.9% hyper
chr7:138835717-138836274 105.72 77.1% 47.2% 29.9% hyper
chr8:108090552-108090881 75.50 50.2% 20.4% 29.8% hyper
chr5:103954986-103955263 65.17 90.0% 60.2% 29.8% hyper
chr5:56235254-56235473 90.55 80.8% 51.0% 29.8% hyper
chr8:73121547-73121732 65.54 51.1% 21.4% 29.7% hyper
chrX:4906716-4907109 83.50 82.8% 53.1% 29.7% hyper
chr4:101189001-101189294 81.81 90.7% 60.9% 29.7% hyper
chr15:39945555-39946960 190.41 67.6% 37.9% 29.7% hyper
chr9:96714563-96714689 95.84 89.4% 59.8% 29.7% hyper
chr11:4139573-4139951 115.01 80.5% 50.9% 29.6% hyper
chr15:102780161-102780416 80.93 53.0% 23.5% 29.6% hyper
chr5:118887676-118888683 85.61 57.9% 28.4% 29.6% hyper
chr11:85738410-85738910 84.01 73.6% 44.1% 29.6% hyper
chr2:29736055-29736324 68.60 74.8% 45.3% 29.5% hyper
chr2:17854469-17854935 72.99 64.4% 34.9% 29.5% hyper
chr16:90132564-90133273 135.78 73.1% 43.7% 29.4% hyper
chr2:18477581-18478236 95.65 80.9% 51.5% 29.4% hyper
chr5:34035168-34035359 58.35 47.9% 18.5% 29.4% hyper
chr6:148930872-148931889 77.66 79.3% 50.0% 29.4% hyper
chr5:102317190-102317415 88.50 85.1% 55.8% 29.3% hyper
chr6:134569347-134569912 91.37 86.3% 57.0% 29.3% hyper
chr7:31299458-31300412 108.19 66.3% 37.0% 29.3% hyper
chr7:119885156-119885680 89.87 66.5% 37.2% 29.3% hyper
chr3:31107154-31108172 103.55 73.3% 44.0% 29.3% hyper
chr15:100499800-100500090 63.25 85.6% 56.4% 29.3% hyper
chr11:120122554-120122994 80.02 76.1% 46.9% 29.3% hyper
chr12:74894209-74894870 118.88 61.8% 32.5% 29.3% hyper
chr15:80780036-80781106 65.71 86.8% 57.5% 29.2% hyper
chr9:56284989-56285562 179.15 86.6% 57.5% 29.1% hyper
chr19:45641609-45642656 168.07 65.4% 36.3% 29.1% hyper
chr7:20055181-20055460 96.30 73.0% 43.9% 29.1% hyper
chr11:94011846-94012759 78.66 63.8% 34.7% 29.1% hyper
chr17:32470744-32470984 74.77 86.3% 57.3% 29.1% hyper
chr1:137114015-137114765 85.15 71.5% 42.4% 29.1% hyper
chr11:51781864-51783034 99.54 84.0% 55.0% 29.0% hyper
chr7:38264507-38264994 92.57 86.3% 57.4% 29.0% hyper
chr4:124906417-124906697 80.62 77.6% 48.6% 29.0% hyper
chr9:92347926-92348281 87.40 87.6% 58.7% 28.9% hyper
chr7:144017249-144017637 92.09 78.9% 49.9% 28.9% hyper
chr17:7408875-7409589 82.42 72.4% 43.5% 28.9% hyper
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chr5:53916450-53917327 141.88 81.7% 52.8% 28.9% hyper
chr10:37984011-37984378 73.18 83.9% 55.0% 28.9% hyper
chr2:162421258-162422269 96.39 86.6% 57.8% 28.9% hyper
chr12:113027316-113027845 103.18 84.6% 55.8% 28.8% hyper
chr4:136312041-136312761 91.77 61.9% 33.1% 28.8% hyper
chr4:53487926-53488522 94.84 82.9% 54.1% 28.8% hyper
chr8:113890877-113891293 73.39 75.8% 47.0% 28.8% hyper
chr7:125633459-125634228 240.25 53.9% 25.1% 28.8% hyper
chr11:29725201-29725537 128.03 74.1% 45.3% 28.8% hyper
chr13:112538971-112539308 116.77 89.5% 60.7% 28.8% hyper
chr10:26415113-26415689 114.85 55.2% 26.4% 28.8% hyper
chr10:79616502-79616904 105.56 83.4% 54.6% 28.8% hyper
chr8:82579585-82580748 128.78 71.3% 42.5% 28.8% hyper
chr4:126002087-126002467 76.15 74.6% 45.8% 28.8% hyper
chr8:107860607-107860809 59.26 73.6% 44.9% 28.7% hyper
chr12:107167434-107168267 136.43 76.7% 48.0% 28.7% hyper
chr6:125974444-125975093 95.28 86.9% 58.2% 28.7% hyper
chr10:69902227-69902846 78.05 74.6% 45.9% 28.7% hyper
chr6:50272626-50273168 117.61 84.2% 55.6% 28.6% hyper
chr3:78870524-78870792 102.23 84.8% 56.2% 28.6% hyper
chr2:118256446-118256940 155.81 80.9% 52.3% 28.6% hyper
chr10:93986605-93987099 77.34 59.2% 30.6% 28.6% hyper
chr9:46142581-46142954 98.72 83.4% 54.8% 28.6% hyper
chr16:13130132-13130531 137.23 78.4% 49.8% 28.5% hyper
chr7:119253915-119254613 95.30 85.5% 56.9% 28.5% hyper
chr19:59207361-59208191 107.39 84.8% 56.3% 28.5% hyper
chr15:72931701-72932223 93.84 87.2% 58.7% 28.5% hyper
chr19:44060531-44061068 137.67 68.9% 40.4% 28.5% hyper
chr11:117352477-117353581 82.68 83.7% 55.3% 28.5% hyper
chr2:38375524-38376057 79.38 82.5% 54.0% 28.4% hyper
chr4:154357692-154358075 82.48 68.2% 39.7% 28.4% hyper
chr6:89185481-89185884 99.60 85.5% 57.0% 28.4% hyper
chr13:57383559-57383795 71.76 72.0% 43.6% 28.4% hyper
chr4:118108001-118108883 89.93 81.0% 52.6% 28.4% hyper
chr19:7002201-7002565 66.49 82.9% 54.5% 28.3% hyper
chr9:20442956-20443282 57.07 83.6% 55.3% 28.3% hyper
chr9:106549597-106549960 132.66 81.2% 52.9% 28.3% hyper
chr11:103703044-103703659 91.83 52.9% 24.6% 28.3% hyper
chr7:107871216-107872491 87.71 78.2% 49.9% 28.3% hyper
chr2:168098736-168099311 90.35 60.6% 32.3% 28.3% hyper
chr10:122450555-122450964 107.01 75.3% 47.0% 28.3% hyper
chr12:118685936-118686442 84.93 71.5% 43.2% 28.2% hyper
chr12:13215767-13216338 88.71 82.1% 53.9% 28.2% hyper
chr9:99699916-99700608 113.22 72.9% 44.7% 28.2% hyper
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chr19:57729872-57730414 94.27 83.6% 55.4% 28.2% hyper
chr8:63070352-63070835 126.10 79.5% 51.3% 28.2% hyper
chr11:101040115-101040325 61.00 80.7% 52.5% 28.2% hyper
chr12:101419205-101419822 76.28 75.2% 47.0% 28.2% hyper
chr5:150867030-150867522 89.23 83.0% 54.8% 28.2% hyper
chr16:30657082-30657587 126.60 76.7% 48.6% 28.2% hyper
chr18:75738997-75739687 86.72 78.4% 50.3% 28.2% hyper
chr4:118190073-118190950 78.17 61.8% 33.6% 28.1% hyper
chr10:94636961-94637753 77.42 84.3% 56.1% 28.1% hyper
chr10:82360501-82360825 76.01 81.1% 53.0% 28.1% hyper
chrX:107612618-107613043 62.16 79.4% 51.3% 28.1% hyper
chr4:140580938-140581718 236.64 53.4% 25.3% 28.1% hyper
chr14:121634025-121634409 105.29 85.3% 57.2% 28.1% hyper
chr12:64086039-64086347 65.05 86.6% 58.6% 28.1% hyper
chr5:73739585-73740019 84.93 71.8% 43.8% 28.1% hyper
chr13:51503099-51503468 70.30 62.5% 34.4% 28.1% hyper
chr15:61994205-61995363 78.77 78.6% 50.6% 28.0% hyper
chr10:127095769-127096335 108.01 77.6% 49.6% 28.0% hyper
chr5:99908196-99908938 91.57 64.1% 36.0% 28.0% hyper
chr9:41184428-41184772 91.89 69.1% 41.1% 28.0% hyper
chr3:34555551-34556010 64.44 41.7% 13.7% 28.0% hyper
chr5:135442964-135443614 64.01 78.9% 50.9% 28.0% hyper
chr5:92821616-92822293 146.27 80.1% 52.1% 27.9% hyper
chr7:144444832-144445310 70.83 74.0% 46.1% 27.9% hyper
chr6:88009696-88010378 74.74 79.7% 51.7% 27.9% hyper
chr1:181540120-181540428 103.80 77.5% 49.6% 27.9% hyper
chr15:97168983-97169893 106.90 59.0% 31.1% 27.9% hyper
chr17:28685489-28685767 57.81 76.8% 48.9% 27.9% hyper
chr2:38553060-38553686 103.68 84.5% 56.6% 27.9% hyper
chr13:98517257-98517946 91.89 84.9% 57.0% 27.9% hyper
chr3:90664657-90665000 179.74 79.1% 51.3% 27.8% hyper
chr14:104471046-104471213 58.21 78.9% 51.1% 27.8% hyper
chr11:102126990-102127590 125.74 82.1% 54.3% 27.8% hyper
chr3:121787724-121788914 133.80 68.6% 40.8% 27.8% hyper
chr3:84074010-84074594 112.06 63.4% 35.6% 27.8% hyper
chr12:113299102-113299372 111.19 81.3% 53.5% 27.7% hyper
chr9:43071934-43072567 83.40 70.4% 42.7% 27.7% hyper
chr8:124793057-124793175 56.95 72.1% 44.4% 27.7% hyper
chr9:104184599-104185389 107.93 71.8% 44.2% 27.7% hyper
chr17:87777602-87777933 67.23 85.5% 57.9% 27.6% hyper
chr4:139043171-139043699 58.71 83.2% 55.6% 27.6% hyper
chr6:104015173-104015506 59.68 84.6% 57.0% 27.6% hyper
chr1:136981566-136982234 97.23 58.0% 30.4% 27.5% hyper
chr5:44490853-44491527 93.33 55.8% 28.3% 27.5% hyper
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chr4:62832135-62832636 153.21 80.9% 53.3% 27.5% hyper
chr7:105313648-105314322 87.14 77.3% 49.8% 27.5% hyper
chr5:122278315-122278607 143.71 62.6% 35.1% 27.5% hyper
chr5:31354812-31355895 74.28 89.4% 61.8% 27.5% hyper
chr5:113890672-113891443 154.88 73.1% 45.7% 27.5% hyper
chr12:19249790-19250063 166.53 63.8% 36.4% 27.4% hyper
chr16:22266672-22267571 111.09 78.7% 51.3% 27.4% hyper
chr6:10919575-10920994 74.91 72.3% 44.9% 27.4% hyper
chr5:27588319-27588751 85.72 47.3% 20.0% 27.3% hyper
chr11:97777750-97778176 64.38 88.7% 61.4% 27.3% hyper
chr4:138788360-138789119 66.50 58.4% 31.1% 27.3% hyper
chr17:95050620-95051589 94.65 76.2% 48.9% 27.3% hyper
chr10:58135347-58136460 121.53 69.0% 41.8% 27.3% hyper
chr5:115894491-115895052 104.10 88.4% 61.2% 27.2% hyper
chr7:126883460-126883769 90.51 55.2% 28.1% 27.2% hyper
chr2:65656236-65656805 101.59 75.9% 48.8% 27.2% hyper
chr12:70231282-70231733 82.44 65.8% 38.6% 27.1% hyper
chr7:106620147-106620341 74.02 76.8% 49.7% 27.1% hyper
chr2:165136190-165136557 93.54 79.0% 51.9% 27.1% hyper
chr3:45382907-45383143 63.95 86.4% 59.3% 27.1% hyper
chr8:88005832-88007157 95.02 75.4% 48.3% 27.1% hyper
chr14:76654648-76655491 193.10 66.0% 38.9% 27.1% hyper
chr1:182824490-182825286 184.10 54.9% 27.8% 27.1% hyper
chr3:152398249-152398782 111.79 70.0% 42.9% 27.0% hyper
chr3:33813273-33814104 75.22 73.4% 46.3% 27.0% hyper
chr7:52964589-52965359 74.06 82.6% 55.6% 27.0% hyper
chr4:3724809-3725422 66.56 75.1% 48.0% 27.0% hyper
chr11:114647957-114648194 71.64 56.9% 29.8% 27.0% hyper
chr6:30522799-30523141 86.01 88.5% 61.5% 27.0% hyper
chr2:71134095-71134836 107.81 83.5% 56.5% 27.0% hyper
chr14:56223568-56224041 64.75 75.5% 48.5% 27.0% hyper
chr8:73309871-73310263 77.19 80.4% 53.4% 27.0% hyper
chr14:32475104-32475476 123.68 57.5% 30.6% 27.0% hyper
chr12:87418965-87419462 84.89 71.9% 44.9% 27.0% hyper
chr7:51857056-51858580 126.45 52.7% 25.7% 27.0% hyper
chr3:86803170-86803703 93.24 40.1% 13.1% 27.0% hyper
chr6:65165344-65165747 86.22 80.5% 53.6% 27.0% hyper
chr13:55516067-55516245 64.41 56.3% 29.3% 27.0% hyper
chr11:53365100-53365677 123.06 83.6% 56.7% 26.9% hyper
chr12:100878300-100879333 133.05 51.6% 24.7% 26.9% hyper
chr11:4199526-4199942 58.17 76.1% 49.2% 26.9% hyper
chr8:73334834-73335143 64.50 76.8% 49.9% 26.9% hyper
chr9:66362096-66362549 64.50 75.7% 48.8% 26.9% hyper
chr3:9544824-9545687 96.62 84.6% 57.7% 26.9% hyper
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chr4:151357238-151357763 76.61 71.9% 45.0% 26.9% hyper
chr2:180012455-180013174 85.54 83.6% 56.8% 26.8% hyper
chr11:97898955-97899568 96.90 83.2% 56.4% 26.8% hyper
chr7:53917051-53917600 129.61 83.7% 56.9% 26.8% hyper
chr1:88401554-88401922 64.96 41.2% 14.4% 26.8% hyper
chr18:13190385-13190850 67.84 61.5% 34.7% 26.8% hyper
chr19:42734006-42734476 153.50 75.7% 48.9% 26.8% hyper
chr11:60198554-60198867 73.34 49.9% 23.1% 26.8% hyper
chr7:105571609-105572323 72.65 76.4% 49.6% 26.8% hyper
chr2:153448100-153448736 104.69 66.0% 39.3% 26.8% hyper
chr11:115468146-115468403 88.93 87.4% 60.7% 26.8% hyper
chr4:41044457-41044778 63.36 73.1% 46.3% 26.7% hyper
chr5:130508348-130508692 70.14 86.5% 59.8% 26.7% hyper
chr4:45335568-45335834 65.81 86.2% 59.5% 26.7% hyper
chr13:55950222-55951134 105.07 83.3% 56.6% 26.7% hyper
chr14:55503212-55503426 73.10 50.3% 23.6% 26.7% hyper
chr9:42750187-42750934 127.22 65.0% 38.3% 26.7% hyper
chr18:64173299-64174269 138.21 52.2% 25.5% 26.7% hyper
chr5:114150244-114150866 88.12 80.5% 53.9% 26.7% hyper
chr11:94295032-94295559 144.02 54.8% 28.1% 26.7% hyper
chr1:134483359-134484141 89.68 76.7% 50.0% 26.7% hyper
chr2:168645700-168646838 136.32 72.7% 46.0% 26.7% hyper
chr7:50898544-50898991 93.95 83.4% 56.8% 26.7% hyper
chr10:93733993-93734770 71.83 76.9% 50.3% 26.6% hyper
chr6:35821166-35822056 111.68 77.5% 50.8% 26.6% hyper
chr5:139407952-139408794 132.23 60.6% 34.0% 26.6% hyper
chr2:167167083-167167987 77.82 88.6% 62.0% 26.6% hyper
chr2:170114118-170115463 145.35 76.7% 50.1% 26.6% hyper
chr4:153968970-153969275 83.40 72.7% 46.1% 26.6% hyper
chr1:146167850-146168497 148.50 81.8% 55.2% 26.6% hyper
chr1:82816715-82817132 66.91 69.4% 42.8% 26.6% hyper
chr9:34679219-34679789 112.89 82.6% 56.0% 26.6% hyper
chr5:125696058-125696776 183.33 51.2% 24.6% 26.6% hyper
chr17:45942041-45942526 143.95 44.4% 17.8% 26.6% hyper
chr16:48021723-48022248 80.11 79.5% 52.9% 26.6% hyper
chr17:78631549-78632064 96.71 84.6% 58.1% 26.5% hyper
chr18:36093231-36093860 87.55 63.3% 36.7% 26.5% hyper
chr12:119758305-119759413 86.49 57.2% 30.7% 26.5% hyper
chr4:150311839-150312368 103.95 82.5% 56.0% 26.5% hyper
chr2:144219313-144219829 93.07 86.0% 59.5% 26.5% hyper
chr15:84961845-84962260 130.40 61.3% 34.8% 26.5% hyper
chr2:59681288-59681610 96.99 89.0% 62.5% 26.5% hyper
chr18:25748789-25749307 151.84 56.0% 29.6% 26.5% hyper
chr12:105956774-105957339 79.44 89.3% 62.8% 26.5% hyper
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chr10:62884349-62884844 138.69 88.4% 62.0% 26.5% hyper
chr8:123407292-123407972 132.84 62.7% 36.2% 26.5% hyper
chr16:30692101-30692962 165.75 80.2% 53.8% 26.4% hyper
chr4:118716436-118717478 108.51 69.9% 43.5% 26.4% hyper
chr8:10249084-10249470 150.93 70.9% 44.6% 26.4% hyper
chr10:117351541-117352185 83.01 84.3% 57.9% 26.4% hyper
chr8:124860571-124861615 444.71 48.8% 22.4% 26.4% hyper
chr8:28231705-28232025 75.65 52.4% 26.0% 26.4% hyper
chr11:118058984-118059675 82.69 82.9% 56.6% 26.3% hyper
chr15:25375404-25375957 122.34 64.2% 37.9% 26.3% hyper
chr19:47779581-47780615 74.20 84.0% 57.7% 26.3% hyper
chr5:36083518-36083985 73.22 47.7% 21.4% 26.3% hyper
chr9:122656248-122656723 95.27 80.4% 54.1% 26.3% hyper
chr10:111304211-111305093 80.28 56.6% 30.3% 26.3% hyper
chr17:34518802-34519358 61.01 82.6% 56.3% 26.3% hyper
chr2:101819245-101819839 105.28 47.7% 21.5% 26.3% hyper
chr1:75701215-75701860 102.72 66.3% 40.1% 26.3% hyper
chr10:40151916-40152774 67.87 92.3% 66.0% 26.2% hyper
chr19:57216314-57217562 96.32 83.5% 57.3% 26.2% hyper
chr6:85373806-85374206 83.84 65.4% 39.2% 26.2% hyper
chr13:47320013-47320660 83.63 49.5% 23.3% 26.2% hyper
chr15:82841272-82841952 107.02 65.0% 38.9% 26.2% hyper
chr3:105854909-105855384 101.43 76.3% 50.2% 26.2% hyper
chr14:32485016-32485775 95.66 75.7% 49.6% 26.2% hyper
chr16:30129449-30130025 91.63 68.1% 42.0% 26.1% hyper
chr2:171833111-171833641 99.94 89.0% 62.9% 26.1% hyper
chr3:101814502-101815228 79.83 64.9% 38.8% 26.1% hyper
chr3:128941497-128941984 84.74 77.1% 51.0% 26.1% hyper
chr9:72003285-72004022 57.70 73.8% 47.7% 26.1% hyper
chr17:30068209-30068571 69.63 83.2% 57.1% 26.1% hyper
chr19:59007841-59008889 92.62 63.1% 37.0% 26.1% hyper
chr9:72701696-72702187 78.09 84.3% 58.2% 26.1% hyper
chr10:79197762-79198198 324.77 75.5% 49.5% 26.1% hyper
chr1:59219905-59220421 71.52 64.3% 38.3% 26.1% hyper
chr6:48387994-48388871 422.41 45.1% 19.1% 26.0% hyper
chr7:137894203-137894602 88.47 76.5% 50.5% 26.0% hyper
chr3:135147635-135148152 109.27 75.2% 49.2% 26.0% hyper
chr7:148274750-148274879 72.85 78.4% 52.4% 26.0% hyper
chr5:75122364-75122946 69.93 76.5% 50.5% 26.0% hyper
chr5:136209726-136210107 116.28 85.2% 59.2% 26.0% hyper
chr4:148295401-148296206 101.25 82.2% 56.3% 26.0% hyper
chr7:28277102-28277314 76.52 76.3% 50.4% 25.9% hyper
chr9:63382057-63383206 81.11 67.1% 41.2% 25.9% hyper
chr17:5849199-5849791 94.76 65.2% 39.3% 25.9% hyper
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chr15:8790136-8790425 88.62 91.0% 65.1% 25.9% hyper
chr12:111792948-111793412 95.10 93.0% 67.1% 25.9% hyper
chr3:79683120-79683489 73.31 84.2% 58.3% 25.9% hyper
chr6:116528633-116528925 74.34 88.2% 62.4% 25.9% hyper
chr8:68066541-68067285 178.54 84.0% 58.1% 25.9% hyper
chr2:167002280-167003039 83.86 78.2% 52.3% 25.9% hyper
chr15:102889861-102890264 89.35 47.6% 21.7% 25.9% hyper
chr19:6041517-6041969 79.44 84.8% 59.0% 25.9% hyper
chr18:10052318-10052935 79.27 64.4% 38.5% 25.9% hyper
chr8:44688662-44689212 120.60 77.6% 51.7% 25.9% hyper
chr7:28066903-28067263 60.50 76.2% 50.4% 25.8% hyper
chr2:78122006-78122785 90.25 83.0% 57.1% 25.8% hyper
chr5:69923232-69923595 66.74 80.3% 54.5% 25.8% hyper
chr7:148192086-148193168 71.79 88.7% 62.9% 25.8% hyper
chr17:93600126-93600477 67.20 40.3% 14.5% 25.8% hyper
chr13:114377391-114378014 102.98 67.2% 41.5% 25.7% hyper
chr2:44412774-44413769 83.12 63.3% 37.5% 25.7% hyper
chr5:106038942-106039537 74.97 86.2% 60.5% 25.7% hyper
chr11:44654709-44656167 75.49 73.5% 47.8% 25.7% hyper
chr11:70028833-70029223 138.66 53.3% 27.6% 25.7% hyper
chr18:30428994-30429263 93.73 73.4% 47.8% 25.7% hyper
chr4:153764294-153764862 92.65 52.7% 27.1% 25.6% hyper
chr5:65419471-65419822 79.56 85.2% 59.6% 25.6% hyper
chr5:117931378-117931930 76.61 84.5% 58.8% 25.6% hyper
chr2:166141605-166142442 124.06 58.2% 32.6% 25.6% hyper
chr8:71661914-71662550 123.78 85.3% 59.7% 25.6% hyper
chr12:58609755-58610353 90.03 81.3% 55.7% 25.6% hyper
chr2:75828899-75829287 64.37 66.0% 40.4% 25.6% hyper
chr2:11357855-11358212 95.40 86.9% 61.3% 25.6% hyper
chr6:125549217-125549462 73.75 92.2% 66.6% 25.6% hyper
chr9:103345760-103346400 108.09 67.7% 42.1% 25.5% hyper
chr4:127096728-127097149 82.12 80.0% 54.5% 25.5% hyper
chr7:52887987-52888323 148.09 68.3% 42.7% 25.5% hyper
chr11:102852985-102853390 80.96 41.3% 15.8% 25.5% hyper
chr4:150462956-150463253 72.30 83.8% 58.3% 25.5% hyper
chr1:190806696-190806971 65.79 91.3% 65.8% 25.5% hyper
chr4:152373616-152374294 131.83 82.3% 56.8% 25.5% hyper
chr11:114036955-114038045 110.50 83.7% 58.2% 25.5% hyper
chr18:86642977-86643580 77.69 78.1% 52.6% 25.5% hyper
chr1:145617533-145617778 66.73 77.3% 51.8% 25.5% hyper
chr4:83868677-83869492 71.96 88.0% 62.6% 25.5% hyper
chr13:31707063-31707358 116.25 50.2% 24.7% 25.4% hyper
chr2:22086168-22086830 115.78 80.1% 54.6% 25.4% hyper
chr6:49223570-49224587 75.72 79.6% 54.2% 25.4% hyper
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chr10:81091261-81091606 70.80 80.7% 55.3% 25.4% hyper
chr8:26059132-26059550 85.44 80.5% 55.1% 25.4% hyper
chr13:3477491-3477905 159.67 55.9% 30.5% 25.4% hyper
chr12:111186293-111187835 159.35 61.3% 35.9% 25.4% hyper
chr2:143910986-143911396 71.81 83.8% 58.4% 25.4% hyper
chr17:12411691-12412113 97.92 86.6% 61.2% 25.4% hyper
chr10:67808171-67808931 93.36 81.9% 56.5% 25.4% hyper
chr14:122852090-122852827 126.99 69.2% 43.8% 25.4% hyper
chr8:73928811-73929522 90.59 63.0% 37.7% 25.3% hyper
chr1:193040163-193040809 78.85 71.7% 46.3% 25.3% hyper
chr9:63775068-63775725 282.91 50.0% 24.7% 25.3% hyper
chr18:64178234-64179244 87.25 77.2% 51.9% 25.3% hyper
chr10:95179792-95180259 86.26 91.3% 66.0% 25.3% hyper
chr2:132333170-132334036 94.16 80.3% 55.0% 25.3% hyper
chr8:28232239-28232378 86.59 57.5% 32.2% 25.3% hyper
chr19:43645949-43646291 98.47 62.9% 37.6% 25.3% hyper
chr10:41710457-41711981 99.07 58.6% 33.3% 25.2% hyper
chr16:28927071-28927908 90.58 63.8% 38.6% 25.2% hyper
chr17:10098969-10099649 144.62 41.1% 15.9% 25.2% hyper
chr12:118266635-118267509 82.68 82.7% 57.4% 25.2% hyper
chr6:24298057-24298798 82.46 69.8% 44.6% 25.2% hyper
chr7:51806886-51807709 211.34 65.4% 40.3% 25.2% hyper
chr14:104177521-104177819 67.76 65.2% 40.0% 25.1% hyper
chr9:75230655-75231000 84.07 80.2% 55.0% 25.1% hyper
chr17:81286827-81287263 63.61 83.3% 58.2% 25.1% hyper
chr17:27250725-27251157 114.45 88.3% 63.2% 25.1% hyper
chr13:15712273-15713182 131.55 89.6% 64.5% 25.1% hyper
chr3:65197318-65197517 63.84 85.2% 60.1% 25.1% hyper
chr2:6295297-6295664 74.43 78.0% 52.9% 25.1% hyper
chr10:111095698-111096262 73.07 85.9% 60.8% 25.1% hyper
chr3:142350957-142351342 135.81 81.5% 56.4% 25.1% hyper
chr7:142657014-142657380 87.79 63.6% 38.5% 25.1% hyper
chr5:138218953-138219448 71.77 82.3% 57.2% 25.1% hyper
chr10:43608774-43609078 92.32 85.6% 60.6% 25.1% hyper
chr14:55330531-55330769 90.31 87.5% 62.5% 25.0% hyper
chr10:76713115-76714336 138.07 83.3% 58.3% 25.0% hyper
chr14:8560503-8561146 111.59 79.4% 54.4% 25.0% hyper
chr9:107516451-107517018 107.71 86.9% 61.9% 25.0% hyper
chr7:26430147-26430915 66.37 75.7% 50.7% 25.0% hyper
chr11:5394993-5395635 94.37 77.2% 52.2% 25.0% hyper
chr9:62526177-62527084 183.93 63.6% 38.6% 25.0% hyper
chr1:140468006-140468791 169.54 63.0% 38.0% 25.0% hyper
chr18:38749564-38750007 93.52 84.1% 59.1% 25.0% hyper
chr10:80642606-80643127 104.95 86.5% 61.5% 25.0% hyper
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chr16:90849699-90850223 72.78 78.4% 53.5% 25.0% hyper
chr10:87323389-87323840 74.11 57.1% 32.1% 24.9% hyper
chr5:61460063-61460178 70.18 96.1% 71.2% 24.9% hyper
chr15:97966088-97966358 59.77 88.2% 63.3% 24.9% hyper
chr4:124344632-124345709 140.75 61.9% 37.0% 24.9% hyper
chr4:153978242-153978684 83.69 78.4% 53.5% 24.9% hyper
chr2:147849058-147849438 63.19 73.3% 48.4% 24.9% hyper
chr5:65758918-65759438 80.35 87.2% 62.3% 24.9% hyper
chr13:108453432-108454568 97.22 57.0% 32.2% 24.8% hyper
chr3:108684075-108684565 95.63 79.3% 54.4% 24.8% hyper
chr1:89371617-89372259 215.45 36.0% 11.2% 24.8% hyper
chr9:63602401-63603316 168.22 74.6% 49.7% 24.8% hyper
chr5:24481953-24482907 88.62 74.2% 49.4% 24.8% hyper
chr14:61623709-61624298 71.71 38.0% 13.2% 24.8% hyper
chr4:139195967-139196611 98.95 80.7% 56.0% 24.8% hyper
chr5:129099014-129099686 94.15 78.1% 53.3% 24.8% hyper
chr7:150481280-150481610 155.14 50.8% 26.1% 24.7% hyper
chr1:180501898-180502664 97.24 79.3% 54.6% 24.7% hyper
chr16:20701731-20702938 96.31 49.9% 25.2% 24.7% hyper
chr11:61263032-61263505 80.65 84.8% 60.1% 24.7% hyper
chr8:63704673-63705281 110.78 81.2% 56.5% 24.7% hyper
chr3:69529390-69530253 65.32 90.6% 65.9% 24.7% hyper
chr2:73160999-73161557 90.48 82.4% 57.7% 24.7% hyper
chr5:67529680-67530504 78.52 60.3% 35.6% 24.7% hyper
chr8:126416615-126416889 79.38 53.8% 29.1% 24.7% hyper
chr19:3904259-3904600 76.58 79.0% 54.3% 24.7% hyper
chr5:117627706-117628918 116.83 86.2% 61.6% 24.7% hyper
chr2:17821181-17821526 70.03 85.6% 60.9% 24.7% hyper
chr10:10871443-10871705 66.93 89.7% 65.0% 24.7% hyper
chr5:129837005-129837265 64.94 59.5% 34.8% 24.7% hyper
chr13:24613355-24613926 83.51 87.3% 62.7% 24.7% hyper
chr7:26002593-26002783 59.38 83.8% 59.2% 24.6% hyper
chr11:116899342-116900292 80.92 65.1% 40.5% 24.6% hyper
chr17:6940931-6941564 96.63 74.8% 50.2% 24.6% hyper
chr11:119045151-119045702 79.56 82.5% 57.9% 24.6% hyper
chr13:38502240-38502931 82.31 74.0% 49.4% 24.6% hyper
chr11:94104505-94104840 116.06 55.8% 31.2% 24.6% hyper
chr10:60257254-60257825 91.35 56.2% 31.7% 24.6% hyper
chr9:120617893-120618461 81.30 67.6% 43.0% 24.6% hyper
chr4:149507100-149507753 59.97 62.5% 38.0% 24.6% hyper
chr3:153788068-153788365 75.39 84.8% 60.2% 24.5% hyper
chr4:149467829-149468913 83.71 74.3% 49.7% 24.5% hyper
chr6:52053517-52054806 95.06 86.2% 61.6% 24.5% hyper
chr13:72954239-72954833 72.96 59.9% 35.3% 24.5% hyper
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chr1:157338344-157339336 86.19 75.7% 51.2% 24.5% hyper
chr18:61803235-61803777 80.29 54.5% 30.0% 24.5% hyper
chr14:56380507-56380930 128.73 40.6% 16.1% 24.5% hyper
chr8:67236834-67237160 125.73 89.0% 64.5% 24.5% hyper
chr10:57514366-57514805 137.70 43.2% 18.7% 24.4% hyper
chr11:63702619-63702772 95.40 83.6% 59.2% 24.4% hyper
chr3:138368976-138369686 79.81 76.6% 52.2% 24.4% hyper
chr13:34340184-34341500 88.57 62.9% 38.5% 24.4% hyper
chr5:124022234-124022691 91.61 63.4% 39.0% 24.4% hyper
chr4:93791098-93791531 57.58 79.3% 55.0% 24.4% hyper
chr2:6022784-6023798 91.17 88.4% 64.0% 24.4% hyper
chr2:172759340-172759801 155.47 58.1% 33.8% 24.3% hyper
chr4:116502237-116503120 82.03 62.7% 38.4% 24.3% hyper
chr2:172682801-172683281 106.30 85.7% 61.4% 24.3% hyper
chr1:138678412-138679136 112.42 75.4% 51.1% 24.3% hyper
chr4:150132691-150133081 104.19 53.0% 28.7% 24.3% hyper
chr5:143653190-143653867 69.05 80.7% 56.4% 24.3% hyper
chr7:147973535-147973822 84.61 80.3% 56.0% 24.3% hyper
chr10:110196760-110197167 137.00 87.3% 63.0% 24.3% hyper
chr11:94426344-94426681 93.80 51.5% 27.2% 24.3% hyper
chr18:65092959-65093669 113.77 57.3% 33.0% 24.3% hyper
chr16:5007989-5008567 69.40 85.1% 60.8% 24.3% hyper
chr18:64084059-64084745 81.05 70.1% 45.8% 24.3% hyper
chr11:30917179-30917613 65.95 82.6% 58.3% 24.3% hyper
chr4:125092602-125093018 96.87 75.9% 51.6% 24.3% hyper
chr4:133568151-133569516 101.01 55.9% 31.6% 24.3% hyper
chr5:115594001-115595018 100.03 84.8% 60.6% 24.3% hyper
chr3:89029673-89030383 88.41 35.6% 11.3% 24.2% hyper
chr2:158625885-158627235 115.47 86.8% 62.6% 24.2% hyper
chr10:128158210-128158582 67.82 83.9% 59.7% 24.2% hyper
chr3:84548485-84548742 66.08 80.5% 56.4% 24.2% hyper
chr1:80236564-80237093 78.82 76.4% 52.3% 24.2% hyper
chr7:29997949-29998493 72.05 63.5% 39.3% 24.2% hyper
chr6:82863404-82863753 81.37 85.4% 61.2% 24.2% hyper
chr11:84006594-84007596 90.07 87.2% 63.0% 24.2% hyper
chr7:26489381-26490333 188.57 38.0% 13.9% 24.2% hyper
chr18:75082914-75083690 94.35 87.2% 63.0% 24.1% hyper
chr5:148079766-148080598 165.48 44.2% 20.1% 24.1% hyper
chr10:129849444-129849658 129.54 86.6% 62.4% 24.1% hyper
chr5:140740108-140740522 75.24 76.6% 52.5% 24.1% hyper
chr1:21086994-21087549 114.46 84.2% 60.1% 24.1% hyper
chr6:125313074-125313725 91.09 64.9% 40.8% 24.1% hyper
chr8:91496929-91497489 82.18 77.6% 53.5% 24.1% hyper
chr6:144212752-144213405 86.27 77.9% 53.8% 24.1% hyper
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chr12:73564853-73565318 76.55 85.4% 61.3% 24.1% hyper
chr11:48639471-48639827 111.52 46.8% 22.7% 24.1% hyper
chr2:74564000-74564316 77.84 52.3% 28.2% 24.1% hyper
chr18:61104671-61105055 97.36 76.2% 52.2% 24.1% hyper
chr7:31658617-31658960 61.80 79.7% 55.6% 24.1% hyper
chr1:167565599-167566481 87.42 72.5% 48.5% 24.1% hyper
chr10:94773904-94774389 73.26 56.5% 32.5% 24.1% hyper
chr1:193809076-193809500 138.98 85.7% 61.7% 24.1% hyper
chr10:80997859-80998416 108.01 62.9% 38.9% 24.1% hyper
chr12:85105018-85105486 104.26 69.1% 45.1% 24.0% hyper
chr2:105071605-105072267 61.23 75.8% 51.8% 24.0% hyper
chr11:105850073-105850305 118.53 81.7% 57.7% 24.0% hyper
chr16:32238407-32238921 94.00 88.8% 64.7% 24.0% hyper
chr16:29837319-29837762 110.67 66.9% 42.9% 24.0% hyper
chr8:88378216-88378602 74.61 81.9% 57.9% 24.0% hyper
chr2:33772099-33772439 67.70 87.4% 63.4% 24.0% hyper
chr4:129065980-129066304 65.10 87.1% 63.1% 24.0% hyper
chr14:56434090-56434667 128.02 73.2% 49.2% 24.0% hyper
chr13:48878002-48878606 157.73 81.3% 57.4% 24.0% hyper
chr7:31639938-31640405 67.71 83.7% 59.8% 23.9% hyper
chr9:29769692-29770666 143.95 55.4% 31.5% 23.9% hyper
chr11:68948512-68948939 97.70 84.8% 60.9% 23.9% hyper
chr5:92522253-92522998 75.50 77.9% 54.0% 23.9% hyper
chr17:84965826-84966301 88.70 86.0% 62.1% 23.9% hyper
chr10:28916568-28917185 229.11 87.7% 63.8% 23.9% hyper
chr9:97091307-97091832 94.48 89.4% 65.5% 23.9% hyper
chr9:35624933-35625294 62.89 83.1% 59.2% 23.9% hyper
chr11:107564756-107565372 99.99 80.9% 57.0% 23.9% hyper
chr13:38033390-38033995 85.98 83.7% 59.8% 23.9% hyper
chr7:4434397-4434994 68.20 86.5% 62.6% 23.9% hyper
chr1:183783324-183783695 61.99 56.7% 32.8% 23.9% hyper
chr12:3941833-3942325 91.39 70.6% 46.8% 23.9% hyper
chr5:111849752-111850042 91.30 58.3% 34.4% 23.9% hyper
chr2:4861933-4862662 101.54 85.5% 61.7% 23.9% hyper
chr13:91880797-91881264 132.92 41.6% 17.8% 23.9% hyper
chr12:88030038-88030321 84.61 88.0% 64.2% 23.8% hyper
chr13:96764716-96765205 101.85 74.7% 50.9% 23.8% hyper
chr13:98344119-98344970 99.20 81.9% 58.1% 23.8% hyper
chr8:11437736-11438504 126.39 74.3% 50.5% 23.8% hyper
chr19:55769166-55769739 69.39 43.9% 20.0% 23.8% hyper
chr11:100274930-100275365 73.65 72.7% 48.9% 23.8% hyper
chr13:59175359-59175549 63.05 68.0% 44.1% 23.8% hyper
chr10:44729376-44729627 74.98 71.5% 47.7% 23.8% hyper
chr18:76772427-76772881 82.43 65.3% 41.5% 23.8% hyper
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chr11:71842650-71843015 94.79 73.7% 49.9% 23.8% hyper
chr13:38022600-38023145 178.86 87.1% 63.3% 23.8% hyper
chr3:127453146-127453657 72.51 73.6% 49.8% 23.8% hyper
chr10:80870954-80871435 74.95 68.9% 45.2% 23.7% hyper
chr10:59383863-59384262 97.38 51.2% 27.5% 23.7% hyper
chr1:182214270-182214464 76.15 54.2% 30.5% 23.7% hyper
chr10:6382293-6382828 143.64 83.7% 60.0% 23.7% hyper
chr8:64010893-64011317 68.81 80.8% 57.1% 23.7% hyper
chr17:66199213-66199496 106.20 88.3% 64.7% 23.7% hyper
chr16:42955789-42955991 118.39 89.2% 65.6% 23.7% hyper
chr10:62488631-62489358 66.91 78.2% 54.5% 23.7% hyper
chr3:56175569-56175925 71.97 83.8% 60.2% 23.6% hyper
chr5:97516363-97516798 103.60 84.5% 60.8% 23.6% hyper
chr7:144063448-144063895 100.20 64.6% 40.9% 23.6% hyper
chr9:72704445-72704903 115.19 84.9% 61.3% 23.6% hyper
chr5:124799274-124799744 128.32 85.5% 61.9% 23.6% hyper
chr12:106972538-106973124 89.31 81.8% 58.2% 23.6% hyper
chr5:139992139-139992625 91.17 82.4% 58.8% 23.6% hyper
chr9:24132783-24133056 98.34 86.3% 62.7% 23.6% hyper
chr8:90307972-90308453 104.05 63.4% 39.8% 23.6% hyper
chr13:51848252-51848878 65.12 75.4% 51.8% 23.6% hyper
chr17:32975893-32976378 64.98 73.0% 49.4% 23.6% hyper
chr2:115404974-115405886 74.69 56.9% 33.3% 23.6% hyper
chr10:97375927-97376644 118.49 87.8% 64.2% 23.6% hyper
chr4:84928893-84929562 94.45 85.9% 62.3% 23.6% hyper
chr3:95363349-95363851 162.97 86.6% 63.0% 23.6% hyper
chr9:44370960-44371601 68.29 72.5% 48.9% 23.6% hyper
chr3:95636036-95636600 95.16 91.3% 67.7% 23.5% hyper
chr4:139942136-139943259 129.85 86.0% 62.4% 23.5% hyper
chr5:37373158-37373630 109.39 82.1% 58.6% 23.5% hyper
chr12:71328020-71328962 197.34 40.4% 16.9% 23.5% hyper
chr13:39117939-39118651 72.16 94.1% 70.6% 23.5% hyper
chr2:172739426-172739710 59.42 78.6% 55.2% 23.5% hyper
chr11:49078159-49078495 58.24 85.9% 62.4% 23.5% hyper
chr16:91232100-91233291 232.15 41.8% 18.4% 23.5% hyper
chr4:57425340-57426500 87.95 65.8% 42.3% 23.5% hyper
chr3:86354083-86355266 151.50 45.9% 22.5% 23.5% hyper
chr18:3499113-3499302 65.18 76.7% 53.3% 23.4% hyper
chr6:145494660-145495165 70.00 51.4% 27.9% 23.4% hyper
chr8:10793933-10794799 76.78 87.2% 63.7% 23.4% hyper
chr17:64182586-64183094 81.83 87.5% 64.1% 23.4% hyper
chr6:113308644-113309460 87.19 92.8% 69.4% 23.4% hyper
chr19:24258344-24258876 75.04 86.1% 62.7% 23.4% hyper
chr11:74115434-74115990 122.47 83.7% 60.3% 23.4% hyper
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chr3:34793190-34793820 75.33 88.2% 64.8% 23.4% hyper
chr15:78719815-78720340 60.50 64.6% 41.2% 23.4% hyper
chr13:43786356-43786930 60.82 69.6% 46.2% 23.4% hyper
chr12:56961766-56962204 80.43 89.5% 66.2% 23.4% hyper
chr9:77811925-77812241 72.31 82.3% 58.9% 23.4% hyper
chr2:25280567-25280949 86.98 81.9% 58.6% 23.4% hyper
chr18:61228464-61228781 71.32 76.0% 52.7% 23.4% hyper
chr11:17108414-17108700 70.55 92.1% 68.8% 23.4% hyper
chr5:112264855-112266022 115.62 62.6% 39.2% 23.4% hyper
chr4:28227063-28227620 97.49 74.9% 51.5% 23.3% hyper
chr6:54839870-54840604 82.88 78.6% 55.3% 23.3% hyper
chr15:80416857-80417546 107.26 78.6% 55.3% 23.3% hyper
chr11:96338361-96338945 103.93 90.2% 66.9% 23.3% hyper
chr17:86080044-86080530 107.10 54.1% 30.7% 23.3% hyper
chr2:165174873-165175418 82.37 67.8% 44.5% 23.3% hyper
chr11:44119523-44119976 85.03 83.9% 60.6% 23.3% hyper
chr19:55701071-55701907 117.81 89.2% 65.9% 23.3% hyper
chr3:126997110-126997376 70.26 87.7% 64.4% 23.3% hyper
chr1:130336729-130337421 81.79 69.9% 46.6% 23.3% hyper
chr18:36483386-36484009 107.02 68.3% 45.0% 23.3% hyper
chr2:167385052-167385501 61.61 59.8% 36.5% 23.3% hyper
chr7:106554438-106554929 76.01 66.1% 42.8% 23.3% hyper
chr18:76305414-76305883 162.53 83.2% 59.9% 23.3% hyper
chr11:108796718-108797685 77.62 76.9% 53.7% 23.2% hyper
chr4:9420973-9421163 66.24 80.4% 57.2% 23.2% hyper
chr8:121269078-121269783 76.81 90.6% 67.4% 23.2% hyper
chr10:122320820-122321602 59.53 61.1% 37.9% 23.2% hyper
chr2:179319646-179320177 79.99 84.8% 61.6% 23.2% hyper
chr1:159388897-159389356 129.13 40.0% 16.8% 23.2% hyper
chr2:33431053-33431191 57.22 65.1% 41.9% 23.2% hyper
chr17:28995304-28995687 93.15 78.8% 55.6% 23.2% hyper
chr10:42874479-42875539 120.58 70.1% 46.9% 23.2% hyper
chr9:60674035-60674390 58.73 89.1% 65.9% 23.2% hyper
chr3:51025786-51026567 74.56 82.4% 59.2% 23.2% hyper
chr9:14050690-14051104 60.77 61.9% 38.8% 23.2% hyper
chr2:169919826-169920452 111.20 82.6% 59.5% 23.1% hyper
chr1:72284301-72284987 66.95 76.1% 53.0% 23.1% hyper
chr16:92475463-92476098 119.58 55.5% 32.4% 23.1% hyper
chr7:109437703-109438326 70.76 81.2% 58.1% 23.1% hyper
chr1:89023684-89024330 241.75 69.0% 45.9% 23.1% hyper
chr1:108609344-108609850 77.84 67.0% 43.9% 23.1% hyper
chr3:94976010-94976718 263.03 44.5% 21.4% 23.1% hyper
chr16:90712961-90713392 68.88 73.5% 50.4% 23.1% hyper
chr15:76346668-76347120 83.32 83.9% 60.8% 23.1% hyper
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chr5:52759595-52759927 94.04 68.5% 45.4% 23.0% hyper
chr13:23531767-23532126 69.70 63.7% 40.7% 23.0% hyper
chr15:88481461-88481849 81.86 57.0% 34.0% 23.0% hyper
chr6:39296910-39297415 65.32 60.0% 37.0% 23.0% hyper
chr11:99854817-99855240 77.06 75.2% 52.1% 23.0% hyper
chr8:8751043-8751461 85.83 91.4% 68.4% 23.0% hyper
chr1:17081732-17082304 186.00 89.8% 66.8% 23.0% hyper
chr11:102639062-102639563 78.48 65.8% 42.8% 23.0% hyper
chr3:146089317-146090045 88.05 85.9% 62.9% 23.0% hyper
chr12:107122636-107123272 80.46 79.9% 56.9% 23.0% hyper
chr13:114661022-114661863 87.26 84.9% 61.9% 23.0% hyper
chr11:97445466-97446044 64.10 87.4% 64.4% 23.0% hyper
chr10:120979633-120980040 94.45 83.6% 60.7% 23.0% hyper
chr7:35195922-35196505 87.64 87.4% 64.4% 23.0% hyper
chr8:119727721-119728712 228.19 87.0% 64.1% 23.0% hyper
chr13:42288445-42288863 64.82 83.3% 60.3% 23.0% hyper
chr5:86434756-86434999 88.93 88.0% 65.1% 23.0% hyper
chr10:41917209-41917728 207.27 83.0% 60.0% 23.0% hyper
chr4:114751244-114752324 72.31 65.2% 42.3% 23.0% hyper
chr1:34093309-34093859 77.35 84.1% 61.2% 23.0% hyper
chr5:117984058-117984488 77.16 48.1% 25.1% 23.0% hyper
chr8:63726230-63726897 76.22 82.8% 59.8% 22.9% hyper
chr5:106990187-106990322 71.23 60.2% 37.3% 22.9% hyper
chr1:187308178-187308821 115.49 88.1% 65.2% 22.9% hyper
chr2:154471294-154471608 110.93 81.6% 58.6% 22.9% hyper
chr10:29678916-29679417 146.96 87.6% 64.7% 22.9% hyper
chr14:76816192-76816514 86.42 69.1% 46.2% 22.9% hyper
chr10:121336577-121337031 82.55 78.2% 55.3% 22.9% hyper
chr12:86026705-86027689 68.00 84.0% 61.1% 22.9% hyper
chr4:133969284-133969461 59.75 80.9% 58.0% 22.9% hyper
chr2:163307816-163308276 107.60 36.7% 13.8% 22.9% hyper
chr7:31250804-31251368 164.01 37.5% 14.6% 22.9% hyper
chr9:96844894-96845318 96.03 81.7% 58.9% 22.8% hyper
chr12:72196255-72197555 77.35 88.6% 65.7% 22.8% hyper
chr15:82911394-82912030 74.44 77.9% 55.0% 22.8% hyper
chr13:46853486-46854844 125.14 82.0% 59.1% 22.8% hyper
chr9:57357758-57358309 68.11 81.2% 58.4% 22.8% hyper
chr5:121233139-121233546 83.29 79.2% 56.4% 22.8% hyper
chr12:81012117-81013102 104.55 71.8% 49.0% 22.8% hyper
chr10:82482636-82482875 84.40 63.4% 40.7% 22.8% hyper
chr14:120788061-120788917 171.18 33.6% 10.8% 22.8% hyper
chr8:124993740-124994488 87.66 85.3% 62.6% 22.8% hyper
chr6:47893375-47893595 63.96 56.6% 33.8% 22.8% hyper
chr17:66305056-66306620 115.38 84.1% 61.3% 22.8% hyper
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chr18:61225022-61225835 78.32 49.3% 26.6% 22.7% hyper
chr10:42649752-42650359 66.85 86.7% 63.9% 22.7% hyper
chr1:91647503-91647844 89.37 75.5% 52.8% 22.7% hyper
chr16:85145789-85146712 79.87 92.5% 69.8% 22.7% hyper
chr18:80366297-80367149 144.92 62.6% 39.9% 22.7% hyper
chr9:43855567-43856975 83.47 83.7% 61.0% 22.7% hyper
chr8:113329436-113329852 68.90 75.9% 53.2% 22.7% hyper
chr3:28476263-28476574 104.60 81.8% 59.1% 22.7% hyper
chr7:6528466-6529042 95.84 85.5% 62.8% 22.7% hyper
chr8:106771132-106771738 80.48 75.7% 53.0% 22.7% hyper
chr2:119630442-119631561 93.51 43.2% 20.5% 22.7% hyper
chr4:147373363-147374484 81.29 79.1% 56.4% 22.7% hyper
chr10:12396403-12397067 72.22 89.9% 67.2% 22.6% hyper
chr6:127650488-127651824 99.58 76.5% 53.8% 22.6% hyper
chr4:94419178-94419801 66.94 79.1% 56.5% 22.6% hyper
chr12:86542290-86542500 59.13 67.6% 45.0% 22.6% hyper
chr19:45770138-45770706 73.54 76.7% 54.1% 22.6% hyper
chr10:126246956-126247540 127.56 79.0% 56.4% 22.6% hyper
chr3:63843225-63843541 95.22 85.5% 63.0% 22.6% hyper
chr5:149520147-149520962 68.33 71.8% 49.3% 22.5% hyper
chr6:72606706-72607315 60.65 83.7% 61.1% 22.5% hyper
chr11:5697042-5697545 78.46 82.3% 59.8% 22.5% hyper
chr5:104082460-104083278 87.32 72.5% 50.0% 22.5% hyper
chr6:126484574-126484914 115.67 72.8% 50.3% 22.5% hyper
chr15:63506719-63507483 80.80 89.0% 66.5% 22.5% hyper
chr4:125923594-125924274 62.37 82.2% 59.7% 22.5% hyper
chr19:37765321-37765560 140.41 34.0% 11.5% 22.5% hyper
chr4:117825657-117826193 124.43 88.5% 66.0% 22.5% hyper
chr6:85336726-85337105 63.84 68.2% 45.8% 22.4% hyper
chr15:80967859-80968347 66.08 54.5% 32.1% 22.4% hyper
chr7:147862195-147862418 79.42 35.9% 13.4% 22.4% hyper
chr11:63769675-63771299 122.60 58.2% 35.8% 22.4% hyper
chr13:38694526-38695149 67.82 87.0% 64.6% 22.4% hyper
chr11:108810346-108811241 122.60 90.2% 67.8% 22.4% hyper
chr8:74512528-74512971 70.77 45.7% 23.3% 22.4% hyper
chr8:82353425-82353703 69.10 78.5% 56.1% 22.4% hyper
chr17:27281633-27282001 73.28 88.9% 66.5% 22.4% hyper
chr18:67019491-67019879 76.06 60.0% 37.6% 22.4% hyper
chr8:127777838-127778436 98.93 67.7% 45.4% 22.4% hyper
chr19:9021542-9022076 72.24 90.5% 68.1% 22.4% hyper
chr8:59888760-59889406 117.24 50.6% 28.2% 22.4% hyper
chr8:10899833-10900540 80.52 70.5% 48.1% 22.3% hyper
chr12:5050749-5051275 78.76 82.9% 60.5% 22.3% hyper
chr10:61914187-61914973 94.93 78.5% 56.2% 22.3% hyper
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chr16:92468411-92468768 59.51 80.5% 58.2% 22.3% hyper
chr1:135331374-135331790 87.54 61.4% 39.2% 22.3% hyper
chr11:28969443-28969774 83.02 77.5% 55.2% 22.3% hyper
chr6:122513110-122513678 96.79 79.8% 57.5% 22.3% hyper
chr9:96337251-96337716 73.04 60.7% 38.4% 22.3% hyper
chr17:46657374-46657774 68.11 73.5% 51.3% 22.3% hyper
chr5:147531605-147532266 116.14 86.5% 64.2% 22.2% hyper
chr2:60390849-60391113 76.37 51.3% 29.0% 22.2% hyper
chr15:76004856-76005224 86.13 90.2% 67.9% 22.2% hyper
chr14:61325576-61325840 76.70 82.8% 60.6% 22.2% hyper
chr8:116162286-116162581 56.65 85.3% 63.0% 22.2% hyper
chr11:119872794-119873431 93.26 81.1% 58.8% 22.2% hyper
chr19:46509452-46510022 79.47 77.2% 55.0% 22.2% hyper
chr19:37507291-37507847 81.73 76.1% 53.9% 22.2% hyper
chr3:66023593-66024140 93.45 41.8% 19.6% 22.2% hyper
chr11:68246148-68246397 74.41 63.2% 41.1% 22.2% hyper
chr15:85337985-85338351 62.79 81.0% 58.9% 22.2% hyper
chr8:129775777-129776347 91.46 85.5% 63.4% 22.1% hyper
chr16:35920309-35920878 68.84 83.0% 60.9% 22.1% hyper
chr9:45743927-45744341 73.68 41.0% 18.9% 22.1% hyper
chr10:42293263-42294335 70.39 51.8% 29.7% 22.1% hyper
chr10:117100737-117101367 71.60 69.6% 47.5% 22.1% hyper
chr17:43393338-43393805 92.45 86.5% 64.4% 22.1% hyper
chr7:138741192-138741932 75.42 64.7% 42.7% 22.1% hyper
chr14:61152407-61152863 108.72 79.1% 57.0% 22.1% hyper
chr5:142985452-142985996 66.06 42.3% 20.2% 22.1% hyper
chr19:48059826-48060423 72.43 79.9% 57.8% 22.1% hyper
chr12:104553034-104553537 127.46 64.1% 42.0% 22.0% hyper
chr19:23731825-23732552 89.14 76.2% 54.1% 22.0% hyper
chr17:66289705-66289832 55.86 87.3% 65.2% 22.0% hyper
chr1:69703523-69703976 81.90 70.8% 48.8% 22.0% hyper
chr4:140147769-140147994 72.52 84.1% 62.0% 22.0% hyper
chr5:72655316-72655932 99.86 73.2% 51.2% 22.0% hyper
chr19:6121712-6122132 64.88 53.2% 31.1% 22.0% hyper
chr5:108146908-108147700 59.62 74.0% 52.0% 22.0% hyper
chr10:127036675-127037461 123.93 76.2% 54.2% 22.0% hyper
chr14:60245599-60246377 64.55 63.6% 41.6% 22.0% hyper
chr11:97556787-97557163 68.52 79.9% 57.9% 22.0% hyper
chr17:29693507-29693978 98.42 84.3% 62.3% 22.0% hyper
chr4:139560544-139561096 72.65 58.0% 36.0% 22.0% hyper
chr3:9158996-9159640 78.56 52.4% 30.4% 22.0% hyper
chr17:35154731-35154891 60.54 80.8% 58.8% 22.0% hyper
chr10:44719902-44720497 98.83 70.7% 48.7% 22.0% hyper
chr12:105934923-105935367 81.03 82.8% 60.8% 22.0% hyper
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chr10:43443124-43443663 103.77 39.1% 17.2% 21.9% hyper
chr11:102217890-102218476 114.99 79.4% 57.5% 21.9% hyper
chr4:57650902-57651446 117.19 78.4% 56.5% 21.9% hyper
chr3:52070595-52070889 67.55 43.4% 21.5% 21.9% hyper
chr4:155165951-155166417 89.90 88.2% 66.3% 21.9% hyper
chr13:108662920-108663746 68.85 85.1% 63.2% 21.9% hyper
chr9:120640980-120641601 71.18 53.1% 31.2% 21.9% hyper
chr6:24464803-24465275 64.45 50.7% 28.8% 21.9% hyper
chr17:79293671-79295137 105.26 75.0% 53.1% 21.9% hyper
chr14:52608848-52609340 73.18 75.5% 53.6% 21.9% hyper
chr12:52276394-52276733 75.41 82.5% 60.6% 21.9% hyper
chr5:37113779-37115016 87.95 88.5% 66.6% 21.9% hyper
chr10:126394056-126394363 69.11 38.4% 16.5% 21.9% hyper
chr15:102986159-102986548 115.48 81.0% 59.2% 21.9% hyper
chr5:13879511-13880234 116.88 81.6% 59.7% 21.8% hyper
chr10:86193710-86194242 82.12 40.1% 18.2% 21.8% hyper
chr9:56746871-56747490 82.50 90.9% 69.1% 21.8% hyper
chr1:181127803-181129014 61.19 84.7% 62.9% 21.8% hyper
chr11:35610726-35611148 95.58 73.5% 51.7% 21.8% hyper
chr6:83664659-83664893 91.07 35.0% 13.3% 21.8% hyper
chr1:134719445-134720265 98.17 87.4% 65.6% 21.8% hyper
chr11:49403109-49403751 193.15 85.9% 64.2% 21.8% hyper
chr10:127001091-127001544 62.29 70.6% 48.8% 21.8% hyper
chr6:134743474-134744132 63.10 71.6% 49.9% 21.7% hyper
chr2:80997423-80997784 80.91 86.6% 64.8% 21.7% hyper
chr19:12321876-12322262 104.86 86.3% 64.5% 21.7% hyper
chr11:84332644-84333069 89.85 50.6% 28.8% 21.7% hyper
chr3:81949308-81949647 86.37 36.8% 15.0% 21.7% hyper
chr7:105878281-105878743 109.25 59.1% 37.4% 21.7% hyper
chr1:165861254-165861544 63.11 67.1% 45.4% 21.7% hyper
chr1:36001284-36002222 75.32 79.5% 57.8% 21.7% hyper
chr2:29050993-29051328 91.02 46.1% 24.4% 21.7% hyper
chr5:139296867-139297159 85.42 64.0% 42.3% 21.7% hyper
chr10:79976503-79977367 154.97 71.6% 49.9% 21.7% hyper
chr5:116052592-116052896 65.26 87.6% 65.9% 21.7% hyper
chr18:75582931-75583247 93.21 84.3% 62.6% 21.7% hyper
chr15:89246899-89247470 82.93 85.8% 64.1% 21.7% hyper
chr5:117690695-117691301 124.58 42.9% 21.2% 21.7% hyper
chr9:108856210-108856568 76.45 62.3% 40.7% 21.7% hyper
chr13:107958666-107959036 73.79 67.1% 45.5% 21.7% hyper
chr10:61128047-61128375 58.04 92.1% 70.4% 21.7% hyper
chr16:91156270-91157008 100.42 81.9% 60.3% 21.6% hyper
chr15:35846613-35847040 89.60 81.7% 60.1% 21.6% hyper
chr6:31546422-31547644 106.32 61.7% 40.1% 21.6% hyper
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chr18:82741129-82741340 65.06 82.0% 60.4% 21.6% hyper
chr4:138134311-138134655 86.50 85.3% 63.7% 21.6% hyper
chr9:119214019-119214528 68.42 87.4% 65.8% 21.6% hyper
chr7:35537983-35538645 177.04 81.7% 60.0% 21.6% hyper
chr5:123832415-123832981 68.44 83.3% 61.7% 21.6% hyper
chr15:98626660-98627388 73.19 60.9% 39.3% 21.6% hyper
chr1:138696965-138697319 79.39 91.0% 69.4% 21.6% hyper
chr4:85129168-85129530 73.11 85.8% 64.2% 21.6% hyper
chr14:59486254-59487060 71.95 86.1% 64.5% 21.6% hyper
chr10:79382809-79383539 107.33 54.6% 33.0% 21.6% hyper
chr15:99358058-99358530 97.77 67.4% 45.8% 21.6% hyper
chr12:114054801-114055414 66.22 76.4% 54.8% 21.6% hyper
chr10:66944845-66945381 69.92 85.2% 63.6% 21.5% hyper
chr3:88990959-88991286 85.98 81.5% 59.9% 21.5% hyper
chr11:17360956-17361270 84.95 55.2% 33.7% 21.5% hyper
chr11:74671143-74671414 71.32 87.3% 65.8% 21.5% hyper
chr10:22531874-22532521 79.46 79.5% 58.0% 21.5% hyper
chr7:139158709-139159377 332.90 53.6% 32.2% 21.5% hyper
chr3:18871881-18872531 90.09 83.6% 62.1% 21.5% hyper
chr9:61421304-61421799 66.55 74.1% 52.6% 21.5% hyper
chr14:70408834-70409366 82.90 73.0% 51.5% 21.5% hyper
chr15:82038214-82038624 73.33 49.1% 27.7% 21.5% hyper
chr1:40381923-40383583 313.07 43.0% 21.6% 21.5% hyper
chr10:59570816-59571512 83.86 58.2% 36.8% 21.4% hyper
chr3:97494897-97495488 67.01 81.5% 60.0% 21.4% hyper
chr18:74090433-74090815 134.35 91.2% 69.7% 21.4% hyper
chr14:26577035-26577596 63.27 77.8% 56.4% 21.4% hyper
chr10:110510234-110510688 69.35 78.5% 57.1% 21.4% hyper
chr16:13541050-13541709 71.60 80.5% 59.1% 21.4% hyper
chr4:129807866-129808438 63.64 73.3% 51.9% 21.4% hyper
chr2:152201019-152201471 66.04 52.6% 31.2% 21.4% hyper
chr17:81246598-81246934 98.43 84.5% 63.1% 21.4% hyper
chrX:50251732-50251950 73.79 84.1% 62.7% 21.4% hyper
chr18:38234553-38235532 94.89 38.7% 17.3% 21.4% hyper
chr17:24853108-24853646 91.47 91.3% 70.0% 21.3% hyper
chr9:74856794-74857461 98.09 78.8% 57.5% 21.3% hyper
chr18:9280454-9280994 83.76 86.1% 64.8% 21.3% hyper
chr5:112430812-112431751 149.42 63.6% 42.3% 21.3% hyper
chr19:16021483-16021844 61.27 80.2% 58.9% 21.3% hyper
chr19:45237509-45238254 118.53 40.8% 19.5% 21.3% hyper
chr3:107286320-107286787 91.80 81.2% 59.9% 21.3% hyper
chr1:33720597-33720867 79.31 82.8% 61.5% 21.3% hyper
chr6:115912422-115912546 74.82 84.0% 62.7% 21.3% hyper
chr6:30625449-30625743 59.20 67.3% 46.0% 21.3% hyper
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chr18:53620153-53621344 168.87 41.2% 19.9% 21.3% hyper
chr17:6988252-6988957 63.62 80.4% 59.1% 21.3% hyper
chr12:107004564-107005251 111.33 80.8% 59.5% 21.3% hyper
chr5:141088065-141088599 99.91 55.9% 34.7% 21.2% hyper
chr8:110395832-110396267 90.22 86.0% 64.8% 21.2% hyper
chr8:111884528-111885110 99.86 75.8% 54.6% 21.2% hyper
chr6:38876247-38877355 185.69 77.8% 56.6% 21.2% hyper
chr17:15519420-15519960 65.68 80.6% 59.4% 21.2% hyper
chr17:48195064-48195640 70.47 71.5% 50.3% 21.2% hyper
chr5:140275986-140276250 90.29 89.5% 68.3% 21.2% hyper
chr4:133091530-133092205 85.82 89.7% 68.5% 21.2% hyper
chr18:10541487-10541931 68.54 90.1% 68.9% 21.2% hyper
chr4:129825701-129826354 86.66 87.5% 66.4% 21.1% hyper
chr9:118156308-118156805 72.99 80.4% 59.3% 21.1% hyper
chr13:53648996-53649858 80.20 71.0% 49.8% 21.1% hyper
chr9:63000214-63000906 71.32 82.0% 60.9% 21.1% hyper
chr12:13362825-13363327 64.44 86.8% 65.7% 21.1% hyper
chr9:106723350-106723628 65.71 70.5% 49.4% 21.1% hyper
chr19:17639325-17640374 86.05 94.2% 73.1% 21.1% hyper
chr12:87584914-87585281 91.72 87.6% 66.6% 21.1% hyper
chr12:104125669-104126130 59.23 81.9% 60.8% 21.1% hyper
chr2:13051266-13051893 75.30 85.8% 64.7% 21.1% hyper
chr8:122691960-122692397 60.95 85.4% 64.3% 21.0% hyper
chr5:125537788-125538345 78.77 44.1% 23.0% 21.0% hyper
chr1:188243897-188244383 65.06 88.6% 67.6% 21.0% hyper
chr2:156536576-156537170 151.53 81.0% 60.0% 21.0% hyper
chr17:5308142-5308630 78.75 85.8% 64.8% 21.0% hyper
chr6:88154810-88156434 163.82 62.6% 41.6% 21.0% hyper
chr11:116848981-116849900 71.46 86.0% 65.0% 21.0% hyper
chr7:143238179-143239028 76.72 70.8% 49.8% 21.0% hyper
chr16:57473874-57474235 84.08 83.4% 62.4% 21.0% hyper
chr5:113901210-113901650 59.60 79.2% 58.3% 20.9% hyper
chr2:46865214-46865441 62.99 78.2% 57.3% 20.9% hyper
chr7:30884161-30884649 78.88 79.2% 58.4% 20.9% hyper
chr19:5751116-5751276 55.05 40.8% 19.9% 20.9% hyper
chr13:38404035-38404691 80.95 84.3% 63.5% 20.9% hyper
chr2:158222992-158223588 72.03 87.9% 67.0% 20.9% hyper
chr7:104473728-104473923 101.86 40.5% 19.7% 20.9% hyper
chr7:151793769-151793980 90.62 90.6% 69.7% 20.9% hyper
chr18:50289206-50289570 76.90 85.5% 64.7% 20.8% hyper
chr18:56933833-56934296 91.43 53.0% 32.2% 20.8% hyper
chr6:102723509-102724005 79.53 85.7% 64.9% 20.8% hyper
chr19:34749463-34749849 136.60 87.3% 66.5% 20.8% hyper
chr14:78607638-78608465 82.08 88.4% 67.5% 20.8% hyper
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chr3:138451219-138452302 80.05 79.7% 58.9% 20.8% hyper
chr12:74468614-74468871 70.93 57.2% 36.4% 20.8% hyper
chr2:4524706-4524912 64.89 84.4% 63.6% 20.8% hyper
chr2:56960315-56961087 75.23 55.7% 34.9% 20.8% hyper
chr2:52614822-52615371 78.52 86.3% 65.5% 20.8% hyper
chr10:3996841-3997235 67.42 80.9% 60.1% 20.8% hyper
chr12:74136398-74136874 62.82 27.5% 6.7% 20.8% hyper
chr7:139439228-139439778 93.39 56.6% 35.8% 20.8% hyper
chr1:34617333-34617818 81.34 87.8% 67.0% 20.8% hyper
chr7:117952877-117953693 82.11 86.9% 66.2% 20.8% hyper
chr2:181687545-181688517 108.20 61.0% 40.2% 20.8% hyper
chr13:51324601-51324899 76.18 68.0% 47.2% 20.8% hyper
chr4:150096149-150096619 66.24 78.7% 58.0% 20.8% hyper
chr9:74866935-74867563 64.64 88.2% 67.4% 20.7% hyper
chr6:35766730-35767088 95.15 86.6% 65.8% 20.7% hyper
chr4:107732383-107733085 66.09 79.1% 58.4% 20.7% hyper
chr1:190479902-190480475 78.33 90.2% 69.5% 20.7% hyper
chr12:86021533-86021896 83.02 78.0% 57.4% 20.6% hyper
chr1:94745279-94745786 72.23 47.4% 26.8% 20.6% hyper
chr19:28240382-28240692 69.82 77.0% 56.4% 20.6% hyper
chr5:116728472-116728957 79.14 89.9% 69.3% 20.6% hyper
chr14:80754829-80755288 65.35 84.5% 63.9% 20.6% hyper
chr2:173876541-173876778 87.42 55.9% 35.3% 20.6% hyper
chr1:94120717-94121373 97.04 80.6% 60.0% 20.6% hyper
chr11:99793470-99793616 77.62 78.0% 57.4% 20.6% hyper
chr4:151685683-151686122 74.61 73.5% 52.9% 20.6% hyper
chr1:55249035-55249479 71.90 65.1% 44.5% 20.6% hyper
chr5:34073804-34074166 104.01 78.3% 57.7% 20.6% hyper
chr18:67632405-67632679 73.84 79.6% 59.1% 20.6% hyper
chr9:31020271-31021226 78.26 76.7% 56.1% 20.6% hyper
chr17:31418966-31419653 100.94 59.2% 38.7% 20.6% hyper
chr19:21218809-21219751 67.19 52.2% 31.6% 20.5% hyper
chr15:75608662-75609044 81.55 89.4% 68.9% 20.5% hyper
chr17:7296414-7296733 80.20 87.6% 67.1% 20.5% hyper
chr11:69234465-69235215 83.79 73.5% 53.0% 20.5% hyper
chr2:106636573-106637888 63.52 78.7% 58.2% 20.5% hyper
chr9:6168439-6168894 65.11 58.1% 37.7% 20.5% hyper
chr19:55662831-55663951 92.40 49.1% 28.6% 20.5% hyper
chr7:137910559-137911014 68.48 81.1% 60.6% 20.5% hyper
chr14:120003673-120004158 88.51 81.2% 60.8% 20.5% hyper
chr1:184002222-184002965 89.19 85.4% 64.9% 20.5% hyper
chr16:22766850-22767373 78.19 83.9% 63.4% 20.5% hyper
chr11:4170937-4171826 169.12 58.1% 37.6% 20.5% hyper
chr9:21578977-21579304 83.94 87.0% 66.6% 20.4% hyper
271
chr10:93982857-93983441 65.92 79.6% 59.1% 20.4% hyper
chr1:88967343-88967536 72.15 73.5% 53.1% 20.4% hyper
chr5:36656105-36656649 59.01 69.3% 48.8% 20.4% hyper
chr11:76165957-76166324 61.96 79.5% 59.1% 20.4% hyper
chr11:105317580-105317884 69.27 41.4% 21.0% 20.4% hyper
chr9:119392885-119393333 84.51 74.8% 54.5% 20.4% hyper
chr4:54833930-54834429 80.40 82.0% 61.7% 20.3% hyper
chr6:4943803-4944395 65.94 76.2% 55.9% 20.3% hyper
chr3:54921411-54921698 69.29 86.7% 66.4% 20.3% hyper
chr4:106499486-106500075 75.77 72.0% 51.7% 20.3% hyper
chr5:115179095-115179494 82.56 85.4% 65.2% 20.3% hyper
chr11:100819860-100820506 370.50 45.7% 25.5% 20.2% hyper
chr3:85422589-85423143 70.74 87.1% 66.9% 20.2% hyper
chr19:37762177-37762475 90.42 52.9% 32.7% 20.2% hyper
chr7:130228326-130228563 71.50 63.4% 43.2% 20.2% hyper
chr12:100249122-100249527 68.65 32.5% 12.3% 20.2% hyper
chr4:131478296-131478516 61.17 62.6% 42.4% 20.1% hyper
chr4:137037907-137039268 89.64 78.3% 58.2% 20.1% hyper
chr6:69443602-69444004 91.52 82.9% 62.8% 20.1% hyper
chr2:152896544-152896824 107.10 43.1% 23.0% 20.1% hyper
chr3:133028693-133029300 61.33 86.7% 66.6% 20.1% hyper
chr11:94984140-94984908 87.77 65.4% 45.3% 20.1% hyper
chr5:38757804-38758370 78.51 49.0% 28.9% 20.1% hyper
chr10:22682551-22683395 98.52 86.8% 66.7% 20.1% hyper
chr13:38286975-38287243 59.31 86.2% 66.1% 20.1% hyper
chr13:31903632-31904069 183.77 48.6% 28.6% 20.1% hyper
chr1:91822191-91822657 61.02 60.7% 40.7% 20.0% hyper
chr4:104608426-104609225 72.67 79.5% 59.4% 20.0% hyper
chr7:105995667-105995984 118.12 89.7% 69.6% 20.0% hyper
chr3:68558045-68558680 102.49 92.4% 72.4% 20.0% hyper
chr12:112661520-112662384 282.90 40.5% 20.5% 20.0% hyper
chr14:43390982-43391331 79.60 77.8% 57.8% 20.0% hyper
chr4:141920022-141920620 -88.12 68.3% 88.5% -20.2% hypo
chr2:26330278-26331358 -107.29 41.9% 62.2% -20.3% hypo
chr18:35253226-35254646 -132.46 36.2% 56.6% -20.3% hypo
chr9:63766729-63767498 -119.88 53.8% 74.2% -20.4% hypo
chr4:45801580-45802815 -138.63 58.7% 79.1% -20.4% hypo
chr12:105844170-105844806 -203.50 48.0% 68.4% -20.4% hypo
chr8:124820289-124820793 -128.09 30.6% 51.1% -20.6% hypo
chr8:123356063-123357085 -71.23 31.1% 51.7% -20.7% hypo
chr10:74450441-74451189 -110.64 57.1% 77.8% -20.7% hypo
chr13:112658019-112658630 -157.80 54.8% 75.5% -20.7% hypo
chr1:143038343-143039131 -113.58 44.5% 65.3% -20.8% hypo
chr2:163054748-163055533 -133.32 55.3% 76.3% -21.0% hypo
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chr11:103662445-103663150 -91.48 60.6% 81.6% -21.0% hypo
chr11:84514834-84515530 -142.14 35.6% 56.7% -21.1% hypo
chr18:60868700-60869625 -133.94 34.8% 56.0% -21.1% hypo
chr19:37814091-37814949 -99.55 56.4% 77.6% -21.2% hypo
chr8:124849801-124850807 -90.20 24.3% 45.6% -21.4% hypo
chr11:19863627-19864000 -115.18 48.3% 69.8% -21.5% hypo
chr2:92500709-92501400 -81.88 39.1% 60.5% -21.5% hypo
chr10:19660665-19661177 -105.00 57.8% 79.4% -21.6% hypo
chr14:47323625-47324529 -91.32 52.8% 74.5% -21.7% hypo
chr11:78646352-78647093 -125.08 44.8% 66.8% -21.9% hypo
chr7:150243615-150244503 -96.66 37.8% 59.7% -21.9% hypo
chr10:74816185-74817404 -110.76 58.1% 80.1% -22.0% hypo
chr8:124845529-124845986 -78.30 35.3% 57.8% -22.4% hypo
chr13:45126721-45127513 -128.04 49.8% 72.3% -22.5% hypo
chr10:125222250-125223145 -100.75 23.9% 46.8% -22.9% hypo
chr19:9553902-9554571 -62.90 53.7% 76.6% -22.9% hypo
chr4:134156973-134158045 -98.26 52.0% 75.0% -23.0% hypo
chr5:150057323-150058420 -112.98 35.9% 59.0% -23.1% hypo
chr5:120465365-120465988 -99.10 47.1% 70.4% -23.3% hypo
chr19:36203637-36204826 -160.14 22.1% 46.3% -24.2% hypo
chr8:11775411-11776517 -129.38 45.8% 70.1% -24.3% hypo
chr8:94041532-94042770 -121.68 49.6% 74.2% -24.6% hypo
chr15:73828139-73828384 -72.18 42.8% 68.0% -25.1% hypo
chr8:123710976-123711748 -135.34 57.7% 83.3% -25.6% hypo
chr6:100521027-100521575 -118.13 35.4% 61.2% -25.8% hypo
chr8:118084907-118086074 -130.17 52.8% 79.5% -26.7% hypo
chr7:86503189-86504238 -141.57 35.9% 63.3% -27.5% hypo
chr9:114899857-114900413 -104.43 29.5% 58.3% -28.8% hypo
chr2:34619760-34620350 -81.89 36.6% 65.9% -29.3% hypo
chr2:101613620-101614322 -123.00 49.9% 79.5% -29.6% hypo
chr11:109292480-109293051 -133.48 40.1% 70.6% -30.5% hypo
chr17:6208973-6209578 -107.73 38.8% 70.9% -32.1% hypo
chr3:157574510-157574815 -118.13 43.1% 76.9% -33.8% hypo
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Table A.4: Complete list of differentially regulated genes between the endo-
cardium and the endothelium sorted by Fold Change.
Gene Locus EC Expression ET expression p-value q-value Fold Change
Oit3 chr10:58885707-58904527 5.20 0.30 5.00E-05 2.50E-03 4.10
Slc32a1 chr2:158436493-158441483 5.13 0.31 5.00E-05 2.50E-03 4.05
Gad2 chr2:22477846-22549397 4.57 0.43 5.00E-05 2.50E-03 3.42
Ptprb chr10:115738429-115826594 2.53 0.25 5.00E-05 2.50E-03 3.31
- chr15:72333348-72335718 2.09 0.22 5.50E-04 1.78E-02 3.26
Sost chr11:101823771-101828329 4.49 0.51 5.00E-05 2.50E-03 3.13
Ccm2l chr2:152891690-152907471 2.85 0.34 1.15E-03 3.19E-02 3.05
Cdh5 chr8:106625524-106668402 37.48 4.59 5.00E-05 2.50E-03 3.03
Sox7 chr14:64562542-64569569 10.68 1.39 5.00E-05 2.50E-03 2.94
Erg chr16:95581810-95751972 11.47 1.51 5.00E-05 2.50E-03 2.92
Nos3 chr5:23870636-23897961 6.88 0.94 5.00E-05 2.50E-03 2.88
Grap chr11:61466822-61486279 6.70 0.91 5.00E-05 2.50E-03 2.87
Lyve1 chr7:117994120-118006467 1.68 0.23 1.25E-03 3.41E-02 2.87
Dusp2 chr2:127161894-127164113 7.11 0.98 5.00E-05 2.50E-03 2.86
Rasip1 chr7:52882906-52894462 12.56 1.84 5.00E-05 2.50E-03 2.77
Eltd1 chr3:151100845-151208045 3.66 0.54 5.00E-05 2.50E-03 2.77
Skap1 chr11:96325904-96620936 5.66 0.84 5.00E-05 2.50E-03 2.76
Gimap4 chr6:48634576-48642061 2.02 0.30 2.00E-04 7.94E-03 2.74
Samsn1 chr16:75859038-75909511 4.03 0.62 5.00E-05 2.50E-03 2.70
Ushbp1 chr8:73908172-73919704 2.22 0.35 5.00E-05 2.50E-03 2.66
Tie1 chr4:118143795-118162454 40.45 6.62 5.00E-05 2.50E-03 2.61
Cd93 chr2:148262386-148269271 13.66 2.26 5.00E-05 2.50E-03 2.60
Kcne3 chr7:107325179-107333379 8.80 1.46 5.00E-05 2.50E-03 2.59
- chr15:72337445-72342362 1.73 0.29 1.00E-04 4.56E-03 2.58
- chr16:95580786-95581555 10.43 1.76 5.00E-05 2.50E-03 2.57
Adra2a chr19:54119671-54123472 3.92 0.67 5.00E-05 2.50E-03 2.56
Icam2 chr11:106238969-106243955 13.43 2.29 5.00E-05 2.50E-03 2.55
Gimap6 chr6:48651581-48658243 6.43 1.11 5.00E-05 2.50E-03 2.54
Emcn chr3:137004041-137094033 7.16 1.24 5.00E-05 2.50E-03 2.53
Ikzf1 chr11:11586215-11672929 4.18 0.74 5.00E-05 2.50E-03 2.50
Esam chr9:37335673-37345904 3.97 0.72 1.70E-03 4.33E-02 2.47
Egfl7 chr2:26436575-26448202 12.09 2.19 5.00E-05 2.50E-03 2.47
Myct1 chr10:4739751-4752813 2.78 0.51 1.50E-04 6.36E-03 2.46
Myzap chr9:71352153-71440167 9.76 1.79 5.00E-05 2.50E-03 2.45
Esam chr9:37335673-37345904 27.65 5.10 5.00E-05 2.50E-03 2.44
Tspan8 chr10:115254339-115286949 2.12 0.39 7.00E-04 2.15E-02 2.43
Gfi1b chr2:28464969-28477502 8.33 1.54 5.00E-05 2.50E-03 2.43
Abi3 chr11:95685813-95707045 4.32 0.83 1.00E-04 4.56E-03 2.38
Pcdh12 chr18:38426745-38444055 3.60 0.70 5.00E-05 2.50E-03 2.36
Sox18 chr2:181404541-181406345 4.31 0.85 1.50E-04 6.36E-03 2.34
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Csgalnact1 chr8:70880679-71259045 4.68 0.93 5.00E-05 2.50E-03 2.34
Adora2a chr10:74779687-74797533 4.71 0.93 5.00E-05 2.50E-03 2.34
Mmrn2 chr14:35188689-35217472 12.11 2.41 5.00E-05 2.50E-03 2.33
Acer2 chr4:86520317-86566785 13.32 2.66 5.00E-05 2.50E-03 2.32
Thsd1 chr8:23337774-23371804 4.92 0.99 5.00E-05 2.50E-03 2.32
Tal1 chr4:114729365-114744360 31.18 6.31 5.00E-05 2.50E-03 2.31
Mpo chr11:87607285-87617914 2.37 0.48 5.50E-04 1.78E-02 2.30
Afap1l1 chr18:61889053-61946316 17.92 3.69 5.00E-05 2.50E-03 2.28
Gngt2 chr11:95685813-95707045 21.37 4.46 1.75E-03 4.41E-02 2.26
Igf1 chr10:87321800-87399792 8.47 1.78 5.00E-05 2.50E-03 2.25
Tal1 chr4:114729365-114744360 5.76 1.21 1.15E-03 3.19E-02 2.25
Pde2a chr7:108570204-108661343 8.98 1.90 5.00E-05 2.50E-03 2.24
Bcl6b chr11:70037628-70043300 4.24 0.90 5.00E-05 2.50E-03 2.23
Tal1 chr4:114729365-114744360 6.20 1.32 6.50E-04 2.05E-02 2.23
Robo4 chr9:37209630-37221607 3.30 0.72 5.00E-05 2.50E-03 2.20
Reln chr5:21390271-21850523 9.72 2.15 5.00E-05 2.50E-03 2.17
Cav2 chr6:17231340-17239011 1.81 0.40 6.00E-04 1.93E-02 2.17
Car8 chr4:8068639-8166188 2.54 0.57 5.00E-05 2.50E-03 2.16
Hapln1 chr13:89680240-89751437 42.57 9.67 5.00E-05 2.50E-03 2.14
- chr18:38158929-38159188 80.70 18.33 1.00E-04 4.56E-03 2.14
Lmo2 chr2:103798151-103822035 26.72 6.16 5.00E-05 2.50E-03 2.12
Fxyd5 chr7:31817741-31827341 8.40 1.94 1.50E-04 6.36E-03 2.12
Scarf1 chr11:75327042-75340082 9.77 2.27 5.00E-05 2.50E-03 2.10
Stab1 chr14:31944314-31981827 15.70 3.68 5.00E-05 2.50E-03 2.09
Nfatc1 chr18:80802943-80909810 11.84 2.78 5.00E-05 2.50E-03 2.09
C1qc chr4:136445716-136448829 7.76 1.84 9.00E-04 2.63E-02 2.07
Flt4 chr11:49423180-49466241 14.91 3.56 5.00E-05 2.50E-03 2.07
Rasgrp3 chr17:75835244-75928393 11.17 2.72 5.00E-05 2.50E-03 2.04
Rhoj chr12:76409299-76502442 8.84 2.16 5.00E-05 2.50E-03 2.04
Gata2 chr6:88148657-88157026 8.45 2.07 5.00E-05 2.50E-03 2.03
Ctla2b chr13:60996711-60998808 7.13 1.76 8.50E-04 2.53E-02 2.02
Fli1 chr9:32229792-32349149 8.58 2.14 5.00E-05 2.50E-03 2.00
Gmfg chr7:29222465-29231914 15.05 3.75 1.50E-04 6.36E-03 2.00
Afp chr5:90919739-90937933 3.51 0.88 5.50E-04 1.78E-02 2.00
Plvap chr8:74021651-74035668 19.45 4.98 5.00E-05 2.50E-03 1.96
She chr3:89635291-89662768 3.96 1.03 5.00E-05 2.50E-03 1.94
Gja4 chr4:126988663-126991283 9.52 2.49 5.00E-05 2.50E-03 1.93
Cav1 chr6:17256334-17291328 3.82 1.01 1.50E-04 6.36E-03 1.92
Hhex chr19:37509330-37515221 15.41 4.11 5.00E-05 2.50E-03 1.91
Dll4 chr2:119146934-119161402 4.04 1.08 5.00E-05 2.50E-03 1.90
Wnk4 chr11:101121880-101140262 11.85 3.24 5.00E-05 2.50E-03 1.87
Gng11 chr6:3953986-3958445 13.02 3.58 1.50E-04 6.36E-03 1.86
Mrc1 chr2:14151040-14253650 7.45 2.08 5.00E-05 2.50E-03 1.84
Spns2 chr11:72265139-72303422 13.03 3.64 5.00E-05 2.50E-03 1.84
276
Asic4 chr1:75447084-75470915 5.47 1.54 5.00E-05 2.50E-03 1.83
C430049B03Rik, Mir322, Mir351, Mir503 chrX:50406288-50410367 33.35 9.37 5.00E-05 2.50E-03 1.83
Alox5ap chr5:150076633-150099623 13.46 3.78 1.50E-04 6.36E-03 1.83
Fgf3 chr7:152024516-152030660 14.53 4.09 5.00E-05 2.50E-03 1.83
Sema3g chr14:32031058-32042697 1.80 0.51 5.50E-04 1.78E-02 1.83
Kcnj5 chr9:32122367-32151822 2.19 0.62 5.00E-05 2.50E-03 1.82
Ctla2a chr13:61035515-61037986 23.45 6.68 5.00E-05 2.50E-03 1.81
Gpm6b chrX:162676874-162826965 10.21 2.91 5.00E-05 2.50E-03 1.81
Emr1 chr17:57498108-57622952 2.88 0.83 4.00E-04 1.40E-02 1.80
Ramp2 chr11:101107647-101109564 49.56 14.33 5.00E-05 2.50E-03 1.79
Fam212a chr9:107886554-107888247 23.05 6.77 5.00E-05 2.50E-03 1.77
Cldn5 chr16:18776939-18778355 9.86 2.92 5.00E-05 2.50E-03 1.76
Ccl9 chr11:83386418-83392138 4.27 1.26 5.00E-04 1.67E-02 1.76
Eng chr2:32502114-32549695 17.93 5.32 5.00E-05 2.50E-03 1.75
Notch4 chr17:34701239-34725488 3.50 1.04 5.00E-05 2.50E-03 1.75
Aqp1 chr6:55286292-55298549 2.07 0.62 1.65E-03 4.22E-02 1.74
Myb chr10:20844735-20880790 6.65 2.01 5.00E-05 2.50E-03 1.73
Arhgef15 chr11:68756655-68770424 5.36 1.62 5.00E-05 2.50E-03 1.72
Tnfaip2 chr12:112680871-112693229 24.62 7.49 5.00E-05 2.50E-03 1.72
Lmo2 chr2:103798151-103822035 3.42 1.04 1.30E-03 3.52E-02 1.72
Gp49a chr10:51200484-51206025 2.61 0.80 1.00E-03 2.86E-02 1.71
Lyl1 chr8:87225355-87229783 7.54 2.30 1.50E-04 6.36E-03 1.71
Cd34 chr1:196765014-196803153 28.63 8.75 5.00E-05 2.50E-03 1.71
Sox17 chr1:4481008-4486494 2.22 0.68 1.35E-03 3.63E-02 1.70
S1pr1 chr3:115413350-115417973 7.94 2.45 5.00E-05 2.50E-03 1.69
Slc18a2 chr19:59335367-59370502 16.84 5.23 5.00E-05 2.50E-03 1.69
Plxnd1 chr6:115904828-115945023 42.55 13.29 5.00E-05 2.50E-03 1.68
Exoc3l chr8:107813823-107820136 4.72 1.48 1.00E-04 4.56E-03 1.68
Ctse chr1:133534890-133572084 7.22 2.26 5.00E-05 2.50E-03 1.67
Cd38 chr5:44260065-44303613 5.10 1.61 5.00E-05 2.50E-03 1.66
P2rx1 chr11:72812646-72828699 9.37 2.97 5.00E-05 2.50E-03 1.66
Cbfa2t3 chr8:125149035-125223009 5.00 1.60 5.00E-05 2.50E-03 1.64
Prkch chr12:74686027-74879171 3.08 0.99 2.00E-04 7.94E-03 1.64
Lgr5 chr10:114887369-115024836 2.48 0.79 1.50E-04 6.36E-03 1.64
Calcrl chr2:84170782-84265423 11.18 3.59 5.00E-05 2.50E-03 1.64
Vav3 chr3:109143600-109488612 7.50 2.41 5.00E-05 2.50E-03 1.64
F10 chr8:13037307-13056676 5.10 1.64 2.50E-04 9.49E-03 1.63
Fgf3 chr7:152024516-152030660 17.22 5.56 1.00E-04 4.56E-03 1.63
Fcgr3 chr1:172981299-172989534 5.17 1.68 1.90E-03 4.71E-02 1.62
C3ar1 chr6:122797157-122806175 2.62 0.86 7.50E-04 2.27E-02 1.60
Fam198b chr3:79689851-79750200 2.95 0.97 5.00E-05 2.50E-03 1.60
Adcy4 chr14:56387928-56402856 3.60 1.19 5.00E-05 2.50E-03 1.60
C1qb chr4:136436060-136442092 11.57 3.85 7.00E-04 2.15E-02 1.59
Ets2 chr16:95924013-95942656 28.51 9.59 5.00E-05 2.50E-03 1.57
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Lilrb4 chr10:51210780-51216417 5.39 1.81 5.00E-05 2.50E-03 1.57
Klhl4 chrX:111588128-111674307 4.11 1.39 5.00E-05 2.50E-03 1.57
Enpp1 chr10:24361216-24431908 5.02 1.70 5.00E-05 2.50E-03 1.56
Cyth4 chr15:78427476-78452449 4.13 1.40 6.50E-04 2.05E-02 1.56
Tyrobp chr7:31198806-31202598 30.08 10.23 2.00E-04 7.94E-03 1.56
Gata1 chrX:7536385-7545036 9.11 3.12 5.00E-05 2.50E-03 1.55
Klhl6 chr16:19946585-19983122 5.38 1.86 5.00E-04 1.67E-02 1.53
Clic6 chr16:92498391-92541486 9.27 3.22 5.00E-05 2.50E-03 1.53
- chr7:20080256-20082313 5.02 1.75 4.50E-04 1.54E-02 1.52
Tmem255a chrX:35550477-35605658 1.71 0.60 2.00E-03 4.91E-02 1.52
Nfe2 chr15:103078648-103085847 7.17 2.56 5.00E-04 1.67E-02 1.48
Col15a1 chr4:47220883-47326037 1.66 0.59 8.50E-04 2.53E-02 1.48
Rapgef3 chr15:97575200-97598097 2.75 1.00 6.50E-04 2.05E-02 1.46
Runx1 chr16:92601710-92826311 5.95 2.17 5.00E-05 2.50E-03 1.45
Nckap1l chr15:103284255-103329231 2.56 0.94 5.50E-04 1.78E-02 1.45
Etv2 chr7:31418634-31421103 13.03 4.80 5.50E-04 1.78E-02 1.44
Myo1f chr17:33692651-33744709 2.70 1.00 1.40E-03 3.74E-02 1.44
Arap3 chr18:38132276-38158623 27.01 9.96 5.00E-05 2.50E-03 1.44
Ptpre chr7:142729506-142877977 7.29 2.69 5.00E-05 2.50E-03 1.44
Padi3 chr4:140341283-140366563 11.43 4.26 5.00E-05 2.50E-03 1.42
Shank3 chr15:89330287-89390691 5.83 2.19 5.00E-05 2.50E-03 1.41
Trf chr9:103111205-103132616 3.96 1.50 1.30E-03 3.52E-02 1.40
Stat5a chr11:100720664-100746483 4.92 1.87 5.00E-05 2.50E-03 1.40
Aplnr chr2:84976516-84980080 53.46 20.67 5.00E-05 2.50E-03 1.37
Csf1r chr18:61265225-61290793 10.79 4.20 5.00E-05 2.50E-03 1.36
Car2 chr3:14886425-14900770 39.24 15.35 5.00E-05 2.50E-03 1.35
Fgd5 chr6:91937103-92025999 12.15 4.77 5.00E-05 2.50E-03 1.35
Ubash3b chr9:40819212-40965577 7.64 3.00 5.00E-05 2.50E-03 1.35
Rspo3 chr10:29166747-29255673 32.90 12.93 5.00E-05 2.50E-03 1.35
Edil3 chr13:88961076-89462830 9.67 3.81 5.00E-05 2.50E-03 1.35
Tiam1 chr16:89787355-89974944 18.79 7.41 5.00E-05 2.50E-03 1.34
Hid1 chr11:115209022-115229033 3.61 1.42 7.50E-04 2.27E-02 1.34
Plxnc1 chr10:94253611-94407212 5.73 2.26 5.00E-05 2.50E-03 1.34
Atp2a3 chr11:72774670-72806545 22.50 8.95 5.00E-05 2.50E-03 1.33
Flt1 chr5:148373771-148537564 10.32 4.11 3.50E-04 1.26E-02 1.33
Fam78a chr2:31922404-31939225 3.42 1.38 3.50E-04 1.26E-02 1.31
Cped1 chr6:21935909-22205606 2.87 1.15 3.00E-04 1.11E-02 1.31
Sepp1 chr15:3220766-3230508 61.77 24.94 5.00E-05 2.50E-03 1.31
Slc30a10 chr1:187270994-187292640 4.53 1.83 5.00E-05 2.50E-03 1.31
Kdr chr5:76329298-76374453 113.86 46.03 5.00E-05 2.50E-03 1.31
Pdgfb chr15:79826305-79845238 8.94 3.63 1.00E-04 4.56E-03 1.30
Cx3cr1 chr9:119957800-119977414 11.84 4.81 5.00E-05 2.50E-03 1.30
Lrrc33 chr16:32142910-32165562 4.36 1.78 3.00E-04 1.11E-02 1.29
Tgm2 chr2:157942140-157972128 13.27 5.47 5.00E-05 2.50E-03 1.28
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Prkar2b chr12:32643343-32746144 37.23 15.50 5.00E-05 2.50E-03 1.26
Map4k2 chr19:6341249-6356180 13.10 5.47 5.00E-05 2.50E-03 1.26
Ptprc chr1:139959435-140071882 2.51 1.05 1.05E-03 2.98E-02 1.26
Egfl7 chr2:26436575-26448202 74.37 31.21 5.00E-05 2.50E-03 1.25
Epor chr9:21763342-21768020 11.37 4.80 4.50E-04 1.54E-02 1.25
Shank3 chr15:89330287-89390691 8.22 3.53 5.00E-05 2.50E-03 1.22
Myl7 chr11:5796639-5798785 50.63 22.05 1.00E-04 4.56E-03 1.20
Flt1 chr5:148373771-148537564 17.26 7.59 5.00E-05 2.50E-03 1.18
Arhgap18 chr10:26492317-26638454 6.39 2.82 5.00E-05 2.50E-03 1.18
Gpr116 chr17:43526414-43596506 4.36 1.93 5.00E-05 2.50E-03 1.18
Lcp1 chr14:75530929-75630649 7.34 3.26 1.00E-04 4.56E-03 1.17
Laptm5 chr4:130469248-130492063 20.37 9.05 5.00E-05 2.50E-03 1.17
Unc13d chr11:115923409-115939275 4.32 1.93 5.00E-04 1.67E-02 1.16
Rapgef5 chr12:118754951-118998177 8.03 3.60 1.35E-03 3.63E-02 1.16
Slc7a8 chr14:55341051-55400723 4.96 2.23 4.50E-04 1.54E-02 1.15
Pear1 chr3:87553018-87572875 13.00 5.88 5.00E-05 2.50E-03 1.14
Dock8 chr19:25074018-25276922 2.22 1.01 3.50E-04 1.26E-02 1.14
Thbd chr2:148230206-148233924 2.88 1.31 1.60E-03 4.12E-02 1.14
Map4k2 chr19:6341249-6356180 20.97 9.53 5.00E-05 2.50E-03 1.14
Zfp711 chrX:109714134-109748671 4.05 1.84 2.00E-04 7.94E-03 1.14
Adamtsl2 chr2:26934900-26964133 7.79 3.54 2.00E-04 7.94E-03 1.14
Cyp26b1 chr6:84521407-84543902 3.51 1.61 9.00E-04 2.63E-02 1.12
Ecscr chr18:35872742-35881145 27.04 12.51 1.50E-04 6.36E-03 1.11
Klhl6 chr16:19946585-19983122 29.47 13.65 5.00E-05 2.50E-03 1.11
Elk3 chr10:92710160-92773904 18.79 8.73 5.00E-05 2.50E-03 1.11
Mef2c chr13:83643032-83806684 7.42 3.45 5.00E-05 2.50E-03 1.11
Sh3tc1 chr5:36039828-36071925 3.92 1.83 6.50E-04 2.05E-02 1.10
Exoc6 chr19:37624907-37758502 8.05 3.77 2.50E-04 9.49E-03 1.10
Rnd2 chr11:101329651-101333780 231.55 109.41 5.00E-05 2.50E-03 1.08
Ets1 chr9:32503626-32565405 32.05 15.19 5.00E-05 2.50E-03 1.08
Capn5 chr7:105270074-105333309 15.25 7.23 5.00E-05 2.50E-03 1.08
Acvrl1 chr15:100958967-100975767 19.44 9.29 5.00E-05 2.50E-03 1.07
Fam43a chr16:30599808-30602883 7.78 3.72 2.50E-04 9.49E-03 1.07
Myo7a chr7:105199563-105268003 3.38 1.62 2.00E-04 7.94E-03 1.06
Actc1 chr2:113873024-113878547 29.34 14.07 5.00E-05 2.50E-03 1.06
Sh2b3 chr5:122265469-122286810 17.13 8.22 4.00E-04 1.40E-02 1.06
Bmp2 chr2:133377982-133388621 18.03 8.75 5.00E-05 2.50E-03 1.04
Tspan12 chr6:21721394-21802515 21.86 10.67 5.00E-05 2.50E-03 1.03
St8sia1 chr6:142762750-142912972 2.09 1.02 9.00E-04 2.63E-02 1.03
Zfp711 chrX:109714134-109748671 18.31 8.96 5.00E-05 2.50E-03 1.03
Zfpm1 chr8:124806040-124861147 28.72 14.06 5.00E-05 2.50E-03 1.03
Slc39a8 chr3:135488454-135551536 18.65 9.15 5.00E-05 2.50E-03 1.03
Stat5b chr11:100642044-100711899 15.20 7.51 5.00E-05 2.50E-03 1.02
Ppp1r16b chr2:158492468-158592070 3.22 1.60 8.50E-04 2.53E-02 1.01
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Grap2 chr15:80453912-80483450 10.22 5.09 8.00E-04 2.41E-02 1.01
Tnnc1 chr14:32021497-32024897 58.41 29.17 1.50E-04 6.36E-03 1.00
Abca1 chr4:53043660-53172767 1.85 0.93 1.00E-03 2.86E-02 1.00
Mpeg1 chr19:12535268-12539775 5.05 2.58 1.90E-03 4.71E-02 0.97
Hspa12a chr19:58870240-58935474 5.16 2.64 1.00E-04 4.56E-03 0.97
Kctd12 chr14:103375797-103381854 5.78 2.98 2.00E-04 7.94E-03 0.96
Insl3, Jak3 chr8:74200281-74214476 14.58 7.56 5.00E-05 2.50E-03 0.95
Rcsd1 chr1:167579075-167638225 20.12 10.46 5.00E-05 2.50E-03 0.94
Elmo1 chr13:20182375-20700222 3.40 1.80 1.10E-03 3.09E-02 0.92
St3gal1 chr15:66934436-67008444 13.70 7.32 5.00E-05 2.50E-03 0.90
Fam65a chr8:108129128-108146118 37.58 20.41 8.50E-04 2.53E-02 0.88
Pecam1 chr11:106515531-106585695 52.41 28.46 5.00E-05 2.50E-03 0.88
Mtus1 chr8:42076265-42219080 5.64 3.07 9.00E-04 2.63E-02 0.88
Ddah1 chr3:145421655-145557241 9.42 5.14 2.00E-04 7.94E-03 0.87
Itga9 chr9:118515826-118810121 14.29 7.81 5.00E-05 2.50E-03 0.87
Cd109 chr9:78463352-78564067 4.66 2.56 8.00E-04 2.41E-02 0.86
Lrrc8b chr5:105844793-105919065 8.42 4.64 1.05E-03 2.98E-02 0.86
Gfod1 chr13:43290887-43399541 5.89 3.25 1.00E-04 4.56E-03 0.86
Cyp26a1 chr19:37772297-37776026 19.22 10.68 2.50E-04 9.49E-03 0.85
Sh2d3c chr2:32576574-32610527 9.35 5.20 9.00E-04 2.63E-02 0.85
Ptprm chr17:67016187-67703799 7.79 4.35 1.00E-04 4.56E-03 0.84
Gypc chr18:32687973-32719688 12.88 7.20 1.20E-03 3.30E-02 0.84
Hoxb3 chr11:96184439-96210872 16.92 9.53 1.00E-04 4.56E-03 0.83
Phlda1 chr10:110943341-110945705 18.76 10.62 5.50E-04 1.78E-02 0.82
Gcnt1 chr19:17400630-17447334 5.63 3.23 1.35E-03 3.63E-02 0.80
Rassf2 chr2:131818585-131855724 6.65 3.82 7.00E-04 2.15E-02 0.80
Bgn chrX:70728973-70741275 22.34 12.91 1.50E-04 6.36E-03 0.79
Gab2 chr7:104230260-104457461 5.14 2.97 1.05E-03 2.98E-02 0.79
Tnnt2 chr1:137732910-137748845 56.65 32.88 2.50E-04 9.49E-03 0.79
Col23a1 chr11:51103421-51397427 10.51 6.19 5.00E-05 2.50E-03 0.76
Dysf chr6:83958583-84161036 11.99 7.13 5.00E-05 2.50E-03 0.75
Cap2 chr13:46597271-46745650 9.08 5.40 1.15E-03 3.19E-02 0.75
Taok3 chr5:117570137-117725107 9.12 5.43 1.15E-03 3.19E-02 0.75
Plcl2 chr17:50648871-50827819 7.69 4.61 1.50E-03 3.92E-02 0.74
Dgkz chr2:91772978-91803720 50.56 30.34 5.00E-05 2.50E-03 0.74
Ppp1r13b chr12:113066668-113146266 14.51 8.75 5.00E-05 2.50E-03 0.73
Arhgap31 chr16:38598455-38713148 8.98 5.44 3.00E-04 1.11E-02 0.72
Ehbp1l1 chr19:5707373-5726317 10.02 6.10 1.10E-03 3.09E-02 0.72
Gpatch8, Itga2b chr11:102314610-102417472 60.21 36.80 7.00E-04 2.15E-02 0.71
Hdac7 chr15:97614795-97674933 38.74 23.81 1.00E-04 4.56E-03 0.70
Rasa3 chr8:13567217-13677587 23.38 14.45 5.00E-05 2.50E-03 0.69
Prcp chr7:100023762-100083091 25.59 15.89 2.50E-04 9.49E-03 0.69
Eln chr5:135178465-135223124 12.58 7.82 1.55E-03 4.03E-02 0.69
Foxh1 chr15:76498736-76500303 70.89 44.41 2.00E-04 7.94E-03 0.67
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Gfra2 chr14:71289936-71379645 11.85 7.47 1.50E-03 3.92E-02 0.66
Plk2 chr13:111185251-111191051 25.16 15.88 5.00E-04 1.67E-02 0.66
Msn chrX:93291383-93363892 146.07 92.20 1.00E-04 4.56E-03 0.66
Polg chr7:86537223-86611159 83.43 52.70 1.00E-04 4.56E-03 0.66
Stat3 chr11:100748123-100800825 23.79 15.08 1.25E-03 3.41E-02 0.66
Fzd10 chr5:129106980-129109968 13.82 8.78 1.85E-03 4.62E-02 0.65
Abcb10 chr8:126476358-126507022 23.67 15.08 2.00E-04 7.94E-03 0.65
St6galnac3 chr3:152865472-153388097 12.63 8.05 9.50E-04 2.74E-02 0.65
Myc chr15:61816895-61821916 18.56 11.86 2.00E-03 4.91E-02 0.65
Map3k11 chr19:5689130-5702864 21.06 13.52 1.10E-03 3.09E-02 0.64
Sipa1 chr19:5651184-5663707 15.84 10.17 1.80E-03 4.51E-02 0.64
Pitpnm2 chr5:124568698-124666427 13.13 8.43 5.00E-05 2.50E-03 0.64
Lama4 chr10:38685320-38829994 30.63 19.68 5.00E-05 2.50E-03 0.64
Rap1b chr10:117251652-117283030 93.60 60.33 4.50E-04 1.54E-02 0.63
Adam15 chr3:89143561-89153932 19.09 12.36 2.00E-03 4.91E-02 0.63
F2r chr13:96371743-96388388 210.88 137.19 1.00E-04 4.56E-03 0.62
Ablim1 chr19:57107753-57290522 15.33 10.01 3.50E-04 1.26E-02 0.61
Rreb1 chr13:37917906-38043929 11.15 7.28 4.00E-04 1.40E-02 0.61
Akap5 chr12:77425877-77435138 7.41 4.84 2.00E-03 4.91E-02 0.61
Pros1 chr16:62854159-62929166 27.42 18.01 7.50E-04 2.27E-02 0.61
Cited2 chr10:17443033-17445480 32.47 21.33 1.15E-03 3.19E-02 0.61
Fth1 chr19:10055089-10059601 394.95 260.12 2.00E-04 7.94E-03 0.60
Tgfb1 chr7:26472020-26490015 41.90 27.61 1.30E-03 3.52E-02 0.60
Tmem164 chrX:139115942-139278037 33.81 22.36 4.00E-04 1.40E-02 0.60
Rab11a chr9:64563106-64585563 33.45 22.17 1.85E-03 4.62E-02 0.59
Vat1 chr11:101320061-101327513 97.84 65.00 2.50E-04 9.49E-03 0.59
Arrb1 chr7:106683995-106755281 22.70 15.08 1.50E-04 6.36E-03 0.59
Prdx3 chr19:60939968-60950441 47.19 31.46 1.75E-03 4.41E-02 0.59
Smad6 chr9:63800882-63869866 22.69 15.14 1.45E-03 3.82E-02 0.58
Ptrf chr11:100818050-100831931 26.92 18.03 1.45E-03 3.82E-02 0.58
Cycs chr6:50512561-50516473 30.70 20.60 7.00E-04 2.15E-02 0.58
Epb4.1 chr4:131477064-131631228 37.69 25.74 6.50E-04 2.05E-02 0.55
Ddah2 chr17:35195979-35199044 158.03 108.21 7.50E-04 2.27E-02 0.55
Cpox chr16:58670320-58680502 29.84 20.43 1.90E-03 4.71E-02 0.55
Sdcbp chr4:6292826-6323269 53.07 36.38 1.60E-03 4.12E-02 0.54
S100a10 chr3:93359038-93368567 279.31 192.31 1.65E-03 4.22E-02 0.54
Asb4 chr6:5333385-5383021 44.71 31.11 1.70E-03 4.33E-02 0.52
Apoe chr7:20281592-20284515 422.02 294.88 1.45E-03 3.82E-02 0.52
Slc25a5 chrX:34335646-34338801 200.40 141.61 1.45E-03 3.82E-02 0.50
Ezr chr17:6942479-6987129 55.86 79.12 1.65E-03 4.22E-02 0.50
Sulf1 chr1:12682510-12850453 52.53 74.66 1.50E-03 3.92E-02 0.51
Slit2 chr5:48374393-48697017 19.12 27.22 1.10E-03 3.09E-02 0.51
Fat1 chr8:46020611-46137611 22.46 32.66 7.00E-04 2.15E-02 0.54
Tmem132c chr5:127722195-128046160 9.49 14.00 1.45E-03 3.82E-02 0.56
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Spon1 chr7:120909511-121186889 11.86 17.50 1.20E-03 3.30E-02 0.56
Lama5 chr2:179911077-179960564 22.43 33.20 3.50E-04 1.26E-02 0.57
Atp6v0a4, D630045J12Rik chr6:37998482-38204009 4.41 6.54 1.45E-03 3.82E-02 0.57
Axl chr7:26541518-26573752 14.99 22.37 1.20E-03 3.30E-02 0.58
Ephb2 chr4:136203513-136391850 21.67 32.36 1.15E-03 3.19E-02 0.58
Sall2 chr14:52930851-52948345 11.61 17.42 9.00E-04 2.63E-02 0.59
Bcam chr7:20341486-20355881 32.47 48.88 4.50E-04 1.54E-02 0.59
Cxcl12 chr6:117118552-117131386 39.00 58.83 1.30E-03 3.52E-02 0.59
Kif5c chr2:49474833-49630298 8.06 12.30 4.50E-04 1.54E-02 0.61
Nav2 chr7:56214442-56865458 3.35 5.13 1.80E-03 4.51E-02 0.61
Tinagl1 chr4:129842843-129852366 27.21 41.91 8.50E-04 2.53E-02 0.62
Tenm3 chr8:49311018-49760044 16.79 25.92 1.50E-04 6.36E-03 0.63
Sulf2 chr2:165899398-165981183 50.42 77.94 5.00E-05 2.50E-03 0.63
Dsg2 chr18:20716616-20763027 7.66 11.89 9.00E-04 2.63E-02 0.63
Col11a1 chr3:113733457-113923244 16.74 26.04 2.50E-04 9.49E-03 0.64
Cep170b chr12:113960384-113984802 6.79 10.60 5.50E-04 1.78E-02 0.64
Snhg11 chr2:158201373-158211881 13.70 21.40 1.50E-04 6.36E-03 0.64
Ifi30 chr8:73286671-73291611 38.63 60.68 2.00E-03 4.91E-02 0.65
Emb chr13:118009379-118063222 44.84 70.69 5.00E-05 2.50E-03 0.66
Cxadr chr16:78301915-78360030 14.18 22.46 2.50E-04 9.49E-03 0.66
Dlk1 chr12:110691032-110701546 87.66 138.97 4.00E-04 1.40E-02 0.66
Ogdhl chr14:33135204-33161006 10.68 17.12 2.50E-04 9.49E-03 0.68
Frem1 chr4:82543823-82698071 10.44 16.84 5.00E-05 2.50E-03 0.69
Sesn3 chr9:14080744-14137524 6.57 10.60 5.50E-04 1.78E-02 0.69
Ptprk chr10:27794625-28317203 11.82 19.20 1.00E-04 4.56E-03 0.70
Ptch1 chr13:63609640-63666828 29.34 47.88 1.10E-03 3.09E-02 0.71
Rpl13a chr7:52380932-52384115 819.29 1341.58 2.00E-04 7.94E-03 0.71
Dst chr1:34068669-34365497 9.80 16.06 5.00E-05 2.50E-03 0.71
Ckb chr12:112907565-112910549 36.01 59.46 5.00E-05 2.50E-03 0.72
Lrrc16b chr14:56109929-56127101 4.15 6.87 1.90E-03 4.71E-02 0.73
Cacna1h chr17:25507497-25570728 3.84 6.38 5.50E-04 1.78E-02 0.73
Plat chr8:23868215-23893320 17.99 30.03 1.00E-04 4.56E-03 0.74
Tenm4 chr7:103359146-104059589 9.33 15.58 2.00E-04 7.94E-03 0.74
H2-Q4 chr17:35516561-35521619 10.87 18.21 1.75E-03 4.41E-02 0.74
Tet1 chr10:62267317-62342762 4.11 6.92 5.00E-05 2.50E-03 0.75
Col8a2 chr4:125964037-125991574 8.90 15.02 5.00E-05 2.50E-03 0.76
Gpc4 chrX:49403563-49518100 10.37 17.60 1.45E-03 3.82E-02 0.76
Shroom3 chr5:93112460-93394785 6.34 10.78 5.00E-05 2.50E-03 0.77
Adamts15 chr9:30706739-30730037 10.68 18.20 5.00E-05 2.50E-03 0.77
Cadm1 chr9:47338434-47661468 21.86 37.48 5.00E-05 2.50E-03 0.78
Sall1 chr8:91551142-91568061 5.43 9.32 5.00E-05 2.50E-03 0.78
Col5a2 chr1:45431175-45560127 31.08 53.48 5.00E-05 2.50E-03 0.78
Skida1 chr2:17965713-17970076 3.51 6.09 1.50E-03 3.92E-02 0.80
Igdcc4 chr9:64949301-64985750 8.44 14.70 5.00E-05 2.50E-03 0.80
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Igdcc3 chr9:64988995-65034829 31.48 54.86 5.00E-05 2.50E-03 0.80
Stx3 chr19:11849607-11894262 6.22 10.87 1.80E-03 4.51E-02 0.80
Cdh3 chr8:109034790-109080808 50.76 89.21 5.00E-05 2.50E-03 0.81
Plxnb1 chr9:108997249-109022429 10.67 18.83 5.00E-05 2.50E-03 0.82
Sema4b chr7:87331726-87371410 5.86 10.35 2.00E-04 7.94E-03 0.82
Arvcf chr16:18348274-18479166 8.77 15.54 9.50E-04 2.74E-02 0.83
B4galnt4 chr7:148247172-148258018 8.56 15.26 2.50E-04 9.49E-03 0.83
Ptprn2 chr12:117724192-118575485 2.72 4.89 1.75E-03 4.41E-02 0.84
Ptgs2 chr1:151947253-151955142 4.18 7.51 5.50E-04 1.78E-02 0.85
- chr8:124783835-124796514 1.80 3.24 2.00E-04 7.94E-03 0.85
Pdpn chr4:142857324-142889410 7.57 13.75 1.45E-03 3.82E-02 0.86
Abca4 chr3:121747377-121882979 1.80 3.28 1.20E-03 3.30E-02 0.87
Fras1 chr5:96802973-97213747 2.85 5.21 5.00E-05 2.50E-03 0.87
Msi1 chr5:115879693-115905695 23.36 42.97 1.25E-03 3.41E-02 0.88
Postn chr3:54165028-54194963 316.53 583.45 7.50E-04 2.27E-02 0.88
Tnfrsf19 chr14:61582670-61665692 9.47 17.47 5.00E-05 2.50E-03 0.88
Ifitm1 chr7:148153327-148155726 49.99 92.19 5.00E-05 2.50E-03 0.88
Flrt3 chr2:140221165-142215786 8.15 15.09 5.00E-05 2.50E-03 0.89
Cyfip2 chr11:46007350-46126361 2.60 4.82 2.50E-04 9.49E-03 0.89
2610203C20Rik chr9:41389421-41400570 2.05 3.82 1.75E-03 4.41E-02 0.90
Crabp1 chr9:54612614-54620916 21.95 40.90 1.05E-03 2.98E-02 0.90
Tpbg chr9:85735986-85740662 5.07 9.48 1.00E-04 4.56E-03 0.90
Kif1a chr1:94912032-94998442 9.29 17.41 5.00E-05 2.50E-03 0.91
Smoc1 chr12:82120441-82287401 3.28 6.18 1.80E-03 4.51E-02 0.92
Igfbp2 chr1:72871053-72899045 223.16 420.79 5.00E-05 2.50E-03 0.92
Gstm1 chr3:107815167-107820891 12.07 22.79 7.00E-04 2.15E-02 0.92
Sbk1 chr7:133416132-133438513 4.88 9.22 1.50E-04 6.36E-03 0.92
Frzb chr2:80252126-80287553 6.44 12.21 2.00E-04 7.94E-03 0.92
Fat3 chr9:15714636-16182675 1.07 2.03 1.50E-04 6.36E-03 0.93
Thsd7a chr6:12261607-12699253 2.27 4.32 5.00E-05 2.50E-03 0.93
Lmo7 chr14:102129144-102333910 3.24 6.19 5.00E-05 2.50E-03 0.93
Crispld2 chr8:122516369-122576693 6.10 11.67 5.00E-05 2.50E-03 0.94
Sfrp1 chr8:24521973-24560104 18.93 36.25 5.00E-05 2.50E-03 0.94
A830080D01Rik chrX:155970599-156031013 2.15 4.14 1.75E-03 4.41E-02 0.94
Dkk1 chr19:30620373-30623986 7.78 15.00 2.00E-04 7.94E-03 0.95
2510009E07Rik chr16:21649117-21694738 2.71 5.23 2.50E-04 9.49E-03 0.95
Fzd3 chr14:65811277-65881300 3.16 6.11 5.00E-05 2.50E-03 0.95
Nr2f2 chr7:77496835-77556032 2.90 5.63 7.00E-04 2.15E-02 0.96
Atp10a chr7:65913571-66084796 1.91 3.78 7.50E-04 2.27E-02 0.98
Syt11 chr3:88548622-88576521 5.33 10.59 5.00E-05 2.50E-03 0.99
Plagl1 chr10:12810593-12851501 54.21 107.83 5.00E-05 2.50E-03 0.99
Dsc2 chr18:20189298-20218006 6.72 13.40 5.00E-05 2.50E-03 1.00
D430019H16Rik chr12:106692065-106731305 1.72 3.43 9.00E-04 2.63E-02 1.00
Mbnl3 chrX:48466670-48559009 0.92 1.83 1.55E-03 4.03E-02 1.00
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Sema3e chr5:14025275-14256689 2.48 4.99 5.00E-05 2.50E-03 1.01
Arnt2 chr7:91394788-91558469 2.04 4.11 1.50E-04 6.36E-03 1.01
Syt7 chr19:10463579-10527671 1.86 3.78 1.50E-04 6.36E-03 1.02
Sfrp2 chr3:83570242-83578236 6.14 12.49 3.50E-04 1.26E-02 1.03
Col22a1 chr15:71628905-71864657 2.02 4.12 3.00E-04 1.11E-02 1.03
Hbb-y chr7:111000267-111001721 90.25 185.04 5.00E-05 2.50E-03 1.04
Ptn chr6:36664884-36761361 12.51 25.83 5.00E-05 2.50E-03 1.05
Bai2 chr4:129662321-129699877 1.40 2.94 1.45E-03 3.82E-02 1.07
Magel2 chr7:69521864-69526526 1.55 3.24 9.50E-04 2.74E-02 1.07
Grem2 chr1:176763915-176851950 3.53 7.44 1.00E-04 4.56E-03 1.07
Prkcz chr4:154634228-154735500 1.79 3.80 7.00E-04 2.15E-02 1.09
Tpd52 chr3:8929435-9004515 8.47 17.99 5.00E-05 2.50E-03 1.09
Slc4a5 chr6:83187368-83254939 1.67 3.54 4.00E-04 1.40E-02 1.09
Slc8a2 chr7:16715648-16745860 1.96 4.16 5.50E-04 1.78E-02 1.09
Bnc1 chr7:89111547-89137185 3.62 7.76 5.00E-05 2.50E-03 1.10
Trim2 chr3:83964360-84108697 1.22 2.62 3.00E-04 1.11E-02 1.11
Dclk2 chr3:86590071-86724806 2.16 4.67 2.00E-04 7.94E-03 1.11
Mapk8ip1 chr2:92223821-92241420 3.73 8.06 1.00E-04 4.56E-03 1.11
Adamtsl1 chr4:85699818-86074286 1.08 2.33 3.00E-04 1.11E-02 1.11
Epha7 chr4:28740294-28894649 5.19 11.23 5.00E-05 2.50E-03 1.11
Cdon chr9:35259660-35315237 11.71 25.37 5.00E-05 2.50E-03 1.11
Ltbp4 chr7:28090159-28122631 5.45 11.82 5.00E-05 2.50E-03 1.12
Camsap3 chr8:3587449-3609738 4.31 9.36 5.00E-05 2.50E-03 1.12
Pgap1 chr1:54529843-54614528 2.05 4.46 5.00E-05 2.50E-03 1.12
Lox chr18:52675724-52689362 4.08 8.89 1.00E-04 4.56E-03 1.12
Prom1 chr5:44384860-44492975 11.51 25.09 5.00E-05 2.50E-03 1.12
Wfdc2 chr2:164388215-164394006 13.61 29.70 9.00E-04 2.63E-02 1.13
Hspa4l chr3:40549534-40600019 2.80 6.12 5.50E-04 1.78E-02 1.13
Kbtbd11 chr8:15011024-15033332 1.01 2.22 4.00E-04 1.40E-02 1.13
Col9a2 chr4:120712170-120727930 12.56 27.63 5.00E-05 2.50E-03 1.14
Srgap3 chr6:112667965-112897260 2.23 4.91 5.00E-05 2.50E-03 1.14
Mycl1 chr4:122673341-122679723 2.51 5.54 5.00E-05 2.50E-03 1.14
Megf6 chr4:153544821-153649830 3.83 8.47 5.00E-05 2.50E-03 1.14
Zfp534 chr4:147047611-147076662 3.47 7.72 5.00E-05 2.50E-03 1.15
Pim2 chrX:7455431-7460558 4.53 10.09 3.00E-04 1.11E-02 1.16
Col6a3 chr1:92663434-92740548 4.13 9.26 5.00E-05 2.50E-03 1.17
Slc6a15 chr10:102830441-102882013 1.61 3.64 1.45E-03 3.82E-02 1.18
Stag3 chr5:138721736-138753621 3.81 8.60 5.00E-05 2.50E-03 1.18
Sema3d chr5:12383165-12588943 1.06 2.40 5.50E-04 1.78E-02 1.18
Fmod chr1:135934091-135944854 2.68 6.13 4.00E-04 1.40E-02 1.19
Mkrn1 chr6:39347819-39370368 9.75 22.42 5.00E-05 2.50E-03 1.20
Sorl1 chr9:41772812-41932372 3.19 7.36 5.00E-05 2.50E-03 1.21
Nptx2 chr5:145306755-145318347 1.88 4.34 1.25E-03 3.41E-02 1.21
Uchl1 chr5:67067359-67078473 6.04 14.02 8.50E-04 2.53E-02 1.21
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Sema3a chr5:13396783-13603485 1.41 3.29 5.00E-05 2.50E-03 1.22
Sdc4 chr2:164249746-164268688 11.55 26.93 5.00E-05 2.50E-03 1.22
Rhpn2 chr7:36119255-36181786 3.14 7.34 1.50E-04 6.36E-03 1.22
Cdhr1 chr14:37891034-37911497 1.13 2.66 7.00E-04 2.15E-02 1.24
Zfp503 chr14:22803183-22808823 4.30 10.16 5.00E-05 2.50E-03 1.24
Gli1 chr10:126760782-126778635 4.81 11.42 5.00E-05 2.50E-03 1.25
Dnm1 chr2:32163990-32208824 1.35 3.20 2.00E-04 7.94E-03 1.25
Wwc1 chr11:35651913-35793591 3.52 8.43 5.00E-05 2.50E-03 1.26
Zbtb16 chr9:48462401-48644050 2.07 4.96 5.00E-05 2.50E-03 1.26
Dnaaf3 chr7:4469909-4484044 3.67 8.86 6.50E-04 2.05E-02 1.27
Ret chr6:118101765-118147762 0.88 2.14 5.00E-04 1.67E-02 1.28
Slitrk4 chrX:61522618-61530171 0.94 2.29 1.90E-03 4.71E-02 1.28
Nup210 chr6:90963060-91066820 6.56 15.92 5.00E-05 2.50E-03 1.28
Rims3 chr4:120550473-120569173 1.17 2.84 4.50E-04 1.54E-02 1.28
Ccdc88c chr12:102149752-102267193 1.73 4.22 1.00E-04 4.56E-03 1.29
Epha1 chr6:42308485-42330557 1.18 2.88 1.65E-03 4.22E-02 1.29
Pnpla3 chr15:83998245-84019951 1.09 2.67 7.00E-04 2.15E-02 1.29
Lfng chr5:141083294-141091499 2.40 5.90 1.50E-04 6.36E-03 1.30
- chr13:19617298-19620037 2.47 6.06 2.00E-04 7.94E-03 1.30
Dtx4 chr19:12540825-12576486 1.57 3.87 5.00E-05 2.50E-03 1.30
Phf19 chr2:34749274-34769496 1.09 2.68 1.00E-03 2.86E-02 1.30
Plekha7 chr7:123267104-123333355 5.00 12.33 5.00E-05 2.50E-03 1.30
Upk3b chr5:136514365-136520863 6.82 16.85 5.00E-05 2.50E-03 1.30
Clip4 chr17:72119030-72213550 1.17 2.89 1.50E-03 3.92E-02 1.31
Usp44 chr10:93294299-93320832 1.48 3.67 1.40E-03 3.74E-02 1.31
Igsf9 chr1:174412343-174429008 6.51 16.20 5.00E-05 2.50E-03 1.31
Zfhx4 chr3:5177827-5415855 0.90 2.26 5.00E-05 2.50E-03 1.32
Zswim5 chr4:116550006-116661710 0.80 2.00 9.50E-04 2.74E-02 1.32
Slc4a1 chr11:102210133-102226595 1.60 4.06 1.00E-04 4.56E-03 1.34
Adam11 chr11:102622752-102641576 0.78 1.98 8.00E-04 2.41E-02 1.34
Pdzd4 chrX:71038423-71070308 2.11 5.39 1.00E-04 4.56E-03 1.35
Sept3 chr15:82105364-82124872 2.77 7.13 5.00E-05 2.50E-03 1.36
1700001L05Rik chr15:83184276-83197727 0.60 1.54 1.05E-03 2.98E-02 1.36
Gldc chr19:30172930-30249931 8.30 21.36 5.00E-05 2.50E-03 1.36
Fbxl16 chr17:25946029-25958210 0.87 2.26 2.00E-03 4.91E-02 1.37
Phf21b chr15:84615805-84686559 1.37 3.54 1.40E-03 3.74E-02 1.37
Celsr1 chr15:85729187-85864207 2.19 5.69 5.00E-05 2.50E-03 1.37
Rgma chr7:80458691-80565871 2.12 5.50 5.00E-05 2.50E-03 1.38
Rab11fip4 chr11:79404713-79511635 2.67 6.95 4.00E-04 1.40E-02 1.38
Cldn6 chr17:23816331-23819414 9.36 24.38 5.00E-05 2.50E-03 1.38
Cadm4 chr7:25267041-25289552 2.35 6.12 4.00E-04 1.40E-02 1.38
Zic2 chr14:122874605-122879550 1.97 5.17 1.50E-04 6.36E-03 1.39
Rfx2 chr17:56915319-56970431 0.92 2.44 1.00E-03 2.86E-02 1.40
Pappa chr4:64785207-65018543 1.42 3.74 5.00E-05 2.50E-03 1.40
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Slc4a8 chr15:100592177-100654402 0.55 1.47 2.50E-04 9.49E-03 1.41
Ldhb chr6:142438768-142456463 30.96 82.29 5.00E-05 2.50E-03 1.41
4930470H14Rik chr17:4044657-4082995 7.45 19.94 5.00E-05 2.50E-03 1.42
Myh14 chr7:51861172-51926213 0.49 1.32 7.50E-04 2.27E-02 1.42
Rragb chrX:149574500-149606486 0.72 1.95 6.00E-04 1.93E-02 1.43
Spint2 chr7:30041348-30066996 7.60 20.60 5.00E-05 2.50E-03 1.44
Col2a1 chr15:97806032-97835155 21.41 58.08 5.00E-05 2.50E-03 1.44
Dtna chr18:23573915-23818215 1.18 3.21 3.50E-04 1.26E-02 1.44
Nrk chrX:135448968-135545068 4.28 11.73 5.00E-05 2.50E-03 1.46
Glb1l2 chr9:26570628-26614002 1.01 2.78 6.00E-04 1.93E-02 1.46
Cyp2s1 chr7:26587494-26601549 1.49 4.13 5.00E-04 1.67E-02 1.47
Map7 chr10:19868725-20001396 1.59 4.47 5.00E-05 2.50E-03 1.49
Cbx7 chr15:79746236-79763076 3.52 9.92 5.00E-05 2.50E-03 1.50
Robo3 chr9:37223629-37240760 0.97 2.74 7.00E-04 2.15E-02 1.50
Pcsk9 chr4:106114938-106136930 1.27 3.59 4.00E-04 1.40E-02 1.50
Ephb1 chr9:101824457-102257023 0.86 2.44 2.00E-04 7.94E-03 1.50
Cbx7 chr15:79746236-79763076 1.50 4.27 9.50E-04 2.74E-02 1.51
Elavl2 chr4:90917456-91066675 1.01 2.90 3.00E-04 1.11E-02 1.51
Scube1 chr15:83433012-83555469 6.87 19.73 5.00E-05 2.50E-03 1.52
Nlrp1a chr11:70904698-70958206 1.24 3.58 5.00E-05 2.50E-03 1.54
Lum chr10:97028134-97035337 30.29 88.17 5.00E-05 2.50E-03 1.54
F2rl1 chr13:96281683-96295195 2.47 7.21 5.00E-05 2.50E-03 1.55
Cmah chr13:24419288-24569154 2.03 5.95 5.00E-05 2.50E-03 1.55
Sfmbt2 chr2:10292077-10516880 1.76 5.16 5.00E-05 2.50E-03 1.55
Adamts19 chr18:58996417-59213332 0.70 2.05 5.00E-04 1.67E-02 1.55
Vtn chr11:78312621-78315827 2.51 7.36 4.50E-04 1.54E-02 1.55
Cgn chr3:94563991-94590437 2.37 7.03 5.00E-05 2.50E-03 1.57
Epb4.1l4a chr18:33955980-34166860 1.74 5.17 5.00E-05 2.50E-03 1.57
Celsr2 chr3:108193765-108218412 1.98 5.90 5.00E-05 2.50E-03 1.58
Map3k9 chr12:82815936-82882157 0.45 1.33 4.50E-04 1.54E-02 1.58
Cobl chr11:12136678-12364963 0.45 1.35 1.75E-03 4.41E-02 1.58
Fzd5 chr1:64777131-64784324 1.88 5.64 5.00E-05 2.50E-03 1.58
Dppa4 chr16:48283847-48294405 3.61 10.85 3.00E-04 1.11E-02 1.59
Frem2 chr3:53317859-53461277 5.29 16.01 5.00E-05 2.50E-03 1.60
Mt1 chr8:96702988-96704227 22.15 67.24 5.00E-05 2.50E-03 1.60
Rab11fip4 chr11:79404713-79511635 3.11 9.50 5.00E-05 2.50E-03 1.61
Kif21a chr15:90763706-90880379 2.92 8.92 5.00E-05 2.50E-03 1.61
Lrp2 chr2:69262391-69424124 6.40 19.65 5.00E-05 2.50E-03 1.62
Slc45a3 chr1:133859491-133879549 0.48 1.47 1.55E-03 4.03E-02 1.63
Camkv chr9:107838250-107852022 1.56 4.88 2.00E-04 7.94E-03 1.65
Dnahc8 chr17:30763880-31012209 0.43 1.34 5.00E-05 2.50E-03 1.65
Cpz chr5:35844866-35868275 3.14 9.95 5.00E-05 2.50E-03 1.66
Lrrn1 chr6:107479719-107520222 0.68 2.16 2.50E-04 9.49E-03 1.67
Pcsk6 chr7:73007021-73195272 1.12 3.57 5.00E-05 2.50E-03 1.67
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Dcn chr10:96942133-96980796 6.02 19.18 5.00E-05 2.50E-03 1.67
Nuak2 chr1:134212701-134230065 1.44 4.60 5.00E-05 2.50E-03 1.67
Clstn3 chr6:124380773-124414802 1.46 4.67 5.00E-05 2.50E-03 1.67
Galnt16 chr12:81619976-81704883 1.23 3.97 5.00E-05 2.50E-03 1.68
Fcho1 chr8:74232285-74249580 1.13 3.64 5.00E-05 2.50E-03 1.69
Crabp2 chr3:87750395-87757294 14.17 46.02 5.00E-05 2.50E-03 1.70
Slc35f2 chr9:53619341-53665968 3.66 12.02 5.00E-05 2.50E-03 1.72
Pramef12 chr4:143981576-143998367 0.84 2.77 6.50E-04 2.05E-02 1.72
Rspo2 chr15:42852340-43002364 0.70 2.30 1.60E-03 4.12E-02 1.72
AI414108 chr9:27160269-27165128 1.32 4.34 5.00E-05 2.50E-03 1.72
Hook1 chr4:95626401-95692055 3.03 10.23 5.00E-05 2.50E-03 1.75
Dll1 chr17:15504317-15512787 1.08 3.65 5.00E-05 2.50E-03 1.75
Alpl chr4:137297646-137352292 8.15 27.70 5.00E-05 2.50E-03 1.76
Gm13051 chr4:146064712-146094024 1.72 5.86 5.00E-05 2.50E-03 1.77
Fabp3 chr4:129986021-129992707 13.10 44.92 5.00E-05 2.50E-03 1.78
St14 chr9:30896174-30939384 1.84 6.32 5.00E-05 2.50E-03 1.78
Trh chr6:92192055-92194642 11.81 40.60 5.00E-05 2.50E-03 1.78
- chr9:75318079-75322594 0.50 1.72 5.00E-04 1.67E-02 1.78
Spint1 chr2:119063095-119075249 2.79 9.63 5.00E-05 2.50E-03 1.79
Mylpf chr7:134355121-134357801 3.51 12.13 4.50E-04 1.54E-02 1.79
Adam23 chr1:63492477-63643089 0.71 2.45 5.00E-05 2.50E-03 1.80
Slc35f1 chr10:52410306-52831428 0.52 1.82 2.50E-04 9.49E-03 1.80
Cenpv chr11:62338445-62352763 0.72 2.52 5.00E-05 2.50E-03 1.80
- chr9:27159455-27160230 2.20 7.72 1.60E-03 4.12E-02 1.81
Chchd10 chr10:75398317-75400479 3.28 11.49 4.00E-04 1.40E-02 1.81
Spock2 chr10:59569004-59597899 1.23 4.31 5.00E-05 2.50E-03 1.81
Slit1 chr19:41674746-41818346 2.13 7.52 5.00E-05 2.50E-03 1.82
Slc4a11 chr2:130509843-130523255 0.51 1.82 3.50E-04 1.26E-02 1.83
Pou3f1 chr4:124334888-124337899 0.40 1.43 1.25E-03 3.41E-02 1.83
Cdh6 chr15:12958488-13103394 3.31 11.83 5.00E-05 2.50E-03 1.84
Cdh6 chr15:12958488-13103394 2.02 7.23 5.00E-05 2.50E-03 1.84
Syt9 chr7:114514303-114692169 0.47 1.68 3.00E-04 1.11E-02 1.84
Atp1a3 chr7:25763187-25790914 0.48 1.73 7.00E-04 2.15E-02 1.86
Glyctk chr9:106055190-106062000 0.41 1.50 5.00E-04 1.67E-02 1.86
Grik3 chr4:125168074-125391417 0.68 2.47 5.00E-05 2.50E-03 1.87
Nr5a2 chr1:138740160-138857025 0.40 1.46 1.30E-03 3.52E-02 1.88
Grin1 chr2:25145430-25174683 0.47 1.72 3.50E-04 1.26E-02 1.88
Foxa2 chr2:147868613-147872705 0.96 3.54 6.50E-04 2.05E-02 1.88
Tox3 chr8:92771010-92872151 1.09 4.02 5.00E-05 2.50E-03 1.88
Fgfbp3 chr19:36992039-36994089 3.30 12.20 5.00E-05 2.50E-03 1.89
Pax6 chr2:105376236-105540183 0.86 3.19 5.00E-05 2.50E-03 1.89
- chr19:41672351-41674323 1.26 4.70 4.00E-04 1.40E-02 1.90
Wnk2 chr13:49131670-49243383 0.51 1.92 5.00E-05 2.50E-03 1.91
Shh chr5:28783379-29045749 3.16 12.03 5.00E-05 2.50E-03 1.93
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- chr9:27153357-27159388 0.81 3.09 5.00E-05 2.50E-03 1.93
Ybx2 chr11:69749400-69755101 2.24 8.56 5.00E-05 2.50E-03 1.93
Plch1 chr3:63500155-63654913 0.81 3.10 5.00E-05 2.50E-03 1.94
Abcc4 chr14:118881913-119105441 0.96 3.74 5.00E-05 2.50E-03 1.96
Fst chr13:115242469-115248938 2.10 8.17 5.00E-05 2.50E-03 1.96
Ttc39b chr4:82866204-82970093 0.74 2.89 5.00E-05 2.50E-03 1.96
Sema5b chr16:35541447-35664344 0.88 3.44 5.00E-05 2.50E-03 1.96
Jam2 chr16:84774367-84826620 0.65 2.61 1.50E-04 6.36E-03 2.00
Zic3 chrX:55283804-55289807 1.53 6.18 5.00E-05 2.50E-03 2.01
Islr2 chr9:58044103-58056615 0.46 1.86 1.00E-04 4.56E-03 2.01
Sox21 chr14:118632455-118636252 0.43 1.77 1.50E-04 6.36E-03 2.03
Eya2 chr2:165420527-165597227 0.79 3.23 5.00E-05 2.50E-03 2.03
Igfbpl1 chr4:45822378-45839699 0.68 2.82 1.50E-04 6.36E-03 2.04
Slain1 chr14:104049459-104104016 0.41 1.69 7.00E-04 2.15E-02 2.05
Mpzl2 chr9:44850426-44862126 0.40 1.65 7.50E-04 2.27E-02 2.06
Elovl2 chr13:41277750-41315772 0.71 2.96 5.00E-05 2.50E-03 2.06
Grhl2 chr15:37162790-37293323 0.39 1.65 1.00E-04 4.56E-03 2.06
Kcnk1 chr8:128519001-128554585 1.30 5.47 5.00E-05 2.50E-03 2.07
Ephx2 chr14:66703208-66743359 1.23 5.20 1.00E-04 4.56E-03 2.08
Lefty1 chr1:182865169-182868532 1.09 4.65 2.50E-04 9.49E-03 2.09
Cdh1 chr8:109127267-109194146 7.05 30.06 5.00E-05 2.50E-03 2.09
Mreg chr1:72205806-72258881 1.53 6.53 5.00E-05 2.50E-03 2.10
Lmx1a chr1:169619688-169778864 0.94 4.02 5.00E-05 2.50E-03 2.10
Map2 chr1:66221902-66489157 0.80 3.44 5.00E-05 2.50E-03 2.10
Otx2 chr14:49276684-49282547 5.19 22.75 5.00E-05 2.50E-03 2.13
Tdgf1 chr9:110842111-110848662 3.34 14.76 5.00E-05 2.50E-03 2.14
Epcam chr17:88035318-88050467 4.43 19.85 5.00E-05 2.50E-03 2.16
Sox2 chr3:34459302-34576915 7.80 35.12 5.00E-05 2.50E-03 2.17
Hap1 chr11:100208640-100217455 1.35 6.12 5.00E-05 2.50E-03 2.18
Sox3 chrX:58144540-58146605 0.42 1.88 5.50E-04 1.78E-02 2.18
Gyltl1b chr2:92205202-92211193 1.76 8.01 5.00E-05 2.50E-03 2.19
Esrp1 chr4:11259184-11313930 0.94 4.26 5.00E-05 2.50E-03 2.19
Pax3 chr1:78097841-78193711 0.30 1.36 2.50E-04 9.49E-03 2.20
H2-Bl chr17:36217133-36221194 0.85 3.95 1.10E-03 3.09E-02 2.21
Fez1 chr9:36651243-36686225 0.83 3.87 9.00E-04 2.63E-02 2.22
BC068157 chr8:4209542-4217312 0.61 2.88 5.00E-05 2.50E-03 2.23
Irs4 chrX:138145540-138159760 0.43 2.03 5.00E-05 2.50E-03 2.25
Lhx2 chr2:38206827-38225248 0.93 4.51 5.00E-05 2.50E-03 2.28
Cldn4 chr5:135420992-135422804 3.95 19.31 5.00E-05 2.50E-03 2.29
Mapk13 chr17:28906261-28915649 0.90 4.42 2.00E-04 7.94E-03 2.29
Kif5a chr10:126662750-126700419 0.51 2.49 5.00E-05 2.50E-03 2.29
Calca chr7:121774991-121779871 0.82 4.03 1.35E-03 3.63E-02 2.29
B4galnt3 chr6:120150837-120244577 0.58 2.87 5.00E-04 1.67E-02 2.31
Cbs chr17:31749567-31774150 0.52 2.58 5.00E-05 2.50E-03 2.32
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C1s chr6:124480361-124492377 0.28 1.42 5.50E-04 1.78E-02 2.33
- chr8:3585435-3587396 0.47 2.37 6.00E-04 1.93E-02 2.34
Mgat5b chr11:116780176-116848258 0.29 1.48 1.50E-04 6.36E-03 2.34
Enpp3 chr10:24493619-24556001 2.39 12.15 5.00E-05 2.50E-03 2.35
Aqp3 chr4:41039756-41045216 0.86 4.42 5.00E-04 1.67E-02 2.35
Cldn7 chr11:69778280-69781388 1.77 9.05 5.00E-05 2.50E-03 2.36
Zfp296 chr7:20162635-20166005 0.45 2.29 1.80E-03 4.51E-02 2.36
Tfap2a chr13:40811043-40829192 0.62 3.18 5.00E-05 2.50E-03 2.36
Rnf17 chr14:57021533-57143868 0.34 1.78 5.00E-05 2.50E-03 2.38
Ttyh1 chr7:4025726-4088528 0.31 1.62 5.00E-05 2.50E-03 2.40
Dmrt1 chr19:25580195-25678818 0.42 2.26 3.50E-04 1.26E-02 2.44
L1td1 chr4:98393444-98405177 1.34 7.26 5.00E-05 2.50E-03 2.44
- chr14:49282574-49287385 1.05 5.70 5.00E-05 2.50E-03 2.44
Pipox chr11:77694116-77707374 1.02 5.53 5.00E-05 2.50E-03 2.44
Cpne5 chr17:29293465-29374735 0.29 1.61 5.00E-05 2.50E-03 2.46
Srcin1 chr11:97370653-97436440 0.33 1.81 5.00E-05 2.50E-03 2.47
Erbb3 chr10:128004594-128026557 1.11 6.16 3.00E-04 1.11E-02 2.47
Ntn1 chr11:68022865-68200328 3.13 17.49 5.00E-05 2.50E-03 2.48
Fgfbp1 chr5:44370096-44373038 0.81 4.61 1.50E-04 6.36E-03 2.50
B4galnt3 chr6:120150837-120244577 0.50 2.87 6.50E-04 2.05E-02 2.52
C130021I20Rik chr2:33496712-33501823 0.64 3.68 5.00E-05 2.50E-03 2.53
Nell2 chr15:95049880-95359137 0.26 1.50 3.00E-04 1.11E-02 2.55
Kcnj3 chr2:55289566-55450492 0.38 2.31 1.20E-03 3.30E-02 2.60
Cldn3 chr5:135462083-135477220 0.59 3.61 9.50E-04 2.74E-02 2.60
Fmr1nb chrX:66015013-66057735 0.75 4.57 1.00E-03 2.86E-02 2.61
Mir135a-2 chr10:91534360-91534930 5.20 32.18 5.00E-05 2.50E-03 2.63
Liph chr16:21953890-21995615 0.34 2.11 2.00E-04 7.94E-03 2.64
Erbb3 chr10:128004594-128026557 0.84 5.22 5.00E-05 2.50E-03 2.64
Fam181b chr7:100228388-100230231 0.71 4.46 1.00E-04 4.56E-03 2.66
Gpr98 chr13:81234066-81772143 0.33 2.11 5.00E-05 2.50E-03 2.66
Six3 chr17:86020173-86025531 0.56 3.65 5.00E-05 2.50E-03 2.70
Six3os1 chr17:86001271-86017736 0.45 3.03 6.50E-04 2.05E-02 2.74
Tfcp2l1 chr1:120524521-120581745 0.45 3.00 5.00E-05 2.50E-03 2.75
Otx1 chr11:21894766-21901654 0.34 2.29 1.50E-04 6.36E-03 2.76
Tcea3 chr4:135803871-135830814 0.73 4.96 8.00E-04 2.41E-02 2.76
Gjb3 chr4:127002478-127008080 1.58 10.71 5.00E-05 2.50E-03 2.76
Morc1 chr16:48431349-48631018 0.26 1.80 3.50E-04 1.26E-02 2.77
Mt2 chr8:96696517-96697467 11.26 77.75 5.00E-05 2.50E-03 2.79
Ildr2 chr1:168184269-168246963 0.95 6.65 5.00E-05 2.50E-03 2.80
Ap1m2 chr9:21099900-21116777 0.34 2.40 1.00E-03 2.86E-02 2.80
4930500J02Rik chr2:104399333-104411586 1.92 13.64 9.00E-04 2.63E-02 2.83
Gstp2 chr19:4040287-4042221 1.62 11.68 1.30E-03 3.52E-02 2.85
Gpat2 chr2:127250934-127261949 0.40 2.88 1.50E-04 6.36E-03 2.85
B3gnt7 chr1:88199795-88203880 1.39 10.04 5.00E-05 2.50E-03 2.86
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Elf3 chr1:137150150-137155049 0.66 4.83 5.00E-05 2.50E-03 2.87
Six3os1 chr17:86001271-86017736 0.99 7.33 5.00E-05 2.50E-03 2.88
Nrcam chr12:45429871-45702833 0.66 4.91 5.00E-05 2.50E-03 2.89
Dbx1 chr7:56886868-56892205 0.51 3.88 3.00E-04 1.11E-02 2.92
D7Ertd143e chr7:3217861-3221016 0.61 4.87 5.00E-05 2.50E-03 3.01
Mpped1 chr15:83610452-83688904 0.21 1.72 5.00E-05 2.50E-03 3.01
Pcdh8 chr14:80166578-80171119 0.64 5.20 5.00E-05 2.50E-03 3.02
Sim2 chr16:94085504-94348638 0.47 3.80 5.00E-05 2.50E-03 3.02
Miat chr5:112642247-112657968 1.81 14.87 5.00E-05 2.50E-03 3.04
Nanog chr6:122657585-122664639 2.20 18.08 5.00E-05 2.50E-03 3.04
Mlxipl chr5:135582760-135614252 0.18 1.50 3.50E-04 1.26E-02 3.05
Foxb1 chr9:69605516-69608747 0.19 1.63 1.70E-03 4.33E-02 3.07
Dppa5a chr9:78214860-78216006 35.20 298.69 5.00E-05 2.50E-03 3.09
Wnt7b chr15:85365866-85424138 0.26 2.20 5.00E-05 2.50E-03 3.09
2410141K09Rik chr13:66519049-66542054 2.10 18.01 1.15E-03 3.19E-02 3.10
Wnt1 chr15:98620287-98624261 0.64 5.51 5.00E-05 2.50E-03 3.10
Fezf2 chr14:13174405-13179290 0.43 3.69 2.00E-04 7.94E-03 3.12
Gm13247 chr4:145651165-145696039 0.53 4.69 5.00E-05 2.50E-03 3.14
Nkx2-1 chr12:57632923-57637895 0.36 3.25 2.00E-04 7.94E-03 3.16
Rfx4 chr10:84218792-84369283 0.33 2.99 5.00E-05 2.50E-03 3.19
Ap3b2 chr7:88605284-88638811 0.29 2.64 5.00E-05 2.50E-03 3.20
Smc1b chr15:84895118-84962387 0.23 2.12 1.00E-04 4.56E-03 3.21
Wnt8b chr19:44567961-44590041 0.30 2.83 1.00E-04 4.56E-03 3.22
Ano9 chr7:148287117-148303705 0.31 2.86 1.00E-04 4.56E-03 3.22
Sox1 chr8:12385770-12436732 0.34 3.21 5.00E-05 2.50E-03 3.24
Tfap2c chr2:172375092-172384121 0.41 3.92 5.00E-05 2.50E-03 3.25
Gm13242 chr4:145126547-145419626 0.55 5.21 1.60E-03 4.12E-02 3.26
Zfp42 chr8:44380420-44392363 1.04 10.10 5.00E-05 2.50E-03 3.28
Esrrb chr12:87702066-87862578 0.65 6.28 5.00E-05 2.50E-03 3.28
Mcf2 chrX:57309132-57400820 0.16 1.51 1.55E-03 4.03E-02 3.28
Trap1a chrX:135774764-135892277 1.38 13.49 5.00E-05 2.50E-03 3.29
Aire chr10:77492766-77526360 0.31 3.04 5.00E-05 2.50E-03 3.29
Slc28a1 chr7:88259684-88315302 0.23 2.23 2.00E-04 7.94E-03 3.29
Esrp1 chr4:11259184-11313930 0.23 2.27 1.40E-03 3.74E-02 3.31
Pou5f1 chr17:35642976-35647722 3.87 39.95 5.00E-05 2.50E-03 3.37
Folr1 chr7:109006844-109019302 0.43 4.59 5.00E-05 2.50E-03 3.41
Gpa33 chr1:168060590-168096641 0.30 3.20 4.00E-04 1.40E-02 3.41
Sptbn2 chr19:4711222-4752352 0.39 4.13 5.00E-05 2.50E-03 3.41
Utf1 chr7:147129754-147131011 0.85 9.21 2.00E-04 7.94E-03 3.43
Alox15 chr11:70157648-70165533 0.29 3.16 1.00E-04 4.56E-03 3.45
- chr9:118308486-118313594 0.15 1.77 2.50E-04 9.49E-03 3.56
Fgf4 chr7:152047290-152051148 0.36 4.35 5.00E-05 2.50E-03 3.61
BC024139, Eppk1 chr15:75931917-75956986 0.12 1.47 2.50E-04 9.49E-03 3.62
Tdrd12 chr7:36278628-36322763 0.40 5.02 1.60E-03 4.12E-02 3.65
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AU018091 chr7:3154659-3169204 0.88 11.07 5.00E-05 2.50E-03 3.65
Gm2381 chr7:50067562-50122604 0.19 2.64 5.00E-04 1.67E-02 3.77
Gdf3 chr6:122555420-122560089 0.28 4.04 5.00E-04 1.67E-02 3.85
Tdh chr14:64111183-64127929 0.75 10.95 5.00E-05 2.50E-03 3.86
- chr13:98278330-98283216 0.11 1.78 6.50E-04 2.05E-02 4.05
4930500J02Rik chr2:104399333-104411586 0.10 1.60 9.50E-04 2.74E-02 4.06
- chr13:98252715-98274765 0.12 2.13 5.00E-05 2.50E-03 4.11
Gm10324 chr13:66214388-66223772 0.22 6.41 9.50E-04 2.74E-02 4.87
- chr15:96991387-96991826 0.00 2.55 5.00E-05 2.50E-03 Infinite
- chr7:36255279-36256279 0.00 38.35 2.00E-03 4.91E-02 Infinite
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Table A.5: Significantly overrepresented, pruned, biological process GO terms
from the differential expression analysis. Terms are sorted by ascending ad-
justed p-value and then by descending Z-score.
Ontology Name (Ontology-ID) Percent Changed Z-Score Adjusted p-value
developmental process(GO:0032502) 8.06 16.86 1.01E-02
cell adhesion(GO:0007155) 13.56 14.43 1.01E-02
regulation of developmental process(GO:0050793) 9.63 12.97 1.01E-02
regulation of cell migration(GO:0030334) 15.00 12.17 1.01E-02
regulation of response to stimulus(GO:0048583) 7.94 11.07 1.01E-02
positive regulation of biological process(GO:0048518) 6.71 11.05 1.01E-02
regulation of cell proliferation(GO:0042127) 9.29 10.83 1.01E-02
response to external stimulus(GO:0009605) 9.87 10.55 1.01E-02
negative regulation of cellular process(GO:0048523) 6.88 10.17 1.01E-02
negative regulation of locomotion(GO:0040013) 20.35 10.17 1.01E-02
locomotion(GO:0040011) 10.32 10.01 1.01E-02
regulation of transcription from RNA polymerase II promoter(GO:0006357) 8.62 9.88 1.01E-02
regulation of signaling(GO:0023051) 7.58 9.76 1.01E-02
regulation of cell adhesion(GO:0030155) 14.16 9.33 1.01E-02
tissue remodeling(GO:0048771) 22.39 8.75 1.01E-02
regulation of gamma-delta T cell activation(GO:0046643) 66.67 8.68 1.01E-02
regulation of cellular component organization(GO:0051128) 7.90 8.52 1.01E-02
regulation of cell communication(GO:0010646) 7.58 8.50 1.01E-02
JAK-STAT cascade involved in growth hormone signaling pathway(GO:0060397) 75.00 8.02 1.01E-02
enzyme linked receptor protein signaling pathway(GO:0007167) 10.86 7.98 1.01E-02
cell communication(GO:0007154) 9.53 7.67 1.01E-02
response to fluid shear stress(GO:0034405) 37.50 7.66 1.01E-02
regulation of biological quality(GO:0065008) 6.55 7.56 1.01E-02
cellular response to chemical stimulus(GO:0070887) 7.52 7.32 1.01E-02
circulatory system process(GO:0003013) 16.13 6.94 1.01E-02
immune system process(GO:0002376) 7.70 6.89 1.01E-02
negative regulation of ossification(GO:0030279) 25.93 6.58 1.01E-02
molting cycle process(GO:0022404) 17.14 6.49 1.01E-02
regulation of coagulation(GO:0050818) 19.23 6.43 1.01E-02
response to wounding(GO:0009611) 8.96 6.41 1.01E-02
Wnt receptor signaling pathway involved in somitogenesis(GO:0090244) 50.00 6.40 1.01E-02
response to endogenous stimulus(GO:0009719) 7.29 6.31 1.01E-02
peptidyl-tyrosine modification(GO:0018212) 17.46 6.30 1.01E-02
regulation of kinase activity(GO:0043549) 8.18 6.03 1.01E-02
extracellular structure organization(GO:0043062) 10.94 5.95 1.01E-02
positive regulation of molecular function(GO:0044093) 6.72 5.90 1.01E-02
cell proliferation involved in metanephros development(GO:0072203) 42.86 5.86 1.01E-02
peptide cross-linking via chondroitin 4-sulfate glycosaminoglycan(GO:0019800) 42.86 5.86 1.01E-02
regulation of apoptosis(GO:0042981) 6.46 5.81 1.01E-02
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canonical Wnt receptor signaling pathway(GO:0060070) 14.29 5.64 1.01E-02
regulation of cell division(GO:0051302) 15.07 5.63 1.01E-02
signaling(GO:0023052) 9.26 5.51 1.01E-02
regulation of bone remodeling(GO:0046850) 22.22 5.50 1.01E-02
regulation of vasodilation(GO:0042312) 21.43 5.37 1.01E-02
negative regulation of catalytic activity(GO:0043086) 7.36 5.23 1.01E-02
membrane invagination(GO:0010324) 9.28 5.18 1.01E-02
response to hypoxia(GO:0001666) 9.29 5.07 1.01E-02
locomotory behavior(GO:0007626) 10.67 5.06 1.01E-02
cell projection organization(GO:0030030) 7.48 4.88 1.01E-02
regulation of cyclic nucleotide metabolic process(GO:0030799) 10.69 4.74 1.01E-02
female pregnancy(GO:0007565) 14.81 4.74 1.01E-02
regulation of cellular component biogenesis(GO:0044087) 8.30 4.58 1.01E-02
regulation of nucleotide biosynthetic process(GO:0030808) 10.48 4.49 1.01E-02
regulation of muscle system process(GO:0090257) 11.46 4.48 1.01E-02
establishment or maintenance of cell polarity(GO:0007163) 12.68 4.43 1.01E-02
response to pain(GO:0048265) 18.52 4.43 1.01E-02
regulation of actin filament-based process(GO:0032970) 9.86 4.39 1.01E-02
non-canonical Wnt receptor signaling pathway(GO:0035567) 17.24 4.20 1.01E-02
second-messenger-mediated signaling(GO:0019932) 8.59 4.18 1.01E-02
actin filament-based process(GO:0030029) 7.81 4.16 1.01E-02
regulation of binding(GO:0051098) 9.04 4.15 1.01E-02
regulation of calcium ion transport(GO:0051924) 9.63 4.13 1.01E-02
response to growth factor stimulus(GO:0070848) 10.00 4.12 1.01E-02
ossification(GO:0001503) 9.71 3.65 1.01E-02
response to molecule of bacterial origin(GO:0002237) 7.49 3.55 1.01E-02
secretion(GO:0046903) 6.77 3.53 1.01E-02
response to ethanol(GO:0045471) 9.09 3.41 1.01E-02
polyol transport(GO:0015791) 37.50 5.41 1.83E-02
regulation of calcium ion-dependent exocytosis(GO:0017158) 20.00 4.67 1.83E-02
regulation of leukocyte mediated cytotoxicity(GO:0001910) 14.29 3.99 1.83E-02
Ras protein signal transduction(GO:0007265) 10.47 3.72 1.83E-02
regulation of leukocyte mediated immunity(GO:0002703) 9.90 3.72 1.83E-02
proteoglycan metabolic process(GO:0006029) 20.00 4.67 2.56E-02
fluid transport(GO:0042044) 20.00 4.18 2.56E-02
vesicle fusion(GO:0006906) 20.00 4.18 2.56E-02
coagulation(GO:0050817) 11.67 3.63 2.56E-02
protein processing(GO:0016485) 10.53 3.53 2.56E-02
transcription from RNA polymerase II promoter(GO:0006366) 8.33 3.24 2.56E-02
luteinization(GO:0001553) 37.50 5.41 3.26E-02
serotonin transport(GO:0006837) 33.33 5.04 3.26E-02
sexual reproduction(GO:0019953) 30.00 4.72 3.26E-02
MAPKKK cascade(GO:0000165) 8.91 3.16 3.26E-02
regulation of establishment or maintenance of cell polarity(GO:0032878) 37.50 5.41 3.90E-02
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succinate metabolic process(GO:0006105) 30.00 4.72 3.90E-02
nitric oxide mediated signal transduction(GO:0007263) 27.27 4.45 3.90E-02
response to X-ray(GO:0010165) 16.00 3.55 3.90E-02
lipid localization(GO:0010876) 21.05 4.33 4.50E-02
peptidyl-tyrosine dephosphorylation(GO:0035335) 12.50 3.57 4.50E-02
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Table A.6: Significantly overrepresented, pruned, cellular component GO terms
from the differential expression analysis. Terms are sorted by ascending ad-
justed p-value and then by descending Z-score.
Ontology Name(Ontology-ID) Percent Changed Z-Score Adjusted p-value
extracellular region part(GO:0044421) 9.31 11.34 1.01E-02
plasma membrane part(GO:0044459) 7.58 11.03 1.01E-02
cell surface(GO:0009986) 13.41 10.80 1.01E-02
plasma membrane(GO:0005886) 6.61 10.59 1.01E-02
neuron projection(GO:0043005) 9.38 8.04 1.01E-02
dendrite terminus(GO:0044292) 75.00 8.02 1.01E-02
extracellular region(GO:0005576) 6.71 7.74 1.01E-02
membrane raft(GO:0045121) 10.14 5.54 1.01E-02
cell periphery(GO:0071944) 21.74 4.95 1.01E-02
extrinsic to membrane(GO:0019898) 10.92 4.67 1.01E-02
transport vesicle(GO:0030133) 14.29 4.60 1.01E-02
secretory granule membrane(GO:0030667) 15.56 4.60 1.01E-02
apical part of cell(GO:0045177) 12.05 4.47 1.01E-02
axon part(GO:0033267) 9.68 4.46 1.01E-02
cell fraction(GO:0000267) 5.48 4.30 1.01E-02
synapse(GO:0045202) 7.28 4.25 1.01E-02
synapse part(GO:0044456) 6.95 3.99 1.01E-02
perinuclear region of cytoplasm(GO:0048471) 6.68 3.91 1.01E-02
uropod(GO:0001931) 42.86 5.86 1.83E-02
transcription factor complex(GO:0005667) 6.33 3.03 1.83E-02
cell cortex part(GO:0044448) 9.52 3.20 3.26E-02
cell body(GO:0044297) 6.27 3.06 3.90E-02
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Table A.7: Significantly overrepresented, pruned, molecular function GO terms
from the differential expression analysis. Terms are sorted by ascending ad-
justed p-value and then by descending Z-score.
Ontology Name(Ontology-ID) Percent Changed Z-Score Adjusted p-value
protein binding(GO:0005515) 4.93 11.59 1.01E-02
pattern binding(GO:0001871) 18.07 10.69 1.01E-02
calcium ion binding(GO:0005509) 10.87 10.52 1.01E-02
extracellular matrix binding(GO:0050840) 28.95 8.85 1.01E-02
RNA polymerase II regulatory region sequence-specific DNA binding(GO:0000977) 22.22 8.41 1.01E-02
Wnt receptor activity(GO:0042813) 35.00 7.93 1.01E-02
chemorepellent activity(GO:0045499) 60.00 7.09 1.01E-02
retinoic acid binding(GO:0001972) 44.44 6.91 1.01E-02
transmembrane receptor protein kinase activity(GO:0019199) 16.67 6.87 1.01E-02
icosanoid binding(GO:0050542) 50.00 6.40 1.01E-02
sequence-specific DNA binding transcription factor activity(GO:0003700) 7.20 6.38 1.01E-02
inorganic anion exchanger activity(GO:0005452) 33.33 5.82 1.01E-02
core promoter sequence-specific DNA binding(GO:0001046) 23.08 5.64 1.01E-02
chromatin binding(GO:0003682) 9.16 5.23 1.01E-02
enhancer sequence-specific DNA binding(GO:0001158) 23.81 5.26 1.83E-02
scavenger receptor activity(GO:0005044) 14.29 3.99 1.83E-02
miRNA binding(GO:0035198) 42.86 5.86 2.56E-02
receptor signaling protein activity(GO:0005057) 10.26 3.44 2.56E-02
protein tyrosine phosphatase activity(GO:0004725) 9.28 3.30 2.56E-02
water channel activity(GO:0015250) 27.27 4.45 3.26E-02
protein serine/threonine kinase activity(GO:0004674) 5.54 2.95 3.90E-02
GTPase regulator activity(GO:0030695) 5.76 2.83 3.90E-02
axon guidance receptor activity(GO:0008046) 37.50 5.41 4.50E-02
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Table A.8: Significantly overrepresented, pruned, biological process GO terms
from the genes upregulated in the endocardium. Terms are sorted by ascending
adjusted p-value and then by descending Z-score.
Ontology Name (Ontology-ID) Percent Changed Z-Score Adjusted p-value
regulation of erythrocyte differentiation(GO:0045646) 32.26 14.55 1.20E-02
regulation of mast cell differentiation(GO:0060375) 100.00 14.46 1.20E-02
endothelial cell differentiation(GO:0045446) 55.56 13.75 1.20E-02
regulation of gamma-delta T cell activation(GO:0046643) 66.67 13.53 1.20E-02
angiogenesis(GO:0001525) 12.90 13.33 1.20E-02
JAK-STAT cascade involved in growth hormone signaling pathway(GO:0060397) 75.00 12.46 1.20E-02
regulation of cell motility(GO:2000145) 9.07 12.28 1.20E-02
response to fluid shear stress(GO:0034405) 37.50 12.22 1.20E-02
regulation of angiogenesis(GO:0045765) 13.64 11.93 1.20E-02
hemopoiesis(GO:0030097) 15.79 11.89 1.20E-02
negative regulation of protein autophosphorylation(GO:0031953) 50.00 11.64 1.20E-02
regulation of response to stimulus(GO:0048583) 4.57 11.40 1.20E-02
granulocyte differentiation(GO:0030851) 38.46 11.31 1.20E-02
platelet formation(GO:0030220) 44.44 10.93 1.20E-02
vasculogenesis(GO:0001570) 16.44 10.89 1.20E-02
negative regulation of endothelial cell proliferation(GO:0001937) 28.57 10.54 1.20E-02
positive regulation of myeloid cell differentiation(GO:0045639) 16.95 10.12 1.20E-02
positive regulation of cellular component movement(GO:0051272) 9.01 9.63 1.20E-02
tissue remodeling(GO:0048771) 14.93 9.38 1.20E-02
megakaryocyte differentiation(GO:0030219) 42.86 9.28 1.20E-02
germinal center formation(GO:0002467) 42.86 9.28 1.20E-02
positive regulation of metabolic process(GO:0009893) 4.01 9.00 1.20E-02
anatomical structure morphogenesis(GO:0009653) 4.44 8.76 1.20E-02
peptidyl-tyrosine phosphorylation(GO:0018108) 14.29 8.66 1.20E-02
Peyer’s patch development(GO:0048541) 37.50 8.64 1.20E-02
regulation of establishment or maintenance of cell polarity(GO:0032878) 37.50 8.64 1.20E-02
luteinization(GO:0001553) 37.50 8.64 1.20E-02
positive regulation of catalytic activity(GO:0043085) 5.03 8.47 1.20E-02
positive regulation of B cell activation(GO:0050871) 15.09 8.44 1.20E-02
positive regulation of cell proliferation(GO:0008284) 5.34 8.14 1.20E-02
serotonin transport(GO:0006837) 33.33 8.11 1.20E-02
citrulline metabolic process(GO:0000052) 33.33 8.11 1.20E-02
negative regulation of coagulation(GO:0050819) 20.83 8.06 1.20E-02
cellular response to drug(GO:0035690) 25.00 7.99 1.20E-02
transforming growth factor beta receptor signaling pathway(GO:0007179) 13.11 7.75 1.20E-02
regulation of biological quality(GO:0065008) 3.59 7.66 1.20E-02
sexual reproduction(GO:0019953) 30.00 7.65 1.20E-02
succinate metabolic process(GO:0006105) 30.00 7.65 1.20E-02
natural killer cell differentiation(GO:0001779) 30.00 7.65 1.20E-02
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circulatory system process(GO:0003013) 10.75 7.64 1.20E-02
positive regulation of vasoconstriction(GO:0045907) 18.52 7.53 1.20E-02
negative regulation of ossification(GO:0030279) 18.52 7.53 1.20E-02
positive regulation of cell communication(GO:0010647) 4.87 7.51 1.20E-02
positive regulation of signaling(GO:0023056) 4.81 7.43 1.20E-02
lipid storage(GO:0019915) 21.05 7.25 1.20E-02
response to retinoic acid(GO:0032526) 10.59 7.18 1.20E-02
regulation of cellular component organization(GO:0051128) 3.95 7.11 1.20E-02
negative regulation of myeloid leukocyte differentiation(GO:0002762) 16.67 7.08 1.20E-02
regulation of nucleotide biosynthetic process(GO:0030808) 8.87 7.05 1.20E-02
vesicle fusion(GO:0006906) 20.00 7.04 1.20E-02
phagocytosis(GO:0006909) 13.95 6.97 1.20E-02
small GTPase mediated signal transduction(GO:0007264) 6.21 6.96 1.20E-02
gland development(GO:0048732) 8.66 6.94 1.20E-02
arginine metabolic process(GO:0006525) 25.00 6.92 1.20E-02
regulation of muscle system process(GO:0090257) 9.38 6.62 1.20E-02
regulation of cell adhesion(GO:0030155) 6.44 6.53 1.20E-02
regulation of survival gene product expression(GO:0045884) 17.39 6.49 1.20E-02
endoderm formation(GO:0001706) 21.43 6.34 1.20E-02
regulation of tissue remodeling(GO:0034103) 13.51 6.24 1.20E-02
blood vessel development(GO:0001568) 9.09 6.11 1.20E-02
erythrocyte development(GO:0048821) 20.00 6.10 1.20E-02
female pregnancy(GO:0007565) 11.11 6.04 1.20E-02
response to estrogen stimulus(GO:0043627) 6.67 5.99 1.20E-02
regulation of fat cell differentiation(GO:0045598) 10.91 5.97 1.20E-02
vasculature development(GO:0001944) 12.50 5.94 1.20E-02
leukocyte migration(GO:0050900) 8.70 5.93 1.20E-02
negative regulation of peptidyl-tyrosine phosphorylation(GO:0050732) 18.75 5.87 1.20E-02
negative regulation of striated muscle tissue development(GO:0045843) 18.75 5.87 1.20E-02
wound healing(GO:0042060) 9.33 5.82 1.20E-02
regulation of vasodilation(GO:0042312) 14.29 5.77 1.20E-02
inner ear development(GO:0048839) 10.34 5.77 1.20E-02
heart development(GO:0007507) 6.32 5.75 1.20E-02
cell adhesion(GO:0007155) 4.08 5.68 1.20E-02
cardiac cell differentiation(GO:0035051) 11.36 5.59 1.20E-02
second-messenger-mediated signaling(GO:0019932) 6.06 5.56 1.20E-02
response to hypoxia(GO:0001666) 5.75 5.55 1.20E-02
MAPKKK cascade(GO:0000165) 7.92 5.55 1.20E-02
erythrocyte differentiation(GO:0030218) 11.11 5.51 1.20E-02
B cell differentiation(GO:0030183) 11.11 5.51 1.20E-02
regulation of caspase activity(GO:0043281) 6.71 5.49 1.20E-02
receptor-mediated endocytosis(GO:0006898) 9.52 5.46 1.20E-02
regulation of ion homeostasis(GO:2000021) 7.69 5.43 1.20E-02
transmembrane receptor protein tyrosine kinase signaling pathway(GO:0007169) 5.46 5.32 1.20E-02
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SMAD protein signal transduction(GO:0060395) 15.79 5.31 1.20E-02
embryo development(GO:0009790) 4.82 5.30 1.20E-02
positive regulation of transport(GO:0051050) 4.38 5.29 1.20E-02
transcription from RNA polymerase II promoter(GO:0006366) 6.82 5.27 1.20E-02
regulation of calcium ion transport(GO:0051924) 6.67 5.18 1.20E-02
embryonic heart tube development(GO:0035050) 15.00 5.15 1.20E-02
negative regulation of transcription from RNA polymerase II promoter(GO:0000122) 4.13 5.13 1.20E-02
positive regulation of mitotic cell cycle(GO:0045931) 11.76 5.11 1.20E-02
regulation of binding(GO:0051098) 6.02 5.05 1.20E-02
regulation of bone mineralization(GO:0030500) 9.62 5.01 1.20E-02
regulation of actin filament-based process(GO:0032970) 6.34 4.98 1.20E-02
cellular response to lipopolysaccharide(GO:0071222) 8.22 4.93 1.20E-02
negative regulation of signaling(GO:0023057) 4.02 4.85 1.20E-02
negative regulation of cell communication(GO:0010648) 4.01 4.84 1.20E-02
actin filament-based process(GO:0030029) 4.83 4.78 1.20E-02
positive regulation of immune effector process(GO:0002699) 6.86 4.67 1.20E-02
divalent metal ion transport(GO:0070838) 5.07 4.58 1.20E-02
response to mechanical stimulus(GO:0009612) 6.11 4.56 1.20E-02
regulation of cytokine production(GO:0001817) 4.35 4.33 1.20E-02
regulation of cellular component biogenesis(GO:0044087) 4.53 4.32 1.20E-02
positive regulation of apoptosis(GO:0043065) 3.62 4.09 1.20E-02
developmental maturation(GO:0021700) 5.74 4.05 1.20E-02
response to metal ion(GO:0010038) 4.40 4.02 1.20E-02
aging(GO:0007568) 4.89 4.01 1.20E-02
tissue development(GO:0009888) 3.52 3.97 1.20E-02
secretion(GO:0046903) 3.69 3.51 1.20E-02
lymph vessel development(GO:0001945) 27.27 7.26 2.18E-02
phagocytosis & engulfment(GO:0006911) 21.43 6.34 2.18E-02
negative regulation of epithelial cell differentiation(GO:0030857) 18.75 5.87 2.18E-02
cAMP biosynthetic process(GO:0006171) 18.75 5.87 2.18E-02
regulation of cyclase activity(GO:0031279) 6.82 4.30 2.18E-02
regulation of multicellular organism growth(GO:0040014) 7.46 4.20 2.18E-02
regulation of lyase activity(GO:0051339) 6.59 4.19 2.18E-02
positive regulation of neurogenesis(GO:0050769) 5.51 3.92 2.18E-02
regulation of protein transport(GO:0051223) 4.02 3.32 2.18E-02
cell proliferation(GO:0008283) 3.29 3.06 2.18E-02
regulation of endothelial cell differentiation(GO:0045601) 21.43 6.34 3.09E-02
cell fate determination(GO:0001709) 12.50 5.31 3.09E-02
hemopoietic progenitor cell differentiation(GO:0002244) 12.00 4.48 3.09E-02
regulation of leukocyte mediated immunity(GO:0002703) 5.94 3.86 3.09E-02
cell fate commitment(GO:0045165) 5.26 3.49 3.09E-02
neuron differentiation(GO:0030182) 4.26 3.31 3.09E-02
signaling(GO:0023052) 3.70 3.21 3.09E-02
osteoclast differentiation(GO:0030316) 15.00 5.15 3.89E-02
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regulation of alpha-beta T cell activation(GO:0046634) 8.77 4.71 3.89E-02
cellular response to hydrogen peroxide(GO:0070301) 10.26 4.68 3.89E-02
myeloid leukocyte activation(GO:0002274) 8.20 4.49 3.89E-02
membrane docking(GO:0022406) 11.11 4.27 3.89E-02
peptidyl-tyrosine dephosphorylation(GO:0035335) 8.33 4.06 3.89E-02
regulation of intracellular transport(GO:0032386) 4.90 3.54 3.89E-02
cellular response to hormone stimulus(GO:0032870) 3.68 3.18 3.89E-02
glutamine family amino acid catabolic process(GO:0009065) 17.65 5.67 4.66E-02
response to ethanol(GO:0045471) 5.45 3.60 4.66E-02
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Table A.9: Significantly overrepresented, pruned, cellular component GO terms
from the genes upregulated in the endocardium. Terms are sorted by ascending
adjusted p-value and then by descending Z-score.
Ontology Name (Ontology-ID) Percent Changed Z-Score Adjusted p-value
plasma membrane(GO:0005886) 3.25 8.90 1.20E-02
cell periphery(GO:0071944) 21.74 8.26 1.20E-02
cell surface(GO:0009986) 6.15 7.65 1.20E-02
plasma membrane part(GO:0044459) 3.24 7.12 1.20E-02
acrosomal membrane(GO:0002080) 25.00 6.92 1.20E-02
transport vesicle(GO:0030133) 10.71 5.90 1.20E-02
extracellular region part(GO:0044421) 3.26 5.26 1.20E-02
cell projection(GO:0042995) 3.21 5.01 1.20E-02
cell fraction(GO:0000267) 2.66 3.70 1.20E-02
intrinsic to Golgi membrane(GO:0031228) 11.11 4.93 2.18E-02
extrinsic to membrane(GO:0019898) 5.88 4.14 2.18E-02
Golgi membrane(GO:0000139) 3.12 2.86 3.89E-02
cell cortex part(GO:0044448) 5.95 3.53 4.66E-02
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Table A.10: Significantly overrepresented, pruned, molecular function GO
terms from the genes upregulated in the endocardium. Terms are sorted by
ascending adjusted p-value and then by descending Z-score.
Ontology Name (Ontology-ID) Percent Changed Z-Score Adjusted p-value
RNA polymerase II regulatory region sequence-specific DNA binding(GO:0000977) 15.87 9.73 1.20E-02
protein binding(GO:0005515) 2.32 9.73 1.20E-02
pattern binding(GO:0001871) 7.23 6.37 1.20E-02
calcium ion binding(GO:0005509) 4.35 6.17 1.20E-02
core promoter sequence-specific DNA binding(GO:0001046) 15.38 6.03 1.20E-02
sequence-specific DNA binding transcription factor activity(GO:0003700) 3.54 5.26 1.20E-02
guanyl-nucleotide exchange factor activity(GO:0005085) 6.33 5.25 1.20E-02
enzyme activator activity(GO:0008047) 4.49 4.80 1.20E-02
chromatin binding(GO:0003682) 4.38 4.01 1.20E-02
receptor signaling protein activity(GO:0005057) 6.41 3.74 1.20E-02
vascular endothelial growth factor receptor activity(GO:0005021) 37.50 8.64 2.18E-02
hydrolase activity & acting on carbon-nitrogen (but not peptide) bonds & in linear amidines(GO:0016813) 27.27 7.26 2.18E-02
sialyltransferase activity(GO:0008373) 15.79 5.31 3.09E-02
cAMP binding(GO:0030552) 16.67 5.48 3.89E-02
protein tyrosine phosphatase activity(GO:0004725) 6.19 3.99 3.89E-02
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Table A.11: Significantly overrepresented, pruned, biological process GO terms
from the genes upregulated in the endothelium. Terms are sorted by ascending
adjusted p-value and then by descending Z-score.
Ontology Name(Ontology-ID) Percent Changed Z-Score Adjusted p-value
cell-cell adhesion(GO:0016337) 14.44 15.26 2.07E-02
anatomical structure development(GO:0048856) 5.84 13.59 2.07E-02
embryonic pattern specification(GO:0009880) 25.49 12.40 2.07E-02
forebrain anterior/posterior pattern formation(GO:0021797) 66.67 11.66 2.07E-02
anatomical structure morphogenesis(GO:0009653) 6.52 11.65 2.07E-02
axon guidance(GO:0007411) 15.75 11.51 2.07E-02
axis specification(GO:0009798) 20.00 11.15 2.07E-02
multicellular organismal development(GO:0007275) 6.83 11.02 2.07E-02
tube formation(GO:0035148) 16.16 10.46 2.07E-02
cellular developmental process(GO:0048869) 4.87 9.78 2.07E-02
negative regulation of cell differentiation(GO:0045596) 8.13 8.89 2.07E-02
Wnt receptor signaling pathway involved in somitogenesis(GO:0090244) 50.00 8.66 2.07E-02
response to vitamin(GO:0033273) 10.39 7.78 2.07E-02
regulation of nervous system development(GO:0051960) 6.82 7.68 2.07E-02
hair cycle process(GO:0022405) 14.29 7.63 2.07E-02
regulation of transcription from RNA polymerase II promoter(GO:0006357) 4.98 7.55 2.07E-02
cell migration(GO:0016477) 6.70 7.44 2.07E-02
positive regulation of fat cell differentiation(GO:0045600) 23.81 7.38 2.07E-02
negative chemotaxis(GO:0050919) 28.57 7.34 2.07E-02
regulation of cell fate commitment(GO:0010453) 22.73 7.18 2.07E-02
primitive streak formation(GO:0090009) 33.33 6.93 2.07E-02
development of primary sexual characteristics(GO:0045137) 33.33 6.93 2.07E-02
cell communication(GO:0007154) 6.14 6.88 2.07E-02
cellular component maintenance(GO:0043954) 17.65 6.76 2.07E-02
extracellular structure organization(GO:0043062) 8.33 6.59 2.07E-02
regulation of cell adhesion(GO:0030155) 7.73 6.58 2.07E-02
regulation of embryonic development(GO:0045995) 12.33 6.57 2.07E-02
mammary gland involution(GO:0060056) 30.00 6.53 2.07E-02
negative regulation of JUN kinase activity(GO:0043508) 30.00 6.53 2.07E-02
regulation of cell proliferation(GO:0042127) 4.55 6.31 2.07E-02
neg. reg. of TM receptor protein Ser/Thr kinase signaling pathway(GO:0090101) 12.50 6.25 2.07E-02
dorsal/ventral pattern formation(GO:0009953) 12.31 6.18 2.07E-02
positive regulation of Notch signaling pathway(GO:0045747) 21.05 6.14 2.07E-02
positive regulation of transcription & DNA-dependent(GO:0045893) 4.57 6.11 2.07E-02
segmentation(GO:0035282) 13.21 6.06 2.07E-02
regulation of smoothened signaling pathway(GO:0008589) 14.63 6.00 2.07E-02
regulation of Wnt receptor signaling pathway(GO:0030111) 8.00 5.52 2.07E-02
regulation of cell migration(GO:0030334) 5.88 5.46 2.07E-02
negative regulation of locomotion(GO:0040013) 8.85 5.45 2.07E-02
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regulation of calcium ion-dependent exocytosis(GO:0017158) 16.00 5.19 2.07E-02
canonical Wnt receptor signaling pathway(GO:0060070) 9.52 5.15 2.07E-02
negative regulation of transcription & DNA-dependent(GO:0045892) 4.38 5.12 2.07E-02
developmental growth involved in morphogenesis(GO:0060560) 11.32 5.05 2.07E-02
establishment or maintenance of cell polarity(GO:0007163) 9.86 4.94 2.07E-02
cell proliferation(GO:0008283) 5.21 4.70 2.07E-02
locomotory behavior(GO:0007626) 6.67 4.32 2.07E-02
response to endogenous stimulus(GO:0009719) 3.91 4.19 2.07E-02
cellular response to chemical stimulus(GO:0070887) 3.70 4.14 2.07E-02
response to wounding(GO:0009611) 4.48 3.85 2.07E-02
sensory perception of sound(GO:0007605) 7.14 3.83 2.07E-02
embryo development(GO:0009790) 4.52 3.55 2.07E-02
cellular process involved in reproduction(GO:0048610) 4.82 3.42 2.07E-02
regulation of biological quality(GO:0065008) 2.96 3.28 2.07E-02
detection of mechanical stimulus involved in sensory perception of sound(GO:0050910) 25.00 5.88 3.84E-02
regulation of cell division(GO:0051302) 8.22 3.98 3.84E-02
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Table A.12: Significantly overrepresented, pruned, cellular component GO
terms from the genes upregulated in the endothelium. Terms are sorted by
ascending adjusted p-value and then by descending Z-score.
Ontology Name(Ontology-ID) Percent Changed Z-Score Adjusted p-value
extracellular matrix(GO:0031012) 9.94 10.87 2.07E-02
cell-cell junction(GO:0005911) 9.06 8.63 2.07E-02
extracellular region(GO:0005576) 4.67 8.30 2.07E-02
fibrillar collagen(GO:0005583) 33.33 8.00 2.07E-02
extracellular space(GO:0005615) 5.60 7.80 2.07E-02
cell surface(GO:0009986) 7.26 7.54 2.07E-02
lateral plasma membrane(GO:0016328) 20.69 7.44 2.07E-02
axon(GO:0030424) 8.37 6.82 2.07E-02
apical plasma membrane(GO:0016324) 7.73 6.40 2.07E-02
plasma membrane(GO:0005886) 3.36 6.18 2.07E-02
intrinsic to plasma membrane(GO:0031226) 5.34 5.67 2.07E-02
dendrite(GO:0030425) 6.51 5.53 2.07E-02
anchoring junction(GO:0070161) 7.11 5.41 2.07E-02
basement membrane(GO:0005604) 9.64 5.20 2.07E-02
cell projection part(GO:0044463) 4.72 4.95 2.07E-02
site of polarized growth(GO:0030427) 8.51 4.73 2.07E-02
synapse(GO:0045202) 5.04 4.42 2.07E-02
filopodium(GO:0030175) 10.64 4.41 2.07E-02
basolateral plasma membrane(GO:0016323) 6.71 4.34 2.07E-02
synapse part(GO:0044456) 4.28 3.43 2.07E-02
perinuclear region of cytoplasm(GO:0048471) 4.06 3.30 2.07E-02
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Table A.13: Significantly overrepresented, pruned, molecular function GO
terms from the genes upregulated in the endothelium. Terms are sorted by
ascending adjusted p-value and then by descending Z-score.
Ontology Name(Ontology-ID) Percent Changed Z-Score Adjusted p-value
chemorepellent activity(GO:0045499) 60.00 9.55 2.07E-02
extracellular matrix binding(GO:0050840) 21.05 8.69 2.07E-02
transmembrane-ephrin receptor activity(GO:0005005) 50.00 8.66 2.07E-02
pattern binding(GO:0001871) 10.84 8.51 2.07E-02
calcium ion binding(GO:0005509) 6.52 8.46 2.07E-02
inorganic anion exchanger activity(GO:0005452) 33.33 8.00 2.07E-02
Wnt receptor activity(GO:0042813) 25.00 7.60 2.07E-02
axon guidance receptor activity(GO:0008046) 37.50 7.40 2.07E-02
heparan sulfate proteoglycan binding(GO:0043395) 28.57 7.34 2.07E-02
Wnt-protein binding(GO:0017147) 20.00 6.66 2.07E-02
PDZ domain binding(GO:0030165) 7.92 4.47 2.07E-02
sequence-specific DNA binding RNA polymerase II transcription factor activity(GO:0000981) 6.36 4.34 2.07E-02
receptor binding(GO:0005102) 3.23 3.33 2.07E-02
identical protein binding(GO:0042802) 3.27 3.05 2.07E-02
growth factor binding(GO:0019838) 7.14 4.10 3.84E-02
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A.6 TF Distribution near Transcription Start Sites
308
Figure A.1: Distribution of transcription factors Nrsf and Srf in the vicinity of TSS. Plots
produced with publicly available data. The x axis denotes distance from the TSS and the
y peak density.
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Figure A.2: Distribution of transcription factors Max and Mxi1 in the vicinity of TSS.
Plots produced with publicly available data. The x axis denotes distance from the TSS
and the y peak density.
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Figure A.3: Distribution of transcription factors Nrf2 and Tal1 in the vicinity of TSS.
Plots produced with publicly available data. The x axis denotes distance from the TSS
and the y peak density.
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Figure A.4: Distribution of transcription factors Tcf3 and Tcf12 in the vicinity of TSS.
Plots produced with publicly available data. The x axis denotes distance from the TSS
and the y peak density.
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Figure A.5: Distribution of transcription factor Usf1 in the vicinity of TSS. Plots produced
with publicly available data. The x axis denotes distance from the TSS and the y peak
density.
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A.7 Overlap of Differentially Methylated Genomic Regions
and Differentially Expressed Genes
314
Table A.14: Overlap of Differentially Methylated Genomic Regions and Differ-
entially Expressed Genes
CGI Locus EC CGI methylation Gene Locus Gene Name log2(FC) in EC
chr2:152896544-152896824 hyper chr2:152891690-152907471 Ccm2l 3.05366
chr7:117952877-117953693 hyper chr7:117994120-118006467 Lyve1 2.86907
chr7:52887987-52888323 hyper chr7:52882906-52894462 Rasip1 2.76976
chr11:96440246-96440681 hyper chr11:96325904-96620936 Skap1 2.7605
chr11:96338361-96338945 hyper chr11:96325904-96620936 Skap1 2.7605
chr8:73928811-73929522 hyper chr8:73908172-73919704 Ushbp1 2.66224
chr4:118108001-118108883 hyper chr4:118143795-118162454 Tie1 2.61175
chr4:118190073-118190950 hyper chr4:118143795-118162454 Tie1 2.61175
chr10:74816185-74817404 hypo chr10:74779687-74797533 Adora2a 2.33696
chr4:114751244-114752324 hyper chr4:114729365-114744360 Tal1 2.30528
chr10:87323389-87323840 hyper chr10:87321800-87399792 Igf1 2.25402
chr4:114751244-114752324 hyper chr4:114729365-114744360 Tal1 2.24749
chr11:70028833-70029223 hyper chr11:70037628-70043300 Bcl6b 2.23097
chr4:114751244-114752324 hyper chr4:114729365-114744360 Tal1 2.22898
chr2:103843358-103843795 hyper chr2:103798151-103822035 Lmo2 2.11793
chr11:49403109-49403751 hyper chr11:49423180-49466241 Flt4 2.06644
chr6:88154810-88156434 hyper chr6:88148657-88157026 Gata2 2.03072
chr19:37507291-37507847 hyper chr19:37509330-37515221 Hhex 1.90728
chr5:150057323-150058420 hypo chr5:150076633-150099623 Alox5ap 1.83045
chr12:112661520-112662384 hyper chr12:112680871-112693229 Tnfaip2 1.71677
chr2:103843358-103843795 hyper chr2:103798151-103822035 Lmo2 1.71509
chr6:115912422-115912546 hyper chr6:115904828-115945023 Plxnd1 1.6793
chr8:107860607-107860809 hyper chr8:107813823-107820136 Exoc3l 1.677
chr12:74894209-74894870 hyper chr12:74686027-74879171 Prkch 1.64118
chr3:79683120-79683489 hyper chr3:79689851-79750200 Fam198b 1.60056
chr14:56380507-56380930 hyper chr14:56387928-56402856 Adcy4 1.59697
chr14:56434090-56434667 hyper chr14:56387928-56402856 Adcy4 1.59697
chr7:31250804-31251368 hyper chr7:31198806-31202598 Tyrobp 1.55592
chr16:92475463-92476098 hyper chr16:92498391-92541486 Clic6 1.5264
chr16:92468411-92468768 hyper chr16:92498391-92541486 Clic6 1.5264
chr7:20055181-20055460 hyper chr7:20080256-20082313 - 1.52238
chr18:61228464-61228781 hyper chr18:61265225-61290793 Csf1r 1.3623
chr18:61225022-61225835 hyper chr18:61265225-61290793 Csf1r 1.3623
chr1:187308178-187308821 hyper chr1:187270994-187292640 Slc30a10 1.30679
chr14:55330531-55330769 hyper chr14:55341051-55400723 Slc7a8 1.14997
chr5:36083518-36083985 hyper chr5:36039828-36071925 Sh3tc1 1.10348
chr19:37765321-37765560 hyper chr19:37624907-37758502 Exoc6 1.09551
chr19:37762177-37762475 hyper chr19:37624907-37758502 Exoc6 1.09551
chr7:105313648-105314322 hyper chr7:105270074-105333309 Capn5 1.07571
chr7:105313648-105314322 hyper chr7:105199563-105268003 Myo7a 1.06466
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chr5:122278315-122278607 hyper chr5:122265469-122286810 Sh2b3 1.06012
chr6:142845417-142846067 hyper chr6:142762750-142912972 St8sia1 1.03431
chr8:124859685-124859999 hyper chr8:124806040-124861147 Zfpm1 1.03023
chr8:124793057-124793175 hyper chr8:124806040-124861147 Zfpm1 1.03023
chr8:124860571-124861615 hyper chr8:124806040-124861147 Zfpm1 1.03023
chr8:124820289-124820793 hypo chr8:124806040-124861147 Zfpm1 1.03023
chr8:124849801-124850807 hypo chr8:124806040-124861147 Zfpm1 1.03023
chr8:124845529-124845986 hypo chr8:124806040-124861147 Zfpm1 1.03023
chr2:158625885-158627235 hyper chr2:158492468-158592070 Ppp1r16b 1.00864
chr15:80416857-80417546 hyper chr15:80453912-80483450 Grap2 1.00605
chr1:167565599-167566481 hyper chr1:167579075-167638225 Rcsd1 0.943436
chr8:108090552-108090881 hyper chr8:108129128-108146118 Fam65a 0.881099
chr11:106468008-106468818 hyper chr11:106515531-106585695 Pecam1 0.881004
chr19:37765321-37765560 hyper chr19:37772297-37776026 Cyp26a1 0.848688
chr19:37762177-37762475 hyper chr19:37772297-37776026 Cyp26a1 0.848688
chr19:37814091-37814949 hypo chr19:37772297-37776026 Cyp26a1 0.848688
chr7:104473728-104473923 hyper chr7:104230260-104457461 Gab2 0.790224
chr5:117627706-117628918 hyper chr5:117570137-117725107 Taok3 0.747814
chr5:117690695-117691301 hyper chr5:117570137-117725107 Taok3 0.747814
chr12:113027316-113027845 hyper chr12:113066668-113146266 Ppp1r13b 0.729111
chr19:5751116-5751276 hyper chr19:5707373-5726317 Ehbp1l1 0.716896
chr7:86503189-86504238 hypo chr7:86537223-86611159 Polg 0.662579
chr11:100819860-100820506 hyper chr11:100748123-100800825 Stat3 0.65769
chr5:129099014-129099686 hyper chr5:129106980-129109968 Fzd10 0.654989
chr19:5751116-5751276 hyper chr19:5689130-5702864 Map3k11 0.640204
chr19:57064818-57065598 hyper chr19:57107753-57290522 Ablim1 0.614848
chr19:57216314-57217562 hyper chr19:57107753-57290522 Ablim1 0.614848
chr13:38033390-38033995 hyper chr13:37917906-38043929 Rreb1 0.614741
chr13:38022600-38023145 hyper chr13:37917906-38043929 Rreb1 0.614741
chr7:26430147-26430915 hyper chr7:26472020-26490015 Tgfb1 0.601568
chr7:26489381-26490333 hyper chr7:26472020-26490015 Tgfb1 0.601568
chr9:63801417-63801870 hyper chr9:63800882-63869866 Smad6 0.58375
chr9:63775068-63775725 hyper chr9:63800882-63869866 Smad6 0.58375
chr9:63766729-63767498 hypo chr9:63800882-63869866 Smad6 0.58375
chr11:100819860-100820506 hyper chr11:100818050-100831931 Ptrf 0.57786
chr4:131478296-131478516 hyper chr4:131477064-131631228 Epb4.1 0.550298
chr17:35154731-35154891 hyper chr17:35195979-35199044 Ddah2 0.546457
chr17:6940931-6941564 hyper chr17:6942479-6987129 Ezr -0.502139
chr17:6988252-6988957 hyper chr17:6942479-6987129 Ezr -0.502139
chr8:46136332-46136765 hyper chr8:46020611-46137611 Fat1 -0.540317
chr4:136312041-136312761 hyper chr4:136203513-136391850 Ephb2 -0.578212
chr7:56887804-56888417 hyper chr7:56214442-56865458 Nav2 -0.614748
chr4:129807866-129808438 hyper chr4:129842843-129852366 Tinagl1 -0.622873
chr4:129825701-129826354 hyper chr4:129842843-129852366 Tinagl1 -0.622873
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chr18:20759818-20760284 hyper chr18:20716616-20763027 Dsg2 -0.634473
chr12:113958407-113959505 hyper chr12:113960384-113984802 Cep170b -0.642405
chr2:158222992-158223588 hyper chr2:158201373-158211881 Snhg11 -0.643023
chr8:73269722-73269943 hyper chr8:73286671-73291611 Ifi30 -0.651521
chr8:73309871-73310263 hyper chr8:73286671-73291611 Ifi30 -0.651521
chr8:73334834-73335143 hyper chr8:73286671-73291611 Ifi30 -0.651521
chr9:14050690-14051104 hyper chr9:14080744-14137524 Sesn3 -0.690743
chr1:34093309-34093859 hyper chr1:34068669-34365497 Dst -0.712324
chr4:126002087-126002467 hyper chr4:125964037-125991574 Col8a2 -0.755375
chr4:125923594-125924274 hyper chr4:125964037-125991574 Col8a2 -0.755375
chr7:148211594-148212613 hyper chr7:148247172-148258018 B4galnt4 -0.834077
chr7:148274750-148274879 hyper chr7:148247172-148258018 B4galnt4 -0.834077
chr12:118397824-118398305 hyper chr12:117724192-118575485 Ptprn2 -0.844585
chr12:118266635-118267509 hyper chr12:117724192-118575485 Ptprn2 -0.844585
chr8:124793057-124793175 hyper chr8:124783835-124796514 - -0.849553
chr8:124820289-124820793 hypo chr8:124783835-124796514 - -0.849553
chr8:124845529-124845986 hypo chr8:124783835-124796514 - -0.849553
chr3:121787724-121788914 hyper chr3:121747377-121882979 Abca4 -0.865933
chr5:115894491-115895052 hyper chr5:115879693-115905695 Msi1 -0.879537
chr14:61623709-61624298 hyper chr14:61582670-61665692 Tnfrsf19 -0.882696
chr7:148192086-148193168 hyper chr7:148153327-148155726 Ifitm1 -0.882976
chr3:84074010-84074594 hyper chr3:83964360-84108697 Trim2 -1.1074
chr7:28066903-28067263 hyper chr7:28090159-28122631 Ltbp4 -1.11708
chr5:44490853-44491527 hyper chr5:44384860-44492975 Prom1 -1.12478
chr11:35610726-35611148 hyper chr11:35651913-35793591 Wwc1 -1.25767
chr7:4434397-4434994 hyper chr7:4469909-4484044 Dnaaf3 -1.2718
chr5:141088065-141088599 hyper chr5:141083294-141091499 Lfng -1.29608
chr4:116502237-116503120 hyper chr4:116550006-116661710 Zswim5 -1.32418
chr11:102217890-102218476 hyper chr11:102210133-102226595 Slc4a1 -1.34342
chr11:102639062-102639563 hyper chr11:102622752-102641576 Adam11 -1.34449
chr14:122852090-122852827 hyper chr14:122874605-122879550 Zic2 -1.39138
chr7:51857056-51858580 hyper chr7:51861172-51926213 Myh14 -1.42359
chr7:29997949-29998493 hyper chr7:30041348-30066996 Spint2 -1.43921
chr10:19861332-19862037 hyper chr10:19868725-20001396 Map7 -1.49083
chr13:24613355-24613926 hyper chr13:24419288-24569154 Cmah -1.54945
chr3:108187823-108188389 hyper chr3:108193765-108218412 Celsr2 -1.57786
chr17:15519420-15519960 hyper chr17:15504317-15512787 Dll1 -1.75381
chr10:59570816-59571512 hyper chr10:59569004-59597899 Spock2 -1.81204
chr4:124344632-124345709 hyper chr4:124334888-124337899 Pou3f1 -1.83496
chr4:125212061-125213486 hyper chr4:125168074-125391417 Grik3 -1.86844
chr4:125222430-125222877 hyper chr4:125168074-125391417 Grik3 -1.86844
chr1:138696965-138697319 hyper chr1:138740160-138857025 Nr5a2 -1.87529
chr2:147849058-147849438 hyper chr2:147868613-147872705 Foxa2 -1.87655
chr4:45801580-45802815 hypo chr4:45822378-45839699 Igfbpl1 -2.0404
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chr1:182824490-182825286 hyper chr1:182865169-182868532 Lefty1 -2.09009
chr8:109241931-109242163 hyper chr8:109127267-109194146 Cdh1 -2.09257
chr1:72284301-72284987 hyper chr1:72205806-72258881 Mreg -2.09585
chr9:110817103-110817617 hyper chr9:110842111-110848662 Tdgf1 -2.14115
chr3:34555551-34556010 hyper chr3:34459302-34576915 Sox2 -2.17126
chr8:4206269-4206850 hyper chr8:4209542-4217312 BC068157 -2.22997
chr5:135442964-135443614 hyper chr5:135420992-135422804 Cldn4 -2.28976
chr11:116848981-116849900 hyper chr11:116780176-116848258 Mgat5b -2.33929
chr4:41044457-41044778 hyper chr4:41039756-41045216 Aqp3 -2.3542
chr11:97445466-97446044 hyper chr11:97370653-97436440 Srcin1 -2.46769
chr11:68246148-68246397 hyper chr11:68022865-68200328 Ntn1 -2.48021
chr5:135442964-135443614 hyper chr5:135462083-135477220 Cldn3 -2.60028
chr4:135846684-135847192 hyper chr4:135803871-135830814 Tcea3 -2.75576
chr1:137114015-137114765 hyper chr1:137150150-137155049 Elf3 -2.87026
chr7:56887804-56888417 hyper chr7:56886868-56892205 Dbx1 -2.92245
chr15:85337985-85338351 hyper chr15:85365866-85424138 Wnt7b -3.09208
chr15:98626660-98627388 hyper chr15:98620287-98624261 Wnt1 -3.09913
chr15:84961845-84962260 hyper chr15:84895118-84962387 Smc1b -3.21409
chr7:148274750-148274879 hyper chr7:148287117-148303705 Ano9 -3.22434
chr12:87720288-87721157 hyper chr12:87702066-87862578 Esrrb -3.27954
chr15:76004856-76005224 hyper chr15:75931917-75956986 BC024139 & Eppk1 -3.62001






Genome-wide and parental allele-specific analysis
of CTCF and cohesin DNA binding in mouse
brain reveals a tissue-specific binding pattern
and an association with imprinted differentially
methylated regions
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DNA binding factors are essential for regulating gene expression. CTCF and cohesin are DNA binding factors with central
roles in chromatin organization and gene expression. We determined the sites of CTCF and cohesin binding to DNA in
mouse brain, genome wide and in an allele-specific manner with high read-depth ChIP-seq. By comparing our results with
existing data for mouse liver and embryonic stem (ES) cells, we investigated the tissue specificity of CTCF binding sites. ES
cells have fewer unique CTCF binding sites occupied than liver and brain, consistent with a ground-state pattern of CTCF
binding that is elaborated during differentiation. CTCF binding sites without the canonical consensus motif were highly
tissue specific. In brain, a third of CTCF and cohesin binding sites coincide, consistent with the potential for many
interactions between cohesin and CTCF but also many instances of independent action. In the context of genomic im-
printing, CTCF and/or cohesin bind to a majority but not all differentially methylated regions, with preferential binding
to the unmethylated parental allele. Whether the parental allele-specific methylation was established in the parental
germlines or post-fertilization in the embryo is not a determinant in CTCF or cohesin binding. These findings link CTCF
and cohesin with the control regions of a subset of imprinted genes, supporting the notion that imprinting control is
mechanistically diverse.
[Supplemental material is available for this article.]
DNA sequences that control transcription are frequently located in
the noncoding portion of the mammalian genome (The ENCODE
Project Consortium 2012). These elements can act over long dis-
tances (Noonan and McCallion 2010). The identification of these
control elements is important for elucidating human genetic dis-
ease since genome-wide association studies regularly point to
noncoding regions as candidates in disease etiology (Manolio
2010). One of the proteins that contributes to the regulation of
gene expression across the genome is CTCF (CCCTC-binding fac-
tor), a protein with 11 zinc fingers (Filippova et al. 1996) and mul-
tiple regulatory functions (Ohlsson 2001; Gaszner and Felsenfeld
2006). CTCF can act as an insulator by blocking interactions be-
tween enhancers and promoters (Bell et al. 1999), it can directly
regulate chromosomal interactions (Yusufzai and Felsenfeld 2004;
Hadjur et al. 2009), and it can act as an enhancer of transcription
(Kuzmin et al. 2005). CTCF binds regions of DNA with high se-
quence specificity and is sensitive to DNA methylation, having
a lower binding affinity for methylated DNA (Mukhopadhyay et al.
2004). The canonical consensus bindingmotif ofCTCF and the sites
of CTCF binding are evolutionarily conserved between mammals
and birds (Martin et al. 2011; Schmidt et al. 2012). In vitro assays
have shown that CTCF can use different combinations of its zinc
fingers to bind to distinct DNA sequences (Filippova et al. 1996).
CTCF interacts with a variety of other factors. In particular, the
cohesin complex, best known for its role in mediating sister-
chromatid cohesion during cell division, has been found to fre-
quently colocalize with CTCF during interphase (Parelho et al.
2008; Rubio et al. 2008; Wendt et al. 2008; Xiao et al. 2011) with
consequences for gene expression. At specific loci, cohesin is re-
quired for cell-type-specific long-range chromosomal interactions
in cis during cellular differentiation (Hadjur et al. 2009).
Genomic imprinting refers to the parental allele-specific
transcription of a subset of genes inmammals and flowering plants
(Reik and Walter 2001; da Rocha et al. 2008). Roughly 140 tran-
scripts are known to be imprinted inmammals (Schulz et al. 2008).
Imprinting is controlled by epigenetic modifications that differ
between the two parental genomes, including differences in DNA
methylation (Li et al. 1993). Imprinted genes can occur in large,
coordinately regulated clusters exemplified by the Gnas locus
(Peters and Williamson 2007); they can form small domains such
as the Mcts2/H13 locus (Wood et al. 2008) that are comprised of
only two genes (McCole and Oakey 2008), or they can be single-
tons like Impact (Hagiwara et al. 1997). In all cases, their parental
allele-specific expression is ultimately due to an imprinting control
region (ICR), a region of DNA that is differentially methylated be-
tween the parental alleles. The parental allele-specific methylation
of a differentially methylated region (DMR) is in most cases the
consequence of the sex-specific epigenetic reprogramming of the
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parental germ cells (Edwards and Ferguson-Smith 2007; Bartolomei
2009). In addition,DMRs are actively protected frompost-fertilization
epigenetic reprogramming (Quenneville et al. 2012) and, thus, persist
into adulthood. In some cases, the parental allele-specific meth-
ylation of a DMR is set up post-fertilization during early embryo-
genesis (somaticDMRs) (Kobayashi et al. 2012). DMRswith a direct
germline origin are referred to as germline DMRs (gDMRs). Dis-
ruption of imprinted gene expression after deletion of a DMR is
considered evidence that the latter functions as an ICR. There are
22 well-established gDMRs in mouse, of which 19 are maternally
methylated and three are paternally methylated. Many mecha-
nisms exist to ‘‘translate’’ allele-specific methylation into differ-
ential gene expression, including differential protein binding
(Lewis and Reik 2006).
CTCF has long been associated with genomic imprinting due
to its selective binding of the unmethylated maternal allele of the
Igf2/H19 ICR resulting in parent-of-origin-specific expression of
Igf2 andH19 in mouse and human (Bell and Felsenfeld 2000; Hark
et al. 2000; Kanduri et al. 2000; Fedoriw et al. 2004; Szabo et al.
2004). CTCFhas been studied at several other imprinted loci, and it
binds the unmethylated allele at the gDMRs of Rasgrf1, Peg13,
Kcnq1ot1 (Yoon et al. 2005; Fitzpatrick et al. 2007; Singh et al.
2011), andGrb10 (Hikichi et al. 2003; Mukhopadhyay et al. 2004).
CTCF-mediated regulation is postulated to be one of two major
control mechanisms operating at ICRs (Lewis and Reik 2006; Kim
et al. 2009). Cohesin also has been linked to imprinting through
its association with CTCF at the H19/Igf2 and Kcnq1ot1 DMRs
(Stedman et al. 2008; Lin et al. 2011), and a role for cohesin in the
allele-specific organization of higher-order chromatin has been
proposed (Nativio et al. 2009). Here we present the first compre-
hensive analysis of allele-specific CTCF and cohesin binding at all
known DMRs in a single tissue, providing an unbiased assessment
of the extent to which CTCF and cohesin are involved in im-
printing control.
Genome-wide ChIP-seq in mouse ES cells (Chen et al. 2008;
Kagey et al. 2010) and human cells (Kim et al. 2007b) has shown
that CTCF and cohesin bind tens of thousands of discrete sites
across the genome, and CTCF binding is enriched in and near
genes, consistent with a role in the control of gene expression.
Mouse embryonic stem (ES) cell data identify CTCF and cohesin
binding at the gDMRs of Peg13, Zim2 (Peg3), Peg10, Grb10, and
Mest but not at theH19/Igf2 ICR, even thoughCTCF is known to be
important for imprinting regulation at this domain. Imprinting is
dispensable in ES cells, where loss of imprinting frequently occurs
without affecting viability in culture (Kim et al. 2007a; Rugg-Gunn
et al. 2007; Frost et al. 2011). The same is true for Dnmt1/,
Dnmt3a/, Dnmt3b/ triple knockout mouse ES cells that con-
sequently lack all DNA methylation imprints but yet are viable
(Tsumura et al. 2006). In contrast, a differentiated tissue where im-
printingplays an important role is the brain (Davies et al. 2007), and
this is supported by multiple lines of evidence. Firstly, the human
imprinting disorders Prader-Willi syndrome and Angelman syn-
drome present with behavioral and neurodevelopmental pheno-
types (Cassidy et al. 2000; Lossie et al. 2001; Williams et al. 2006);
secondly, of the ;140 imprinted gene transcripts in the mouse,
more than 50 are expressed in brain (Wilkins 2008); thirdly, the
disruption of certain mouse imprinted genes, including Peg3 (Li
et al. 1999),Mest (Lefebvre et al. 1998), Nesp55 (Plagge et al. 2005),
and Grb10 (Garfield et al. 2011), results in behavioral phenotypes;
finally, genome-wide allele-specific studies of transcription in
mouse brain suggest that this tissue is a focus for imprinted gene
expression (Gregg et al. 2010a,b; DeVeale et al. 2012).
Our analyses of CTCF and cohesin binding inmouse brain are
based on ChIP-seq data of high quality and an order of magnitude
higher read depth than existing data. The use of reciprocal inter-
subspecies hybrid mice enabled independent interrogation of the
parental alleles in terms of CTCF and cohesin binding in un-
precedented detail. We examined postnatal day 21 (P21) mouse
brain, a time point in development shortly after the growth spurt
in neurogenesis that occurs in the first 2 wk of postnatal devel-
opment (Lyck et al. 2007). In the adult mouse brain,;56% of cells
are neurons and 44% are nonneuronal cells (Fu et al. 2012). Neu-
rons and the principle type of nonneuronal cells, the macroglia,
both derive from the neuroepithelium. These data are representa-
tive of adult rather than immature brain cell types and are un-
affected by long-term aging effects.
Results
We demonstrate that inmouse brain, CTCF and cohesin each bind
to;50,000 sites in the genome, with;27,000 sites bound by both
factors, indicative of CTCF and cohesin acting throughout the
genome both in concert as well as independently. Genes are
enriched for CTCF binding sites, while intergenic regions are de-
pleted. The binding sites are highly enriched for the canonical
consensus binding motif. CTCF binding sites are relatively hypo-
methylated, both in the CpG and non-CpG sequence context.
Parental allele-specific CTCF binding is rare, with most sites at or
near imprinted loci. However, a majority but not all DMRs are
bound by CTCF (or cohesin), and the binding is not necessarily
allele specific. The Magel2/Peg12 imprinted locus is unique in the
genome, comprising a cluster of eight allele-specific CTCF binding
sites. Comprehensive expression profiling in mouse brain of genes
near allele-specific CTCF binding sites not previously associated
with imprinting did not reveal novel imprinted genes. No allele-
specific cohesin binding sites of genome-wide significance were
found, although at allele-specific CTCF binding sites, there is
a trend for cohesin to bind the same allele.
Deep ChIP-seq for CTCF and cohesin to detect parental
allele-specific binding
Sites of CTCF and cohesin binding to DNA were determined ge-
nome wide in whole P21 mouse brain by chromatin immuno-
precipitation (ChIP) using antibodies specific to CTCF and the
RAD21 cohesin subunit followed by high-throughput sequencing
(ChIP-seq). Themicewere the offspring of crosses betweenC57BL/6
(Bl6) females and Mus musculus castaneus (cast) males (B 3 C), and
vice versa (C 3 B) (Fig. 1A). We generated 235 million and 231
million high-quality and uniquely mapping sequence reads for
CTCF and cohesin, respectively (Fig. 1A). The percentage of reads
representing clonal duplication was below 6.2% for all samples
(Supplemental Fig. S1). Duplicate reads were excluded from further
analysis, and regions of CTCF and RAD21 binding were identified
using USeq and assigned to either the Bl6 or cast genome based on
known SNPs (Fig. 1B; Supplemental Fig. S2; Supplemental Table S1;
Keane et al. 2011; Yalcin et al. 2011).
A systematic read mapping bias toward the reference Bl6 ge-
nome was observed, consistent with a Bl6 allele read in a poly-
morphic region being more likely to align for both CTCF and
cohesin. However, our use of reciprocal crosses prevented parental
allele-specific binding being confounded: Therewas no overall bias
toward either of the parental alleles when the reads generated from
both reciprocal crosses were considered together (Fig. 1C,D).
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CTCF and cohesin binding in mouse brain
Genome wide, we detected 49,358 CTCF and 52,938 cohesin
binding sites with a high degree of statistical confidence. Of these,
27,241 sites were bound by both CTCF and cohesin, accounting
for 55.3% of the CTCF and 51.5% of the cohesin binding sites,
respectively (Fig. 2). This is consistent with previous studies that
show both independent and coordinated roles for these factors
(Wendt et al. 2008; Lin et al. 2011).
CTCF binds to regions containing the canonical
consensus motif
CTCF binds to a specific DNA sequence motif in ES cells (Chen
et al. 2008) and liver (Schmidt et al. 2012). To search for CTCF
binding motifs in brain, we applied the MEME de novo motif-
finding tool to the sequences of all CTCF binding regions in P21
mouse brain (Fig. 3A). Themost significantmotif (P = 2.93 10199)
is highly similar to the published CTCF binding motif (Chen et al.
2008; Schmidt et al. 2010, 2012). To ensure the consistency of the
comparison, we repeated the MEME analysis using identical pa-
rameters on CTCF binding regions previously identified using
ChIP-seq in ES cells and liver (Chen et al. 2008; Schmidt et al. 2012).
Again, the canonical motif was identified as the most significant
motif in both ES cells (P = 7.43 10924) and liver (P = 1.43 10367).
All three motifs display a high degree of sequence homology, par-
ticularly at the core 12-bp sequence at the center of the identified
motifs (Fig. 3A).
CTCF binding sites are hypomethylated
The preference of CTCF to bind unmethylatedDNAwas confirmed
by assessing the level of cytosine methylation at CTCF binding
sites in brain. Using genome-wide bisulfite-sequencing (BS-seq)
data for adult mouse brain (Xie et al. 2012), we compared the
overall genome-wide level of methylation at cytosine residues,
separately for CpG dinucleotides and non-CpG cytosines, with the
portion of the genome corresponding to regions of CTCF binding.
We found that methylation at CpG dinucleotides appears to have
a greater influence on CTCF binding than non-CpG methylation.
Genome wide, 60.8% of CpGs are methylated in the mouse brain,
in contrast to 51.9% of CpGs in regions of CTCF binding. Non-
CpG methylation also is less frequent in regions of CTCF binding
(2.1%) compared with the genome-wide level (2.5%) (Fig. 3B).
These differences are statistically significant (x2 test, P < 13 106).
CTCF preferentially binds near genes
We explored the genome-wide location of both CTCF binding re-
gions and parent-of-origin-specific CTCF binding regions using
the cis-regulatory element annotation (CEAS) tool (Shin et al.
2009). CTCF binding is particularly enriched in regions up to63 kb
upstream of and downstream from genes, but is depleted in inter-
genic regions (Fig. 3C). This is consistentwith the insulator function
of CTCF and, more generally, its involvement in controlling gene
expression.Whenwe limited our analysis to parent-of-origin-specific
CTCF binding sites, we found the results to be similar. However,
intronic regions appeared to be slightly underrepresented and
intergenic regions slightly overrepresented relative to the distri-
bution of all CTCF binding sites (Fig. 3C). Given the small number
of parent-of-origin-specific CTCF binding sites, these differences
are likely due to chance.
Noncanonical CTCF binding sites are tissue specific
Wecompared the locations of CTCF binding sites in P21 brainwith
those reported for mouse ES cells and liver (Chen et al. 2008;
Figure 1. (A) ChIP-seq was performed for CTCF and cohesin (RAD21)
on P21 brain in B 3 C and C 3 B F1 hybrid animals. The experimental
design and number of uniquely mapped reads taken forward for further
analysis are shown. (B) Regions of CTCF and RAD21 binding were iden-
tified using the Useq, and regions identified with a FDR of <13 were
considered significant and were tested for parent-of-origin-specific bind-
ing. (Black bar) The number of reads for each experiment that fell at, or
within 6500 bp of a binding region; (white bar) indicates reads in bind-
ing regions that aligned over a SNP between C57BL/6 (Bl6) and Mus
m. castaneus (cast); (gray bar) the number of reads after the paired reads
are considered together and the best-quality read is used to map the read
to Bl6 or cast. (Hatched bar) The final number of reads assigned. Therewas
a consistent bias toward the reference sequence (C ); however, this effect
was eliminated after we combined B 3 C and C 3 B reads (D).
Figure 2. Overlap of the 49,358 CTCF and 52,938 cohesin binding
regions in mouse brain. This demonstrates that just over half of CTCF
(55%) and cohesin (51%) binding sites are shared, suggesting both in-
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Schmidt et al. 2012). The incidence of overlap between sites
reported in different studies increases with increasing the peak size
used for the comparison. Beyond a certain peak size, increases in
overlap are mostly due to chance. Therefore, we iteratively in-
creased peak size and compared the incidence of overlap between
sites in ES cells, liver, and brain with randomized site locations.
Beyond a peak size of 1 kb, increases in the incidence of overlaps
were likely due to chance (Supplemental Fig. S3). For a common
peak size of 1 kb, 32.0% of all binding sites were shared between ES
cells, brain, and liver, suggesting that they are invariant during
differentiation and regardless of cell type (Fig. 4A). Only 1893
binding sites were occupied exclusively in ES cells (5.1% of ES-cell
binding sites), suggesting that most CTCF binding sites in ES cells
represent a ground state that is added to during differentiation,
with few binding sites being characteristic of pluripotency per se.
In differentiated tissues, 29.1% of brain and 31.2% of liver binding
sites are unique to the respective tissue. These analyses were re-
peated using alternativeCTCFChIP-seq data fromES cells and liver
(Shen et al. 2012), producing similar results, even though signifi-
cantly fewer binding sites were identified in these studies because
of limited read depth and quality (Supplemental Fig. S4). We hy-
pothesize that the canonical consensus CTCF binding motif may
be at the core of binding sites that are largely invariant with respect
to cell type, concordantwith other findings (Essien et al. 2009).We
restricted the above overlap analysis to CTCF binding sites that
lack the canonical binding motif. There was a large reduction in
the number of binding sites shared between tissue types (Fig. 4A),
with most binding sites now being tissue specific: 84.2% of bind-
ing sites in brain that lack the canonical motif were brain specific,
and similarly for ES cells (81.2%) and liver (82.9%) (Fig. 4B). These
results suggest thatCTCFbinding to tissue-specific sitesmay involve
other consensus motifs recognized by cofactors or tissue-specific
conformations of the 11 zinc finger domains of CTCF itself.
Parent-of-origin-specific CTCF and/or cohesin binding
is limited to specific DMRs
We systematically investigated the binding of CTCF and cohesin at
or near 22 known well-characterized mouse gDMRs (Table 1) as-
sociated with imprinted gene expression (most of which are clas-
sified as ICRs). Of the 22 gDMRs (Table 1), 19 have a CTCF and/or
cohesin binding site in brain within 2.5 kb. Of these sites, 12 are
bound by both CTCF and cohesin, three by CTCF alone and four
by cohesin alone. gDMRs with both CTCF and cohesin binding
Figure 3. CTCF binding analysis. (A) MEME motif finder was executed
on the CTCF binding locations identified by ChIP-seq in brain and com-
pared with motifs identified using previously published ES cells and liver
binding locations. Each data set found the canonical motif with high de-
grees of certainty. (B) The level of cytosine methylation within CTCF
binding sites in the brain was compared with that across the whole ge-
nome using data from Xie et al. (2012). In both CpG and non-CpG con-
text cytosine methylation, cytosines within CTCF binding sites are
methylated less than those outside CTCF binding sites (x2 contingency
table tests, P < 0.001 for CpG and non-CpG context), confirming that
CTCF prefers to bind to unmethylated DNA. (C ) Genomic locations of
CTCF binding are normalized to the proportion of the genome that
constitutes each location (represented by the red line). This was consid-
ered for all CTCF peaks called with an FDR < 13 and separately for the 116
regions where CTCF binding was seen on one parental allele only (regions
identifiedwith a P < 0.001). CTCF is significantly enriched at genic regions,
but depleted in distal intergenic regions. Parent-of-origin-specific CTCF
binding locations are similar but show that binding is depleted in introns
but not in intergenic regions.
Figure 4. (A) Proportional Venn diagrams comparing coincidence of
CTCF binding sites between ES cells, liver, and brain demonstrate significant
overlap of CTCF binding in these tissues, Coincident binding was also con-
sidered after the removal of binding regions containing the consensus CTCF
motif; overlap of CTCF binding in the absence of the consensus motif was
much lower thanwhenall binding siteswere considered. (B) Thepercentages
of shared peaks for each tissue type for all peaks and for nonmotif peaks.
Genome-wide binding of CTCF and cohesin
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sites within 2 kb formed two categories: those where CTCF and
cohesin colocalized precisely at the gDMR (eight regions), and
a further four regionswhere binding occurrednear but not over the
gDMR and CTCF and cohesin each bound distinct sites (Table 1).
Where the two factors are precisely colocalized on the DNA,
cohesin binding is probably linkedmechanistically to CTCF, while
this is less likely at gDMRs where binding sites do not coincide.
For gDMRs where genome-wide significant (P < 1 3 106)
parent-of-origin-specific binding events for CTCF (Table 1) were
detected (H19/Igf2,Mest, Peg13, andZim2 [Peg3]), binding occurred
as expected on the unmethylated allele (Table 1). TheMest andZim2
gDMRs were not previously known to bind CTCF in a parent-of-
origin-specific manner. In addition, the 95% confidence intervals
(Supplemental Fig. S5; Supplemental Table S2) for parent-of-origin-
specific binding showed a trend toward preferential binding of
CTCF to the unmethylated alleles of the Grb10, Mcts2, Cdh15,
Nespos, Zrsr1, Peg10, and Meg3/Dlk1 gDMRs. We considered CTCF
binding to be completely biallelic if the 95% confidence interval
for the maternal-over-paternal read ratio was between 0.35 and
0.65 and spanned 0.5. This was the case for the Inpp5f_v2 and
Plagl1 gDMRs. At H19/Igf2 and Peg13, parent-of-origin-specific
binding of cohesin was detected but was not genome-wide sig-
nificant after Bonferroni multiple testing correction (Table 1). The
overall pattern of the 95% confidence intervals for the ratio of
maternal-to-paternal reads for CTCF and cohesin suggests that in
comparison to CTCF, cohesin binding is less biased toward the
unmethylated parental allele (Supplemental Fig. S5; Supple-
mental Table S2). This is consistent with increased recruitment of
cohesin to sites bound by CTCF.
Parent-of-origin-specific CTCF and cohesin binding at gDMRs
could only be tested where a Bl6-cast SNP is within the bound re-
gion (Table 1). In addition, CTCF and cohesin peaks did not always
overlap perfectly so that for some gDMRs, a SNP was informative
for one factor but not the other. Another limitation for the de-
tection of parent-of-origin-specific binding arose when a SNP was
located at the periphery of the respectively bound region where
fewer reads align and the statistical power of the binomial test was
diminished. For CTCF, these limitations applied in particular to the
Grb10, Mcts2, Nnat, Nespos, Zrsr1, Impact, and Peg10 gDMRs. For
cohesin, the above limitations applied to half of the cohesin-
bound gDMRs (Supplemental Table S2). The results for CTCF
support the notion that it plays a central role in imprinting control
at several loci. This is in contrast to cohesin, in particular, four
gDMRs (Gnas-exon1A, Igf2r-air, Kcnq1ot1, and Snurf/Snrpn) were
bound by cohesin but not by CTCF; here binding was not parental
allele specific. Cohesin binding independently of CTCF is not
unprecedented (Schmidt et al. 2012), and there is evidence that it is
more generally involved in transcriptional activation (Kagey et al.
2010).
Genome-wide, parental allele-specific binding of CTCF
and cohesin is rare and mostly restricted to imprinted loci
CTCF binding efficiency to methylated DNA is reduced compared
with unmethylated DNA (Mukhopadhyay et al. 2004) explaining
parental allele-specific binding at theH19/Igf2 and other gDMRs. If
CTCF and cohesin are exerting a key regulatory role at several
imprinted loci, then genome wide, other occurrences of parental
allele-specific CTCF and/or cohesin binding may identify novel
DMRs and imprinted genes. Four known ICRs—H19/Igf2, Peg13,
Zim2 (Peg3), andMest—met the genome-wide significance threshold
for parental allele-specific CTCF binding providing proof of principle.
Only an additional 17 regions reached genome-wide signifi-
cance (Fig. 5; Supplemental Fig. S3; Table 2). Eight of these sites
clustered in a 250-kb region on chromosome 7 at the Peg12/Magel2
imprinted domain (Fig. 6). A further four sites were within 6Mb of
other known imprinted regions. Two more are 30 kb apart on chro-
mosome 14 (Fig. 5). Many chromosomes were devoid of parental
allele-specific CTCF binding, and no cohesin binding regions were
detected at genome-wide significance (Supplemental Table S3). Of all
21 genome-wide significant parental allele-specific CTCF binding
sites, sixwere on thematernal and15on thepaternal allele.We tested
all gene transcripts at or near these sites not previously reported as
imprinted for parental allele-specific expression in mouse brain.
Many showed a complex organization of transcripts (Supplemen-
tal Fig. S6), but none were imprinted (Supplemental Table S4).
Eight sites of parental allele-specific CTCF binding at the
Peg12/Magel2 imprinted domain (Fig. 6) bound CTCF on the pa-
ternal allele, indicating maternal methylation. We assayed meth-
ylation of the CpG island at the promoter of Magel2, which is in
close proximity to two CTCF sites and maternally methylated
(Supplemental Fig. S7). This is confirmation of the parental allele-
specific methylation of the region recently reported (Xie et al.
2012). The Magel2 DMR is likely somatic and established post-
fertilization that is supported by genome-widemethylation data in
oocytes (Smallwood et al. 2011). In addition, Dnmt3L/+ 8.5 days
postcoitum (dpc) embryos are unchanged at the Magel2 promoter
relative to wild type and are unmethylated (Proudhon et al. 2012).
This suggests that the maternal allele-specific methylation at the
Magel2 promoter, and presumably the other sites of paternal allele-
specific CTCF binding in the domain, is established post-implan-
tation and/or is brain specific. The regulation of the imprinted
domain comprising Ndn, Magel2, Mkrn3, and Peg12 deserves fur-
ther study since the human orthologs of Ndn, Magel2, and Mkrn3
are in the region associated with Prader-Willi syndrome (Lee and
Wevrick 2000), with patients displaying a notable range of neu-
rological symptoms. Given this extensive investigation of parental
allele-specific CTCF binding, we predict that there are few addi-
tional DMRs in the adult mouse brain bound by CTCF.
Validation of CTCF and cohesin binding at specific loci
Quantitative assays for H19/Igf2, Peg10, Nap1l5, Nnat, and Grb10
DMR validated that the ChIP-seq data (Supplemental Fig. S8A,B)
Figure 5. Chromosomal location of genome-wide significant parent-
of-origin-specific CTCF binding regions. Where CTCF is bound on the
maternally inherited allele, this is illustrated with a circle; where CTCF is
bound on the paternally inherited allele, this is illustrated with a square.
Only chromosomes where parent-of-origin-specific binding was seen are
shown. CpG density is indicated.
Genome-wide binding of CTCF and cohesin
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results were in agreement (Table 1) with the exception of CTCF
binding at Nnat and cohesin binding at Peg10. Both are borderline
cases. Using qPCR to detect CTCF binding at the Nnat DMR
resulted in P = 0.08, just above our cutoff for binding, At Peg10,
RAD21 binding was detected by qPCR, but no peak was identified
by ChIP-seq. When the stringency of the ChIP-seq peak detection
is relaxed, two RAD21 binding regions ;1 kb either side of the
qPCR regions are detected (Supplemental Fig. S8C).
Validation of parental allele-specific binding
To validate allele-specific binding we pyrosequenced ChIP’d mouse
brain from reciprocal crosses. We selected three representa-
tive DMRs, based on the ChIP-seq results: Inpp5f_v2, where
biallelic CTCF binding was detected; Mest, where we detected pa-
ternal allele-specific binding; and Peg10, where the CTCF binding
site did not meet the significance threshold for allele-specific
binding but where the 95% confidence interval was suggestive of
CTCF binding on the paternal allele. These results agreed with our
ChIP-seq data (Supplemental Fig. S9): Inpp5f_v2 does not deviate
from the expected 50:50 allelic ratio (P = 0.3214), Mest shows pa-
ternal binding (P = 0.0017), and Peg10 shows a bias toward en-
richment of the paternal allele (P = 0.0813).
CTCF and cohesin binding at somatic DMRs
A set of 23 known somatic and novel putative somatic DMR co-
ordinates has recently been defined by whole-genome bisulfite
sequencing (BS-seq) in mouse brain (Xie et al. 2012). We evaluated
CTCF and cohesin binding in the somatic DMRs identified in this
study (Supplemental Table S5). We found 13 instances of CTCF
binding, two of which were parental allele specific (P < 1 3 106)
and 14 instances of cohesin binding, none of which were parental
allele specific. All parental allele-specific binding involved the





binding:nonbinding Nearest genes Notes
chr7: 149,764,416–149,768,874 Maternal 1.11 3 1074 10.3 H19, Igf2 Known imprinted gene region
chr15: 72,638,890–72,641,957 Paternal 1.35 3 1057 12.6 Peg13, Trappc9 Known imprinted gene region
chr7: 6,678,325–6,681,689 Paternal 1.17 3 1030 5.5 Zim2 (Peg3) Known imprinted gene region
chr6: 30,686,300–30,688,046 Paternal 9.10 3 1015 9.4 Mest Known imprinted gene region
chr7: 69,543,049–39,547,037 Paternal 1.35 3 1012 3.4 Magel2 Known imprinted gene region
chr7: 69,580,613–69,582,990 Paternal 2.05 3 1010 5.6 Magel2 Known imprinted gene region
chr7: 69,323,407–69,325,218 Paternal 3.91 3 1010 6.6 Magel2 Known imprinted gene region
chr10: 74,395,653–74,404,537 Maternal 1.28 3 109 1.5 Rtdr1, Gnaz No known imprinted genes
within 20 Mb
chr7: 69,526,343–69,528,366 Paternal 3.10 3 109 4.1 Magel2 Known imprinted gene region
chr7: 69,372,124–69,373,922 Paternal 3.26 3 109 8.0 Ndn, Magel2 Known imprinted gene region
chr2: 180,079,574–180,091,367 Maternal 5.84 3 109 1.5 Gata5, Gm14318 6 Mb from Gnas locus
chr7: 69,608,918–69,610,897 Paternal 6.90 3 109 5.6 Peg12, Mkrn3 Known imprinted gene regions
chr14: 69,941,084–69,946,555 Paternal 1.68 3 108 1.5 Gm16677, Entpd4, Loxl2 5 Mb from Htr2a imprinted locus
chr7: 69,353,580–69,355,185 Paternal 2.15 3 108 5.1 Ndn, Magel2 Known imprinted gene regions
chr7: 69,519,941–69,521,489 Paternal 3.38 3 108 5.3 Magel2 Known imprinted gene regions
chr14: 69,994,239–70,003,685 Paternal 3.98 3 108 1.5 Entpd4, AK086749, Loxl2 5 Mb from Htr2a imprinted locus
chr10: 120,737,183–120,739,873 Paternal 4.75 3 108 2.7 Tbc1d30 No known imprinted genes
within 20 Mb
chr3: 121,236,161–121,244,419 Maternal 6.85 3 108 1.7 A530020G20Rik, Slc44a3 No known imprinted genes
on chromosome 3
chr15: 27,817,069–27,819,622 Maternal 6.95 3 108 2.3 Trio No known imprinted genes
within 20 Mb
chr13: 25,098,042–25,100,314 Maternal 9.98 3 108 2.1 Mrs2, Gpld1 No known imprinted genes
within 20 Mb
chr6: 60,631,333–60,634,328 Paternal 2.47 3 107 2.2 Snca 1.6 Mb from Herc3
After correction for multiple testing, regions are ranked in order of statistical significance (P-value). Twelve regions are associated with known imprinted
genes, of which eight are associated with the Peg12/Magel2 imprinted locus. Four further regions occur within close proximity of an imprinted locus. All
novel candidates were tested for imprinting (Supplemental Table S4).
Figure 6. Multiple parent-of-origin-specific CTCF binding sites are observed on the paternal allele at the Magel2/Peg12 locus. (Triangles) Paternally
bound CTCF binding sites. Genes and CpG islands are indicated. This region represents a unique example in the mouse genome of CTCF bound only on
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unmethylated allele. Overall, the results for somatic DMRs (Sup-
plemental Table S6) are in close agreement with the results for
gDMRs (Table 1) so that the origin of a DMR, germline versus so-
matic, is not a determinant of CTCF and/or cohesin involvement
in the regulation of imprinting.
Discussion
CTCF and cohesin act synergistically and independently
in mouse brain and show tissue-specific distributions
compared with undifferentiated cells
Several studies have examined the colocalization of CTCF with
cohesin (Chen et al. 2008; Parelho et al. 2008; Rubio et al. 2008;
Kagey et al. 2010; Schmidt et al. 2012), and CTCF physically asso-
ciates with cohesin via the Stag1 (Scc3/SA1) subunit in human cells
(Wendt et al. 2008). Here 55% of CTCF binding sites overlap with
cohesin binding, and the remaining sites binding independently
(Fig. 2), indicating that CTCF fulfils a role independent from as well
as in combinationwith cohesin in brain. This supports the idea that
different functions may be a result of the context of CTCF binding
(Gaszner and Felsenfeld 2006), and it is possible that coordinate
binding of cohesin may influence CTCF. Cohesin is involved in
tissue-specific transcriptional control (Faure et al. 2012) and asso-
ciated with the Mediator complex, which has a role in transcrip-
tional activation (Taatjes 2012). Studies have shown a link between
cohesin, the Mediator complex, transcription, and chromatin loop-
ing (Kagey et al. 2010). We report that 51% of cohesin sites in brain
are not coincident with CTCF, consistent with CTCF not being re-
quired for the loading of cohesin onto DNA (Rubio et al. 2008).
This comparison of CTCF binding in ES cells, liver, and brain
revealsmore unique CTCF binding sites in differentiated cells than
in ES cells, suggesting tissue-specific CTCF binding in the specifi-
cation and/or maintenance of differentiated tissue. We observe
a significant overlap in CTCF binding between tissues (Fig. 4A),
consistent with studies reporting highly conserved CTCF binding
between cell types (Kim et al. 2007b).
CTCF binding
In brain, CTCF binds to unmethylated regions of DNA, usually to
the canonical CTCF motif (Chen et al. 2008; Schmidt et al. 2010,
2012). CTCF binding outside this motif is much more tissue spe-
cific, and there is little overlap between tissues (Fig. 4A). This is
consistent with evidence from CTCF knockout mouse studies,
which exhibit embryonic lethality prior to implantation (Splinter
et al. 2006). We found that the canonical consensus bindingmotif
is most frequent at CTCF binding sites shared between ES cells,
brain, and liver; thus, it is associatedwith invariant binding during
differentiation. CTCF binding appears overrepresented just up or
downstream from gene bodies with a paucity in distal intergenic
regions, unsurprising given the known role of CTCF in gene ex-
pression (Bell et al. 1999; Cuddapah et al. 2009). CTCF mediates
long-range chromosomal interactions genome wide in cis and in
trans in ES cells (Handoko et al. 2011), and we provide additional
evidence genome wide that CTCF is an insulator at or near gene
coding regions by binding to noncoding DNA.
Cytosine methylation at CTCF binding regions
Cytosine methylation in both a CpG and non-CpG context is re-
duced in regions of CTCF binding compared with the level observed
genome wide, consistent with published data (Mukhopadhyay
et al. 2004). Interestingly the canonical motif lacks CpG di-
nucleotides, suggesting that methylation of DNA in the motif does
not preclude CTCF binding, but surrounding methylation is
important. The canonical motif may not function alone, but in
concert with another region of DNA ;20 bp downstream, sug-
gesting thatCTCF interactionwithDNA is not limited to the 20-mer
motifs (Schmidt et al. 2012).
Parent-of-origin-specific CTCF and cohesin binding
CTCF and cohesin bind at numerous imprinting control regions
and other DMRs as previously detected, but not systematically
tested. The presence of CTCF and cohesin together at 12 im-
printing associated gDMRs in brain (Table 1) is consistent with
a regulatory role for these proteins at imprinted loci. Studies using
3C and 4C have shown that several imprinted domains are
physically clustered (Sandhu et al. 2009), in part because CTCF
(Botta et al. 2010) and cohesin (Murrell et al. 2004; Nativio et al.
2009) form loops that contribute to three-dimensional (3D) nu-
clear architecture (Phillips and Corces 2009). The CTCF and
cohesin binding (Table 1) supports the idea of three types of im-
printing mechanisms: CTCF dependent, CTCF/cohesin medi-
ated, and CTCF/cohesin independent.
CTCF and cohesin bind at somatic DMRs, suggesting a role
for them here. Parental allele-specific binding of CTCF together
with cohesin regulates allele-specific expression in somatic cells
(Lin et al. 2011), while cohesin binding alone may be involved
in the transcriptional regulation of imprinted gene expression
generally. CTCF and cohesin are likely to have distinct functions
in different cell types at a subset of targets (Lin et al. 2011), and
findings in mouse brain support the idea that these proteins play
a role in imprinting at some loci and at others they act more
generally.
These data provide a resource for interrogating the roles of
CTCF and cohesin and point to a role at more imprinted loci than
was previously appreciated, although further functional studies
would be needed to confirm this. Three gDMRs do not bind either
factor, illustrating the heterogeneous nature of gDMRs as a group
of regulatory regions. For example, the four imprinted retrogene/
host gene pairs Mcts2/H13, Nap1l5/Herc3, Inpp5f/Inpp5f_v2, and
Zrsr1/Commd1 share several sequence-based and genomic con-
text–related features (Wood et al. 2007). Since within this group,
Mcts2 binds bothCTCF and cohesin together,Nap1l5 bindsneither
CTCF nor cohesin, Inpp5f_v2 binds CTCF on both parental alleles
equally, and Zrsr1 binds both CTCF and cohesin, but they do not
colocalize, this suggests no consistent mechanism for imprinting
control despite the other shared features.
CTCF binding profiles vary between different tissues. We
show that many CTCF binding sites are shared between ES cells
and differentiated tissues and that this type of invariant CTCF
binding is associated with the canonical CTCF motif. CTCF bind-




Chromatin from whole tissue was isolated, sonicated, and immu-
noprecipitated for ChIP-seq library preparation according to Sup-
plemental Methods 1.
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Next-generation sequencing
Library preparation
DNA enriched through ChIP was quantified using the Qubit
(Invitrogen) and Quant-iT dsDNA high-sensitivity assay kit
(Invitrogen:Q32854) and was sized using the Agilent Bioanalyzer
with a High Sensitivity DNA Bioanalyzer kit (5067-4626). DNA was
fragmented to a size appropriate for the library preparation step
using the Covaris S220, samples were sheared over two cycles: 5%
duty cycle, 3 intensity, 200 cycles per burst, and time of 65 sec. DNA
from ChIPs performed on chromatin extracted from two mice was
pooled.
ChIP-seq libraries were prepared using the Illumina ChIP-seq
library preparation kit (IP-102-1001) and the NEBNext ChIP-seq li-
brary preparation kit (E6240). Libraries were sized and quantified
using anAgilent Bioanalyzer and aHigh Sensitivity Kit (5067-4626).
ChIP-seq data analysis
Sequence reads were aligned to the mouse reference genome
(mm9) using Novoalign (v. 2.01.13; http://www.novocraft.com/).
USeq (Nix et al. 2008) was used to identify mean peak shift sepa-
rately for CTCF and cohesin reads using only the first of each pair-
end matched read. Peaks were identified using peak shifts and
window sizes of 138 bp and 144 bp for CTCF and cohesin, re-
spectively, and a False Discovery Rate (FDR) of 95% (Supplemental
Table S2A). A subset of peaks was obtained to a false discovery ratio
of 5% (Phred-scaled FDR 13) expanded by 500 bp upstream and
downstream and overlapping peaks merged prior to further
analysis. Refer to Supplemental Table S2A for the number of raw
reads that pass a quality control map in a CTCF or cohesin binding
region.
Parental allele-specific binding analysis
Parental allele-specific binding was assessed by binomial testing, us-
ing a custom bioinformatics pipeline. For performance reasons, only
reads of interest, which overlapped the previously identified CTCF or
RAD21 binding sites and a SNP between the two parental strains,
were extracted from the SAM files and used for subsequent analysis.
Individual reads were assigned to one of the parental alleles
using a custom Perl script, using the SAMtools Perl library. Each
read was mapped as either derived from the reference sequence
(Bl6) or from the cast allele on the basis of a SNP between the pa-
rental strains. If more than one SNP was present, the SNP with the
best quality of read sequencewas used. Reads were only considered
for subsequent analysis if the Phred-scaled alignment mapping
quality exceeded 50 and the base call quality at the SNP used for
mapping of the read exceeded 20.
Paired reads were mapped to parental strains separately and
merged. Because paired reads are not independent data points,
when they were in disagreement (<1%) the read pair was assigned
on the basis of the best SNP in either of the two reads.
Assigned reads were converted to maternally or paternally
derived, and data from both B 3 C and C 3 B reciprocal crosses
were merged for the CTCF and RAD21 data sets independently.
Counts of maternal and paternal reads were obtained on a per-re-
gion basis using MySQL. Binding regions were only tested for
parent-of-origin-specific expression if three or more reads could be
mapped.
Parental allele-specific binding was assessed using a two-sided
binomial test (implemented in R) of the maternal-versus-paternal
allelic read counts. Regions were sorted by P-value score using
MySQL. The genome-wide significance of P-values was assessed by
means of Bonferroni correction. UCSCBED tracks were prepared at
different cutoffs with maternal/paternal annotation.
Peak intersections
All subsequent bioinformatic analyseswere performed on expanded
regions unless otherwise specified. CTCF peak intersections be-
tween ES cell, brain, and liver data were performed using an opti-
mized peak size of 1 kb for all data sets. ES cell datawere converted to
mm9 using the UCSC liftOver tool. Peak overlap counts were
obtained used the BEDTools intersectBed command. For each in-
tersection, counts of the intersecting peaks were calculated in both
possible ways, and the peaks count reported was the mean of the
two measurements. For intersections of more than two data sets,
only one of the possible configurations of intersections was exam-
ined; the same configuration was used for all analyses.
Identification of non-motif-containing peaks
Peaks that did not contain the CTCF motif were identified using
the FIMO tool from the MEME suite (Grant et al. 2011). Peak se-
quenceswere obtained using theUCSCGenome Browser table tool
in FASTA format with repeat sequences masked. The CTCF motif
identified from the brain data set was used throughout, and the
threshold fordetectionwas set to103.CustomUNIXshell scriptswere
used to extract the coordinates of the peaks from the FIMO output.
Motif finding
Motif finding was performed using MEME (Bailey et al. 2009) on
binding regions using default MEME parameters. For the brain
data, the best subwindow coordinates were used.
Genomic distribution of peaks
The CEAS tool (Shin et al. 2009) was used to assess the genomic
distribution of unexpanded CTCF binding regions, and unex-
panded parent-of-origin-specific CTCF binding sites were detected
with a P < 0.001. Relative abundance was normalized to the pro-
portion of the genome represented by each genomic region. For
the CEAS analysis, parent-of-origin-specific CTCF expanded re-
gions were assigned back to their original constituent unexpanded
peaks using bedmap (Neph et al. 2012).
Quantitative PCR validation of CTCF and cohesin ChIP-seq
These assays are detailed in Supplemental Methods 1.
Validation of parent-of-origin-specific binding using pyrosequencing
Chromatinwas extracted from four biological replicates, two B3C
and twoC3B P21 brains. Pyrosequencing validatedCTCF binding
at three regions (Supplemental Table S6). ChIP was performed as
for ChIP-seq. Maternal-to-paternal proportions were assigned us-
ing SNPs between Bl6 and cast. Allelic proportions were normal-
ized to input DNA, which represents a 50:50 ratio of maternal-to-
paternal reads. Using the normalized maternal proportion, a two-
sided t-test against a 0.5 null proportion was performed.
Testing for imprinted expression
Transcripts were tested for allele-specific expression using PCR fol-
lowed by Sanger sequencing (using the primers in Supplemental
Table S7).
Bisulfite mutagenesis
Genomic DNA from B3C and C3 B intercross mouse brain tissue
was converted using the Zymo EZ DNA Methylation-Direct Kit
(D5020). Amplified regions of interest were ligated into pGEM-T
Easy (Promega:A1360), transformed into competent Escherichia
coli, and sequenced. Primers were designed with MethPrimer
(For:GTGTTTGTTGAGAGTTGTTGAGAGA; Rev: ACCAAACAACC
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Data access
Primary sequencing data have been deposited in the NCBI Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/)
under accession number GSE35140.
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1 #!/ apps / p e r l / 5 . 15 . 1/ b in / p e r l
2 #/usr / b in / p e r l
3
4 # Copyr i gh t 2010 N iko l ao s Barkas
5 # Al l r i g h t s r e s e r v e d .
6
7 # Author : N i ko l ao s Barkas
8 # Date : October 2010
9 # Des c r i p t i on : A program f o r t h e ass ignment o f new g ene r a t i on s e quen s i n g reads to a l l e l e s
10
11 # L i b r a r i e s and pragmas
12 use s t r i c t ;
13 use POSIX ;
14 use Bio : :DB: : Sam;
15 use Getopt : : Long ;
16
17 # Input f i l e s − Change t h i s to a c c ep t parameters from the command l i n e
18 my $snpsF i l e ;
19 my $bamFile ;
20 my $showHelp ;
21
22 &GetOptions (
23 ”bam=s” => \$bamFile ,
24 ” snps=s” => \ $snpsFi l e ,
25 ” help ” => \$showHelp
26 ) ;
27
28 i f ( $showHelp ) {
29 usage ( ) ;
30 exit 0 ;
31 }
32
33 i f ( ! $bamFile | | ! −e $bamFile ) {
34 e r r o r ( ”Bam F i l e not found ” . $bamFile ) ;




39 i f ( ! $ snpsF i l e | | ! −e $ snpsF i l e ) {
40 e r r o r ( ”Snps f i l e not found ” . $ snpsF i l e ) ;




45 sub usage {
46 print ”mapReadsToAlleles −−bam=bamFile −−snp=snpsF i l e \n” ;
47 }
48
49 sub e r r o r {
50 print ”Error : $ [ 0 ] \ n” ;
51 }
52
53 # TODO: Load Genomic r e g i on s
54
55
56 # Load SNPs
57 # I n i t i a l i s e Chromosome SNP Hash
58 # Each e lement in t h e hash p o i n t s to an array
59 # Which i s an array o f snps
60 my %snpChrHash = ( ) ;
61 open(SNPS, $ snpsF i l e ) ;
62 while (my $ l i n e = <SNPS>) {
63 chomp( $ l i n e ) ;
64 my @spl i tL ine = sp l i t ( ”\ t ” , $ l i n e ) ;
65 my $chr = l c ( $ s p l i t L i n e [ 0 ] ) ;
332
66 push @{ $snpChrHash{$chr} } , \@spl i tL ine ;
67 }
68 close (SNPS) ;
69
70 # Sor t t h e SNP Arrays by chromosomal p o s i t i o n
71 # so t h a t we can run b ina ry s earch on t h e s e
72 foreach my $key (keys %snpChrHash ) {
73 my @chrArray = @{$snpChrHash{$key }} ;
74 @chrArray = sort { @$a [ 1 ] <=> @$b [ 1 ] } @chrArray ;
75 }
76
77 # Open Sam f i l e
78 my $sam = Bio : :DB: : Sam−>new( −bam => $bamFile ) ;
79 my @alignments = $sam−>f e a t u r e s ( ) ;
80
81 for my $a ( @alignments ) {
82 # A v a r i a b l e h o l d i n g t h e ou tpu t f o r each en t r y u n t i l t h e t ime
83 # i t i s to be p r i n t e d to s t d o u t . We wr i t e to t h i s v a r i a b l e
84 # as opposed to s t d o u t d i r e c t y to a l l ow f o r p a r a l l e l i s a t i o n o f t h i s l oop
85 # acro s s mu l t i p l e co r e s w i t hou t caus ing i n c o n s i s t e n t ou tpu t
86 my $ l i n eBu f f e r = ’ ’ ;
87
88 # Informat ion f o r t h i s p a r t i c u l a r a l i gnment
89 my $chromosome = $a−>s e q i d ;
90 my $star tReg ion = $a−>s t a r t ;
91 my $endRegion = $a−>end ;
92 my $primaryId = $a−>pr imary id ;
93
94 # Prin t out t h e r e g i on in f o rma t i on
95 $ l i n eBu f f e r = $chromosome . ”\ t ” . $s tar tReg ion . ”\ t ” . $endRegion . ”\ t ” ;
96
97 # The array in t h e snp hash which ho l d s snp i n f o
98 # fo r t h e chromosome on which t h i s read was mapped to
99 my @chromosomeSnps = @{$snpChrHash{ lc ( $chromosome ) }} ;
100
101 # Naive approach , l oop over a l l snps
102 sub getSnpsInRegion {
103 my @matchedSnps = ( ) ;
104 my @chromosomeSnps = @{ $ [ 0 ] } ;
105 my $star tReg ion = $ [ 1 ] ;
106 my $endRegion = $ [ 2 ] ;
107
108 for my $ i ( 0 . . $#{@chromosomeSnps} ) {
109 my $snpPos i t ion = $chromosomeSnps [ $ i ] [ 1 ] ;
110 my $snpAlle leOne = $chromosomeSnps [ $ i ] [ 2 ] ;
111 my $snpAlleleTwo = $chromosomeSnps [ $ i ] [ 3 ] ;
112
113 i f ( $s tar tReg ion <= $snpPos i t ion && $snpPos i t ion <= $endRegion ) {
114 push( @matchedSnps , [ ’ chromosome ’ , $snpPos it ion , $snpAlleleOne ,
$snpAlleleTwo ] ) ;
115 }
116 }
117 return @matchedSnps ;
118 }
119
120 # Binary search i n t o snp array
121 sub getSnpsInRegionBinary {
122 my @chromosomeSnps = @{ $ [ 0 ] } ;
123 my $star tReg ion = $ [ 1 ] ;
124 my $endRegion = $ [ 2 ] ;
125
126 #Locate S t a r t Po s i t i o n
127 my $upperLimitPos = $#chromosomeSnps − 1 ;
128 my $lowerLimitPos = 0 ;
129 while ( $upperLimitPos > $lowerLimitPos + 1 ) {
130 # Half−way through the e x i s t i n g range
131 my $ i = $lowerLimitPos + c e i l ( ( $upperLimitPos − $lowerLimitPos ) /2) ;
132 i f ( $s tar tReg ion < $chromosomeSnps [ $ i ] [ 1 ] ) {
133 $upperLimitPos = $ i ;
134 } e l s i f ( $s tar tReg ion >= $chromosomeSnps [ $ i ] [ 1 ] ){
135 $lowerLimitPos = $ i ;
136 }
137 }
138 my $reg ionStar t Index = $lowerLimitPos + 1 ;
139
140 #Locate End Po s i t i o n
141 my $upperLimitPos = $#chromosomeSnps −1;
142 my $lowerLimitPos = 0 ; #$ r e g i o nS t a r t I n d e x ; # C l e a r l y t h e end p o s i t i o n w i l l be
a f t e r t h e s t a r t
143 while ( $upperLimitPos > $lowerLimitPos + 1 ) {
144 # Half−way through e x i s t i n g range
145 my $ i = $lowerLimitPos + c e i l ( ( $upperLimitPos − $lowerLimitPos ) /2) ;
146 i f ( $endRegion < $chromosomeSnps [ $ i ] [ 1 ] ) {
147 $upperLimitPos = $ i ;
148 } e l s i f ( $endRegion >= $chromosomeSnps [ $ i ] [ 1 ] ){
149 $lowerLimitPos = $ i ;
150 }
151 }
152 my $regionEndIndex = $upperLimitPos − 1 ;
153
154 # Get array s l i c e w i th SNPs o f i n t e r e s t




159 # SNP lookup method
160 my @matchedSnps = getSnpsInRegionBinary (\@chromosomeSnps , $startRegion , $endRegion ) ;
161
162 # A l t e r n a t i v e l i n e a r search , much much s l owe r
163 # my @matchedSnps = ge tSnps InReg ion (\@chromosomeSnps , $ s t a r tReg i on , $endRegion ) ;
164
165 # From the SNPs we have j u s t found in t h e read in t he r e g i on
166 # we need to p i c k t h e r i g h t one to use to do the ass i gnment w i th
333
167
168 # The s c o r e s o f t h e SNPs
169 my @scores = $a−>qscore ;
170
171 # The mapping q u a l i t y o f t h e read
172 my $match qual = $a−>qual ;
173
174 # Read s t a r t p o s i t i o n on the r e f e r e n c e
175 my $readStart = $a−>s t a r t ;
176
177 # Best h i t c oun t e r s
178 my $maxScoreValue = 0 ;
179 my $maxScorePosit ion = −1;
180 my $maxScoreSnpIndex = 0 ;
181
182 sub pos it ionInBedRegion {
183 return 1 ;
184 }
185
186 # Best SNP s e l e c t i o n
187 for my $ j ( 0 . . $#matchedSnps ) {
188 my $snpPos i t ion = $matchedSnps [ $ j ] [ 1 ] ;
189 my $snpPosit ionInRead = $snpPos i t ion − $readStart ;
190
191 # TODO: Apply e x t r a f i l t e r to ensure t h a t t h e a c t u a l
192 # SNP used mapped to a genomic p o s i t i o n which i s in
193 # a reg i on on i n t e r e s t . This i s p a r t i c u l a r l y impor tan t
194 # fo r RNA−s eq data were s y s t ema t i c a r t i f a c t s may a r i s e
195 # i f f l a n k i n g genomic r e g i on s are used .
196
197 # Pick t h e b e s t SNP
198 i f ( $ s co r e s [ $snpPosit ionInRead ] > $maxScoreValue && pos it ionInBedRegion (
$snpPos i t ion ) ) {
199 $maxScoreValue = @scores [ $snpPosit ionInRead ] ;
200 $maxScorePosit ion = $snpPosit ionInRead ;




205 # Get t h e base read in th e p o s i t i o n co r r e spond ing to t h e snp
206 my $snpReadBase = substr ( $a−>query−>dna , $maxScorePosit ion , 1) ;
207
208 # Get t h e p o s s i b l e a l l e l e b a s e s
209 my $a l l e l eOneBase = $matchedSnps [ $maxScoreSnpIndex ] [ 2 ] ;
210 my $al le leTwoBase = $matchedSnps [ $maxScoreSnpIndex ] [ 3 ] ;
211
212 # Do ass ignment
213 # Base one i s a lwa t s ATGC in the inpu t f i l e
214 i f ( $snpReadBase eq $a l l e l eOneBase ) {
215 $ l i n eBu f f e r = $ l i n eBu f f e r . ’ 1 ’ ;
216 } else {
217 # But base 2 may use a b b r e v i a t i o n s
218 # The a b b r e v i a t i o n s are ( ’ h t t p ://www. chem . qmul . ac . uk/ iubmb/misc / naseq . html #201 ’)
219 # R −−> AG
220 # Y −−> CT
221 # W −−> AT
222 # S −−> GC
223 # M −−> AC
224 # K −−> GT
225 # H −−> !G
226 # B −−> !A
227 # V −−> !T
228 # D −−> !C
229 # N −−> ATGC
230 # Of t h e s e on l y t h e p a i r s are used in t he inpu t
231
232 i f ( $snpReadBase eq $al le leTwoBase ) {
233 # The s imp l e case
234 $ l i n eBu f f e r = $ l i n eBu f f e r . ’ 2 ’ ;
235 } e l s i f ( $al le leTwoBase eq ”R” ) {
236 i f ( $snpReadBase eq ”A” | | $snpReadBase eq ”G” ) {
237 $ l i n eBu f f e r = $ l i n eBu f f e r . ’ 2 ’ ;
238 } else {
239 $ l i n eBu f f e r = $ l i n eBu f f e r . ’X ’ ;
240 }
241 } e l s i f ( $al le leTwoBase eq ”Y” ) {
242 i f ( $snpReadBase eq ”C” | | $snpReadBase eq ”T” ) {
243 $ l i n eBu f f e r = $ l i n eBu f f e r . ’ 2 ’ ;
244 } else {
245 $ l i n eBu f f e r = $ l i n eBu f f e r . ’X ’ ;
246 }
247 } e l s i f ( $al le leTwoBase eq ”W” ) {
248 i f ( $snpReadBase eq ”A” | | $snpReadBase eq ”T” ) {
249 $ l i n eBu f f e r = $ l i n eBu f f e r . ’ 2 ’ ;
250 } else {
251 $ l i n eBu f f e r = $ l i n eBu f f e r . ’X ’ ;
252 }
253 } e l s i f ( $al le leTwoBase eq ”S” ) {
254 i f ( $snpReadBase eq ”G” | | $snpReadBase eq ”C” ) {
255 $ l i n eBu f f e r = $ l i n eBu f f e r . ’ 2 ’ ;
256 } else {
257 $ l i n eBu f f e r = $ l i n eBu f f e r . ’X ’ ;
258 }
259 } e l s i f ( $al le leTwoBase eq ”M” ) {
260 i f ( $snpReadBase eq ”A” | | $snpReadBase eq ”C” ) {
261 $ l i n eBu f f e r = $ l i n eBu f f e r . ’ 2 ’ ;
262 } else {
263 $ l i n eBu f f e r = $ l i n eBu f f e r . ’X ’ ;
264 }
265 } e l s i f ( $al le leTwoBase eq ”K” ) {
266 i f ( $snpReadBase eq ”G” | | $snpReadBase eq ”T” ) {
267 $ l i n eBu f f e r = $ l i n eBu f f e r . ’ 2 ’ ;
268 } else {
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269 $ l i n eBu f f e r = $ l i n eBu f f e r . ’X ’ ;
270 }
271 } else {
272 # Unknown A l l e l e 2 code
273 $ l i n eBu f f e r = $ l i n eBu f f e r . ’X ’ ;
274 }
275 }
276 $ l i n eBu f f e r = $ l i n eBu f f e r . ”\ t ” . $maxScoreValue . ”\ t ” . $match qual . ”\ t ” .
$primaryId ;
277
278 # TODO: S u b s t i t u t e t h i s w i th a t h r ead s a f e v e r s i o n and p a r a l l e l i s e




2 #!/ usr / b in / p e r l
3
4 use s t r i c t ;
5
6 my %methStatus = ( ) ;
7
8 while(<>) {
9 chomp( ) ;
10 my @f i e l d s = sp l i t /\ t / ;
11
12 my $chr = $ f i e l d s [ 2 ] ;
13 my $pos = $ f i e l d s [ 3 ] ;





19 foreach my $key ( sort keys %methStatus ) {
20 foreach my $key2 ( sort keys %{ $methStatus{$key} } ) {
21 my $me ;
22 my $unme ;
23
24 i f (defined $methStatus{$key}{$key2}{”+”}) {
25 $me = $methStatus{$key}{$key2}{”+” } ;
26 } else {
27 $me = 0 ;
28 }
29
30 i f (defined $methStatus{$key}{$key2}{”−”}) {
31 $unme = $methStatus{$key}{$key2}{”−” } ;
32 } else {
33 $unme = 0 ;
34 }
35
36 my $count = $me + $unme ;
37 i f ( $count > 0) {
38 my $percent = $me / $count ∗ 100 ;






2 l i b r a r y ( ”GenomicRanges” )
3 l i b r a r y ( ” ggplot2 ” )
4
5 # Load CGIs
6 cgi meth <− read . csv ( ’ input / r e s u l t s . csv ’ )
7 mean . meth <− apply (X=cgi meth [ , c ( ” ec r ep1 ” , ” ec r ep2 ” , ” e t r ep1 ” , ” e t r ep2 ” ) ] ,MARGIN=1 , FUN=mean)
8 cgi meth . gr <− GRanges ( seqnames = Rle ( cg i meth$chr ) ,
9 ranges = IRanges ( s t a r t=cg i meth$star t , end=cgi meth$end ) )
10 cgi meth . gr$methylat ion <− mean . meth
11 rm( cgi meth , mean . meth )
12
13 # Load gene expre s s i on
14 gene exp <− read . table ( ’ input / gene exp . d i f f ’ , header=T, as . i s=T)
15 seqnames <− f a c t o r ( sapply ( s t r s p l i t ( gene exp [ [ ” l o cu s ” ] ] , ’ : ’ ) , ’ [ ’ , 1 ) )
16 p o s i t i o n s <− sapply ( s t r s p l i t ( gene exp [ [ ” l o cu s ” ] ] , ’ : ’ ) , ’ [ ’ , 2 )
17 s t a r t <− as .numeric ( sapply ( s t r s p l i t ( po s i t i on s , ’− ’ ) , ’ [ ’ , 1 ) )
18 end <− as .numeric ( sapply ( s t r s p l i t ( po s i t i on s , ’− ’ ) , ’ [ ’ , 2 ) )
19 expr <− apply ( gene exp [ , c ( ” va lue 1 ” , ” va lue 2 ” ) ] , MARGIN=1, mean)
20 gene exp . gr <− GRanges ( seqnames= Rle ( seqnames ) , ranges = IRanges ( s t a r t=sta r t , end=s t a r t +1) )
21 gene exp . gr$expr <− expr
22 rm( expr , s ta r t , end , p o s i t i on s , seqnames , gene exp )
23
24
25 gaps <− data . frame ( gap=c ( seq (0 ,10000 ,100) , seq (10000 ,300000 ,1000) ) )
26
27 ge tOve r l apS i gn i f i c anc e <− f unc t i on (x ) {
28 h i t s <− f indOver laps ( cgi meth . gr , gene exp . gr , maxgap = x)
29 comp <− data . frame ( methylat ion=cgi meth . gr [ queryHits ( h i t s ) , ] $methylation , expr=gene exp . gr [
s ub j e c tH i t s ( h i t s ) , ] $expr )
30 comp$meth . level <− cut ( comp$methylation , breaks=c (−1 ,50 ,100) , l a b e l s = c ( ” low” , ”high ” ) )
31 high <− subset (comp , meth . level ==”high” )
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32 low <− subset (comp , meth . level ==”low” )
33 t . t e s t ( x=high$expr , y=low$expr ) $p . value
34 }
35
36 getOver lapRatio <− f unc t i on (x ) {
37 h i t s <− f indOver laps ( cgi meth . gr , gene exp . gr , maxgap = x)
38 comp <− data . frame ( methylat ion=cgi meth . gr [ queryHits ( h i t s ) , ] $methylation , expr=gene exp . gr [
s ub j e c tH i t s ( h i t s ) , ] $expr )
39 comp$meth . level <− cut ( comp$methylation , breaks=c (−1 ,50 ,100) , l a b e l s = c ( ” low” , ”high ” ) )
40 high <− subset (comp , meth . level ==”high” )
41 low <− subset (comp , meth . level ==”low” )
42 mean( high$expr +0.01) /mean( low$expr +0.01)
43 }
44
45 p . va l s <− apply ( gaps , MARGIN=1, g e tOve r l apS i gn i f i c anc e )
46 r a t i o s <− apply ( gaps , MARGIN=1, getOver lapRatio )
47
48 l i b r a r y ( ’ s c a l e s ’ )
49
50 l i b r a r y ( ’ reshape2 ’ )
51 r e s <− data . frame ( d i s t ance=gaps$gap , p . value=p . vals , r a t i o=ra t i o s , s i g n i f i c a n t =(p . va l s < 0 . 05 ) )
52 r e s .m <− melt ( res , id . vars = c ( ” d i s t ance ” , ” s i g n i f i c a n t ” ) )
53 p <− ggp lot ( r e s .m, aes (x=dis tance , y=value , c o l o r=s i g n i f i c a n t ) ) + geom point ( ) +
54 f a c e t g r i d ( va r i ab l e ˜ . , s c a l e s=” f r e e y ” ) + theme bw ( ) + s ca l e y c on t i nuou s (name=”” ) +
55 s c a l e x c on t i nuou s ( l a b e l s=comma, name=”Distance in ba s epa i r s ” )
56 ggsave ( ’ output/methExprDista . png ’ )
57 p <− ggp lot ( subset ( r e s .m, va r i ab l e==” r a t i o ” ) , aes (x=dis tance , y=value , c o l o r=s i g n i f i c a n t ) ) +
geom point ( ) + geom smooth ( ) +
58 theme bw ( ) + s ca l e y c on t i nuou s (name=”” ) +
59 s c a l e x c on t i nuou s ( l a b e l s=comma, name=”Distance in ba s epa i r s ” , l imit=c (0 ,10000) )
60 ggsave ( ’ output/methExprDistaZoom . png ’ )
61
62 # And a boxplot f o r immediate overlaps
63
64 h i t s <− f indOver laps ( cgi meth . gr , gene exp . gr )
65 comp <− data . frame ( methylat ion=cgi meth . gr [ queryHits ( h i t s ) , ] $methylation , expr=gene exp . gr [
s ub j e c tH i t s ( h i t s ) , ] $expr )
66 comp$meth . level <− cut ( comp$methylation , breaks=c (−1 ,50 ,100) , l a b e l s = c ( ” low” , ”high ” ) )
67 high <− subset (comp , meth . level ==”high” )
68 low <− subset (comp , meth . level ==”low” )
69
70 p <− ggp lot (comp , aes (x=meth . level , y=log ( expr ) ) ) + geom boxplot ( ) + theme bw ( ) +
71 s c a l e x d i s c r e t e (name=”Methylation Level ” ) + s ca l e y c on t i nuou s (name=” log (Mean Express ion ) ” )
72 ggsave ( ’ output/boxPlotImmediate . png ’ )
73
74 ge tOve r l apS i gn i f i c anc e (0)
75
76 ##########
77 # Now do the same thing per sample (EC)
78 ##########
79 # Load CGIs
80 cgi meth <− read . csv ( ’ input / r e s u l t s . csv ’ )
81 mean . meth <− apply (X=cgi meth [ , c ( ” ec r ep1 ” , ” ec r ep2 ” ) ] ,MARGIN=1 , FUN=mean)
82 cgi meth . gr <− GRanges ( seqnames = Rle ( cg i meth$chr ) ,
83 ranges = IRanges ( s t a r t=cg i meth$star t , end=cgi meth$end ) )
84 cgi meth . gr$methylat ion <− mean . meth
85 rm( cgi meth , mean . meth )
86
87 # Load gene expre s s i on
88 gene exp <− read . table ( ’ input / gene exp . d i f f ’ , header=T, as . i s=T)
89 seqnames <− f a c t o r ( sapply ( s t r s p l i t ( gene exp [ [ ” l o cu s ” ] ] , ’ : ’ ) , ’ [ ’ , 1 ) )
90 p o s i t i o n s <− sapply ( s t r s p l i t ( gene exp [ [ ” l o cu s ” ] ] , ’ : ’ ) , ’ [ ’ , 2 )
91 s t a r t <− as .numeric ( sapply ( s t r s p l i t ( po s i t i on s , ’− ’ ) , ’ [ ’ , 1 ) )
92 end <− as .numeric ( sapply ( s t r s p l i t ( po s i t i on s , ’− ’ ) , ’ [ ’ , 2 ) )
93 expr <− gene exp [ , c ( ” va lue 1 ” ) ]
94 gene exp . gr <− GRanges ( seqnames= Rle ( seqnames ) , ranges = IRanges ( s t a r t=sta r t , end=s t a r t +1) )
95 gene exp . gr$expr <− expr
96 rm( expr , s ta r t , end , p o s i t i on s , seqnames , gene exp )
97
98 p . va l s <− apply ( gaps , MARGIN=1, g e tOve r l apS i gn i f i c anc e )
99 r a t i o s <− apply ( gaps , MARGIN=1, getOver lapRatio )
100
101 r e s <− data . frame ( d i s t ance=gaps$gap , p . value=p . vals , r a t i o=ra t i o s , s i g n i f i c a n t =(p . va l s < 0 . 05 ) )
102 r e s .m <− melt ( res , id . vars = c ( ” d i s t ance ” , ” s i g n i f i c a n t ” ) )
103 p <− ggp lot ( r e s .m, aes (x=dis tance , y=value , c o l o r=s i g n i f i c a n t ) ) + geom point ( ) +
104 f a c e t g r i d ( va r i ab l e ˜ . , s c a l e s=” f r e e y ” ) + theme bw ( ) + s ca l e y c on t i nuou s (name=”” ) +
105 s c a l e x c on t i nuou s ( l a b e l s=comma, name=”Distance in ba s epa i r s ” )
106 ggsave ( ’ output/ ec . methExprDista . png ’ )
107 p <− ggp lot ( subset ( r e s .m, va r i ab l e==” r a t i o ” ) , aes (x=dis tance , y=value , c o l o r=s i g n i f i c a n t ) ) +
geom point ( ) + geom smooth ( ) +
108 theme bw ( ) + s ca l e y c on t i nuou s (name=”” ) +
109 s c a l e x c on t i nuou s ( l a b e l s=comma, name=”Distance in ba s epa i r s ” , l imit=c (0 ,10000) )
110 ggsave ( ’ output/ ec . methExprDistaZoom . png ’ )
111
112 # And a boxplot f o r immediate overlaps
113
114 h i t s <− f indOver laps ( cgi meth . gr , gene exp . gr )
115 comp <− data . frame ( methylat ion=cgi meth . gr [ queryHits ( h i t s ) , ] $methylation , expr=gene exp . gr [
s ub j e c tH i t s ( h i t s ) , ] $expr )
116 comp$meth . level <− cut ( comp$methylation , breaks=c (−1 ,50 ,100) , l a b e l s = c ( ” low” , ”high ” ) )
117 high <− subset (comp , meth . level ==”high” )
118 low <− subset (comp , meth . level ==”low” )
119
120 p <− ggp lot (comp , aes (x=meth . level , y=log ( expr ) ) ) + geom boxplot ( ) + theme bw ( ) +
121 s c a l e x d i s c r e t e (name=”Methylation Level ” ) + s ca l e y c on t i nuou s (name=” log (Mean Express ion ) ” )
122 ggsave ( ’ output/ ec . boxPlotImmediate . png ’ )
123
124 ge tOve r l apS i gn i f i c anc e (0)
125
126 ##########
127 # do the same thing per sample (ET)
128 ##########
129 # Load CGIs
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130 cgi meth <− read . csv ( ’ input / r e s u l t s . csv ’ )
131 mean . meth <− apply (X=cgi meth [ , c ( ” e t r ep1 ” , ” e t r ep2 ” ) ] ,MARGIN=1 , FUN=mean)
132 cgi meth . gr <− GRanges ( seqnames = Rle ( cg i meth$chr ) ,
133 ranges = IRanges ( s t a r t=cg i meth$star t , end=cgi meth$end ) )
134 cgi meth . gr$methylat ion <− mean . meth
135 rm( cgi meth , mean . meth )
136
137 # Load gene expre s s i on
138 gene exp <− read . table ( ’ input / gene exp . d i f f ’ , header=T, as . i s=T)
139 seqnames <− f a c t o r ( sapply ( s t r s p l i t ( gene exp [ [ ” l o cu s ” ] ] , ’ : ’ ) , ’ [ ’ , 1 ) )
140 p o s i t i o n s <− sapply ( s t r s p l i t ( gene exp [ [ ” l o cu s ” ] ] , ’ : ’ ) , ’ [ ’ , 2 )
141 s t a r t <− as .numeric ( sapply ( s t r s p l i t ( po s i t i on s , ’− ’ ) , ’ [ ’ , 1 ) )
142 end <− as .numeric ( sapply ( s t r s p l i t ( po s i t i on s , ’− ’ ) , ’ [ ’ , 2 ) )
143 expr <− gene exp [ , c ( ” va lue 2 ” ) ]
144 gene exp . gr <− GRanges ( seqnames= Rle ( seqnames ) , ranges = IRanges ( s t a r t=sta r t , end=s t a r t +1) )
145 gene exp . gr$expr <− expr
146 rm( expr , s ta r t , end , p o s i t i on s , seqnames , gene exp )
147
148 p . va l s <− apply ( gaps , MARGIN=1, g e tOve r l apS i gn i f i c anc e )
149 r a t i o s <− apply ( gaps , MARGIN=1, getOver lapRatio )
150
151 r e s <− data . frame ( d i s t ance=gaps$gap , p . value=p . vals , r a t i o=ra t i o s , s i g n i f i c a n t =(p . va l s < 0 . 05 ) )
152 r e s .m <− melt ( res , id . vars = c ( ” d i s t ance ” , ” s i g n i f i c a n t ” ) )
153 p <− ggp lot ( r e s .m, aes (x=dis tance , y=value , c o l o r=s i g n i f i c a n t ) ) + geom point ( ) +
154 f a c e t g r i d ( va r i ab l e ˜ . , s c a l e s=” f r e e y ” ) + theme bw ( ) + s ca l e y c on t i nuou s (name=”” ) +
155 s c a l e x c on t i nuou s ( l a b e l s=comma, name=”Distance in ba s epa i r s ” )
156 ggsave ( ’ output/ et . methExprDista . png ’ )
157 p <− ggp lot ( subset ( r e s .m, va r i ab l e==” r a t i o ” ) , aes (x=dis tance , y=value , c o l o r=s i g n i f i c a n t ) ) +
geom point ( ) + geom smooth ( ) +
158 theme bw ( ) + s ca l e y c on t i nuou s (name=”” ) +
159 s c a l e x c on t i nuou s ( l a b e l s=comma, name=”Distance in ba s epa i r s ” , l imit=c (0 ,10000) )
160 ggsave ( ’ output/ et . methExprDistaZoom . png ’ )
161
162 # a boxplot f o r immediate overlaps
163 h i t s <− f indOver laps ( cgi meth . gr , gene exp . gr )
164 comp <− data . frame ( methylat ion=cgi meth . gr [ queryHits ( h i t s ) , ] $methylation , expr=gene exp . gr [
s ub j e c tH i t s ( h i t s ) , ] $expr )
165 comp$meth . level <− cut ( comp$methylation , breaks=c (−1 ,50 ,100) , l a b e l s = c ( ” low” , ”high ” ) )
166 high <− subset (comp , meth . level ==”high” )
167 low <− subset (comp , meth . level ==”low” )
168
169
170 p <− ggp lot (comp , aes (x=meth . level , y=log ( expr ) ) ) + geom boxplot ( ) + theme bw ( ) +
171 s c a l e x d i s c r e t e (name=”Methylation Level ” ) + s ca l e y c on t i nuou s (name=” log (Mean Express ion ) ” )
172 ggsave ( ’ output/ et . boxPlotImmediate . png ’ )
173
174 ge tOve r l apS i gn i f i c anc e (0)
175
176 save . image ( ’ f i n a l . RData ’ )
C.4 getTFsByGOterm.pl
1
2 drop table i f exists t f s ;
3
4
5 create table t f s select gene product . symbol from
6 mygo . spec i e s ,
7 mygo . gene product ,
8 mygo . a s s o c i a t i on ,
9 mygo . term
10 where
11 mygo . s p e c i e s . genus=”Mus” and
12 mygo . s p e c i e s . s p e c i e s=”musculus” and
13 mygo . gene product . s p e c i e s i d=mygo . s p e c i e s . id and
14 mygo . a s s o c i a t i o n . i s n o t = 0 and
15 mygo . a s s o c i a t i o n . term id = mygo . term . id and
16 mygo . a s s o c i a t i o n . gene product id = mygo . gene product . id and
17 mygo . term . acc=”GO:0003700 ” ;
18
19
20 drop table i f exists up ;
21 drop table i f exists down ;
22
23 create table up( gene varchar (255) ) ;
24 create table down( gene varchar (255) ) ;
25
26 load data local i n f i l e ’ tmp/Upregulated . txt ’ into table up ;
27 load data local i n f i l e ’ tmp/Downregulated . txt ’ into table down ;
28
29
30 select dist inct t f s . symbol from t f s , up where t f s . symbol = up . gene ;
31 select dist inct t f s . symbol from t f s , down where t f s . symbol = down . gene ;
C.5 encodeTFdistribution.R
1 l ibrary ( ”RMySQL” )
2 l ibrary ( ”GenomicRanges” )
3 l ibrary ( ”GenomicFeatures” )
4 l ibrary ( ’ ChIPseeker ’ )
5 l ibrary ( ’TxDb. Mmusculus .UCSC.mm9. knownGene ’ )
6 l ibrary ( ’ c l u s t e r P r o f i l e r ’ )
7
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8 con = dbConnect (RMySQL: :MySQL( ) , host = ”genome−mysql . c se . ucsc . edu” , user = ”genome” , password =
”” , dbname = ”mm9” )
9
10 plotEncodeTSSdistr ibut ion <− function ( con=NULL, tableName=NULL, txdb=TxDb. Mmusculus .UCSC.mm9.
knownGene , searchRadius=10000)
11 {
12 query <− paste0 ( ” s e l e c t ∗ from ” , tableName )
13 r e s <− dbGetQuery ( con , query )
14 r e s$ strand [ r e s$ strand == ’ . ’ ]=”∗”
15 peaks <− GRanges ( seqnames=Rle ( r e s$chrom) , ranges=IRanges ( r e s$chromStart , end=re s$chromEnd ,
names=re s$name) , strand=Rle ( r e s$ strand ) , s co r e=re s$ s co r e )
16 promoter <− getPromoters (TxDb=txdb , upstream=searchRadius , downstream=searchRadius )
17 tagMatrix <− getTagMatrix ( peaks , windows=promoter )
18 plot ( plotAvgProf ( tagMatrix , xlim=c(−searchRadius , searchRadius ) , xlab=”Genomic Region (5 ’−>3 ’)
” , y=”Peak Density ” ) )
19 }
20
21 makePlot <− function ( tableName=NULL) {
22 pdf ( paste0 ( ’ output/ ’ , tableName , ’ . pdf ’ ) )
23 p lotEncodeTSSdist r ibut ion ( con=con , tableName=tableName , searchRadius=20000)
24 dev . of f ( )
25 }
26
27 t ab l e s <− read . csv ( ’ t ab l e s . csv ’ , as . i s=T)
28
29 for ( i in 1 :dim( t ab l e s ) [ 1 ] ) {
30 makePlot ( t ab l e s [ i , ] )
31 }
C.6 getTSSsequences.R
1 l ibrary ( ’ org .Mm. eg . db ’ )
2 l ibrary ( ”GenomicRanges” )
3 l ibrary ( ”TxDb. Mmusculus .UCSC.mm9. knownGene” )
4 l ibrary ( ”BSgenome . Mmusculus .UCSC.mm9” )
5 l ibrary ( ”BSgenome” )
6 l ibrary ( ” B i o s t r i n g s ” )
7
8 s t ab l e . genes . symbol <− read . csv ( ’ genesForMoti f// s t ab l e genes . csv ’ , as . i s=T, header=F)
9 upregulated . genes . symbol <− read . csv ( ’ genesForMoti f//upregulated . txt ’ , as . i s=T, header=F)
10
11 db <− TxDb. Mmusculus .UCSC.mm9. knownGene
12 a l l . promoters .mm9 <− promoters (db , upstream=5000 ,downstream=5000)
13 kgXref <− read . csv ( ’ kgXref .mm9. csv ’ )
14 ucsc2symbol <− kgXref [ , c ( ”X. kgID” , ”geneSymbol” ) ]
15
16 s t ab l e . genes . ucsc <− ucsc2symbol [which ( ucsc2symbol$geneSymbol %in% s t ab l e . genes . symbol [ , 1 ] ) , ]
17 up . genes . ucsc <− ucsc2symbol [which ( ucsc2symbol$geneSymbol %in% upregulated . genes . symbol [ , 1 ] ) , ]
18
19 s t ab l e . promoters <− a l l . promoters .mm9[which ( a l l . promoters .mm9$tx name %in% s t ab l e . genes . ucsc$X.
kgID ) , ]
20 up . promoters <− a l l . promoters .mm9[which ( a l l . promoters .mm9$tx name %in% up . genes . ucsc$X. kgID ) , ]
21
22 makeDirectionalPromoterWindow <− function ( promoters , s t a r tO f f s e t , windowSize ) {
23 windowSize <− windowSize −1
24
25 promoters . pos <− promoters [ strand ( promoters ) == ’+’ ]
26 promoters . neg <− promoters [ strand ( promoters ) == ’− ’ ]
27
28 start ( ranges ( promoters . pos ) ) <− start ( ranges ( promoters . pos ) ) + s t a r tO f f s e t
29 end( ranges ( promoters . pos ) ) <− start ( ranges ( promoters . pos ) ) + windowSize
30
31 end( ranges ( promoters . neg ) ) <− end( ranges ( promoters . neg ) ) − s t a r tO f f s e t
32 start ( ranges ( promoters . neg ) ) <− end( ranges ( promoters . neg ) ) − windowSize
33
34 c ( promoters .pos , promoters . neg )
35 }
36
37 writeGenomicRangesAsBed <− function ( gr , bedFi l e ) {
38 df <− data . frame ( seqnames=seqnames ( gr ) ,
39 s t a r t s=start ( gr )−1,
40 ends=end( gr ) ,
41 names=gr$tx name ,
42 s c o r e s=c ( rep ( ” . ” , length ( gr ) ) ) ,
43 s t rands=strand ( gr ) )
44
45 write . table (df , f i l e=bedFi le , quote=F, sep=”\ t ” , row .names=F, col .names=F)
46 }
47
48 mm9 <− BSgenome . Mmusculus .UCSC.mm9
49
50 windowSize <− 1000
51 windowStep <− 500
52 for ( i in seq (0 ,9000 , windowStep ) ) {
53 s t ab l e . promoters .window <− makeDirectionalPromoterWindow ( s t ab l e . promoters , i , windowSize )
54
55 # Make the windows unique ac ro s s t h e genome
56 s t ab l e . promoters .window <− s t ab l e . promoters .window [ ! duplicated ( s t ab l e . promoters .window) ]
57
58
59 writeGenomicRangesAsBed ( s t ab l e . promoters .window , paste0 ( ”output/ s t ab l e window ” , i , ” . bed” ) )
60 s t ab l e . seq <− getSeq (x=mm9,names=seqnames ( s t ab l e . promoters .window) ,
61 start=start ( s t ab l e . promoters .window) ,
62 end=end( s t ab l e . promoters .window) ,
63 strand=strand ( s t ab l e . promoters .window) )
64 names( s t ab l e . seq ) <− s t ab l e . promoters .window$tx name




68 up . promoters .window <− makeDirectionalPromoterWindow (up . promoters , i , windowSize )
69 up . promoters .window <− up . promoters .window [ ! duplicated (up . promoters .window) ]
70
71 writeGenomicRangesAsBed (up . promoters .window , paste0 ( ”output/up window ” , i , ” . bed” ) )
72 up . seq <− getSeq (x=mm9,names=seqnames (up . promoters .window) ,
73 start=start (up . promoters .window) ,
74 end=end(up . promoters .window) ,
75 strand=strand (up . promoters .window) )
76 names(up . seq ) <− up . promoters .window$tx name
77 wr i teXStr ingSet (up . seq , paste0 ( ”output/up window ” , i , ” . f a s t a ” ) )
78 }
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